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Insulin resistance has been shown to be caused by saturated fatty acids 
(SFA), especially palmitate found in abundance in the Western diet. The enzyme 
phosphatidylinositol 3 kinase (PI3K) has been identified as a key modulator of SFA-
induced insulin resistance. To further the current understanding of the molecular 
mechanisms at play, we performed a transcriptome analysis comparing the gene 
expression profiles of 3T3-L1 adipocytes treated with palmitate, in the presence or 
absence of an inhibitor selective for p110α, one of the catalytic subunits of class IA 
PI3K. It revealed that the expression of a number of genes induced by type I 
interferon (IFN) is stimulated in response to palmitate, an effect abrogated by p110α 
inhibition. Such finding was of particular interest as IFN is known, like palmitate, to 
trigger insulin resistance. We studied the molecular links between IFN- and 
palmitate-mediated insulin resistance in both murine and human pre- and mature 
adipocytes. This allowed the confirmation of the positive metabolic effect of 
inhibiting p110α. The effect of palmitate on components of the IFN pathway was 
further explored and led to the establishment of a pivotal role of IFN-stimulated 









The material presented in this thesis constitutes primary research on the topic 
of insulin resistance. This metabolic dysregulation is one of the principal causes of 
type 2 diabetes (T2D) and is associated with obesity. With an estimated 422 million 
of type 2 diabetic adults in 2014 and obesity reaching a toll of 650 million adults in 
2016 worldwide, tackling this pandemic is now at the forefront of the public health 
agenda (World Health Organisation 2016). To this end, it is critical to further 
investigate the molecular mechanisms at the core of insulin resistance in hope of 
improving the treatment and prevention of the aforementioned metabolic diseases. 
 
Dietary saturated fatty acids (SFAs) have been implicated in the development 
of insulin resistance. We investigated the molecular signalling underlying the onset 
this state following SFA overload in mouse and human adipocytes. More 
specifically, we focused our attention on the cellular consequences of palmitate 
overload, a SFA found in abundance in the Western diet. For the first time, its effect 
on the phosphorylation of the downstream effectors of the IFN pathway (signal 
transducer and activator of transcription 3 [STAT3] and STAT1) was explored in 
adipocytes. We were able to demonstrate that palmitate induced the activation of 
STAT3 in mouse fat cells, thus establishing a role for the IFN signalling pathway 
amongst the molecular mediators of obesity as a sustained state of inflammation. 
Furthermore, our study stands as the first investigation exploring the palmitate-
mediated modulation of the autophagic response of 3T3-L1 pre-adipocytes and 
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evidences the pro-autophagic role of SFA. In addition, we provide new insight on the 
role of a key IFN pathway component, namely Isg15, in the modulation of the 
metabolic effect of insulin and of autophagy in the context of SFA overload.  
 
Collectively, these results outline a new axis of research that aims to better 
understand and cure metabolic disorders such as obesity and T2D exploiting 
components of cell signalling pathways as potential therapeutic targets. Further work 
will be needed to ascertain these findings and testing them into animal models and, 
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I. 1.   Insulin, a critical regulator of metabolism 
I. 1. 1. The regulation of glucose homeostasis  
 Glucose homeostasis is essential to sustain bodily functions. Through the 
secretion of various hormones, the pancreas is able to maintain the extracellular 
concentration of this simple sugar within the narrow range of 4 to 6 mM (Roder 
2016). Pancreatic endocrine cells form clusters known as islets of Langerhans, 
accounting for only 1 to 2% of the organ’s mass. Five distinct cell types constitute 
these structures: α-, β-, γ-, δ- and ε-cells. As shown in table 1, α- and β-cells form 
the bulk of the islets and secrete glucagon and insulin, respectively. These two 
hormones work in tandem to promote opposite effects on circulating blood glucose.  
 
Table 1. The five endocrine cell types constituting the pancreatic islets of Langerhans. Each hormone 
secreted has a specific function. For instance, while glucagon increases blood glucose levels, insulin 
promotes the opposite effect. Although the overall cellular composition of the islets is conserved 
across vertebrates, the details of their cytoarchitecture can vary considerably from species to species 
(Roder 2016). 
 
Cell type Occurrence (%) Hormone secreted 





δ-cells 3-10 Somatostatin 
γ-cells 3-5 Pancreatic polypeptide 





In a postprandial state, pancreatic β-cells are able to detect a rise in 
exogenous glucose levels, prompting the release of insulin into the bloodstream. This 
hormone down-regulates glucose concentration through three processes (Aronoff 
2004): firstly, it promotes glucose uptake in its target cells such as adipocytes and 
muscle cells; secondly, insulin stimulates hepatic glycogenesis hence allowing for 
excessive glucose to be converted into glycogen (H. K. Han 2016); and lastly, this 
hormone stalls liver-mediated glucose production by inhibiting both glycogenolysis 
and gluconeogenesis (Figure 1). In addition to modulating blood glucose 
homeostasis, insulin promotes a range of anabolic reactions including lipogenesis 
and protein synthesis (Aronoff 2004). Conversely, as illustrated in figure 1, the 
fasting state is characterised by a combination of catabolic processes initiated by 
glucagon-secreting α-cells. While an overall switch from glucose to fat burning 
occurs, glucose-dependent tissues, such as the brain, are fuelled by endogenous 
glucose released via hepatic glycogenolysis and gluconeogenesis (Roder 2016). 
  
Disturbances of the endocrine system described above are becoming 
increasingly prevalent, especially insulin resistance, which refers to the failure of a 
known quantity of insulin to stimulate glucose uptake in an individual compared to a 
healthy population (Lebovitz 2001). This common pathophysiological condition 
seeds a range of metabolic symptoms such as obesity, hyperlipidemia, hypertension 
and hyperglycemia, clustered under the umbrella term “Syndrome X” or “metabolic 
syndrome” (Moller 2005, Reaven 1988). The metabolic syndrome constitutes a key 
risk factor for T2D, a chronic disease affecting over 422 million adults worldwide in 
2014 (World Health Organisation 2016). Such disorder is characterised by the 
inability of pancreatic β-cells to produce sufficient levels of insulin leading to the 
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release of abnormally large amounts of hepatic glucose into the bloodstream 
(Lebovitz 2001). The World Health Organisation defines the diagnostic criteria for 
T2D as a fasting plasma glucose concentration ≥ 7.0 mmol/L or a plasma glucose 
concentration ≥ 11.1 mmol/L two hours after the oral dose used in a glucose 
tolerance test (World Health Organisation 2006). 
 
 
Figure 1. The complementary role of insulin and glucagon in glucose homeostasis. After a meal, the 
pancreatic β-cells secrete insulin into the bloodstream. This hormone promotes the storage of energy 
by stimulating glycogenesis in the liver. Meanwhile, insulin inhibits hepatic glucose production 
through the down-regulation of gluconeogenesis and glycogenolysis. In target tissues such as skeletal 
muscles and adipose tissue, glucose uptake is then enhanced. Together these reactions lower blood 
glucose concentration. When the latter reaches a certain threshold, the α-cells of the pancreas secrete 
the catabolic hormone glucagon, which induces hepatic gluconeogenesis and glycogenolysis to 
increase circulating glucose levels. 
 
 
I. 1. 2. Overview of the insulin pathway 
In order to improve the treatment and prevention of T2D, it is critical to 
thoroughly understand the molecular signalling mediating insulin action. Figure 2 
presents an overview of the cascades activated by this hormone. These are initiated 
by the binding of insulin to the extracellular α-subunit of its receptor that dimerises 
to form the α2β2 complex. This event allows for the autophosphorylation of the 
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insulin receptor (IR) β-subunits (Guo 2014). Upon activation, the receptor recruits 
and phosphorylates various substrates including IR substrate-1 to 4 (IRS1-4) and the 
adaptor Src homology 2 (SH2) domain-containing transforming protein (SHC), 
which serve as docking sites for other downstream signalling proteins. In turn, these 
proteins promote the activation of two main branching pathways: the Ras/mitogen-
activated protein kinase (MAPK) and the PI3K/Akt cascades, involved in the 
regulation of cell growth, metabolism and survival (Guo 2014). As shown in figure 
2, the former is induced by the interaction of SHC with the docking protein growth 
factor receptor-bound protein 2 and the guanine nucleotide exchange factor son of 
sevenless. The resulting complex drives the activation of the downstream Ras-Raf-
MAPK-extracellular signal-regulated kinase (ERK) pathway through a series of 
phosphorylation events (Van den Berghe 2004).  
 
On the other hand, the PI3K cascade stems from the binding of tyrosine 
phosphorylated IRS to the SH2 domain of PI3K. By phosphorylating 
phosphatidylinositol (4,5)-bisphosphate to generate phosphatidylinositol (3,4,5)-
triphosphate, this enzyme, which will be the focus of the next section, enables the 
activation of 3-phosphoinositide dependent protein kinases -1 and -2 (PDK1 and 
PDK2). Together, these kinases are responsible for the stimulation of the protein 
kinase Akt at residues Thr308 and Ser473, respectively (Guo 2014). The functional 
role of the putative PDK2 is exerted by the mammalian target of rapamycin complex 






Figure 2. Overview of the insulin signalling and its relevance to cell metabolism. The binding of 
insulin to its receptor triggers an array of downstream reactions initiated by the phosphorylation of 
insulin receptor substrates (IRS) and the adaptor Src homology 2 (SH2) domain-containing 
transforming protein (SHC). Phosphatidylinositol 3-kinase (PI3K) is then stimulated inducing, in turn, 
the phosphorylation of Akt at Thr308 and Ser473 through the activation of protein kinase 1 (PDK1) and 
mammalian target of rapamycin complex 2 (mTORC2), respectively. This results in the modulation 
of a range of cellular functions including glucose transport, lipogenesis, protein synthesis, hepatic 
glucose synthesis and hepatic gluconeogenesis, as well as cell proliferation and apoptosis. AS160: Akt 
substrate of 160 kDa; CBP: CREB binding protein; CREB: cyclic adenosine monophosphate response 
element-binding protein; CRTC2: CREB regulated transcription coactivator 2; DNA: 
deoxyribonucleic acid; ERK: extracellular signal-regulated kinases; FOXO1: forkhead box O1; 
GLUT4: glucose transporter type 4; GRB2: growth factor receptor-bound protein 2; GS: glycogen 
synthase; GSK3β: glycogen synthase kinase-3β; IR: insulin receptor; MEK: mitogen-activated protein 
kinase (MAPK)/Erk kinase; PI(3,4,5)P3: phosphatidylinositol (3,4,5)-triphosphate; PI(4,5)P2: 
phosphatidylinositol (4,5)-bisphosphate; SIK2: salt inducible kinase 2; SOS: son of sevenless; 
SREBP1: sterol regulatory element-binding protein 1; S6K: ribosomal protein S6 kinase; TSC2: 
tuberous sclerosis complex 2.  
 
 
As illustrated in figure 2, the downstream effects of Akt activation are 
numerous and diverse. For instance, mTORC2-mediated serine phosphorylation of 
Akt induces hepatic lipid and cholesterol synthesis by activating sterol regulatory 
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element-binding protein 1 (SREBP1). Akt stimulation also results in the inhibition of 
tuberous sclerosis complex 2 (TSC2), thereby up-regulating mTORC1, the other 
mTOR complex. The latter is implicated in an array of cellular functions including 
the modulation of protein synthesis (Sengupta 2010). Moreover, mTORC1 was 
found to induce lipogenesis through promoting the nuclear translocation of Lipin1 
and, in turn, activating SREBP1. The intricacy of the signalling network presently 
described demonstrates the interdependence of the PI3K and the mTOR pathways 
(Sarbassov 2006). 
 
In addition to TSC2 and SREBP1, Akt targets many other mediators of 
metabolic homeostasis. For instance, it hinders the activity of glycogen synthase 
kinase-3β (GSK3β), thus switching on glycogen synthesis via glycogen synthase. It 
also promotes glucose transport through the regulation of Akt substrate of 160 kDa, 
which controls the translocation of glucose transporter type 4 (GLUT4) (Guo 2014). 
Furthermore, Akt is responsible for mediating the expression of many genes by 
modulating the activity of transcription factors such as forkhead box O1 (FOXO1) 
and cyclic adenosine monophosphate (cAMP) response element-binding protein 
(CREB) (Figure 2) (Altarejos 2011). The molecular mechanisms regulated by the 
latter are explored in further detail in Chapter 4. 
 
 
I. 2.   The pivotal role of PI3Ks in the insulin signalling pathway 
I. 2. 1. PI3K classification  
Due to their critical role in the insulin signalling pathway, PI3Ks have been 
identified as potential therapeutic targets in the treatment of metabolic disorders 
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(Engelman 2006). These evolutionary conserved enzymes are divided into three 
classes (I-III) on the basis of sequence homology and substrate preference (Table 2). 
Various isoforms of the catalytic and regulatory subunits can exist depending on the 
organism considered (Figure 3). Members of this family of enzymes are specialised 
in the phosphorylation of the 3’-hydroxyl group of the inositol ring of 
phosphatidylinositol and phosphoinositides. This reaction is at the intersection of 
several intracellular signalling pathways implicated in vesicle trafficking, cell 
metabolism, survival and polarity (Engelman 2006).  
 
Table 2. Substrate preference of PI3K family members in vitro. While, class I PI3K can 
phosphorylate phosphatidylinositol (PI), phosphatidylinositol 4-phosphate [PI(4)P] and PI(4,5)P2 to 
generate phosphatidylinositol 3-phosphate [PI(3)P], phosphatidylinositol (3,4)-bisphosphate 
[PI(3,4)P2] and PI(3,4,5)P3, respectively, class II enzymes preferentially react with PI and PI(4)P and 
class III with PI (Engelman 2006). 
 
Substrate Class of PI3K Product 
PI I, II and III PI(3)P 
PI(4)P I and II PI(3,4)P2 
PI (4,5)P2 I PI (3,4,5)P3 
 
 
With each class of PI3Ks involved in specific cellular functions, class I 
PI3Ks have been shown to mediate growth and metabolism by acting downstream of 
an insulin-like receptor (Figure 2). Such function was conserved throughout 
eukaryotic evolution with corresponding orthologues of class I PI3K pathway 
components found in Caenorhabditis elegans, in Drosophila melanogaster and in 
mammals (LoPiccolo 2008, Vanhaesebroeck 2010, Engelman 2006). As detailed in 
the previous section, class I PI3Ks permits the phosphorylation of Akt through 
activating PDK1 and mTORC2. It also ensures the phosphorylation of other kinases, 
such as protein kinase C (PKC), key in modulating cell growth and metabolism in 
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Figure 3. Domain structures of PI3K family members. Class I PI3Ks are composed of a regulatory 
and a catalytic subunit. Class IA consists of a p85 regulatory subunit counting three isoforms (p85α, 
p85β and p55γ) and a p110 catalytic subunit also comprising three isoforms (p110α, p110β and 
p110δ). Class IB is formed of a regulatory subunit (p101, p84 and p87PIKAP) and a single isoform of 
the p110 catalytic subunit, p110γ.  Class II, on the other hand, counts only a single p110-like subunit 
existing as three isoforms (PIK3C2α, PIK3C2β and PIK3C2γ). Lastly, Class III is represented by a 
single member, vacuolar protein-sorting defective 34 (VPS34) (Engelman 2006). Permission to 
reproduce this figure has been granted by Springer Nature. 
 
 
I. 2. 2. The consequences of blunted PI3K signalling 
A large body of studies has investigated the metabolic consequences of 
blunted PI3K signalling and established a direct link of causality with the 
development of insulin resistance (Guo 2014). The down-regulation of PI3K activity 
can be attributed to the over-consumption of SFAs and in particular palmitate (Hla 
2014). Found in abundance in Western diets, this SFA serves as primary substrate 
for synthesis of ceramides, lipid molecules composed of a sphingosine base linked to 
a fatty acid (FA) (Hla 2014). Although alternative theories exist to explain palmitate-
induced insulin resistance, recent studies propose that the deleterious effect 
associated with this SFA results from its promoting the synthesis of a specific 
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species of ceramide (C16:0) found to be involved in the attenuation of PI3K signalling 
(Hla 2014).  
 
Indeed, Turpin and colleagues report an elevation of C16:0-ceramide levels in 
mice fed a high-fat diet (HFD), along with an increased expression of ceramide 
synthase 6 (CERS6), the enzyme involved in C16:0-ceramide production (Turpin 
2014). Deleting this enzyme, not only reduced C16:0-ceramide levels, but also 
protected the mice from diet-induced obesity and glucose intolerance. In line with 
these findings, the insulin-stimulated phosphorylation of downstream effectors of 
PI3K, Akt and GSK3β, were reportedly enhanced in the liver of knockout CerS6 
mice compared to wild type (WT) (Turpin 2014). In addition, evidence indicates that 
C16:0-ceramide antagonises mitochondrial electron transport inducing the suppression 
of β-oxidation and obesogenic symptoms such as hindered FAs disposal (Figure 4) 
(Turpin 2014). This is consistent with the findings of Hommelberg and colleagues 
showing that palmitate induces the accumulation of diacylglcerol (DAG) in insulin-
resistant skeletal muscle cells (Hommelberg 2011). This lipid metabolite plays a 
critical role in insulin signalling as the increase in its intracellular concentration 
drives the activation of PKC in both hepatocytes and skeletal muscle cells. PKC then 
hinders IRS1 and IRS2 tyrosine phosphorylation required for PI3K induction thereby 




Figure 4. The stimulation of C16:0-ceramide synthesis induced by a high-fat diet (HFD) in the context 
of insulin resistance. Palmitate from HFD promotes the synthesis of C16:0-ceramide in two ways: 
firstly, it serves as primary substrate in the pathway and secondly, it directly stimulates the activity of 
ceramide synthase 6 (CERS6), which catalyses the conversion of sphinganine to C16:0 
dihydroceramide. The production of C16:0-ceramide inhibits Akt as well as the electron transport chain 
in the mitochondria, driving a rise in the accumulation of triacylglycerols (TAGs) in the cell. 
 
 
Investigating the consequences of blunted PI3K signalling, the work of 
Foukas and colleagues has highlighted the pivotal role of p110α – one of three 
isoforms of the catalytic subunit of class IA PI3K (p110) (L. C. Foukas 2006). 
Having generated a strain of mice carrying a loss-of-function mutation of p110α 
(D933A), they observed that while homozygosity caused embryonic lethality, the 
heterozygous genotype was associated with a substantial attenuation of the signalling 
mediated by insulin-receptor substrate proteins (L. C. Foukas 2006). As expected, 
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this translated phenotypically by pre-diabetic symptoms such as hyperinsulinemia, 
glucose intolerance, hyperphagia and increased adiposity in young mice. 
Unexpectedly, their results focusing on the long-term effects of reduced p110α 
signalling revealed an age-dependent beneficial impact on metabolism overriding the 
negative short-term effects in early life (L. B. Foukas 2013). Consistent with this, a 
recent study demonstrated that treatment of obese mice and rhesus monkeys with 
pharmacological inhibitors of PI3K resulted in a considerable reduction of adiposity 
and liver steatosis (Ortega-Molina 2015). The positive effect of long- term p110α 
inhibition points to potential isoform specific interventions in T2D treatments.  
 
 
I. 3.   The importance of adipose tissue in insulin resistance 
I. 3. 1. Adipose tissue, an endocrine organ involved in the 
regulation of energy homeostasis  
 Across eukaryotes, lipid droplets can be found as a form of energy storage. 
Vertebrates, however, are the only subgroup having evolved specialised lipid storing 
cells named adipocytes (Rosen 2014). These cells are found in abundance in adipose 
tissue, which is also composed of additional cell types described as the stromal 
vascular fraction, including stem cells, pre-adipocytes, endothelial cells and immune 
cells such as neutrophils and macrophages (Rafols 2014). Pre-adipocytes In 
mammals, two distinct types of adipose tissues exist: brown adipose tissue (BAT) 
and white adipose tissue (WAT). Adipocytes observed in the latter are characterised 
by a unique large lipid droplet accounting for over 95% of the cellular mass and 
significantly fewer mitochondria compared to BAT. Therefore, it was traditionally 
understood that while BAT was mainly involved in thermogenesis, WAT was an 
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inert organ specialised in fat storage. However, evidence is accumulating in favour 
of a more complex role of WAT (Coelho 2013). Indeed, as reviewed by Zwick et al., 
WAT exerts a range of organ- and tissue-specific functions. For instance, it buffers 
mechanical shock when adjacent to a skeletal structure. WAT depots at the surface 
of the skin and intestine also appear to be a critical player in systemic immune 
response by sensing and responding to bacterial infection (Zwick 2018).  
 
Aside from these organ-specific functions, WAT has surfaced as a 
metabolically dynamic organ, pivotal in glucose and lipid metabolism (Rosen 2014). 
It is in fact the largest endocrine tissue in the human body with cells able to secrete 
various hormones, growth factors, enzymes and cytokines, known as adipokines 
(Coelho 2013). Discovered in 1994, leptin - encoded by the notorious ob gene - was 
the first adipocyte-derived factor identified (Y. P. Zhang 1994). This anorexigenic 
adipokine is sensed by the central nervous system, as well as some peripheral tissues 
where it promotes energy expenditure. Regulation of leptin secretion is mediated by 
a mosaic of factors, some stimulating it, such as glucose, amino acids, insulin and 
overfeeding; others inhibiting it, for instance, free fatty acids (FFA), thyroid 
hormones and fasting (Moon 2013). Interestingly, intrinsic differences in leptin 
expression levels exist between adipose tissue depots. For example, the adipokine is 
synthesised in larger quantities in subcutaneous compared to visceral fat (Coelho 
2013).  
 
Since the discovery of leptin, a large number of additional adipocyte-secreted 
factors have been identified, such as adiponectin. Evidence support that this 30 kDa 
peptide exists as three individual complexes: a high-molecular weight complex, a 
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low-molecular weight complex and a trimeric one. Schraw and colleagues 
demonstrated plasma concentration of the former to be inversely correlated with fat 
mass in human subjects (Schraw 2008). In the liver, adiponectin promotes insulin 
sensitivity as well as FA oxidation, while hindering hepatic glucose production along 
with the influx of FFA. Meanwhile, in skeletal muscles, the adipokine induces 
glucose uptake and FA oxidation. Similarly to leptin, the effect of adiponectin is also 
mediated through the hypothalamus, which enables it to stimulate appetite and 
down-regulate energy expenditure (Coelho 2013).  
 
More recently discovered is resistin, a short peptide of 108 amino acids 
(Steppan 2001). As with leptin, the expression of this adipokine is depot-specific. 
However, in the case of resistin, expression levels are significantly greater in visceral 
compared to subcutaneous adipose tissue (Kershaw. E. and Flier 2004). In vivo 
experiments indicate that resistin impairs glucose tolerance, a metabolic effect 
thought to reflect the ability of the peptide to antagonise insulin action and hinder its 
downstream signalling (Steppan 2001). 
 
Aside from adipokines, adipose tissue also secretes various pro-inflammatory 
cytokines such as tumour necrosis factor α (TNFα) (Kershaw. E. and Flier 2004). In 
its circulating form, TNFα is a 17 kDa peptide produced by adipocytes as well as 
macrophages present in the stromal vascular fraction. As evidenced by Ruan and 
colleagues, this cytokine is able to modulate gene expression in various target 
tissues, including adipose tissue and the liver (H. M. Ruan 2002). Indeed, having 
infused rats with TNFα, they recorded significant alterations in adipocyte gene 
expression profile, promoting FFA, glucose and cytokine release (e.g. adiponectin 
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and interleukin-6 [IL-6], another pro-inflammatory cytokine secreted by adipose 
tissue), while also suppressing transcription factors implicated in adipogenesis and 
lipolysis. In addition, such intervention stimulated FFA and cholesterol synthesis 
through changes in liver gene expression (H. M. Ruan 2002). Furthermore, TNFα 
has been demonstrated to directly interfere with insulin signalling through the 
indirect inhibition of IRS1 and IRS2. This effect was found strengthened by TNFα-
mediated increase in FFA serum concentration, which, as discussed in the previous 
section, also impairs insulin signalling (Kershaw. E. and Flier 2004). 
 
The ability of adipose tissue to secrete factors such as leptin, adiponectin, 
resistin, TNFα and IL-6 positions this organ as a key modulator of energy 
homeostasis and metabolism. Importantly, this organ not only secretes a biochemical 
message but is also able to sense and integrate those emitted by other endocrine 
organs. This crosstalk is mediated through the variety of receptors expressed in the 
adipose tissue, which also enables responses to external cues. Such receptors are 
specific for endocrine hormones such as insulin, glucagon and growth hormone, but 
also bind some of the aforementioned cytokines, including leptin, IL-6 and TNFα 
(Kershaw. E. and Flier 2004). In addition, adipocytes were found to express β- and 
α-adrenergic receptors (β-ARs and α-AR), thus permitting catecholamine-induced 
lipolysis to occur within their lipid droplet. This three-step metabolic process, which 
ensures the breakdown of triacylglycerol (TAG) into glycerol and FA, will be the 
further explored in Chapter 4. Thus the capacity of adipose tissue to integrate and 
respond accordingly to the metabolic status of the whole body makes it a critical 




I. 3. 2. Adipose tissue in obesity  
An outstanding characteristic of adipose tissue is its ability to expand unlike 
any other non-neoplastic tissues. This can occur through two distinct processes: 
hypertrophy, by which individual cells becomes larger, or hyperplasia, which 
describes the recruitment of new adipocytes (Rosen 2014). In humans, over-nutrition 
induces hypertrophy up to the critical threshold of 0.7-0.8 μg per cell across depots. 
Past this weight, Krotkiewski and colleagues were able to establish that the number 
of fat cells rapidly rises, marking the onset of hyperplasia (Krotkiewski 1983). 
Location of fat depots may also influence the type of process at play, with evidence 
indicating hypertrophy to be involved in the expansion of upper body subcutaneous 
fat, while hyperplasia appears to mediate the plasticity of depots found in the lower 
body (Tchoukalova 2010).  
 
Obesity is a direct consequence of overfeeding and is defined by the World 
Health Organisation as an “abnormal and excessive fat accumulation that may impair 
health” (World Health Organisation n.d.). Body mass index (BMI), which integrates 
measures of an individual’s weight and height, is the most commonly used tool to 
diagnose obesity. Such index is associated with mortality following a U-shaped 
distribution. The minimal mortality corresponds to the healthy BMI range of 18.5 to 
25 kg/m3. Values below the lower end of this interval are defined as underweight, 
while those beyond the top end are classified as overweight. Above a BMI of 30 
kg/m3, an individual is recognised as obese (M. a. Muller 2017). It is important to 
note the limitation of this index in the diagnosis of obesity as it fails to provide 




At the cellular level, the expansion of adipose tissue in the context of obesity 
has a considerable impact on the endocrine function of the organ and is associated 
with the onset of insulin resistance. This is clearly illustrated by the metabolic effects 
of genetic leptin deficiency: the ob/ob mouse, unable to successfully synthesise 
leptin, develops early-onset obesity, while also exhibiting hyperphagia, insulin 
resistance and diabetes (Moon 2013). After two weeks of daily intraperitoneal 
injections of recombinant leptin, Halaas et al. recorded a 30% reduction in the body 
weight of the mutant mice while the WT strain was not affected by the intervention 
(Halaas 1995). In contrast, diet-induced obesity is characterised by increased 
circulating leptin levels, which are found to diminish with caloric restriction and 
weight loss (Kershaw. E. and Flier 2004). 
 
Aside from leptin, the secretion of many additional adipokines is affected by 
obesity. Adiponectin plasma concentration, for instance, decreases in obesity and is 
restored after weight loss. An inverse correlation also exists between the total 
concentration of this adipokine and both circulating glucose and TAG levels, insulin 
resistance as well as visceral fat accumulation (Nigro 2014). Administration of 
recombinant adiponectin was reported to rescue these phenotypes (Kershaw. E. and 
Flier 2004). Further validating the importance of adiponectin in the modulation of 
insulin signalling, Combs et al. reported that a transgenic over-expression of the 
peptide in rodents resulted in enhanced insulin sensitivity and glucose tolerance 
(Combs 2004). Similarly, circulating resistin levels were found elevated in murine 
models of diet-induced obesity as well as in genetic models of the condition 
(Steppan 2001). After treatment with recombinant resistin, WT mice exhibited both 
impaired glucose tolerance and insulin resistance. Also vouching for the critical role 
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of adipose tissue in the modulation of systemic insulin sensitivity and energy 
expenditure, a study by Blüher and colleagues reveals that the adipose tissue-specific 
deletion of the IR gene in mice induces the development of obesity and its related 
metabolic dysregulation (Bluher 2002). 
 
Excessive adiposity also alters the secretion of the cytokines previously 
mentioned, TNFα and IL-6. Indeed, plasma concentration of both peptides is 
increased in obesity (Coelho 2013). In the case of TNFα, this up-regulation not only 
impairs insulin sensitivity of local adipocytes but also dampens hepatic and muscle 
insulin sensitivity (Hotamisligil 1993). Corroborating such findings, genetic 
knockout of TNFα or its receptor ameliorates insulin resistance in murine models of 
obesity (H. a. Ruan 2003). IL-6, on the other hand, was shown to hinder insulin 
signalling by down-regulating the expression of elements of its molecular cascade, 
while simultaneously stimulating the expression of suppressor of cytokine signalling 
3 (SOCS3), an inhibitor of IR and IRS1 tyrosine phosphorylation (J. K. Senn 2003).  
 
This obesity-associated rise in pro-inflammatory cytokines is thought to be 
the result of the larger population of M1 macrophages. Unlike the M2 macrophages 
implicated in tissue healing and remodelling, M1 macrophages promote 
inflammation through the secretion of pro-inflammatory cytokines including TNFα 
and IL-6. While M2 macrophages are predominant in lean mice, with obesity the 
M1/M2 ratio shifts in favour of a larger M1 population (Rosen 2014). Histological 
evidence in both obese mice and humans revealed that these cells infiltrated adipose 
tissue to create “crown-like structures” around adipocytes. As macrophage 
infiltration was found particularly pronounced in visceral depots compared to 
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subcutaneous depots, the location of WAT depots is determinant in the profile of 
adipokines produced. This seeds the notion that visceral adiposity may be more 
metabolically detrimental than subcutaneous adiposity (Cinti 2005). In addition to 
macrophages, a mosaic of immune cells was also found to be more abundant in 
obese adipose tissue, including neutrophils, B and T lymphocytes, and each cell type 
was involved in the promotion of insulin resistance (Rosen 2014). Together, these 
findings support obesity as a state of low-grade inflammation. 
 
 
I. 4.   Lipid metabolism in adipocytes 
I. 4. 1. The role of lipolysis in lipid mobilisation 
Obesity not only impacts the hormonal and cytokine profiles of adipose 
tissue, it also alters the metabolism of lipid molecules within adipocytes through the 
promotion of low-grade systemic inflammation. More specifically two processes are 
affected, namely lipolysis and autophagy. The former describes the process by which 
TAG stores are hydrolysed to release FAs and glycerol into the circulation for 
endogenous use, thus allowing cells to cope with starvation. This process takes place 
in all tissues and cells containing lipid droplets in which TAGs accumulate. 
Vertebrates have developed tissues specialised in the deposition and mobilisation of 
TAGs, known as WAT (M. E. Schweiger 2014). By regulating the rates of lipolysis 
and lipogenesis (metabolic formation of fat), WAT maintains a tight control over 
energy homeostasis. The lipolytic process can be broken down into three coordinated 
steps catalysed by individual lipases: adipose triglyceride lipase (ATGL), which 
converts TAG to DAG, hormone-sensitive lipase (HSL), which guaranties the 
hydrolysis of DAG to monoacylglycerol (MAG), and lastly monoglyceride lipase, 
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which generates glycerol from MAG (Figure 5) (J. a. Jocken 2008). Each step of this 
chain reaction releases FAs, which can either enter the bloodstream or migrate to the 
mitochondria to undergo β-oxidation. Alternatively, FAs can be re-esterified to TAG 
using glucose imported in the adipocyte via GLUTs (Altarejos 2011). 
 
Because lipolysis is as critical determinant of cellular energy levels, a range 
of factors is implicated in its regulation. As illustrated by figure 5, WAT lipolysis is 
principally mediated through the release of insulin and catecholamines 
(neurotransmitters including dopamine, epinephrine and norepinephrine) (Kobayashi 
2001). These bind to β-ARs, which induce adenylyl cyclase (AC) activity (Altarejos 
2011). Once activated, the latter catalyses synthesis of cAMP. Increased cellular 
concentration of this secondary messenger allows it to bind to the regulatory 
subunits of protein kinase A (PKA), resulting in the dissociation of the catalytic 
subunits of the kinase. The activated catalytic subunit of PKA then phosphorylates 
HSL at Ser659 and Ser660, permitting its translocation to the lipid droplet where it 
catalyses the second step of lipolysis. In parallel to activating HSL, PKA also 
stimulates lipolytic rates through the phosphorylation of ATGL and perilipin, a 
protein found at the surface of the lipid droplet. This reaction induces a 
conformational change of the protein, which exposes the core of the droplet to p-





Figure 5. Catecholamine-mediated activation of lipolysis. Upon binding of the neurotransmitter to its 
receptors, β-adrenergic receptors (β-ARs), adenylyl cyclase (AC) is stimulated allowing for the 
cellular concentration of cyclic adenosine monophosphate (cAMP) to rise, hence the up-regulation of 
protein kinase A (PKA) activity. The kinase phosphorylates both hormone-sensitive lipase (HSL) and 
perilipin, two enzymes promoting lipolysis. This three-step metabolic process occurring in the lipid 
droplet converts TAG into glycerol and fatty acids (FA) to provide energy to the cell. ATGL: adipose 







I. 4. 2. Autophagy, a process regulated by nutrient concentration 
and energy homeostasis 
The second key metabolic even disrupted by obesity in adipocytes is 
autophagy. It is defined as the catabolic process by which the cell degrades, through 
lysosomal activity, defective or threatening constituents including damaged 
organelles, intracellular pathogens and unfolded proteins (Cahova 2015). Three 
different types of autophagy have so far been characterised namely macro-, micro- 
and chaperone-mediated autophagy. While in macro-autophagy cytosolic 
components are engulfed by the lysosome through the intermediate of a so-called 
autophagosome (a double membrane-bound vesicle), in micro-autophagy, the targets 
are directly absorbed by the lysosome. Both mechanisms are able to cope with large 
cytosolic cargo and can be either selective or non-selective. Chaperone-mediated 
autophagy, on the other hand, has the particularity of relying on the formation of 
protein complex between the target and chaperone proteins recognised by the 
lysosomal membrane receptor lysosomal-associated membrane protein 2A (Glick 






Figure 6. A step-by-step overview of autophagy. The self-degradative process of autophagy is 
initiated by the formation of the isolation membrane, which eventually engulfes the targeted cytosolic 
cargo. At this point, the phagophore interacts with elements of two ubiquitin-like systems: on the one 
hand, autophagy related protein (ATG) 5-ATG12 conjugated complexes (illustrated by black dots), 
and on the other hand microtubule-associated protein 1B-light chain 3 (LC3B-II) (represented by red 
dots). The former is involved in the assymetric recruitment of the later to the membrane, thus 
inducing the curvature around the cargo and the formation of the autophagosome. The outer 
membrane of this organelle fuses with the endosome and in turn the lysosome. The resulting 
autolysosome ensures the degradation of the cargo through the activity of lysosomal hydrolases. It is 
this step of the process that can be inhibited by bafilomycin A1. The building blocks of the digested 
cargo can then be exported to the cytosol for reuse. 
 
 
 Figure 6 provides an overview of the molecular mechanisms at play during 
autophagy. The process is initiated with the de novo formation of an isolation 
membrane, known as phagophore, mostly originated from the endoplasmic reticulum 
(ER) (Biazik 2015). The phagophore extends around the cytosolic cargo, thus 
producing an autophagosome. This double-membrane vesicule is able to fuse with 
the lysosome, unloading its content, which can then be degraded by the lysosomal 
proteases. By-products of autophagy are exported back to the cytoplasm where they 
can be recycled for protein synthesis and used as substrate for adenosine 





Figure 7. Autophagy is regulated by the nutrient-sensing complex mTORC1. If nutrients are scarce, 
mTORC1 is inhibited and no longer hinders autophagosome formation. Autophagy is therefore up-
regulated. mTORC1 activity is also blocked through the stimulation of adenosine monophosphate-
activated serine/threonine protein kinase (AMPK), resulting from the decrease in intracellular 
adenosine triphosphate (ATP) concentration. This kinase promotes TSC2-mediated inhibition of 
Rheb, which would otherwise induce mTORC1. Alternatively, if nutrients are readily available, 
mTORC1 hampers autophagosome formation and down-regulates autophagy. The inhibitory effect of 
TSC2 on Rheb is prevented through the activity of Akt and Erk, which both block TSC2 activity. 
These kinases are stimulated by the rise in insulin levels prompted by the increase in nutrients. 
 
 
Although basal rates of autophagy are maintained in most cell types to 
guaranty the integrity of their organelles and proteins, the homeostatic process can 
be stimulated by variations in nutrients concentration (Glick 2010). Indeed, while 
nutrients are readily available, growth-promoting mTORC1 inhibits autophagosome 
formation. Inversely, amino acid deprivation and hypoxia repress the activity of this 
protein multicomplex, thus prompting a rise in autophagy levels (Cahova 2015). In 
addition, a dip in intracellular ATP ensuing from nutrients depletion stimulates 
adenosine monophosphate-activated serine/threonine protein kinase (AMPK). The 
kinase phosphorylates and activates TSC2, thus further down-regulating mTORC1. 
Indeed, as shown in figure 7, activated TSC2 promotes the inhibition of Rheb, a 
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small Ras-like GTPase found to directly induce mTOR kinase, the core component 
of mTORC1 (Shaw 2009).  
 
Lastly, fluctuations in the activity of downstream effectors of the insulin 
pathway also influence mTORC1 and in turn autophagic rates. For instance, both 
Erk and Akt are able to stimulate mTORC1 by blocking TSC2 activity. Furthermore, 
Akt inhibits the activity of an mTORC1 inhibitor, the proline-rich Akt substrate of 
40 kDa (Shaw 2009). Aside from stimulating mTORC1, Akt also regulates 
autophagy through FOXO1, as this transcription factor was found to mediate the 
transcription of four key pro-autophagic genes: Vps34, Atg12, Atg14 and Gabarpl1 
(H. H. Liu 2009). Overall, inhibition of mTORC1 paired with the dephosphorylation 
of FOXO1 boost autophagic turnover thereby guarantying the availability of amino 
acids necessary for protein synthesis and substrate for metabolism.  
 
 
I. 5.   Transcriptome analysis investigating the impact of p110α 
inhibition on FA-induced insulin resistance  
I. 5. 1. The findings of the transcriptome analysis 
With the advent of bioinformatics, it is now possible to perform high-
throughput transcriptome analyses to identify novel effectors in signalling pathways. 
The present work originates from such an analysis carried out in the Foukas lab 
using ribonucleic acid (RNA) extracted from mouse 3T3-L1 adipocytes. The study 
compared the transcriptome of samples treated with palmitate in the presence or 
absence of a p110α-selective inhibitor (A66) (S. F. Jamieson 2011). Sequencing 
analysis allowed the identification of an array of genes of which expression was 
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altered in response to the treatments. Notably, the expression of a number of genes 
known to be induced by IFN was up-regulated in response to palmitate. This effect 
was abrogated by adding A66 to the SFA treatment (Table 3, the gene list can be 
found in its entirety in table 14). IFNs are cytokines produced by cells in response to 
parasites, viruses, bacteria and tumour cells (S. S.-K. Kaur 2008). Their 
classification relies on the type of receptors mediating their signal: while type I IFNs 
(IFN-α, -β, -o, -ε, -κ, -τ and -δ) interact with the IFN-α/β receptor (IFNAR), type II 
IFN (IFN-γ) requires IFN-γ receptor (IFNGR) and type III IFNs (IFN-λ1, IFN-λ2, 
IFN-λ3 and IFN-λ4) are specific to IFN-λ receptor complex, formed of the specific 
IFN-λ receptor chain 1 and the shared IL-10 receptor chain 2 (De Weerd 2007, 
Vilcek 2003, Wack 2015). Of the genes presented in table 3, all but Iigp1, induced 
by IFN-γ, are stimulated by type I IFN (Uthaiah 2003). 
 
The downstream signalling of each type of IFN has been studied extensively 
since the early 1990s (L. Platanias 2005). Hundreds of genes mediating a range of 
biological responses were found induced by these cytokines, with some genes 
regulated by more than one type of IFNs and others modulated by a specific type of 
IFN. Of the many IFN-dependent pathways, the Janus kinase (JAK) -STAT cascade 
has been the most extensively studied. Evidence supports its involvement in various 
biological processes, such as immune responses, cellular differentiation and the 
regulation of energy homeostasis (Richard 2014).  As illustrated by figure 8, type I 
IFN receptor IFNAR was found to engage the JAK1 and tyrosine kinase 2 (TYK2), 
while evidence supports that IFNGR associates with JAK1 and 2. These tyrosine 
kinases are responsible for the phosphorylation of the cytoplasmic STAT 
transcription factors, more particularly, STAT1, STAT2, and STAT3 in most cell 
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types and STAT4, STAT5A, STAT5B and STAT6 in certain types. Once activated, 
the STAT proteins dimerise and translocate to the nucleus to initiate transcription by 
interacting with the promoter regions of ISGs (Ivashki 2014). 
 
Table 3. List of genes modulated by IFN identified by the transcriptome analysis. The name of the 
genes is followed by their symbol, their National Center for Biotechnology Information (NCBI) ID 
and their Ensembl ID in brackets. Ifit: interferon-induced protein with tetratricopeptide repeats; Irf: 

























Interferon regulatory factor 
9, Irf9 (16391) 
[ENSMUSG00000002325] 
Interferon regulatory factor 
7, Irf7 (54123) 
[ENSMUSG00000025498] 
Interferon-induced protein 
44, Ifi44 (99899) 
[ENSMUSG00000028037] 
Interferon-induced protein 
with tetratricopeptide repeats 
1, Ifit1 (15957) 
[ENSMUSG00000034459] 
Interferon stimulated gene 
15, Isg15 (100038882) 
[ENSMUSG00000035692] 
Interferon activated gene 
203, Ifi203 (15950) 
[ENSMUSG00000039997] 
Interferon inducible GTPase 
1, Iigp1 (60440) 
[ENSMUSG00000054072] 
Interferon induced protein 
with tetratricopeptide repeats 








For instance, type I IFN induces the formation of STAT1/STAT2 
heterodimers, which can then form a tri-molecular complex with IRF9, known as 
ISG factor 3 (ISGF3). By interacting with a unique consensus sequence, IFN-
stimulated responses element (ISRE), ISGF3 regulates the transcription of a subset 
of ISGs involved in the cell’s antimicrobial response (Schoggins 2011). 
Alternatively, both type I and II IFN can induce the formation of other STATs 
dimers, such as STAT1 or STAT3 homodimers. These bind gamma-activated 
sequences (GAS) present in the promoter of certain ISGs, thereby initiating the 
transcription of these pro-inflammatory genes (L. Platanias 2005). As reviewed by 
Ivashki and Donlin, the pleiotropic nature of type I and type II IFN-mediated 
signalling is likely to reflect the wide range of STATs activation patterns triggered 
by the interaction of IFN receptors with the STAT family members (Ivashki 2014). 
 
The set of genes regulated by type III IFNs and type I IFNs overlap and 
promote a strong antiviral state in cells. However, while most nucleated cells 
respond to type I IFNs, only cells found in tissues with a high risk of viral exposure 
and infection - such as the cells of mucosal epithelial tissues - respond to type III 
IFNs (Wack 2015). This permits the host to limit inflammatory cost to only certain 
tissues. Upon ligand binding, the IFN-λ receptor complex activates JAK1 and 
TYK2, similarly to IFNAR. This allows the recruitment and phosphorylation of 
STAT1 and STAT2, which interact with IRF9 to form the tri-molecular complex 
ISGF3 also induced by type I IFN (Zhou 2007). Thus, despite being mediated via 
different receptors, similar transcriptional responses are promoted by type I and type 
III IFN. Nevertheless, the dynamism of the gene expression differs between the two 
types of cytokines. Indeed, as revealed by Bolen et al., the induction driven by IFN-β 
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and IFN-λ is significantly longer lasting than that mediated by IFN-α (Bolen 2014). 
This difference is thought to reflect the inhibitory activity of ubiquitin-specific 




Figure 8. The downstream signalling of type I, II and III interferons (IFN). Type I IFN interacts with 
IFN-α/β receptor (IFNAR) extracellularly to activate tyrosine kinase 2 (TYK2) and Janus kinase 1 
(JAK1) at the intracellular level. This results in the phosphorylation of signal transducer and activator 
transcription 1, 2, 3, 4, 5 and 6 (STAT1 to STAT6), which then form homo- and heterodimers. The 
STAT1-STAT2 heterodimer binds IRF9 to constitute the IFN-stimulated gene (ISG) factor 3 (ISGF3) 
complex that modulates the transcription of a subset of ISGs by interacting with IFN-stimulated 
response element (ISRE). The other STAT dimers bind gamma-activated sequences (GAS), thereby 
regulating another subset of ISGs. On the other hand, type II IFN docks onto its receptor, IFN-γ 
receptor (IFNGR), inducing the activation of JAK1 and JAK2. In turn, STAT1 is stimulated and 
homodimerises in order to translocate to the nucleus where it can bind GAS. Type III IFNs 
specifically induce the dimerisation of STAT1 and STAT2 through the IFN-λ receptor (IFNLR)-
mediated activation of TYK2 and JAK1. This drives the formation of ISGF3 and in turn the 
transcription of a subset of ISGs also induced by type I IFNs. * Possible STAT homodimers: STAT1, 
STAT3, STAT4, STAT5 and STAT6; possible STAT heterodimers: STAT1/STAT2, STAT3, STAT4 
or STAT5; STAT2/STAT3 and STAT5/STAT6 (Hervas-Stubbs 2011). 
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I. 5. 2. IFNs as key players in insulin resistance 
Interestingly, PI3K was reported to play a key role in IFN-mediated 
signalling. As early as 1995, Uddin and colleagues established the ability of IFN-α to 
stimulate the tyrosine phosphorylation of IRS1 and promote the association of PI3K 
with the latter (S. Y. Uddin 1995). The following year, this group reported similar 
effects of IFN-α and -β on IRS2, while type II IFN was found to activate PI3K 
signalling in an IRS-independent manner (L. U. Platanias 1996). Interestingly, type I 
IFN-mediated activation of PI3K was reported to be STAT-independent, hence 
suggesting an absence of interplay between the PI3K and STAT pathways in IFN 
signalling (S. M. Uddin 2000). However, Nguyen and colleagues established that 
phosphorylation of STAT1 Ser727 by IFN-γ requires PI3K and Akt activity (Nguyen 
2001). Consistently, subsequent studies found that PKC-δ, one of fifteen isoforms of 
PKC known to be activated by PI3K, was stimulated following both type I and II 
IFN treatments and formed a complex with STAT1 (Deb 2003, S. S. Uddin 2002). In 
addition, both pharmacological and genetic inhibition of PKC-δ blocked STAT1-
mediated gene transcription through GAS or ISREs. 
 
This link with PI3K resonates with the body of work advocating IFNs as key 
players in the development of insulin resistance. Veikko and colleagues provided an 
initial line of evidence supporting this theory with their insulin-clamp studies 
establishing that IFN treatment induce impaired glucose tolerance and insulin 
sensitivity in the context of viral infections (Koivisto 1989). More recent 
publications shed light on the molecular mechanisms at play by establishing that 
type II IFN treatment impairs insulin signalling through the down-regulation of IR, 
IRS1 and GLUT4 and the reduction of phosphorylation levels of Akt (p-Akt) in 
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human and mouse adipocytes (McGillicuddy 2009). This seemingly contradicts the 
early study of Platanias and colleagues, which supported an IRS-independent 
activation of PI3K by IFN-γ (L. U. Platanias 1996). The insulin resistance triggered 
by IFN-γ treatment is likely to reflect a sustained activation of STAT1 and SOCS1 
and to a lesser extent of STAT3 and SOCS3 (McGillicuddy 2009). SOCS proteins 
are known to be involved in a negative feedback loop which minimises the 
amplitude of type I IFN responses and thereby avoiding potential toxicity for the 
host cell. They are indeed able to compete with STATs for binding of IFNAR and 
suppress JAK activity (Ivashki 2014). 
 
 
I. 5. 3. ISGylation, an event analogous to ubiquitination 
Isg15 became of particular interest in the present investigation because the 
aforementioned transcriptome analysis evidenced that its expression was affected by 
the A66 treatment in mouse adipocytes. Furthermore, the nature of the peptide 
encoded by this gene, discussed in this section, led ISG15 to be identified as a 
potential modulator of the pathways regulating adipocyte metabolism discussed so 
far. Isg15 is one of the most strongly induced ISGs by IFN-α and –β, pathogen 
infections and lipopolysaccharide (LPS) (Pohl 2012). Studying human corneal cells, 
Taylor and colleagues also identified IFN-γ as a stimulus for ISG15 production. 
However, the response to type II IFN was delayed and less intense compared to that 
elicited by type I IFN with ISG15 production peaking 24 h later in response to IFN-γ 
treatment (Taylor 1996).   
 
As illustrated by figure 9, the 17 kDa peptide encoded by this gene is 
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characterised by two ubiquitin-like domains prompting a comparison to di-ubiquitin 
(Sadler 2008). In a sequence of biological events analogous to ubiquitination, ISG15 
has the specificity of being able to conjugate to over 200 cellular proteins (Dai 
2011). Indeed, ISG15 has the ability to conjugate to a large number of proteins via a 
reaction similar to ubiquitination, know as ISGylation (Zhang 2011). Thus, ISG15 is 
likely to affect the activity of various cellular processes including those mediated by 
palmitate. In addition, a cytokine role has emerged for unconjugated ISG15, which 
could be another way by which this peptide could alter SFA-dependent cellular 
processes. This topic will be discussed in depth in Chapter 5. (D. a. Zhang 2011) 
 
A. B.  
Figure 9. A. The tertiary structure of murine ISG15. The ribbon diagram of Narasimhan et al. shows 
the two ubiquitin-like domains of ISG15 characterised by a so-called β-grasp fold. The N-terminus (in 
blue) is connected to the carboxyterminus (in red) by a hinge (in green). The last four residues of the 
C-terminal are disordered and unresolved, suggesting a highly flexible region. B. Overlay of the 
structures of the N-terminus (in blue), the carboxyteminus (in green) and the ubiquitin structure (in 
pink) revealing the similarity of the three folds. Each includes a five-strand mixed β-sheet within 
which is found a three-turn α-helix, along with two 310 helices (Narasimhan 2005). Permission to 





 I. 6.   Hypothesis and aims of the investigation 
 
The experiments presented herein were formulated to test the hypothesis that 
palmitate-induced insulin resistance is mediated through effectors of the IFN 
pathway, such as ISG15. To validate this hypothesis, the present work aimed at 
identifying the mechanism underlying development of insulin resistance by dietary 
FA and the impact of insulin pathway activity on this process. The study used two 
cell-based models: the extensively used murine 3T3-L1 adipocyte model and 
primary human multipotent adipose-derived stem (hMADS) as a human model to 
further ascertain the therapeutic potential of the findings. Experiments were 
performed in both pre-adipocytes and differentiated cells as both cell types are 
present in adipose tissue. The goals of the investigation can be summarised as 
follows: 
1) Characterise the signalling pathways shown by transcriptome analysis to be 
affected by FA in a PI3K dependent manner. 
2) Test the effect of inhibition of specific PI3K isoforms on SFA-induced 
insulin resistance. 








II. 1.   Procedures in mammalian cell culture  
II. 1. 1. Cell lines and culture media 
Two cell lines were used: 3T3-L1 derived from mouse and hMADS. While 
the former were kept in 10% calf serum/Dulbecco’s modified eagle’s medium 
(DMEM) supplemented with penicilin/streptomycin (P/S) (both from Life 
Technologies, Gibco), the latter were grown in complete media (Lonza) (see 
appendix VII. 1 for media preparation). Cells were cultured in sterile cell culture 
filter cap T75 flasks (Greiner Bio-One, Cellstar) and kept at 37ºC in a Binder C 150 
incubator with 5% CO2. At approximately 80% confluency, the cells were sub-
cultured following the protocol below.  
 
Sub-culturing 3T3-L1 cells:  
The following manipulations were performed using aseptic techniques. Fresh 
medium was pre-heated for 30 min in a 37ºC water bath: 
1. When the desired confluency was reached, the media was discarded and 
replaced by 10 mL of sterile phosphate buffered saline (PBS) (Life 
Technologies, Gibco). After gently tipping the flask a few times, the PBS was 
discarded. 
2. 2 mL of trypsin-ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich) 
were added to the culture, rolling the flask to ensure contact with all cells. 
The flask was incubated at 37ºC until full cell detachment was achieved. 
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3. As soon as the cells detached, 8 mL of culture media was added for a total 
volume of 10 mL. The suspension was pipetted up and down to ensure 
homogeneity. 
4. The volume of suspension necessary to achieve the desired split ratio was 
discarded and fresh medium was added for a total volume of 15 mL. 
Homogeneity was maintained by pipetting up and down.  
5. The cells were returned to the incubator. 
 
Sub-culturing hMADS:  
These cells were sub-cultured according to the protocol of Rodriguez and colleagues 
and Zaragosi and colleagues (Zaragosi 2006, Rodriguez 2005). Human fibroblast 




II. 1. 2. Adipocyte differentiation  
See appendix VII. 2 for preparation of reagents and differentiation media. 
Cells were plated in 6-well NuncTM Cell-Culture Treated 6 dishes (Thermo Fisher 
Scientific), in NunclonTM Delta cell culture dishes (10 cm in diameter, a.k.a 10 cm 
Ø) (Thermo Fisher Scientific) or in Cellstar cell culture dishes (6 cm Ø) (Greiner 
Bio-One, Cellstar®). 
 
3T3-L1 adipocytes differentiation:  
1. Cells were plated in 10% fetal bovine serum (FBS)/DMEM high glucose 
(HG) supplemented with P/S (Life Technologies, Gibco) and incubated at 
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37°C in a Binder C 150 CO2 incubator. 
2. After two days post confluency, the cells were stimulated with methyl-
isobutyl-xanthine, dexamethasone, insulin (MDI) induction media (day 0), 
resulting in a distinct change in the morphology of the cells in the next two 
days.  
3. Two days after the addition of the MDI induction media was replaced with 
insulin media. 
4. Two days later the media was changed to 10% FBS/DMEM (HG) 
supplemented with P/S. Media was then replaced every two days until full 
differentiation was achieved by day 8.  
 
hMADS adipocytes differentiation: 
1. Cells were plated in hMADS complete media supplemented with human 
FGF2 and incubated at 37°C in a Binder C 150 CO2 incubator. 
2. After two days post confluency, the media was replaced to hMADS complete 
media without FGF2. 
3. The following day, the cells were stimulated with hMADS differentiation 
media.  
4. Three days later, the media was switched to hMADS differentiation media 
without 3-isobutyl-1-methylxanthine (IBMX) or dexamethasone, which was 







II. 1. 3. Cell treatments 
Both mature and pre-adipocytes were washed with PBS before treatments. 
The latter were treated once 80% confluency was reached. PBS was then aspirated 
and replaced with pre-warmed medium. The chosen treatment was then carried out. 
Suppliers and protocols for stock solutions of palmitate, IFN, LPS, inhibitors, insulin 
and isoproterenol are summarised in table 4. Following treatment, the cells were 
placed on ice and washed with ice cold PBS. 1% Triton X (TX)-100 lysis buffer was 




















Table 4. The reagents used for cell treatments, the company they were purchased from, the solvent 
used to dilute them and the concentrations of stock and working dilutions. * Note two successive 
working dilutions were made to carry out the isoproterenol treatment. 
 
 Purchased from Solvent Stock concentration Working dilution 
Recombinant IFN-α murine BioLegend MilliQ water 
100 ng/μL 
(2 - 10 × 107 U/mg) 
5 ng/μL 
Recombinant IFN-α 2A 
human 
PeproTech MilliQ water 
100 ng/μL  
(≥ 5 × 106 U/mg) 
5 ng/μL 
Recombinant IFN-γ murine PeproTech MilliQ water 
100 ng/μL  
(≥ 5 × 106 U/mg) 
5 ng/μL 
Recombinant IFN-γ human PeproTech MilliQ water 
100 ng/μL  
(≥ 2 × 107 U/mg) 
5 ng/μL 
Recombinant IFN-λ 2 murine PeproTech MilliQ water 100 ng/μL 5 ng/μL 
Recombinant ISG15 human Sino Biological MilliQ water 100 μg/μL 50 μg/μL 
LPS Sigma-Aldrich PBS 1 mg/mL 10 ng/μL 
A66 Tocris Bioscience DMSO 10 mM 1 mM 
D030 (IC87114) Symansis DMSO 10 mM 1 mM 
TAK 242 Cayman Chemical DMSO 10 mM 1 mM 
Myriocin Cayman Chemical DMSO 10 mM 1 mM 
Bafilomycin A1 Cayman Chemical DMSO 1 mM 5 μM 
C16 Cayman Chemical DMSO 10 mM 1 mM 
Bovine insulin Sigma-Aldrich MilliQ water 1 mM 10 μM 
Human insulin Sigma-Aldrich MilliQ water 1 mM 10 μM 
Isoproterenol Sigma-Aldrich MilliQ water 10 mM 







II. 1. 4. Quantitative immunoblot analysis 
Cell lysis and protein content quantification: 
1. The cells were scraped off the dish in lysis buffer and transferred into pre-
cooled eppendorf tubes. 
2. The suspension was centrifuged at 13,300 g at 4ºC in an AccuSpin Micro 
17R centrifuge (Fisher Scientific) for 5 min. 
3. The concentration of protein in the supernatant was determined using either 
the Quick Start Bradford or the Pierce bicinchoninic acid protein assay kits 
(Bio-Rad). The absorbance of the samples was measured using an Infinite 
M200 multimode reader (Tecan) coupled with Magellan 6 software for data 
analysis.  
4. Sample protein concentrations were standardised using 1% TX-100 buffer 
and a solution of electrophoresis sample buffer containing dithiothreitol 
(DTT) (AGTC Bioproducts) was added at a 1:5 ratio (see appendix VII. 5 for 
electrophoresis sample buffer preparation).  
5. The lysates were then heated at 100ºC for 5 min and stored at -20ºC. 
 
Protein separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE): 
See appendix VII. 6 and appendix VII. 7 for gel preparation 10%, 15% SDS 
acrylamide gels and 12% Tris-tricine gels, respectively. Equal amount of lysate 
protein was loaded per lane and 5 μL of Precision Plus Protein All Blue standards 
(Bio Rad). 10% SDS acrylamide gels were run for 2 h at 110 V. To improve the 
resolution of Tris-tricine gels, a lower voltage (60 V) was applied while samples 
were migrating though the stacking to the separating gel. The voltage was then 
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increased to 110 V. 
 
Western blot: 
After discarding the stacking gel, the separating gel was added to the transfer 
stack. The polyvinylidene fluoride membrane used (pore size: 0.45 μm) 
(Immobilon®, Merck Millipore) was activated with methanol (VWR International) 
then rinsed in deionised water and transfer buffer. The transfer was run for 1 h 30 
min at 0.45 A (see appendix VII. 6. D for transfer buffer composition). 
 
Antibody probing and immune-complex detection: 
All subsequent washes and incubations were performed on a see-saw rocker SSL4 
(Stuart): 
1. The membrane was blocked with milk (5% fat-free milk powder diluted in 
Tris-buffered saline – Tween 20 [TBS-T] (Acros Organics)) for 1 h at room 
temperature. 
2. The membrane was then washed in TBS-T three times for 5 min at room 
temperature. 
3. The membrane was incubated overnight with the primary antibody at 4ºC 
(see table 5 for the various primary antibodies used). The protocol for 
preparing the primary antibody solution can be found in appendix VII. 8. 
4. The washes (step 2) were repeated. 
5. The membrane was incubated for 1 h at room temperature with a fluorescent 
secondary antibody diluted in 5% milk (1:5,000). DylightTM 800 Conjugated 
anti-mouse immunoglobulin G (IgG) (H+L) (goat) (Rockland) and Alexa 
Fluor 680 goat anti-rabbit IgG (H+L) (Invitrogen) were used after incubation 
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with a mouse and a rabbit primary antibody, respectively. 
6. The membrane was washed (step 2) and the signal was measured using the 




































β-actin Sigma-Aldrich A2228 Mouse IgG2a 1:5,000 42 
Akt (Pan) (40D4)  CST 2920 Mouse IgG1 1:1,000 60 




LC3B CST 2775 
Rabbit 
antibody 
1:1,000 14, 16 
Perilipin (D1D8) CST 9349 Rabbit IgG 1:1,000 62 
Phospho-Akt (T308) 
(C31E5E) 
CST 2965 Rabbit IgG 1:1,000 60 
Phospho-HSL (S660) CST 4126 
Rabbit 
antibody 




CST 9624 Rabbit IgG 1:1,000 - 
Phospho-STAT1 (S727) 
(D3B7) 
CST 8826 Rabbit IgG 1:1,000 91 
Phospho-STAT1 (Y701) 
(58D6) 
CST 9167 Rabbit IgG 1:1,000 84, 91 






CST 9145 Rabbit IgG 1:1,000 79, 86 




M01 Mouse IgG2a 1:1,000 75 
STAT3 (124H6) CST 9139 Mouse IgG2a 1:1,000 79, 86 
Vinculin Sigma-Aldrich V9131 Mouse IgG1 1:5,000 124 
Total HSL CST 4107 
Rabbit 
antibody 









II. 2.   RNA interference (RNAi) experiments 
 
This section presents the RNAi technique used to silence the target gene 
Isg15. It relies on the delivery of a short hairpin RNA (shRNA) into the cells through 
viral infection. This approach has the benefit of producing long-term silencing of the 
gene and thus allows for experiments to be performed in both pre- and mature-
adipocytes. Figure 10 details the process of producing the two stable cell lines: one 
transduced with the pGIPZ vector carrying the Isg15-targeting shRNA construct and 
the other transduced with the empty pGIPZ vector, used as control. shRNA are 
integrated within the host genome following a reverse transcription step, allowing 
for long-term knockdown of the target gene. Once transcribed, the shRNA 
translocates to the cytosol where it is processed into short interfering RNA (siRNA) 
duplexes by the Dicer enzyme. The oligonucleotides are thus able to associate with 
the target messenger RNA (mRNA), which is then degraded endogenously by the 
RNA-induced silencing complex (Moore 2010). 
 
More specifically, the technique employed to deliver the shRNA within the 
cell is refered to as the calcium phosphate co-precipitation developed in 1973 by 
Graham and van der Eb (Graham 1973). It involves on the formation of a calcium-
phosphate-deoxyribonucleic acid (DNA) co-precipitate from mixing calcium 
chloride in a buffered saline/phosphate solution. The co-precipitate is then dispersed 
onto target cells which engulf the DNA through endocytocis. Calcium phosphate 






Figure 10. Flow chart detailing the process used to produce a stable 3T3-L1 Isg15-knockdown (KD) 
cell line.  The first day, human embryonic kidney (HEK) 293T cells were seeded in two 10 cm dishes. 
The following day, the 3T3-L1 target cells were plated and the HEK 293T cells were transduced with 
the plasmids (including the two packaging plasmids and the pGIPZ-Isg15 shRNA construct or the 
pGIPZ empty vector) using the calcium phosphate co-precipitation method. 24 h post-transduction, 
the media of the HEK 293T cells was changed. On days 4 and 5, the lentivirus-containing supernatant 
of the HEK 293T cells was collected and used to replace the media of the target 3T3-L1 cells. The 
infection of the murine cells included a centrifugation step, thus the name “spinfection”. Because the 
pGIPZ vector includes a turbo green fluorescent protein (turboGFP) reporter, it is possible to monitor 
transduction efficiency (as shown on pictures A, B, C and D included in the figure). Moreover, the 
plasmid counts a puromycin-resistance gene to allow for selection of successfully transduced cells. As 
demonstrated on picture E, the stable cell line produced could be fully differentiated. 
 
 
Day 1: human embryonic kidney (HEK) 293T cells were seeded into two 10 cm 
dishes with 10 mL of 10% FBS/DMEM (HG) supplemented with P/S (Life 
Technologies, Gibco) and incubated at 37ºC  (1.5 million cells per dish);  
 
Day 2: 3T3-L1 target cells were plated in following the protocol below: 
1. When the stock flask of 3T3-L1 reach confluency, wash with 10 mL of PBS 
and add 2 mL of trypsin EDTA. 
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2. Stop the trypsinisation process by adding 8 mL of antibiotics-free 10% 
FBS/DMEM (HG).  
3. Leave 2 mL of the suspension in the stock flask and add 13 mL of 10% calf/ 
DMEM (HG) supplemented with P/S. 
4. Transfer the remaining 8 mL of suspension to a 15 mL falcon tube and 
centrifuge at 1,000 rpm for 5 min using a Multifuge x3R Heraeus (Thermo 
Scientific). 
5. The supernatant was discarded and the cells were resuspended in 5 mL of 
antibiotics-free 10% FBS/DMEM (HG). 
6. The cells were then plated in a 6-well dish at a density of 20 × 103 cells per 
well. 
 
24 h following seeding, the HEK 293T cells were transduced: 
 In a 1.5 mL eppendorf, 61 μL CaCl2 (Sigma-Aldrich) (2 M), 1 μg p8.91 
(Addgene), 1 μg pMDG (Addgene) and either 1.5 μg pGIPZ lentivirus 
expression construct (Dharmacon, see table 6 for details) or 1.5 μg of pGIPZ 
empty vector were diluted to a total volume of 500 μL with MilliQ water (see 
figure 11 for pGIPZ vector elements). 
 This solution was added dropwised to a second eppendrof containing 500 μL 
2X hepes buffered saline (HBS) buffer while forcing air bubles into the mix 
(see appendix VII. 9 for HBS buffer preparation). 
 Following a 20 min incubation at room temperature, the DNA-CaCl2-HBS 




Day 3: 24 h after the transduction, the cells were washed with pre-warmed PBS and 
the medium was replaced to 10 mL of antibiotics-free 10% FBS/DMEM 
supplemented with 1% bovine serum albumine (BSA).  
 
Day 4 and 5: The lentivirus-containing supernatant was harvested 24 and 48 h after 
media change and was used to replace the media of target cells. The media was 
sterile filtered (0.45 μm Minisart filter, Sartorius) and supplemented with Polybrene 
(Sigma-Aldrich) (1:1,000). Target cells are rinced with pre-warmed PBS before 
adding 2 mL of media containing the virus. After changing the media the cells were 
“spinfected” - 45 min at 800 g at 37°C and returned to the incubator. 
 
Day 6: Target cells were returned to 10% FBS/DMEM supplemented with P/S (2 
mL/well) and puromycin (Clontech Laboratories, Inc.) was added to the media (4 
μg/mL). 
 
Table 6. Information on the GIPZ mouse Isg15 shRNA. 
 
Clone ID V2LMM_25376 
Sequence of mature antisense TAAGCGTGTCTACAGTCTG 
Accessions NM_015783 







Figure 11. pGIPZ vector elements (Dharmacon). Short hairpin RNA (shRNA) targeting the gene of 
interest; woodchuck hepatitis post-transcriptional regulatory (WPRE) element to enhance transgene 
expression in the target cells; 3’ self-inactivated long terminal repeat (3’ SIN LTR) for enhanced 
safety when working when lentivirus; SV40 and bGH polyA: mammalian terminator of transcription; 
F1 ori: origin of bacteriophage replication; pUC ori which marks the origin of replication in 
Escherichia coli and SV40 ori allowing this in mammalian cells expressing the SV40 large T-antigen; 
AmpR, ZeoR and PuroR: ampicillin, Zeocin and pruomycin resistance genes allowing for antibiotic-
mediated selection of transduced cells; 5’ long terminal repeat (5’ LTR); Psi (Ψ) packing sequence, 
which permits viral genome packing through lentiviral packaging systems; Rev response element 
(RRE) promoting packaging efficiency of full-length viral genomes thus increasing titre; central 
polypurine tract (cPPT) promotes the translocation of viral vector into the nucleus of non-dividing 
cells; EM7: prokaryotic promoter that allows expression of antibiotic genes; cytomegalovirus (CMV) 
promoter ensuring strong transgene expression; turboGFP reporter, which permits to monitor 
transduction efficiency; internal ribosomal entry site (IRES) which enables the expression of 
turboGFP and PuroR in a single transcript (GIPZ Lentiviral shRNA n.d.). 
 
 
II. 3.   Mass spectrometric analysis of protein ISGylation 
II. 3. 1. Treatments and cell lysis 
3T3-L1 cells were differentiated in NunclonTM Delta cell culture dishes (10 
cm Ø) according to the protocol detailed in section II. 1. 2 of the present chapter. 
Table 7 details the treatments performed on the differentiated cells before processing 
them. The differentiated cells were rinced with PBS and the media was replaced 
before treating them. 
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Table 7. Treatments carried out in 3T3-L1 mature adipocytes before processing them for the mass 
spectrometry experiment. 
 
Dish number Treatment (concentration) Duration (in h) Type of media 
Dish 1 Untreated 12 10% FBS/DMEM 
Dish 2 IFN-α (20 ng/mL) 12 10% FBS/DMEM 
Dish 3 IFN-α (20 ng/mL) 12 10% FBS/DMEM 




Cell lysis and protein content quantification: 
1. Once the treatments completed, the dishes were placed on ice and the media 
was aspirated. Cells were rinsed with ice-cold PBS before lysing in 100 μL 
of buffer (10 mM Tris-HCl, pH 8, 150 mM sodium chloride, 2% SDS, plus 
protease inhibitors used in 1% TX-100 lysis buffer recipe detailed in 
appendix VII. 4). 
2. Cells were scraped off the dishes and transferred into pre-chilled eppendorf 
tubes on ice.  
3. Lysates were passed through a 23 gauge needle to shear the DNA and 
incubated at 100ºC for 5 min. 
4. Lysates were diluted with 900 μL 1% TX-100 lysis buffer. 
5. Suspensions were centrifuged at 13,300 g at 4ºC in an AccuSpin Micro 17R 
centrifuge for 5 min. 
6. The concentration of protein in the supernatant was determined using the 
Pierce bicinchoninic acid protein assay kit. The absorbance of the samples 
was measured using an Infinite M200 multimode reader coupled with 
Magellan 6 software for data analysis.  
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7. Sample concentrations were standardised using 1% TX-100 buffer. For the 
first and second experiments a concentration of 1.4 mg/mL was used and for 
the third experiment a concentration of 0.7 mg/mL was used. The total 
volume was 1 mL for all samples. 
 
 
II. 3. 2. Immunoprecipitation (IP) 
1. The antibodies were added to the samples according to table 8 and the 
samples were incubated for 2 h on a rotator SB3 (Stuart) at 20 rpm at 4ºC. 
2. 15 μL protein-G Sepharose beads (GE Healthcare) were added to each 
sample followed by a second 2 h-long incubation on the rotating wheel at 20 
rpm at 4ºC. 
3. The beeds were washed three times with 0.5 mL lysis buffer, followed by 
three washes with 0.5 mL ammonium bicarbonate (25 mM). 
4. Pellets were stored at -80ºC until transported on dry ice to the mass 
spectrometry laboratory. 
 
Table 8. Summary of the antibodies added to the various samples during the immunoprecipitation 
(IP) experiment. The b3-AR antibody was used as negative control to account for background 
detection. 
 
Treatment (concentration) Antibodies  
Untreated 2 μg ISG15 antibody 
IFN-α (20 ng/mL) 2 μg β3-AR antibody 
IFN-α (20 ng/mL) 2 μg ISG15 antibody 






Table 9. Antibodies used for IPs.  
 





of target (kDa) 
ISG15(F-9) Santa Cruz 166755 Mouse IgG1 15 




II. 3. 3. Mass spectrometry and data analysis 
 The mass spectrometry data was generated by the mass spectrometry lab 
(Barts Cancer Institute, Queen Mary University of London) in collaboration with Dr 
Pedro Cutillas and Dr Vinothini Rajeeve. The data analysis on the protein hits was 
performed using Excel. The signal intensities obtained for a sample incubated with 
an antibody specific for β3-AR (antibody specific to an unrelated target) were 
subtracted to the values obtained for the samples incubated with the ISG15-specific 
antibody as a control for unspecific binding. The database for annotation, 
visualisation and integrated discovery (DAVID) (version 6.8) was employed for 
gene functional classification (Dennis 2003). The search tool for the retrieval of 
interacting genes/protein (STRING) software was used to unravel interactions and 
visualise networks of gene clusters (Szklarczyk 2015). 
 
 
II. 4.   Statistical analysis 
 
Experimental results were reported as averages ± SEM. Differences were 
analysed using one-way and two-way analyses of variance (ANOVA) from IBM 
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SPSS2.2 software package. For the former, Tukey honest significant difference 
(HSD) test was performed as a post hoc test. A p-value < 0.05 was deemed 
significant. For additional insight when the p-value was close to 0.05, a two-tailed 
paired student t-test was used to compare effects of treatments within the same cell 
line or an unpaired t-test when comparing two cell lines. 
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CHAPTER 3.  THE EFFECT OF PALMITATE ON INSULIN AND 




III. 1.   Overview of Chapter 3 
 
As discussed in the introduction, the present work stems from a 
transcriptome analysis, which compared the gene expression profile of 3T3-L1 
adipocytes treated with the SFA palmitate in the presence or absence of a 
pharmacological inhibitor (A66) targeting p110α, one of the catalytic subunits of 
class IA PI3K. The data analysis revealed that the expression of a number of genes 
induced by IFN was stimulated by palmitate and such effect was negated by the 
addition of A66. This chapter presents the preliminary steps towards validating the 
findings of the transcriptome profiling experiment. The groundwork involved 
establishing models of palmitate- and IFN-mediated insulin resistance in both 
murine and human adipocytes. The consequence of p110α inhibition in such models 
was then explored to gain further insight on the findings of Foukas et al. regarding 
the beneficial phenotypic effect of such inhibition in the p110αD933A/WT mice (L. C. 
Foukas 2006). To confirm the interaction between palmitate and the IFN pathway, a 
series of experiments was performed investigating the effect of the SFA on the 
phosphorylation of two downstream effectors of IFN, STAT1 and STAT3. These 
transcription factors were of particular interest as McGillicuddy and colleagues 
demonstrated that IFN-induced insulin resistance is dependent on their sustained 
activation (McGillicuddy 2009). Having demonstrated the palmitate-induced 
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activation of STAT3, further experiments were carried out to probe the molecular 
pathways involved in this crosstalk.  
 
 
III. 1. 1. Aim of Chapter 3  
The aim of the present chapter was to develop a model of both palmitate- and 
IFN-induced insulin resistance. To this end the phosphorylation of a pivotal effector 
of the insulin signalling pathway (Akt) was assessed following treatments with either 
SFA or IFN. In addition, we wanted to verify a potential interaction between the 
palmitate and the IFN pathways. As mentioned previously, this was done through 
monitoring the activation of STAT1 and STAT3 in response to palmitate. A range of 
pharmacological inhibitors was used to shed light on the interaction unveiled 
between palmitate and STAT3. Experiments were performed in both pre- and mature 
3T3-L1 adipocytes and these were mirrored in hMADS adipocytes to further 
ascertain the therapeutic relevance of potential findings. As mentioned in Chapter 1, 
both pre- and mature adipocytes are present in adipose tissue and ensure the 
metabolic function of the organ. Pre-adipocytes have the ability to proliferate and 
differentiate into mature adipocytes. Studying the response of each cell type 
individually provides therefore valuable insight on the molecular mechanism 






III. 2.   Introduction of Chapter 3 
III. 2. 1. The crosstalk between STAT3 and modulators of obesity 
 In Chapter 1, the mechanisms of palmitate- and IFN-induced insulin 
resistance were discussed. In light of the findings of the transcriptome analysis 
indicating the existence of a crosstalk between the two pathways, we hypothesised 
that palmitate-induced insulin resistance was modulated by elements of the IFN 
cascade. As evidenced by McGillicuddy and colleagues, IFN-γ-mediated insulin 
resistance is driven by the sustained activation of STAT1 and to a lesser extent 
STAT3 (McGillicuddy 2009). Therefore, assessing the effect of palmitate on the 
activation of these transcription factors constituted a valid approach to probe a 
potential interaction between SFAs and the interferon signalling.  
 
A body of studies implicates these two transcription factors in the 
pathogenesis of obesity. In the present section, the specific role of STAT3 will be 
explored, focusing initially on the link between STAT3 and adipokines/cytokines 
involved in modulating the development of obesity. For instance, IL-6, which rates 
of secretion are up-regulated in obese individuals, induces the phosphorylation of 
STAT3 in a JAK-dependent manner (Vogt 2011). Furthermore, Jiang and colleagues 
revealed that STAT3 modulated adiponectin expression in cultured 3T3-L1 
adipocytes (C. K. Jiang 2013). Using both chromatin IP and luciferase assays, the 
authors were able to confirm the existence of a functional STAT3-binding site within 
the adiponectin promoter. 
 
In HEK 293T, leptin exposure was found to induce the phosphorylation of 
STAT3 in a biphasic manner including an initial acute phase 15 min following leptin 
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stimulation and a second chronic phase of lesser intensity starting 1 h 35 post-
induction (C. W. Han 2016). The authors were also able to confirm the ability of 
TNFα, another key adipokine implicated in the biochemistry of obesity, to stimulate 
STAT3 phosphorylation. (C. W. Han 2016). The link between leptin and STAT3 had 
been evidenced as early as 1996, when Vaisse and colleagues discovered that the 
adipokine promoted STAT3 activation in the hypothalamus of WT and ob/ob mice 
(Vaisse 1996). Seven years later, Bates et al. confirmed the importance of STAT3 
signalling in leptin-mediated regulation of energy expenditure (Bates 2003). Indeed, 
they observed the onset of obesity and hyperphagia in mice bearing a genetic 
mutation of the leptin receptor long form (Y1138S), a residue known to specifically 
mediate the activation of STAT3.  
 
 In addition to adipokines, the activation of STAT3 was found modulated by 
insulin resistance-inducing nutrients in a variety of metabolic tissues. Indeed, a study 
performed by Kim and colleagues in HepG2 cells demonstrated that silencing stat3 
ameliorated amino acid-mediated suppression of insulin signalling. Furthermore, 
amino acids were found to induce the phosphorylation of STAT3 (J. Y. Kim 2009). 
In WAT and liver, insulin-resistance inducing arginine chronic treatment stimulated 
STAT3 tyrosine phosphorylation in rats (de Castro Barbosa 2009). Relevantly to the 
present work, Oberbach and colleagues evidenced palmitate treatment to enhance 
STAT3 activation in human bladder smooth muscle cells (Oberbach 2010). More 
specifically, the SFA stimulated p-STAT3 Tyr705 levels following an 8 h palmitate 
treatment. However, beyond this time point the SFA had an inhibitory effect on both 
stat3 mRNA and p-STAT3 Tyr705 levels with a maximal down-regulation at 48 h of 
treatment. Inversely, immunofluorescence analysis in cells treated for 48 h with 
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palmitate revealed that both socs3 mRNA and SOCS3 protein expression was 
enhanced in presence of the SFA (Oberbach 2010). The authors postulate that these 
observations manifest the existence of a negative feedback loop mediated by SOCS3 
targeting IL-6 signalling, which concentration they found significantly increased 
following palmitate stimulation at all time points tested.  
 
The effect of palmitate on STAT3 activation was also investigated by Mashili 
and colleagues (Mashili 2013). Having exposed L6 cultured myotubes (derived from 
rat skeletal muscles) to palmitate for 24 h, they noted a significant increase in the 
phosphorylation of STAT3 Tyr705. This was coincident with a stimulation of SOCS3 
expression and a reduction in p-Akt Ser473 levels following insulin stimulation 
compared to untreated control (signifying development of insulin resistance). 
Palmitate-induced activation of STAT3 was sustained after 36 h of treatment. 
Together these results suggest that, at least in skeletal muscle, palmitate-mediated 
insulin resistance is likely to involve a STAT3-dependent mechanism (Mashili 
2013). Aligning with the findings of Mashili and colleagues, Weigert et al. 
demonstrated that a 20 h-long palmitate treatment stimulated both IL-6 protein and 
mRNA expression in a nuclear factor-κB (NF-κB)-dependent manner in human 
myotubes (Weigert 2004). In turn, IL-6 was evidenced to induce STAT3 tyrosine 
phosphorylation.  
 
The study Mashili and colleagues also demonstrates that the sustained 
phosphorylation of STAT3 is determinant in the onset of skeletal muscle insulin 
resistance in T2D (Mashili 2013). Comparing biopsies from overweight, glucose 
tolerant individuals with T2D patients matched for age and BMI, the investigation 
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reveals a 2-fold increase in p-STAT3 Tyr705 in the latter group. Furthermore, a 
positive correlation was observed between plasma FFA levels and skeletal muscle p-
STAT3 concentration, which was negatively correlated with insulin sensitivity in the 
control group (Mashili 2013).  
 
To gain further insight into the metabolic role of STAT3, researchers have 
attempted to knockout stat3 in mice, however no conclusions could be drawn as this 
manipulation induces early embryonic lethality (K. N. Takeda 1997). Instead, tissue-
specific disruptions were performed using the Cre-loxP technique to silence the gene 
during later life. Using this system, Cernkovich and colleagues proceeded to create 
mice bearing an adipocyte-specific disruption of stat3. They reported that the 
transgenic mouse shows increased weight and adiposity linked to adipocyte 
hypertrophy although it does not exhibit hyperphagia or reduced energy expenditure. 
The authors explained these phenotypes through the observed dysregulation of 
leptin-induced lipolysis (Cernkovich 2008). 
 
 
III. 2. 2. The crosstalk between STAT1 and modulators of obesity 
 The role of STAT1 in the context of obesity is mainly understood through its 
interaction with IFN-γ. This cytokine, whose expression is up-regulated in obesity, 
was shown to activate STAT1 (McGillicuddy 2009, Balhoff 1998). IFN-γ-induced 
STAT1 was evidenced to bind the murine promoter of lipoprotein lipase in vitro 
(Hogan 2003). This enzyme is specialised in the hydrolysis of serum TAGs into 
FFAs then stored in fat depots. Both muscle- and liver-specific overexpression of 
lipoprotein lipase in transgenic mice was reported to cause insulin resistance in the 
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corresponding tissues (J. F.-C. Kim 2001). In accordance with these findings, 
Delezie et al. demonstrated that the overexpression of this lipase in muscle and 
adipose tissue promoted obesogenic phenotypes in mice (Delezie 2012). 
 
 In addition to IFN-γ, oncostatin-M was shown to promote the tyrosine 
phosphorylation of STAT1 in 3T3-L1 adipocytes (J. L. Stephens 1998). This 
cytokine, also reported to induce STAT3, belongs to the gp130 family, which 
includes leukemia inhibitory factor (LIF), IL-6, IL-11, IL-27, cardiotrophin-1 (CT-
1), neuropoietin, CT-1-like cytokine and ciliary neurotrophic factor (U. a. White 
2011). Although not secreted by adipocytes, oncostatin-M is produced by the cells of 
the stromal vascular fraction in human adipose tissue, as well as by murine 
macrophages (Sanchez-Infantes 2014). Its release may also be induced by exposing 
neutrophils and dendritic cells to LPS or granulocyte/macrophage-colony stimulating 
factor (Hergovits 2017). Throughout the literature, this cytokine has been associated 
with metabolic dysregulation.  
 
Indeed, it was reported to hinder adipogenesis through the down-regulation 
of peroxisome proliferator-activated receptor-γ (PPARγ) and adiponectin, while also 
promoting insulin resistance in 3T3-L1 adipocytes (U. S. White 2008). Furthermore, 
oncostatin-M was found to stimulate plasminogen activator inhibitor-1 and IL-6 in 
this cell type. The former, expressed by adipose tissue, is associated with the onset of 
T2D as well as being critical in the pathogenesis of obesity (Sanchez-Infantes 2014). 
Sanchez-Infantes et al. established the existence of a positive correlation between 
expression levels of oncostatin-M in human adipose tissue and body weight. 
Inversely, they reported a negative correlation between oncostatin-M and insulin 
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levels. Expression levels of the cytokine were also found increased in epididymal fat 
of ob/ob and HFD-fed mice (Sanchez-Infantes 2014).  
 
Evidence also supports aforementioned LIF to induce STAT1, along with 
STAT3, in 3T3-L1 adipocytes (J. L. Stephens 1998). This gp130 class cytokine is 
synthesised by pre-adipocytes and promotes differentiation through stimulation of 
adipogenic transcription factors PPARγ and CCAAT-enhancer binding proteins 
(C/EBPs) (Aubert 1999). The process of adipogenesis and the role of these 
transcription factors will be further discussed in the following section. LIF was also 
reported to down-regulate the activity of lipoprotein lipase through transcriptional 
regulation in adipocytes (Marshall 1994). In the context of obesity, inhibition of this 
cytokine in mice was associated with the development of glucose intolerance, insulin 
resistance and increased adiposity along with hyperphagia and increased expression 
of pro-inflammatory cytokines including TNFα and IL-6. Collectively, these 
observations support a protective role for LIF in the onset of obesity (Fioravante 
2017). 
 
CT-1, another member of the gp130 family, was also found to activate 
STAT1 and STAT3 in 3T3-L1 adipocytes. Like LIF, CT-1 is anti-inflammatory and 
has been reported to signal through the LIF receptor, resulting in the induction of the 
JAK/STAT cascade (Zvonic 2004). Using a gene targeted ct-1-/- mouse model, 
Moreno-Aliaga revealed that CT-1 is pivotal in the modulation of energy 
homeostasis and metabolism. Indeed, deleting the gene inhibited energy expenditure 
in mice, which also exhibited obesogenic phenotype, T2D and hypercholesterolemia. 
Exposure of ob/ob mice and HFD-fed mice to recombinant CT-1 alleviated 
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symptoms of both obesity and T2D (Moreno-Aliaga 2012). Interestingly, CT-1 
serum concentration was reported to be elevated in obesity potentially in an effort to 
counteract associated metabolic dysfunctions.  
 
In light of these findings, the observations of Zvonic and colleagues seem 
rather unexpected: their study reveals that chronic treatment of 3T3-L1 adipocytes 
with CT-1 hinders the expression of FA synthase and IRS1, while triggering the 
onset of insulin resistance (Zvonic 2004). Moreno-Aliaga et al. address this 
discrepancy focusing on the crosstalk between CT-1 and the STATs cascade known 
to down-regulate insulin signalling: they emphasise that because SOCS3 is 
overexpressed in WAT of murine obese models, the detrimental metabolic effect of 
CT-1 reported by Zvonic et al. is likely to be tissue specific rather than systemic 
(Moreno-Aliaga 2012). In addition, the authors note CT-1 expression is relatively 
low in WAT versus other metabolic tissues such as skeletal muscles. 
 
 Although stat3 deletion causes lethality in mice, stat1 deletion is viable and 
its pathophysiology has been extensively studied in the context of immunity. It is 
only recently that Sisler and colleagues examined the metabolic consequences of 
stat1 deficiency (Sisler 2015). Although no change in body weight was measured 
between the stat1-/- mice and the stat1+/+ control, the former exhibited increased 
adiposity paired with reduced lean mass. During fasting, the authors reported a 
down-regulation of adrenergic-stimulated lipolysis manifested by an impaired lipid 
and glycerol release in the WAT of stat1-/- mice. Paradoxically, these traits coincided 
with enhanced energy expenditure in the knockout model. To explain their 
observations, Sisler et al. propose that FFAs are re-esterified to TAG in the WAT of 
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stat1-/- mice. Furthermore, mitochondrial functions were hindered by the loss of 
stat1. Together, this data suggest a critical role for STAT1 in energy homeostasis, 
TAG turnover and mitochondria biogenesis (Sisler 2015). 
  
 
III. 2. 3. The role of STATs in adipogenesis 
 Collectively, the aforementioned studies demonstrate STATs to be key 
players in the onset of obesity through their role in the regulation of systemic insulin 
sensitivity and inflammation. This role is reinforced by the involvement of these 
transcription factors in adipogenesis, a cellular process describing the differentiation 
of pre-adipocytes into mature adipocytes. Adipocyte development is regulated by a 
number of transcription factors including PPARγ and C/EBPs (K. G. Zhang 2011). 
These transcriptional effectors of adipogenesis modulate different stages of the 
differentiation process: C/EBPβ and C/EBPδ promote the initial mitotic clonal 
expansion phase, while C/EBPα and PPARγ stimulate the terminal differentiation 
phase, characterised by a rise in lipid accumulation and insulin sensitivity (Sarjeant 
2012).  
 
In 1996, Stephens et al. reported a substantial induction of STATs 1, 3 and 5 
during the differentiation of 3T3-L1 adipocytes. The expression of STAT6, however, 
was unchanged. Following TNFα exposure, which stalled the process of 
differentiation, the expression of STATs 1 and 5 was hindered, but that of STAT3 
was unaffected. They concluded that because of the tight correlation of STATs 1 and 
5 to the adipocyte phenotype, these transcription factors were involved in 
adipogenesis (J. M. Stephens 1996). Interestingly, upon differentiation of human 
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subcutaneous pre-adipocytes, Harp and colleagues recorded a decrease in STAT1 
expression, coinciding with an increase in STATs 3 and 5 expression. In line with 
the observations of Stephens et al., they reported STAT6 to be unaffected (Harp 
2001).  
 
The specific role of STAT3 in adipogenesis was further investigated by Deng 
et al. who demonstrated that STAT3 was activated during the proliferative phase and 
that protein inhibitor of activated STAT3 down-regulated adipogenic gene 
expression in 3T3-L1 cells (Deng 2006). Having also established the inhibitory 
effect of suppressing STAT3 on adipogenesis through the use of pharmacological 
inhibitor and siRNA targeting of stat3, Wang and colleagues differentiated 3T3-L1 
pre-adipocytes in the presence or absence of PPARγ agonist troglitazone. The study 
unveiled that troglitazone-induced activation of PPARγ rescued the suppression of 
adipogenesis mediated by STAT3 inhibition (Wang 2009). C/EBPβ was also 
implicated in the modulation of adipocyte differentiation by STAT3. Indeed, 
luciferase reporter assay experiments performed by Zhang et al. identified a direct 
binding of STAT3 to C/EBPβ during the early stages of the adipogenic process (K. 
G. Zhang 2011).  
 
 As discussed in Chapter 1, the study of McGillicuddy and colleagues 
evidenced the ability of IFN-γ to provoke insulin resistance in human adipocytes 
(McGillicuddy 2009). They also reported that the cytokine inhibits adipogenesis and 
lipid storage through down-regulating the expression of PPARγ, FA synthase, 
perilipin and adiponectin. The anti-adipogenic effect of IFN-γ had been reported 
nearly twenty years prior by Grégoire et al. in rodent pre-adipocytes (Gregoire 
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1992). Inhibiting in turn JAK1 and the JAK2 through pharmacological inhibitors 
allowed McGillicuddy and colleagues to conclude that JAK1-STAT1 activation – 
but not JAK2-STAT3 - is critical in the modulation of the anti-adipogenic action of 
IFN-γ. Indeed, blocking JAK1 signalling rescued the effect of the cytokine on 
adipocyte functions, while targeting JAK2 had no effect (McGillicuddy 2009). 
 
 
III. 2. 4. Toll-like receptor 4 (TLR4), a point of overlap in 
palmitate- and IFN-induced pathways 
In addition to investigating the effect of palmitate on the phosphorylation of 
STATs 1 and 3, the present chapter will also focus on a point of overlap between 
palmitate and IFN-γ signaling: TLR4. This 839 amino acids-long peptide is one of 
ten human and twelve murine homologs of type I transmembrane proteins 
characterised by a cytoplasmic domain containing a conserved region (the Toll/IL-1 
receptor domain) and an extracellular domain featuring leucine-rich repeats. While 
most TLRs (including TLR4 and 2) are located on the cell surface, some are found 
on the surface of endosomal/lysosomal compartments (O'Neill 2013).  
 
This class of proteins is principally involved in the induction of inflammatory 
cytokines as part of the immune system in response to various cues. TLR4 has been 
established as the primary receptor for the gram-negative bacterial outer membrane 
LPS (Faure 2001). The binding of LPS requires the association of TLR4 with 
myeloid differentiation factor-2 (MD-2), made distinctive by a β-cup fold, ideal for 
interacting with flat hydrophobic ligands such as LPS. Another modulator of TLR4 
signalling is cluster of differentiation 14 (CD14). This leucine-rich repeat family 
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member recruits LPS to the TLR4-MD-2 complex thus triggering the downstream 
cascade illustrated in figure 12 (B. a. Park 2013). 
 
Upon ligand engagement, TLR4 interacts with its two pairs of adaptor 
proteins: myeloid differentiation primary response 88 (MyD88) and Toll-IL-1 
resistance domain-containing adapter protein (TIRAP), and TIR domain-containing 
adapter-inducing IFN-β (TRIF) and a TRIF-related adapter molecule (TRAM) (Laird 
2009). The recruitment of TIRAP to the membrane requires binding to PI(4,5)P2 and 
allows cytosolic MyD88 to interact with TLR4. Once MyD88 is associated with 
TLR4, IL-1 receptor associated kinase 1 (IRAK1) and IRAK4 are recruited to the 
signalling complex (Laird 2009). While both pairs of adaptors mediate the activation 
of the MAPK and NF-κB cascades, TRIF/TRAM exclusively induces IRF3 
activation and IFN-β production (Schilling 2013). Relevantly to the present work, 
many studies have reported that members of the TLR family are able to stimulate 
class IA PI3K. For instance, Ojaniemi and colleagues provide evidence that TLR4 
promotes the formation of a PI3K-MyD88 complex, which in turn stimulates TLR4 






Figure 12. Overview of the Toll-like receptor 4 (TLR4) signalling pathway. Upon binding of LPS, 
TLR4 activates a pair of adaptor proteins: myeloid differentiation primary response 88 (MyD88) and 
Toll-interleukin-1 resistance domain-containing adapter protein (TIRAP), and TIR domain-containing 
adapter-inducing IFN-β (TRIF) and TRIF-related adapter molecule (TRAM). The former then recruits 
interleukin-1 receptor associated kinase 1 (IRAK1) and IRAK4 to the complex. Both pairs of adaptors 
allow the stimulation of the MAPK pathway and nuclear factor-κB (NF-κB), but only TRIF/TRAM 
induces IFN production.  
 
 
A large body of evidence indicates a critical role for TLR4 in metabolic 
homeostasis through mediation of FFA signalling. Indeed, Shi and colleagues 
demonstrated that mice lacking TLR4 were protected from the deleterious effects of 
systemic lipid infusion on insulin signalling and glucose metabolism (Shi 2006). In 
addition, SFAs were also reported to activate the TLR4 cascade, thereby stimulating 
the rates of de novo ceramide synthesis in skeletal muscle cells (Holland 2011). 
Further emphasising the importance of TLR4 in palmitate-mediated ceramide 
synthesis, Schilling and colleagues reported a synergistic increase in de novo C16:0-
ceramide production in macrophages treated with a combination of palmitate and 
LPS (Schilling 2013). In addition, they demonstrated that FFA-induced 
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inflammatory response was reduced in the absence of the receptor in both adipocytes 
and macrophages (Shi 2006).  
 
The same year, Song and colleagues established that Tlr4 mRNA expression 
was enhanced during 3T3-L1 adipogenesis as well as in adipose tissue of obese 
db/db mice (M. K. Song 2006). LPS- or FFA-mediated stimulation of TLR4 was 
reported to stimulate NF-κB cascade along with the expression of pro-inflammatory 
cytokines (TNFα and IL-6) in the differentiated fat cells, which had become insulin 
resistant (M. K. Song 2006). More recently Kim and colleagues compared the impact 
of diet- and genetically-induced obesity in the activation of TLRs cascades (S. C. 
Kim 2012). Interestingly, it appears that although both types of obesity elicit the up-
regulation of the TLR1, TLR4, TLR5, TLR8, TLR9 and TLR12 genes as well as 
their downstream targets in murine visceral adipose tissue, the magnitude of the 
effect is larger in diet-induced obesity. 
 
Despite the many studies linking TLR4 to FFA-induced metabolic 
dysregulation, the molecular mechanisms involved remained unclear until 2012. 
That year Pal et al. provided strong evidence that TLR4 interacts with SFA through a 
liver secretory glycoprotein known as fetuin-A (FetA) thereby modulating SFA-
induced insulin resistance (Pal 2012). Indeed, silencing fetA protected mice from the 
onset of HFD-induced insulin resistance. Furthermore, targeted mutation 
experiments revealed the ability of FetA to directly bind TLR4 through its 
galactoside terminal. Cleaving this terminal prevented the onset of FFA-induced 
insulin resistance. More recently, a direct interaction between palmitate and the 
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hydrophobic binding pocket of TLR4 adaptor protein MD-2 was evidenced by 
Nicholas et al. in human monocyte derived dentritic cells (Nicholas 2017).  
 
Having highlighted the pivotal role of TLR4 in palmitate-induced insulin 
resistance, it is interesting to focus on the evidence supporting the TLR4 as an 
inducer of the IFN pathway. This topic has been extensively studied over the past 
decade. So far five of the ten human TLRs (TLR3, 4, 7, 8 and 9) have been 
implicated in the induction of type I IFNs (Noppert 2007). Despite some differences 
in downstream effectors, all TLRs were reported to activate the TANK binding 
kinase or the inhibitor of κB kinase ε. This permits the phosphorylation of IRFs, in 
turn leading to the stimulation of IFN genes. LPS, a TLR4 ligand was also found to 
activate a range of type II IFN response genes, including IFN-γ-inducible protein 10, 
as well as type I IFN induced gene such as Isg15 (T. T. Kawai 2001). Likewise, IFN-
γ was reported to induce TLR2 and TLR4 expression in human endothelial cells. 
Interestingly, IFN-γ and LPS were found to act synergistically: while both molecules 
induced TLR2 expression, their effect was enhanced when the cells were treated 
with IFN-γ and LPS simultaneously (Faure 2001).  
 
In the same cell type, LPS-mediated activation of TLR4 was found to drive 
the phosphorylation of STAT3 (Ying 2013). In addition, TLR4 was shown to 
stimulate STAT1 in a PKCδ-dependent manner in macrophages (Rhee 2003). Such 
findings are in line with the study of Dasu and colleagues, showing that TLR4 
expression was reduced upon inhibition of PKC-δ in human monocytes under 
diabetic conditions (Dasu 2008). Although most studies were carried out in 
macrophages, monocytes and dendritic cells, these results point at TLR4 as a key 
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element linking IFN- and palmitate-induced insulin resistance in adipocytes. The 
crosstalk between STATs and the NF-κB/pro-inflammatory cytokines signalling 
explored in this introduction suggests that these two models of insulin resistance are 






III. 3.   Results of Chapter 3 
III. 3. 1. Establishing cell models of FA- and IFN-γ-induced insulin 
resistance 
III. 3. 1. 1. Using 3T3-L1 cell line 
We first intended to reproduce the established model of palmitate- and IFN-γ-
induced insulin resistance using 3T3-L1 pre-adipocytes, a prerequisite for further 
investigations. We assessed insulin sensitivity at the signalling level using Akt 
phosphorylation as a convenient read-out. As mentioned in the introduction, PDK1 
mediates in the phosphorylation of Thr308, while mTORC2 promotes the 
phosphorylation of Akt at Ser473 (Guo 2014). The phosphorylation of residues is 
necessary for maximal activation of Akt, thus both residues can be probed to assess 
insulin sensitivity. Because Foukas et al. had previously demonstrated the importance of 
p110α in the insulin signalling pathway of 3T3-L1 cells by investigating the 
phosphorylation of pAkt Thr308, this residue was selected as read-out in the experiments 
presented in the present work (L. B. Foukas 2013).  
 
Cells were treated with palmitate (500 μM) or IFN-γ (50 ng/mL) for 24 h and 
lysed following acute insulin stimulation (10 nM for 5 min). This preliminary 
experiment was performed in presence or absence of serum. As expected, p-Akt 
drastically increased in response to insulin, indicating enhanced PI3K activity 
(Figures 13A and B). However, contrary to the accepted molecular model, palmitate 
treatment drove a further Akt activation in insulin-stimulated cells. The magnitude of 
the increase was lesser in serum-deprived cells (< 10%) than in those treated in the 
presence of serum (30%). The effect of IFN-γ treatment on insulin-stimulated p-Akt 
levels also appeared to be impacted by serum deprivation: while cells treated in 
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serum containing medium showed a 27% increase in p-Akt signal compared to 
insulin control (Figure 13A), p-Akt levels in cells treated in serum free (SF) medium 




Figure 13. Effect of palmitate and IFN-γ treatment on insulin sensitivity in 3T3-L1 pre-adipocytes. 
3T3-L1 pre-adipocytes were treated for 24 h in 10% FBS/Dulbecco’s modified eagle’s medium 
(DMEM) (HG) (A) or SF DMEM (HG, 0.2% BSA) (B). Palmitate 500 μM was added to the medium 
(24 h treatment) (lanes 3 and 4) or IFN-γ 50 ng/mL (24 h treatment) (lanes 5 and 6). Insulin 
stimulation was with 10 nM for 5 min. In the presence of serum both treatments induced a slight 
increase in p-Akt levels. In the absence of serum palmitate treated cells showed a subtle increase in p-
Akt compared to the untreated control, while there was a 10% decrease in p-Akt level in IFN-γ treated 
cells. Cells were lysed with 150 μL 1% triton X (TX)-100 lysis buffer. 110 μg of protein were loaded 
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In order to magnify the effect of palmitate treatment while maintaining 
physiological significance, cells were treated in serum containing medium for 24 h 
followed by a 3 h-long serum starvation. The pre-adipocytes were then stimulated 
for 15 min with 100 nM insulin (Figure 14A). Under such conditions, the SFA 
induced a 50% decrease in p-Akt signal compared to insulin-stimulated control in 
line with the current paradigm. This effect fell short of reaching statistical 
significance using the one-way ANOVA (F(4,14) = 45.65, p-value = 0; Tukey HSD 
post hoc test between “insulin-stimulated control” and “insulin-stimulated, palmitate 
treatment”: p-value = 0.11), however a paired student t-test produced a p-value of 
0.04. Adding the p110α-selective inhibitor, A66, during treatment abrogated the 
palmitate-mediated inhibition, thus restoring Akt phosphorylation to insulin-
stimulated control levels. When treated with A66 alone, the phosphorylation levels 
following insulin stimulation were more than doubled compared to the insulin-
stimulated control. In light of the previous results (Figure 13), the IFN-γ treatment 
was carried out in SF media. The modest inhibition of insulin-stimulated Akt activity 
caused by the cytokine depicted in figure 13B could not be reproduced (Figure 14B). 
Nevertheless, when combined with A66, IFN-γ treatment promotes a two-fold 
increase of p-Akt levels following insulin stimulation compared to insulin control. 





The experiments presented above were repeated in mature 3T3-L1 
adipocytes. We were able to show a statistically significant 40% decrease of insulin-
stimulated p-Akt levels in response to palmitate treatment compared to insulin-
stimulated control. Such effect was rescued by inhibiting p110α (Figure 15A). 
Having lowered the concentration of IFN-γ ten-fold to reproduce the conditions used 
by McGillicuddy and colleagues we recorded a statistically significant 25% 
reduction in insulin-stimulated p-Akt levels following IFN-γ treatment (Figure 15B) 
(McGillicuddy 2009). The trend suggests that A66 rescues the effect of the cytokine 
treatment although the difference between the insulin-stimulated p-Akt signal 
recorded following IFN-γ treatment alone and combined with A66 is not statistically 
significant (one-way ANOVA F(4,18) = 40.64, p-value = 0.00; Tukey HSD post hoc 
test between “insulin-stimulated, IFN-γ treatment” and “insulin-stimulated, IFN-γ + 
A66 treatment”: p-value = 0.38). The impact of the cytokine treatment on the 
phosphorylation of Akt Ser473 was also examined and produced an inhibition of 
similar amplitude compared to the insulin-stimulated p-Akt levels (data not shown).  
 
Although only one of the ten IFN-stimulated genes identified by the 
transcriptome analysis is induced by IFN-γ, the work presented in this thesis has 
extensively explored the downstream effect of IFN-γ. The reason for this was that 
treatment of 3T3-L1 adipocytes with IFN-α followed by acute insulin stimulation 
had no effect on the phosphorylation levels of Akt (data not shown). Although, in 
our hands, IFN-γ had a minor impact on insulin stimulated Akt phosphorylation, 
IFN-γ-induced insulin resistance in both human and murine adipocytes had been 
demonstrated in the literature (McGillicuddy 2009). Moreover, IFN-γ can be 
produced by leukocytes infiltrating the adipose tissue, whereas a source of type I 
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IFNs in the adipose tissue has not been reported. Thus, because the aim of our study 
was to explore the overlaps between two pathways involved in the onset of insulin 
resistance, we opted for using IFN-γ in subsequent experiments. 
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Figure 14. A. p110α inhibition prevents palmitate-induced insulin resistance in 3T3-L1 pre-adipocytes. The 50% decrease in p-Akt observed in palmitate treated cells (the 
difference between the insulin-stimulated control and the palmitate-treated cells was not statistically significant using the one-way analysis of variance [ANOVA] but the p-value 
was 0.04 when using a paired student t-test) is rescued by A66. 3T3-L1 pre-adipocytes were treated with palmitate (500 μM) (lanes 3 and 4) and A66 (0.5 μM) (lanes 4 and 5) in 
10% FBS/DMEM (HG) for 24 h. Following a 3 h serum deprivation (SF DMEM, HG, 0.2% BSA), cells were stimulated with insulin (100 nM for 15 min). 50 μg of protein were 
loaded per lane (10% SDS-acrylamide gel). Data from four independent experiments. B. IFN-γ treatment does not affect the phosphorylation of Akt Thr308 in 3T3-L1 pre-adipocytes. 
Unlike palmitate, IFN-γ does not inhibit the phosphorylation of Akt. However, the cytokine considerably stimulates p-Akt in the presence of A66. 3T3-L1 pre-adipocytes were 
treated for 24 h in SF DMEM (HG, 0.2% BSA) with IFN-γ (200 ng/mL) (lanes 3 and 4) and A66 (1 μM) (lanes 4 and 5). Media were replaced with fresh serum-free media without 
any additives other than 0.2% BSA and cells were then acutely stimulated with insulin (100 nM for 15 min). 40 μg of protein were loaded per lane (10% SDS-acrylamide gel). Data 
from three independent experiments. For both figures A and B, cells were lysed with 75 μL 1% TX-100 lysis buffer per well and two 6-well plates were pooled together. Statistical 
difference between the untreated control and other treatments is indicated with %; statistical difference between the palmitate treatment and other treatments is indicated with $; ** 
denotes a treatment statistically different from all other treatments (p-value < 0.05). Note: previous work in our lab has shown that A66 alone does not cause a substantial increase in 
p-Akt Thr308 therefore this control was not included in the figure (L. B. Foukas 2013). 
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Figure 15. A. Inhibition of PI3K p110α blocks palmitate-induced insulin resistance in 3T3-L1 mature adipocytes. The decrease in p-Akt level observed when cells were treated with 
palmitate is rescued by A66. 3T3-L1 mature adipocytes were treated with palmitate (500 μM) (lanes 3 and 4) and A66 (1 μM) (lanes 4 and 5) in 10% FBS/DMEM (HG) for 24 h. 
Following a 3 h serum deprivation (SF DMEM, HG, 0.2% BSA), cells were stimulated with insulin (100 nM for 15 min). 100 μg of protein were loaded per lane (10% SDS-
acrylamide gel). Data from three independent experiments. B. IFN-γ induces insulin resistance in 3T3-L1 mature adipocytes. Despite a trend in this direction, inhibition of PI3K 
p110α does not rescue the effect of the cytokine to statically significant levels. 3T3-L1 mature adipocytes were treated for 24 h in SF DMEM (HG, 0.2% BSA) with IFN-γ (20 
ng/mL) (lanes 3 and 4) and A66 (1 μM) (lanes 4 and 5). Media were replaced with fresh serum-free media without any additives other than 0.2% BSA and cells were then acutely 
stimulated with insulin (100 nM for 15 min). 70 μg of protein were loaded per lane (10% SDS-acrylamide gel). Data from six independent experiments. For both figures A and B, 
cells were lysed with 100 μL 1% TX-100 lysis buffer per well. Statistical difference between the insulin stimulated control and other treatments is indicated with &; ** denotes a 
treatment statistically different from all other treatments (p-value < 0.05). 
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III. 3. 1. 2. Using hMADS cell line 
The results presented in this next section sought to reproduce the experiments 
performed in 3T3-L1 in a human cell line, hMADS adipocytes (Figures 16A, 16B, 
17A and 17B). As shown in figure 16A, palmitate treatment of insulin-stimulated 
pre-adipocytes failed to elicit the expected decrease in p-Akt signal. However, IFN-γ 
seems to have an inhibitory effect (57% decrease in insulin-stimulated p-Akt 
compared to insulin-stimulated control), although this effect did not reach statistical 
significance. These cells were much more sensitive than the murine cells to A66 as 
combining palmitate or IFN-γ with the inhibitor produced considerable boost in 
insulin-stimulated p-Akt (3-fold increase) compared to the insulin-stimulated 
control. A66 alone drove a 4.5 fold increase in insulin-stimulated Akt 
phosphorylation.  
 
The experiments presented in figures 17A and B performed in mature 
hMADS mirror those carried out in mature 3T3-L1 recorded in figures 15A and B. 
The human cells responded to the palmitate and A66 treatments similarly to the 
mouse cells, with the p110α inhibitor rescuing the deleterious effect of palmitate on 
insulin-stimulated p-Akt levels (Figure 17A). Although a similar trend could be 
observed with IFN-γ treatment, the cytokine did not affect significantly insulin-
stimulated p-Akt levels compared to the insulin-stimulated control (Figure 17B). 
This experiment was repeated lowering insulin concentration (10 nM) to the order of 
magnitude used by Wada and colleagues (Wada 2011). However, still no effect of 




Table 10 summarises the findings exposed in this section: a model of 
palmitate-induced insulin resistance was successfully established in both 3T3-L1 and 
hMADS mature adipocytes, while that of IFN-γ-mediated insulin resistance could 
only be established in 3T3-L1 mature adipocytes. The trend of the data suggests that 
IFN-γ does inhibit p-Akt signal in hMADS pre- and mature adipocytes. Palmitate, on 
the other hand, appears to hinder Akt activation in 3T3-L1 pre-adipocytes. 
 
Table 10. Summary of the cell lines for which a model of palmitate- or IFN-γ-induced insulin 
resistance was successfully developed using p-Akt as read-out. *The difference between the insulin-
stimulated cells and the palmitate-treated cells reaches statistical significance using a paired student t-
test but not the ANOVA. 
 
Cell line Palmitate-induced insulin resistance IFN-γ-induced insulin resistance 
3T3-L1 pre-adipocytes  Validated model* 
 








           
 
Figure 16. A. Palmitate does not cause insulin-resistance in hMADS pre-adipocytes. p-Akt expression was unaltered after treating the cells with palmitate compared to the insulin-
stimulated control. hMADS pre-adipocytes were treated with palmitate (500 μM) (lanes 3 and 4) and A66 (0.5 μM) (lanes 4 and 5) in complete DMEM (LG) for 24 h. Following a 3 
h serum deprivation (SF DMEM, LG, 0.2% BSA), cells were stimulated with insulin (100 nM for 15 min). Cells were lysed with 75 μL 1% TX-100 lysis buffer per well and two 6-
wells dishes plates were drawn together. 80 μg of protein were loaded per lane (10% SDS-acrylamide gel). B. IFN-γ marginally inhibits the phosphorylation of Akt Thr308 in hMADS 
pre-adipocytes, however this effect falls short of statistical significance. p-Akt expression was unaltered after treating the cells with palmitate compared to the insulin-stimulated 
control. hMADS pre-adipocytes were treated for 24 h in SF DMEM (LG, 0.2% BSA) with IFN-γ (20 ng/mL) (lanes 3 and 4) and A66 (1 μM) (lanes 4 and 5). Cells were then acutely 
stimulated with insulin (100 nM for 15 min) and lysed with 100 μL 1% TX-100 lysis buffer per 10 cm Ø dish. 34 μg of protein were loaded per lane (10% SDS-acrylamide gel). For 
both figures A and B, ** denotes a treatment statistically different from all other treatments. Data from three independent experiments. 
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Figure 17. A. Palmitate causes insulin resistance in hMADS mature adipocytes, rescued by inhibiting PI3K. The decrease in p-Akt expression induced by palmitate is rescued by 
A66. hMADS mature adipocytes were treated with palmitate (500 μM) (lanes 3 and 4) and A66 (1 μM) (lanes 4 and 5) in complete DMEM (LG) for 24 h. Following a 3 h serum 
deprivation (SF DMEM, LG, 0.2% BSA), cells were stimulated with insulin (100 nM for 15 min). 100 μg of protein were loaded per lane (10% SDS-acrylamide gel). B. IFN-γ does 
not cause insulin resistance in hMADS mature adipocytes. p-Akt expression was unaltered by IFN-γ compared to the insulin-stimulated control. hMADS mature adipocytes were 
treated for 24 h in SF DMEM (LG, 0.2% BSA) with IFN-γ (20 ng/mL) (lanes 3 and 4) and A66 (1 μM) (lanes 4 and 5). Media were replaced with fresh serum-free media without 
any additives other than 0.2% BSA and cells were then acutely stimulated with insulin (100 nM for 15 min). 110 μg of protein were loaded per lane (10% SDS-acrylamide gel). For 
both figures A and B, cells were lysed with 75 μL 1% TX-100 lysis buffer per well. Statistical difference between the insulin stimulated control and other treatments is indicated with 
&; statistical difference between the palmitate treatment and other treatments is indicated with $; statistical difference between the A66 treatment and other treatments is indicated 
with £; ** denotes a treatment statistically different from all other treatments (p-value < 0.05). Data from four independent experiments. 
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III. 3. 2. The IFN signalling pathway effector STAT3, but not 
STAT1, is activated by palmitate treatment of adipocytes 
Having investigated the stimulation of PI3K by palmitate and IFN-γ in the 
previous section, the following experiments focused on testing whether the SFA 
promotes activation of STAT1/3, found downstream of the IFN pathway. It has been 
shown that insulin resistance induced by IFN-γ treatment is mediated by the 
sustained activation of STAT1 and to a lesser extent STAT3, in both mouse 3T3-L1 
and human Simpson-Golabi-Behmel syndrome (SGBS) adipocytes (Wada 2011, 
McGillicuddy 2009). Here, we sought to reproduce these findings and compare the 
effect of IFN-γ on STAT1/3 phosphorylation to that of palmitate. To this end, a time 
course experiment was performed in either serum-free or serum containing media, 
treating the cells for 24, 8, 4, 2 and 1 h with either palmitate (500 μM) or IFN-γ (20 
ng/mL).  
 
Four individual western blots were then run to study the phosphorylation 
patterns of STAT1 Tyr701, STAT1 Ser727, STAT3 Tyr705 and STAT3 Ser727. As the 
presence of serum did not affect the response of the cells to treatment, we will 
present the results of the experiments performed in serum containing media for 
added physiological significance.  However, unlike serum, the presence of BSA – 
used as a carrier for palmitate – did interfere with the phosphorylation of STATs. 
Indeed, both palmitate and the BSA control stimulated STAT3 to levels recorded in 
IFN-γ-treated cells (data not shown). Therefore the initial time course experiments 
were repeated using unconjugated palmitate instead of BSA-conjugated palmitate. A 
reason for this apparent BSA-mediated stimulation of STATs is likely due to LPS 
contamination of the BSA preparation, which as mentioned in the introduction of the 
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present chapter, is a well-established TLR4 ligand that can induce the 
phosphorylation of STAT1 and STAT3 (Rhee 2003, Ying 2013). Indeed, in 2009, 
Erridge and Samani were able to evidence that, in both macrophages and HEK 293T 
cells, the effect of SFA on TLR2/4 activation reflected LPS and other lipopeptide 
contamination found in the BSA employed in their experimental design (Erridge 
2009). Such finding seeded a debate over the true role of SFAs in TLR signalling. 
 
 
III. 3. 2. 1. Using 3T3-L1 cell line 
Figures 18 and 19 present the time course experiment performed in 3T3-L1 
pre-adipocytes, investigating STAT3 and STAT1 activation, respectively. In line 
with published data, we observed an increase in phosphorylation for both STAT 
proteins induced by IFN-γ. Consistent with the findings of McGillicuddy and 
colleagues, STAT3 stimulation was more modest than that of STAT1 (McGillicuddy 
2009). Peak levels of tyrosine phosphorylation were recorded for both STAT1 and 
STAT3 at the 1 h time point with a 2,500 fold and a 2.5 fold increase, respectively, 
compared with the untreated control. On the other hand, serine phosphorylation 
peaked at the 24 h time point: p-STAT1 Ser727 and p-STAT3 Ser727 levels were 
multiplied by 5 and 2.5 compared with the untreated control, respectively. As shown 
from lanes 9 to 13, palmitate treatment failed to enhance STAT1/3 activity.  
 
The same experimental protocol was also applied to 3T3-L1 differentiated 
adipocytes (Figures 20 and 21). Comparably to the trend noted in pre-adipocytes, 
IFN-γ triggers the activation of STAT1 and to a lesser extent STAT3. However, 
maximal phosphorylation levels are reached at different time points for the two cell 
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types. Indeed, in 3T3-L1 mature adipocytes the phosphorylation of STAT3 at Tyr705 
and Ser727 residues culminates after 1 h of the cytokine treatment, while that of 
STAT1 at Tyr701 and Ser727 peaks at the 2 h time point. Now focusing on the effect 
of palmitate, it appears that the SFA fails to stimulate p-STAT3 Ser727, p-STAT1 
Tyr701 and p-STAT1 Ser727 levels over the time period investigated. Nevertheless, 
when considering the phosphorylation of STAT3 Tyr705, it seems to induce a 3-fold 
increase at the 8 h time point compared to the untreated control.  
 
Although this effect was not statistically significant when analysing the data 
using the Tukey HSD post hoc test (one-way ANOVA F(12,50) = 5.81, p-value = 
0.00; Tukey HSD post hoc test between “untreated” and “8 h palmitate treatment”: 
p-value = 0.27), the p-value obtained from the least significant difference (LSD) test 
did reach the significance threshold (LSD post hoc test between “untreated” and “8 h 
palmitate treatment”: p-value = 0.00). This suggests that the change in 
phosphorylation observed, although modest, might be real. It would therefore be 
interesting to further investigate the molecular mechanisms underlying the palmitate-





           
 
Figure 18. A. IFN-γ but not palmitate induces the phosphorylation of STAT3 Tyr705 in 3T3-L1 pre-adipocytes, however this effect falls short of statistical significance. B. IFN-γ but 
not palmitate induces the phosphorylation of STAT3 Ser727 in 3T3-L1 pre-adipocytes. For both figure A and B, 3T3-L1 pre-adipocytes were treated with IFN-γ (20 ng/mL) (lanes 3 to 
7), unconjugated palmitate (500 μM) (lanes 9 to 13) in 10% FBS/DMEM (HG). Equivalent volumes of MilliQ water (40 μL) (lane 2) and DMEM (LG) (1 mL) (lane 8) were used as 
control for IFN and palmitate treatments, respectively. Cells were lysed with 150 μL 1% TX-100 lysis buffer per 10 cm Ø dish. 79 μg and 66 μg of protein were loaded per lane in 
figures A and B, respectively (10% SDS-acrylamide gel). Statistical difference between the 24 h IFN-γ treatment and other treatments is indicated with £; statistical difference 




           
 
Figure 19. IFN-γ but not palmitate induces the phosphorylation of both STAT1 Tyr701 (A) and STAT1 Ser727 (B) in 3T3-L1 pre-adipocytes. For both figures A and B, 3T3-L1 pre-
adipocytes were treated with IFN-γ (20 ng/mL) (lanes 3 to 7), unconjugated palmitate (500 μM) (lanes 9 to 13) in 10% FBS/DMEM (HG). Equivalent volumes of MilliQ water (40 
μL) (lane 2) and DMEM (LG) (1 mL) (lane 8) were used as control for IFN and palmitate treatments, respectively. Cells were lysed with 100 μL 1% TX-100 lysis buffer per 10 cm 
Ø dish. 50 μg of protein were loaded per lane (10% SDS-acrylamide gel). Statistical difference between the 24 h IFN-γ treatment and other treatments is indicated with £; statistical 
difference between the 1 h IFN-γ treatment and other treatments is indicated with %; ** denotes a treatment statistically different from all other treatments (p-value < 0.05). Data 




           
 
Figure 20. A. Both IFN-γ and palmitate induce the phosphorylation of STAT3 Tyr705 in 3T3-L1 mature adipocytes. B. IFN-γ but not palmitate induces the phosphorylation of STAT3 
Ser727 in 3T3-L1 mature adipocytes. For both figures A and B, 3T3-L1 mature adipocytes were treated (HG) with IFN-γ (20 ng/mL) (lanes 3 to 7), unconjugated palmitate (500 μM) 
(lanes 9 to 13) in 10% FBS/DMEM. Equivalent volumes of MilliQ water (8 μL) (lane 2) and DMEM (LG) (200 μL) (lane 8) were used as control for IFN and palmitate treatments, 
respectively. Cells were lysed with 80 μL 1% TX-100 lysis buffer per well. 93 μg of protein were loaded per lane (10% SDS-acrylamide gel). Statistical difference between the 1 h 
IFN-γ treatment and other treatments is indicated with % (p-value < 0.05). Data from four independent experiments. 
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Figure 21. IFN-γ but not palmitate induces the phosphorylation of both STAT1 Tyr701 (A) and STAT1 Ser727 (B) in 3T3-L1 mature adipocytes. For both figures A and B, 3T3-L1 
mature adipocytes were treated with IFN-γ (20 ng/mL) (lanes 3 to 7), unconjugated palmitate (500 μM) (lanes 9 to 13) in 10% FBS/DMEM (HG). Equivalent volumes of MilliQ 
water (8 μL) (lane 2) and DMEM (LG) (200 μL) (lane 8) were used as control for IFN and palmitate treatments, respectively. Cells were lysed with 80 μL 1% TX-100 lysis buffer 
per well. 82 μg of protein were loaded per lane (10% SDS-acrylamide gel). Statistical difference between the 24 h IFN-γ treatment and other treatments is indicated with £; statistical 
difference between the 1 h IFN-γ treatment and other treatments is indicated with %; ** denotes a treatment statistically different from all other treatments (p-value < 0.05). Data 
from three independent experiments. 
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III. 3. 2. 2. Using hMADS cell line 
The experiments discussed in the previous section were reproduced in the 
hMADS cell line using both pre- and mature adipocytes. As shown in figures 22 and 
23, similar trends can be noticed in human and mouse undifferentiated cells. IFN-γ 
yielded a much stronger stimulation of STAT1 compared to STAT3, plummeting 
after 1 h of treatment for all residues. While, phosphorylation levels at STAT3 Tyr705 
are multiplied 5-fold in the presence of IFN-γ, those at STAT1 Tyr701 increased by 
over 1500%. As for the serine residues, p-STAT3 Ser727 levels doubled after 
treatment for 1 h with the cytokine - although this effect did not reach statistical 
significant – and p-STAT1 Ser727 levels were multiplied by a factor of 5. Neither 
STAT1 nor STAT3 was activated by the SFA.  
 
Figures 24 and 25 present the response to IFN-γ and palmitate treatments of 
differentiated hMADS cells. As expected, IFN promoted the phosphorylation of 
STAT1 Tyr701 (13-fold increase at 1 h) and to a lesser degree STAT3 Tyr705 (2-fold 
increase at 1 h). Yet, although the cytokine did stimulate p-STAT1 Ser727 7-fold after 
2 h of treatment, its effect on p-STAT3 Ser727 seemed to be inhibitory with a 40% 
decrease compared to untreated control at the same time point (note that this 
difference was not statistically significant). Palmitate also reduced the basal 
phosphorylation of STAT3 Ser727 compared to the untreated control after 4 h and 1 h 
of treatment. However, when compared to the 24 h DMEM treated condition, no 
such difference could be recorded, suggesting that this palmitate-mediated effect is 




Table 11 recapitulates our findings on palmitate-mediated activation of 
STAT1 and STAT3 gathered so far in both 3T3-L1 and hMADS. Overall, STAT1 
activity does not appear to be induced by the SFA unlike STAT3. This could indicate 
that palmitate does not stimulate the STAT pathway through the up-regulation of 
IFN secretion as this would entail both STAT proteins being activated. 
 
Table 11. Summary of the effect of palmitate treatment on STAT1 and STAT3 phosphorylation in 
mouse and human cell lines. *effect not statistically significant when the data was analysed with the 
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Figure 22. A. IFN-γ but not palmitate induces the phosphorylation of STAT3 Tyr705 in hMADS pre-adipocytes. B. Neither IFN-γ nor palmitate induces the phosphorylation of STAT3 
Ser727 in hMADS pre-adipocytes. For both figures A and B, hMADS pre-adipocytes were treated with IFN-γ (20 ng/mL) (lanes 3 to 7), unconjugated palmitate (500 μM) (lanes 9 to 
13) in complete DMEM (LG). Equivalent volumes of MilliQ water (40 μL) (lane 2) and DMEM (LG) (1 mL) (lane 8) were used as control for IFN and palmitate treatments, 
respectively. Cells were lysed with 100 μL 1% TX-100 lysis buffer per 10 cm Ø dish. 39 μg of protein were loaded per lane (10% SDS-acrylamide gel). ** denotes a treatment 





          
 
Figure 23. IFN-γ but not palmitate induces the phosphorylation of both STAT1 Tyr701 (A) and STAT1 Ser727 (B) in hMADS pre-adipocytes. For both figures A and B, hMADS pre-
adipocytes were treated with IFN-γ (20 ng/mL) (lanes 3 to 7), unconjugated palmitate (500 μM) (lanes 9 to 13) in complete DMEM (LG). An equivalent volume of MilliQ water was 
used as control for the IFN-γ treatments (40 μL) (lane 2) and an equivalent volume of DMEM (LG) was used as control for the palmitate treatments (1 mL) (lane 8). Cells were lysed 
with 100 μL 1% TX-100 lysis buffer per 10 cm Ø dish. 39 μg of protein were loaded per lane (10% SDS-acrylamide gel). Statistical difference between the 4 h IFN-γ treatment and 
other treatments is indicated with @; statistical difference between the 2 h IFN-γ treatment and other treatments is indicated with #; statistical difference between the 1 h IFN-γ 




           
 
Figure 24. A. IFN-γ but not palmitate induces the phosphorylation of STAT3 Tyr705 in hMADS mature adipocytes. B. IFN-γ and palmitate inhibit the phosphorylation of STAT3 
Ser727 in hMADS mature adipocytes. For both figures A and B, hMADS mature adipocytes were treated with IFN-γ (20 ng/mL) (lanes 3 to 7), unconjugated palmitate (500 μM) 
(lanes 9 to 13) in complete DMEM (LG). Equivalent volumes of MilliQ water (8 μL) (lane 2) and DMEM (LG) (200 μL) (lane 8) were used as control for IFN and palmitate 
treatments, respectively. Cells were lysed with 80 μL 1% TX-100 lysis buffer per well. 46 μg of protein were loaded per lane (10% SDS-acrylamide gel). Statistical difference 
between the untreated control and other treatments is indicated with +; statistical difference between the 1 h IFN-γ treatment and other treatments is indicated with % (p-value < 
0.05). Data from three independent experiments. 
121 
 
           
 
Figure 25. IFN-γ but not palmitate induces the phosphorylation of both STAT1 Tyr701 (A) and STAT1 Ser727 (B) in hMADS mature adipocytes. For both figures A and B, hMADS 
mature adipocytes were treated with IFN-γ (20 ng/mL) (lanes 3 to 7), unconjugated palmitate (500 μM) (lanes 9 to 13) in complete DMEM (LG). Equivalent volumes of MilliQ 
water (8 μL) (lane 2) and DMEM (LG) (200 μL) (lane 8) were used as control for IFN and palmitate treatments, respectively. Cells were lysed with 80 μL 1% TX-100 lysis buffer 
per well. 24 μg of protein were loaded per lane (10% SDS-acrylamide gel). Statistical difference between the 4 h IFN-γ treatment and other treatments is indicated with @; statistical 
difference between the 2 h IFN-γ treatment and other treatments is indicated with #; statistical difference between the 1 h IFN-γ treatment and other treatments is indicated with % 




III. 3. 3. Palmitate modulates the STAT pathway independently of 
IFN secretion  
The results presented in the previous section suggest that palmitate has an 
effect on the activity of STAT3 but not STAT1 through a mechanism independent of 
IFN-γ secretion. To validate this hypothesis, we sought to confirm that palmitate did 
not trigger STAT1 phosphorylation over a shorter time course. The following section 
therefore compares the effect of the SFA on STAT1 (as well as STAT3) after 1 h, 30 
min, 15 min and 5 min of treatment to the stimulation resulting from treating the 
cells for 1 h with IFN-γ. Figures 26 to 33 clearly show that, across the cell lines 
tested, palmitate fails to promote the short-term activation of STAT3 and, more 
importantly, STAT1. This data seems to signify that the molecular mechanism by 




           
 
Figure 26. Palmitate fails to induce the phosphorylation of STAT3 Tyr705 (A) and STAT3 Ser727 (B) in 3T3-L1 pre-adipocytes over a short time frame. For both figures A and B, 3T3-
L1 pre-adipocytes were treated with IFN-γ (20 ng/mL) (lane 2), unconjugated palmitate (500 μM) (lanes 4 to 7) in 10% FBS/DMEM (HG). An equivalent volume of DMEM (LG) 
was used as control for the palmitate treatments (400 μL) (lanes 3 and 8). Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish. 79 μg of protein were loaded per 
lane (10% SDS-acrylamide gel). Statistical difference between the 60 min IFN-γ treatment and other treatments is indicated with %; ** denotes a treatment statistically different 




           
 
Figure 27. Palmitate fails to induce the phosphorylation of STAT1 Tyr701 (A) and STAT1 Ser727 (B) in 3T3-L1 pre-adipocytes over a short time frame. For both figures A and B, 3T3-
L1 pre-adipocytes were treated with IFN-γ (20 ng/mL) (lane 2), unconjugated palmitate (500 μM) (lanes 4 to 7) in 10% FBS/DMEM (HG). An equivalent volume of DMEM (LG) 
was used as control for the palmitate treatments (400 μL) (lanes 3 and 8). Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish. 26 μg of protein were loaded per 





           
 
Figure 28. Palmitate fails to induce the phosphorylation of STAT3 Tyr705 (A) and STAT3 Ser727 (B) in 3T3-L1 mature adipocytes over a short time frame. For both figures A and B, 
3T3-L1 mature adipocytes were treated with IFN-γ (20 ng/mL) (lane 2), unconjugated palmitate (500 μM) (lanes 4 to 7) in 10% FBS/DMEM (HG). An equivalent volume of DMEM 
(LG) was used as control for the palmitate treatments (200 μL) (lanes 3 and 8). Cells were lysed with 80 μL 1% TX-100 lysis buffer per well. 70 μg of protein were loaded per lane 
(10% SDS-acrylamide gel). Statistical difference between the 15 min palmitate treatment and other treatments is indicated with &; ** denotes a treatment statistically different from 





           
 
Figure 29. Palmitate fails to induce the phosphorylation of STAT1 Tyr701 (A) and STAT1 Ser727 (B) in 3T3-L1 mature adipocytes over a short time frame. For both figure A and B, 
3T3-L1 mature adipocytes were treated with IFN-γ (20 ng/mL) (lane 2), unconjugated palmitate (500 μM) (lanes 4 to 7) in 10% FBS/DMEM (HG). An equivalent volume of DMEM 
(LG) was used as control for the palmitate treatments (200 μL) (lanes 3 and 8). Cells were lysed with 80 μL 1% TX-100 lysis buffer per well. 70 μg and 78 μg of protein were loaded 
per lane for figures A and B, respectively (10% SDS-acrylamide gel). Statistical difference between the 60 min IFN-γ treatment and other treatments is indicated with %; ** denotes 




           
 
Figure 30. Palmitate fails to induce the phosphorylation of STAT3 Tyr705 (A) and STAT3 Ser727 (B) in hMADS pre-adipocytes over a short time frame. For both figures A and B, 
hMADS pre-adipocytes were treated with IFN-γ (20 ng/mL) (lane 2), unconjugated palmitate (500 μM) (lanes 4 to 7) in complete DMEM (LG). An equivalent volume of DMEM 
(LG) was used as control for the palmitate treatments (400 μL) (lanes 3 and 8). Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish. 5 μg of protein were loaded 




           
 
Figure 31. Palmitate fails to induce the phosphorylation of STAT1 Tyr701 (A) and STAT1 Ser727 (B) in hMADS pre-adipocytes over a short time frame. For both figures A and B, 
hMADS pre-adipocytes were treated with IFN-γ (20 ng/mL) (lane 2), unconjugated palmitate (500 μM) (lanes 4 to 7) in complete DMEM (LG). An equivalent volume of DMEM 
(LG) was used as control for the palmitate treatments (400 μL) (lane 3 and 8). Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish. 4 μg of protein were loaded per 




           
 
Figure 32. Palmitate fails to induce the phosphorylation of STAT3 Tyr705 (A) and STAT3 Ser727 (B) in hMADS mature adipocytes over a short time frame. For both figures A and B, 
hMADS mature adipocytes were treated with IFN-γ (20 ng/mL) (lane 2), unconjugated palmitate (500 μM) (lanes 4 to 7) in complete DMEM (LG). An equivalent volume of DMEM 
(LG) was used as control for the palmitate treatments (200 μL) (lanes 3 and 8). Cells were lysed with 80 μL 1% TX-100 lysis buffer per well. 25 μg of protein were loaded per lane 




            
 
Figure 33. Palmitate fails to induce the phosphorylation of STAT1 Tyr701 (A) and STAT1 Ser727 (B) in hMADS mature adipocytes over a short time frame. For both figures A and B, 
hMADS mature adipocytes were treated with IFN-γ (20 ng/mL) (lane 2), unconjugated palmitate (500 μM) (lanes 4 to 7) in complete DMEM (LG). An equivalent volume of DMEM 
(LG) was used as control for the palmitate treatments (200 μL) (lanes 3 and 8). Cells were lysed with 80 μL 1% TX-100 lysis buffer per well. 50 μg of protein were loaded per lane 




III. 3. 4. Palmitate-mediated STAT3 activation 
We further explored the molecular mechanisms underlying palmitate-
mediated modulation of STAT3 phosphorylation investigated previously. More 
specifically, we tested whether pharmacological inhibition of two isoforms of PI3K 
p110 (p110α and p110δ) or inhibition of TLR4 could protect adipocytes from the 
effect of the SFA. Indeed, as discussed in the introduction, the deleterious metabolic 
effect of palmitate was found to be mediated by PI3K (L. B. Foukas 2013, Ortega-
Molina 2015). Furthermore, evidence of a crosstalk between PI3K and TLR4, the 
likely receptor for palmitate, was brought forward by Ojaniemi et al., who 
demonstrated that the downstream signalling of TLR4 is directly stimulated by its 
interaction with PI3K (Ojaniemi 2003). A66 and D030 were used to inhibit p110α 
and p110δ, respectively, while TAK 242 was used to block TLR4 activity. These 
inhibitors were tested in 3T3-L1 mature adipocytes treated for 8 h with unconjugated 
palmitate as palmitate was found to impact STAT3 Tyr705 phosphorylation under 
such conditions (Figure 20A).  
 
As shown in figure 34, the palmitate-induced stimulation of pSTAT3 Tyr705 
following 8 h of treatment recorded in figure 20A could successfully be reproduced. 
However, none of the inhibitors tested affected palmitate-induced effect on STAT 
Tyr705. An additional experiment was carried out to further investigate the effect of 
TAK 242. Figure 35 compares the tyrosine phosphorylation levels of STAT3 of 
mature 3T3-L1 exposed to palmitate for 8 h, in the presence or absence of TAK 242. 
While some cells were treated simultaneously with a combination of palmitate and 
TAK 242, others were pre-treated with the inhibitor for 1 h prior to adding palmitate 
to the media. An LPS control was included to confirm the efficiency of TLR4 
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inhibition. TAK 242 failed to elicit any significant effect in palmitate-stimulated 
cells, whether a pre-treatment was performed or not. However, in LPS-treated cells, 
the TLR4 inhibitor was able to rescue the endotoxin-mediated induction of p-STAT3 
Tyr705 and pre-treatment promoted such effect.  
 
Another inhibitor (myriocin) was tested, this time targeting serine pamitoyl 
transferase (SPT), the enzyme catalysing the first step of de novo ceramide synthesis. 
As discussed in Chapter 1, one of the theories explaining the negative metabolic 
effect of palmitate is its ability to stimulate the production of ceramide (Turpin 
2014). This lipid metabolite was indeed implicated in the down-regulation of PI3K 
signalling thus seeding the onset of insulin resistance (Hla 2014). Moreover, it was 
shown to impair mitochondrial electron transport, thereby antagonising β-oxidation 
and FA disposal (Turpin 2014). As shown in figure 36, adding myriocin to the 
palmitate treatment had no effect on the palmitate-mediated stimulation of p-STAT3 
levels. 
 
Aside for the increase in p-STAT3 Tyr705 recorded in mature 3T3-L1, the 
other time points identified in table 11 were investigated. However, neither the 47% 
nor the 54% decrease in pSTAT3 Ser727 compared to untreated control recorded after 





           
 
Figure 34. Inhibition of PI3K p110α, p110δ and TLR4 do not rescue palmitate-induced 
phosphorylation of STAT3 Tyr705 in 3T3-L1 mature adipocytes after 8 h of treatment. 3T3-L1 mature 
adipocytes were treated with unconjugated palmitate (500 μM) (lanes 3, 8, 9 and 10), A66 (2 μM) 
(lanes 5 and 8), D030 (2 μM) (lanes 6 and 9) and TAK 242 (2 μM) (lanes 7 and 10) in 10% 
FBS/DMEM (HG). Equivalent volumes of DMEM (LG) (200 μL) (lane 2) and DMSO (4 μL) (lane 4) 
were used as control for the palmitate and inhibitors treatments, respectively. Cells were lysed with 
80 μL 1% TX-100 lysis buffer per well. 64 μg of protein were loaded per lane (10% SDS-acrylamide 
gel). Statistical difference between the palmitate treatment and other treatments is indicated with $; 
statistical difference between the A66 treatment and other treatments is indicated with % (p-value < 




       
 
Figure 35. Inhibiting TLR4 rescues the effect of LPS but not of palmitate on the phosphorylation of 
STAT3 Tyr705 in 3T3-L1 mature adipocytes after 8 h of treatment. 3T3-L1 mature adipocytes were 
treated with unconjugated palmitate (500 μM) (lanes 4, 6 and 8), LPS (100 ng/mL) (lanes 10, 11 and 
12) and TAK 242 (2 μM) (lanes 5, 6, 7, 8, 11 and 12) in 10% FBS/DMEM (HG). Equivalent volumes 
of DMEM (LG) (200 μL) (lane 2), PBS (20 μL) (lane 9) and DMSO (4 μL) (lane 3) were used as 
control for the palmitate, LPS and TAK 242 treatments, respectively. For treatments marked with *, 
TAK 242 was added to the media 1 h prior to palmitate and LPS treatments. Cells were lysed with 80 
μL 1% TX-100 lysis buffer per well. 56 μg of protein were loaded per lane (10% SDS-acrylamide 
gel). Statistical difference between the untreated control and other treatments is indicated with +; 
statistical difference between the DMEM control and other treatments is indicated with =; statistical 
difference between the “LPS + TAK 242” treatment and other treatments is indicated with *; ** 









Figure 36. Inhibiting de novo ceramide biosynthesis does not rescue the effect of palmitate and LPS 
on the phosphorylation of STAT3 Tyr705 in 3T3-L1 mature adipocytes after 8 h of treatment. 3T3-L1 
mature adipocytes were treated with unconjugated palmitate (500 μM) (lanes 3 and 6) and myriocin 
(100 nM) (lanes 5 and 6) in 10% FBS/DMEM (HG). Equivalent volumes of DMEM (LG) (200 μL) 
(lane 2) and DMSO (4 μL) (lane 4) were used as control for the palmitate and myriocin treatments, 
respectively. Myriocin and DMSO were added to the media 1 h prior to palmitate treatment. Cells 
were lysed with 80 μL 1% TX-100 lysis buffer per well. 156 μg of protein were loaded per lane (10% 
SDS-acrylamide gel). Statistical difference between the untreated control and other treatments is 
indicated with +; statistical difference between the DMEM control and other treatments is indicated 
with =; (p-value < 0.05). Data from three independent experiments. 
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III. 3. 5. Type I and II IFN, but not type III IFN, activate the STAT 
pathway 
III. 3. 5. 1. Using 3T3-L1 cell line 
In order to thoroughly understand the effect of the IFN family on the STAT 
pathway, the time course experiments investigating IFN-γ- and palmitate-mediated 
stimulation of STAT1 and STAT3 were repeated, this time comparing IFN-α to IFN-
λ treatments. Collectively, these two sets of experiments provide a comprehensive 
overview of the potential role played by all three types of IFN in the activation of the 
two STAT proteins in adipocytes. Data from previous experiments indicates that the 
molecular mechanism by which palmitate modulates STAT3 phosphorylation occurs 
independently of IFN-γ secretion as STAT1 phosphorylation in not affected by the 
SFA. Testing whether type I and III IFN induce STAT1 activation would allow to 
extent this statement to all types of IFN. Indeed, if palmitate stimulated the 
production and signal through either IFN-α or IFN-λ, this would have been missed if 
these did not drive STAT1 phosphorylation. 
 
Figures 37 and 38 explore the response of 3T3-L1 pre-adipocytes to these 
cytokines. Similarly to type II IFN, IFN- is most potent in these cells after 1 h of 
treatment when considering the tyrosine residue of both STAT1 and STAT3. While 
the phosphorylation of the former is increased 15-fold (to levels which remain 
almost 5 times lower than the IFN- induction), that of the latter reaches 4 times 
basal levels (comparable to IFN- induction) (Figures 37A and 38A). Interestingly, 
the phosphorylation of the serine residues was also maximal after 1 h of treatment 
with a 2-fold stimulation at STAT3 Ser727 and a 3-fold one at STAT1 Ser727 versus 
basal. This activation pattern differs from that of IFN-, which although of a similar 
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magnitude, peaked after 24 h of treatment (Figures 37B and 38B). Strikingly, IFN- 
failed to trigger the phosphorylation of STAT across residues. As discussed in the 
next section, the literature on this topic seems to indicate that this type of IFN would 
be able to induce the phosphorylation of STAT1 (Dickensheets 2013). 
 
Focusing on 3T3-L1 mature adipocytes, it appears that neither type I nor type 
III IFN are able to significantly stimulate the transcription factors (Figures 39 and 
40). Indeed, although a subtle up-regulation can be noticed in p-STAT3 Ser727 after 
the 1 h IFN-α treatment and in p-STAT1 Tyr701 after 2 h of the same treatment, these 
were not statistically significant. 
138 
 
       
 
Figure 37. Type I IFN but not type III IFN induces the phosphorylation of both STAT3 Tyr705 (A) and STAT3 Ser727 (B) in 3T3-L1 pre-adipocytes. For both figures A and B, 3T3-L1 
pre-adipocytes were treated with IFN-γ (20 ng/mL) (lane 3), IFN-α (lanes 4 to 8) and IFN-λ (lanes 9 to 13) in 10% FBS/DMEM (HG). An equivalent volume of MilliQ water was 
used as control for the IFN treatments (16 μL) (lane 2). Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish. 64 μg of protein were loaded per lane (10% SDS-
acrylamide gel). Statistical difference between the 1 h IFN-γ treatment and other treatments is indicated with £; statistical difference between the 1 h IFN-α treatment and other 





       
 
Figure 38. Type I IFN but not type III IFN induces the phosphorylation of both STAT1 Tyr701 (A) and STAT1 Ser727 (B) in 3T3-L1 pre-adipocytes. For both figures A and B, 3T3-L1 
pre-adipocytes were treated with IFN-γ (20 ng/mL) (lane 3), IFN-α (lanes 4 to 8) and IFN-λ (lanes 9 to 13) in 10% FBS/DMEM (HG). An equivalent volume of MilliQ water was 
used as control for the IFN treatments (16 μL) (lane 2). Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish. 64 μg of protein were loaded per lane (10% SDS-
acrylamide gel). Statistical difference between the 2 h IFN-α treatment and other treatments is indicated with $; statistical difference between the 1 h IFN-α treatment and other 





       
 
Figure 39. Neither type I nor type III IFN induces the phosphorylation of STAT3 Tyr705 (A) and STAT3 Ser727 (B) in 3T3-L1 mature adipocytes. For both figures A and B, 3T3-L1 
mature adipocytes were treated with IFN-γ (20 ng/mL) (lane 3), IFN-α (lanes 4 to 8) and IFN-λ (lanes 9 to 13) in 10% FBS/DMEM (HG). An equivalent volume of MilliQ water was 
used as control for the IFN treatments (8 μL) (lane 2). Cells were lysed with 80 μL 1% TX-100 lysis buffer per well. 73 μg and 59 μg of protein were loaded per lane in figures A and 
B, respectively (10% SDS-acrylamide gel). Statistical difference between the 1 h IFN-γ treatment and other treatments is indicated with £; ** denotes a treatment statistically 





       
 
Figure 40. Neither type I nor type III IFN induces the phosphorylation of STAT1 Tyr701 (A) and STAT Ser727 (B) in 3T3-L1 mature adipocytes. For both figures A and B, 3T3-L1 
mature adipocytes were treated with IFN-γ (20 ng/mL) (lane 3), IFN-α (lanes 4 to 8) and IFN-λ (lanes 9 to 13) in 10% FBS/DMEM (HG). An equivalent volume of MilliQ water was 
used as control for the IFN treatments (8 μL) (lane 2). Cells were lysed with 80 μL 1% TX-100 lysis buffer per well. 71 μg and 59 μg of protein were loaded per lane in figures A and 





III. 3. 5. 2. Using hMADS cell line 
As previously, the experiments carried out in mice adipocytes were also 
performed in human fat cells. Figures 41 and 42 present the data collected in 
hMADS pre-adipocytes. Neither type I nor type III IFN elicited a statistically 
significant increase in STAT3 phosphorylation, although p-STAT3 Tyr705 levels 
were increased 2.5-fold after a 1 h treatment with IFN- (Figure 41A). Likewise, 
STAT1 activation is not enhanced by the cytokines beyond statistically significance 
(Figure 42). 
 
Lastly, the experiment was performed in differentiated human adipocytes 
(Figures 43 and 44). Although IFN-γ does not induce the previously observed 2-fold 
increase in p-STAT3 Tyr705 after 1 h of treatment shown in figure 24A, IFN-α did 
stimulate phosphorylation in a comparable magnitude with a peak after 1 h treatment 
(Figure 43A). As expected, IFN-γ did not have an effect on the serine residue of 
STAT3 and neither did IFN-α (Figure 43B). IFN type I was also able to boost p-
STAT1 Tyr701 levels with a 300-fold increase at the 2 h time point comparable to the 
IFN-γ-mediated induction (Figure 44A). Peaking after 24 h of treatment, the 
phosphorylation of the STAT1 serine residue was promoted to a lesser extent (30-
fold) (Figure 44B). As for the mouse cells, type III IFN did not enhance the activity 
of either transcription factors in differentiated hMADS adipocytes. 
 
In table 12 are compiled the times at which each type of IFN elicit peak 
stimulation of STAT1 and STAT3 and figures 45, 46, 47 and 48 superimpose the 
patterns of STAT phosphorylation induced by IFN-α, IFN-γ and IFN-λ in each cell 
type tested. For each cell type used (3T3-L1 pre-adipocytes in figure 45, 3T3-L1 
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mature adipocytes in figure 46, hMADS pre-adipocytes in figure 47 and hMADS 
mature adipocytes in figure 48), the phosphorylation levels recorded for each residue 
is plotted against the duration of the treatment (p-STAT3 Tyr705 for the top left-hand 
side panel, p-STAT3 Ser727 for the top right-hand side panel, p-STAT1 Tyr701 for the 
bottom left-hand side panel and, lastly, p-STAT1 Ser727 for the bottom right-hand 
side panel). The blue, red and green plots reflect the variations in phosphorylation 
levels recorded following the IFN-α, IFN-γ and IFN-λ treatments, respectively. The 
first time point of these plots is 1 h as this is the shortest treatment duration 
performed in the time course experiments. 
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Table 12. Summary of the effect of IFN-α, -γ and –λ on the phosphorylation of STAT1 Ser727, STAT1 Tyr701, STAT3 Ser727 and STAT3 Tyr705. Only statistically significant effects are 
recorded in this table. 
 
Cell line 3T3-L1 pre-adipocytes 3T3-L1 mature adipocytes hMADS pre-adipocytes hMADS mature adipocytes 
IFN type α γ λ α γ λ α γ λ α γ λ 
p-STAT1 Ser727 + 210 % (1 h) + 364 % (24 h) 
  
+ 252% (2 h) 
  
+ 413 % (1 h) 
 
+ 317 % (24 h) + 613 % (2 h) 
 
p-STAT1 Tyr701 
+ 15296 % (1 
h) 
+ 2259 % (1 h) 
  
+ 34613% (2 
h) 
  
+ 15818 % (1 
h) 
 
+ 3396 % (2 h) + 1188 % (1 h) 
 
p-STAT3 Ser727 + 94 % (1 h) + 141 % (24 h) 
  
+ 105 % (1 h) 
       
p-STAT3 Tyr705 + 332 % (1 h) + 145 % (1 h) 
  
+ 313 % (1 h) 
  
+ 430 % (1 h) 
 









        
 
Figure 41. A. Type I but not type III IFN induces the phosphorylation of STAT3 Tyr705 in hMADS pre-adipocytes although this effect falls short of reaching statistical significance. 
B. Neither type I nor type III IFN induces the phosphorylation of STAT3 Ser727 in hMADS pre-adipocytes. For both figures A and B, hMADS pre-adipocytes were treated with IFN-γ 
(20 ng/mL) (lane 3), IFN-α (lanes 4 to 8) and IFN-λ (lanes 9 to 13) in complete DMEM (LG). An equivalent volume of MilliQ water was used as control for the IFN treatments (16 
μL) (lane 2). Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish. 4 μg and 14 μg of protein were loaded per lane for figures A and B, respectively (10% SDS-
acrylamide gel). ** denotes a treatment statistically different from all other treatments (p-value < 0.05). Note that to avoid overcrowding figure B, only the differences between the 




       
 
Figure 42. Neither type I nor type III IFN induces the phosphorylation of STAT1 Tyr701 (A) and STAT1 Ser727 (B) in hMADS pre-adipocytes. For both figures A and B, hMADS pre-
adipocytes were treated with IFN-γ (20 ng/mL) (lane 3), IFN-α (lanes 4 to 8) and IFN-λ (lanes 9 to 13) in complete DMEM (LG). An equivalent volume of MilliQ water was used as 
control for the IFN treatments (16 μL) (lane 2). Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish. 8 μg of protein were loaded per lane (10% SDS-acrylamide 
gel). Statistical difference between the 1 h IFN-γ treatment and other treatments is indicated with £; ** denotes a treatment statistically different from all other treatments (p-value < 





       
 
Figure 43. A. Type I IFN but not type III IFN induces the phosphorylation of STAT3 Tyr705 in hMADS mature adipocytes. B. Neither Type I IFN nor type III IFN induces the 
phosphorylation of STAT3 Ser727 in hMADS mature adipocytes. For both figures A and B, hMADS mature adipocytes were treated with IFN-γ (20 ng/mL) (lane 3), IFN-α (lanes 4 to 
8) and IFN-λ (lanes 9 to 13) in complete DMEM (LG). An equivalent volume of MilliQ water was used as control for the IFN treatments (8 μL) (lane 2). Cells were lysed with 80 μL 
1% TX-100 lysis buffer per well. 51 μg of protein were loaded per lane (10% SDS-acrylamide gel). Statistical difference between the 1 h IFN-γ treatment and other treatments is 
indicated with £; statistical difference between the 1 h IFN-α treatment and other treatments is indicated with %; ** denotes a treatment statistically different from all other 




       
 
Figure 44. Type I IFN but not type III IFN induces the phosphorylation of both STAT1 Tyr705 (A) and STAT1 Ser727 (B) in hMADS mature adipocytes. For both figures A and B, 
hMADS mature adipocytes were treated with IFN-γ (20 ng/mL) (lane 3), IFN-α (lanes 4 to 8) and IFN-λ (lanes 9 to 13) in complete DMEM (LG). An equivalent volume of MilliQ 
water was used as control for the IFN treatments (8 μL) (lane 2). Cells were lysed with 80 μL 1% TX-100 lysis buffer per well. 47 μg and 51 μg of protein were loaded per lane for 
figures A and B, respectively (10% SDS-acrylamide gel). Statistical difference between the untreated control and other treatments is indicated with @ (p-value < 0.05). Note that to 
avoid overcrowding both figures, only the differences relevant our analysis are shown, the result in full of the one-way ANOVA analysis can be found in appendix VII. 10. Data from 
three independent experiments. 
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Figure 45. Graph showing the induction of STAT3 Tyr705, STAT3 Ser727, STAT1 Tyr701 and STAT1 Ser727 by IFN-α (in blue), IFN-γ (in red) and IFN-λ (in green) in 3T3-L1 pre-
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Figure 46. Graph showing the induction of STAT3 Tyr705, STAT3 Ser727, STAT1 Tyr701 and STAT1 Ser727 by IFN-α (in blue), IFN-γ (in red) and IFN-λ (in green) in 3T3-L1 mature 
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Figure 47. Graph showing the induction of STAT3 Tyr705, STAT3 Ser727, STAT1 Tyr701 and STAT1 Ser727 by IFN-α (in blue), IFN-γ (in red) and IFN-λ (in green) in hMADS pre-
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Figure 48. Graph showing the induction of STAT3 Tyr705, STAT3 Ser727, STAT1 Tyr701 and STAT1 Ser727 by IFN-α (in blue), IFN-γ (in red) and IFN-λ (in green) in hMADS mature 
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III. 4.   Discussion of Chapter 3 
III. 4. 1. Models of palmitate- and IFN-γ-induced insulin resistance  
Data from preliminary experiments on 3T3-L1 pre-adipocytes, where cells 
were treated either in absence or presence of serum, reveals a minor palmitate-
induced increase in insulin-stimulated Akt phosphorylation relatively to insulin-
stimulated control in both conditions tested (Figure 13). Yet, altering the 
experimental conditions to a 24 h treatment followed by a 3 h serum derivation 
resulted in a SFA-mediated attenuation of insulin-stimulated p-Akt signal in both 
pre-adipocytes and mature adipocytes (Figures 14A and 15A). Such effect was 
rescued by adding A66 to the palmitate treatment, hence validating this cellular 
model of palmitate-induced insulin resistance as well as the positive metabolic 
impact of p110α inhibition. The beneficial effects of blocking this catalytic subunit 
of PI3K had indeed been reported Foukas et al. in 2006, when investigating the 
phenotypic traits of p110αD933A/WT mice (L. C. Foukas 2006). Hence, the present 
results provide an understanding of this phenomenon at the cellular level in 
metabolic tissues. In human cells, the inhibitory effect of palmitate on insulin-
stimulated Akt phosphorylation could only be reproduced in mature adipocytes. 
However, the response of the human pre- and mature adipocytes to the combined 
treatment of palmitate and A66 and A66 alone followed a similar trend as the 
response of murine cells (Figures 16A and 17A). 
 
IFN-γ treatment induced an unexpected increase in insulin-stimulated p-Akt 
in 3T3-L1 pre-adipocytes treated in presence of serum, while the opposite effect was 
recorded under SF conditions (Figure 13). This points to a potential interaction 
between the cytokine and serum-soluble receptors, which may act as competitive 
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inhibitors of IFN-γ activity by reducing its ability to bind cell-surface receptors 
(Oppenheim 1993). However, the inhibitory effect of the cytokine treatment in the 
absence of serum recorded in figure 13 could not be reproduced in figure 14B.  
 
In differentiated 3T3-L1 adipocytes, the cytokine treatment significantly 
inhibited insulin-stimulated phosphorylation of Akt, an effect abrogated with 
exposure to the p110α inhibitor (Figure 15B). A similar trend was observed in the 
mirror experiments carried out in pre- and mature hMADS adipocytes (Figures 16B 
and 17B). Statistical significance of IFN-γ-mediated effect could not be achieved 
despite replicating the experimental conditions used by McGuillicuddy and 
colleagues, which they reported to significantly hinder the phosphorylation of Akt 
(McGillicuddy 2009). A likely explanation for this discrepancy is the difference in 
human adipocytes used: while they performed their experiments in SGBS cells, the 
present work was carried out in hMADS cells. Increasing the concentration of IFN-γ 
used might have allowed to statistically validate the inhibitory effect of the cytokine 
on insulin signalling. 
 
 
III. 4. 2. STAT3, but not STAT1, is activated by palmitate  
Focusing on the impact of palmitate on the phosphorylation of STAT1 and 
STAT3, our results indicate a stimulatory effect on p-STAT3 Tyr705 following an 8 h 
treatment in 3T3-L1 mature adipocytes solely (Figure 20A). The serine residues of 
STAT1 and STAT3, as well as the tyrosine residue of STAT1, were unaffected by 
palmitate treatment (Figures 20B, 21A and 21B). In other cell types tested (3T3-L1 
pre-adipocytes, hMADS pre- and mature adipocytes), the SFA failed to elicit a 
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reproducible effect on either p-STAT3 Tyr705/ Ser727 or p-STAT1 Tyr701/ Ser727 
(Figures 18, 19, 22, 23, 24 and 25). A series of shorter time course experiments was 
performed confirming that neither STAT1 nor STAT3 was activated within an hour 
of the palmitate treatment (Figures 26 to 33). Collectively, these findings suggest 
that the observed palmitate-mediated phosphorylation of STAT3 Tyr705 occurs 
through a mechanism independent of IFN secretion, as STAT1 would have 
otherwise been induced by the SFA. 
 
The induction of STAT3 by palmitate aligns with the studies discussed in the 
introduction of the present chapter. Indeed, Mashili and colleagues demonstrated the 
stimulatory effect of SFA on this tyrosine phosphorylation site of the transcription 
factor (Mashili 2013). Comparable to our findings, the palmitate-induced stimulation 
of STAT3 was associated with down-regulation of the insulin pathway. These results 
were corroborated by the study of Weigert and colleagues who evidenced the 
palmitate-mediated induction of pro-inflammatory IL-6, which in turn promoted the 
phosphorylation of STAT3 Tyr705 (Weigert 2004). These two studies were carried 
out in skeletal muscle cell and, to the best of our knowledge, no study has 
investigated the effect of palmitate on the phosphorylation of STAT3 or STAT1 in 
adipocytes. 
 
Our experiments reveal that although palmitate induces STAT3, it has no 
effect on the phosphorylation of STAT1.  Despite an overlap in the activating factors 
modulating the phosphorylation of the two STATs (e.g. IFN-γ, oncostatin-M, LIF) 
highlighted in the introduction of the present chapter, differences exist in their 
regulation and activity. These will now be explored in further detail to shed light on 
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the potential molecular mechanisms underlying the differential effect of palmitate on 
STATs 1 and 3. For instance, Vaisse et al. reported leptin to activate STAT3 but not 
STAT1 in the hypothalamus of ob/ob and WT mice (Vaisse 1996). Specific nutrients 
such as arginine were also found to induce the tyrosine phosphorylation of STAT3, 
without stimulating STAT1 in WAT (de Castro Barbosa 2009). McGillicuddy and 
colleagues evidenced that in human and murine adipocytes, IFN-γ down-regulates 
insulin signalling through STAT1 and to a lesser extent STAT3 (McGillicuddy 
2009). This differential effect of the cytokine on STAT1 and STAT3 activation had 
been previously reported in human acute myelocytic leukemia cells (Sato 1997). 
 
The differential pattern of activation described by McGillicuddy et al. and 
Sato et al. is characteristic of IFN-mediated STAT phosphorylation. As discussed in 
Chapter 1, IFN-γ promotes the phosphorylation of STATs through IFNGR, which 
interacts with JAK1 and JAK2. These kinases trigger the sustained activation of 
STAT1, while also inducing the activation of STAT3 in a weaker and more transient 
manner (Pensa 2013). As illustrated in figure 8, type I IFN drives the same activation 
pattern in STATs through binding IFNAR, which recruits and phosphorylate JAK1 
and TYK2 (L. Platanias 2005). However, the opposite STAT activation pattern has 
been reported: a prolonged stimulation of STAT3 and transitory activation of STAT1 
(Pensa 2013). Such pattern is associated with the glycoprotein 130 (gp130)-mediated 
induction of STAT.  
 
Gp130 describes a family of cytokines, also known as the IL-6 family, which 
docks to the plasma membrane via receptor complexes characterised by a common 
signal transducing receptor chain, gp130 (P. B.-N. Heinrich 2003). In addition to 
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gp130, each cytokine interacts with another receptor component including the LIF 
receptor and an α receptor specific to each member of this family of proteins. For 
instance, IL-6 engages IL-6 receptor α and associated with a gp130 homodimer (P. 
B.-N. Heinrich 2003). Upon receptor activation, the tyrosine kinases of the JAK 
family (JAK1, JAK2 and TYK2) are induced and enable the binding of STATs to the 
receptor. The highly conserved SH2 domain of STATs mediates this interaction: 
STAT3 was reported to bind the phospho (p)YXXQ motif, while evidence indicates 
STAT1 to interact with the pYXPQ motif. The presence of the proline residue in the 
latter consensus sequence implicates that the interaction of STAT1 with the receptor 
is more restricted compared to STAT3. Thus IL-6 family cytokines were shown to 
be potent activators of STAT3 but minor inducers of STAT1 (A. Costa-Pereira 
2014).  
 
Illustrating the differential effect of IFN and IL-6 family cytokines on STATs 
induction, Costa-Pereira et al. observed that silencing STAT3 in mouse embryonic 
fibroblasts (MEFs) did not affect their IFN-γ response but altered the cellular 
response to IL-6 family cytokines (A. T. Costa-Pereira 2002). Surprisingly, the 
authors evidenced a switch from one cytokine signalling to the other triggered by the 
loss of the signalling component. Consistently with such findings, Hergovits et al. 
demonstrated that treating human fibroblasts with oncostatin-M induced a prolonged 
activation of STAT3 Tyr705, while STAT1 Tyr701 was induced to a lesser extent and 
only transiently (Hergovits 2017). Interestingly, they evidenced that STAT3 acts as a 
negative regulator of STAT1 signalling following oncostatin-M stimulation. Indeed, 
silencing STAT3 was reported not only to inhibit STAT3 mRNA and protein 
expression, as well as pSTAT3 Tyr705, but was also associated with a significant 
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increase in pSTAT1 Tyr701 levels in oncostatin-treated cells. Additional experiments 
indicate that the expression of STAT1 target genes was also altered. The authors 
identify SOCS3 as critical in the counter-regulatory activity of STAT3 (Hergovits 
2017).   
 
Therefore, it is likely that the palmitate-mediated phosphorylation of STAT3 
Tyr705 reported in the present chapter is modulated through the secretion of gp130 
cytokines rather than of IFN. Indeed, no evidence in the literature indicates that 
palmitate does stimulate the secretion of IFN or that adipocytes secrete IFN. Various 
studies, however, highlight the ability of the SFA to induce gp130 cytokines. As 
mentioned previously, both Weigert et al. and Oberbach et al. implicated palmitate 
in the expression of IL-6 in muscle cells (Weigert 2004, Oberbach 2010). The same 
observation was made in human coronary artery endothelial cells and in 3T3-L1 
adipocytes (Staiger 2004, K. a. Ajuwon 2005). This link between palmitate and 
gp130 cytokines echoes the association between the latter and the onset of obesity 
and insulin resistance discussed in the introduction of the present chapter and 
reviewed by White and Stephens (U. a. White 2011).  
 
 
III. 4. 3. The roles of STAT3 serine and tyrosine phosphorylation 
sites  
To understand why only the tyrosine residue of STAT3 was phosphorylated 
in response to palmitate treatment, the individual roles of Ser727 and Tyr705 must be 
further investigated. As discussed by Heinrich et al., the binding of STAT3 to the 
gp130 receptor is followed by the phosphorylation of the Tyr705 residue of the 
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transcription factor. This step is essential for the formation of active STAT3 dimers, 
which can then translocate from the cytoplasm to the nucleus where they modulate 
transcription (P. B.-N. Heinrich 2003). Located in the carboxyterminal, the Ser727 
phosphorylation site, found in STAT1 too, also mediates the transcriptional activity 
of STAT3 but is not necessary for nuclear translocation. Moreover, this site is not 
required for the binding of STAT3 to the promoters of ISGs. Its role is limited to 
allowing full transcriptional activation (Wen 1995). It is unclear which kinase 
executes the phosphorylation of the Ser727 residue but p38 MAPK, MAPK/ERK 
kinase 1, ERK and c-Jun N-terminal kinase (JNK) have been implicated in this 
molecular event (P. B.-N. Heinrich 2003). The downstream effector of Akt, PKCδ, 
was also reported to be essential in the phosphorylation of STAT3 Ser727 in HepG2 
cells. Evidence indicates that this event occurs within the nucleus following the 
phosphorylation of the tyrosine residue (Schuringa 2001). 
 
The biological role of Ser727 phosphorylation is not as well understood as that 
of Tyr705. Kramer and colleague postulated the involvement of the serine residue in a 
non-canonical mitochondrial translocation of STAT3 as a strategy to regulate 
adipogenesis (Kramer 2015). Alternatively, Chung et al. proposed that this site is 
implicated in the modulation of the Tyr705-mediated STAT3 activity. Indeed, they 
provided evidence that STAT3 Ser727 phosphorylation inhibited STAT3 Tyr705 
phosphorylation in COS cells (fibroblast-like) (Chung 1997). This seesaw regulation 
of STAT3 phosphorylation is also reflected by the study of Andersson and 
colleagues in 3T3-L1 adipocytes (Andersson 2007). The authors demonstrated the 
dual role of insulin, which, on the one hand, inhibited tyrosine phosphorylation, 
while simultaneously inducing phosphorylation at the serine position. Furthermore, 
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Andersson and colleagues reveal that the pancreatic hormone antagonises IL-6-
induced STAT3 tyrosine phosphorylation and impairs STAT3 nuclear translocation.  
 
The stimulatory effect of insulin on STAT3 Ser727 phosphorylation was later 
confirmed by Wada et al. in 3T3-L1 adipocytes (Wada, 2010). Similarly, Kim et al. 
reported that overexpressing STAT3-S727D sufficed to hinder insulin signalling in 
HepG2 cells (J. Y. Kim 2009). Together, these studies support the model proposed 
earlier by which gp130 cytokines rather than IFN-γ modulate palmitate-mediated 
phosphorylation of STAT3 Tyr705. Indeed, as palmitate impairs the insulin sensitivity 
of the cell, STAT3 Ser727 phosphorylation is no longer induced and the inhibition of 
STAT3 Tyr705 phosphorylation mediated by both Ser727 phosphorylation and insulin 
is alleviated. Under these conditions, cytokines such as IL-6 would be able to freely 
influence transcription through STAT3 Tyr705 phosphorylation. In favour of this 
model, the phosphorylation of Ser727 was found to be critical in IFN-γ-dependent 
innate immune responses (L. Platanias 2005). 
 
 
III. 4. 4. Palmitate-mediated induction of STAT3 Tyr705 
phosphorylation is TLR4-independent 
Various inhibitors were tested to probe the molecular mechanisms underlying 
palmitate-mediated stimulation of p-STAT3 Tyr705 in 3T3-L1 mature adipocytes. 
More specifically, A66, D030, TAK 242 and myriocin were used, targeting p110α, 
p110δ, TLR4 and SPT, respectively (Figures 34, 35 and 36). However, none of these 
small molecules prevented the SFA-induced stimulation of STAT3. Here, the reason 
why inhibiting TLR4 failed to rescue the palmitate-mediated effect will be explored.  
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As discussed in the introduction of the present chapter, many studies indicate 
that TLR4 mediates palmitate signalling and has the ability to bind the SFA (Shi 
2006, Holland 2011, Schilling 2013, Turpin 2014, Pal 2012, Nicholas 2017). The 
receptor, abundantly expressed in differentiated 3T3-L1 and adipose tissue, was also 
found to be a central modulator of the IFN response (Faure 2001, T. T. Kawai 2001, 
Noppert 2007, M. K. Song 2006). Furthermore, it was directly implicated in the up-
regulation of STAT3 expression in bladder epithelial cells (Ying 2013). Collectively, 
these studies suggest that inhibiting TLR4 would likely affect palmitate-induced 
phosphorylation of STAT3 recorded in figure 20A. However, adding the inhibitor to 
the SFA treatment failed to rescue the palmitate-mediated effect (Figure 34). Pre-
treating the cells with the TLR4 inhibitor (TAK 242) had no significant effect either 
(Figure 35). As TAK 242 successfully rescued the LPS-mediated induction of 
STAT3, the activity of the inhibitor could be verified.  
 
A reason for this could be that in differentiated 3T3-L1, TLR4 mediates only 
the effect of palmitate through the stimulation of IFN secretion. Indeed, according to 
our model palmitate induction of STAT3 is likely to be modulated by gp130 
cytokines, hence the absence of effect on STAT3 phosphorylation when inhibiting 
TLR4. The study of Song et al. supports this theory as they noted that palmitate did 
not significantly affect the expression of TLR4 target genes in mature 3T3-L1 (M. K. 
Song 2006). Therefore another receptor is likely to be mediating the effect of 
palmitate on STAT3. A potential candidate would be TLR2, a TLR homologue 
located at the cell surface which expression was found markedly elevated compared 




This receptor is induced by a range of ligands derived from bacteria (e.g. 
diacyl and triacyl lipopeptides, lipoteichoic acid and glycolipids), fungi (e.g. 
zymosan), protozoans (e.g. glycosylphosphatidylinositol anchor) and viruses (e.g. 
the envelope proteins of measles virus) (Uematsu 2008). Furthermore, similarly to 
TLR4, TLR2 is activated by SFA. For instance, in C2C12 myotubes, palmitate 
triggers the association of TLR2 with its adaptor protein MyD88, while also 
stimulating the downstream kinases JNK, PKC and p38 (J. Senn 2006). Various 
studies substantiated the importance of TRL2 in the development of obesity and its 
associated metabolic disorders. Indeed, Kim et al. report the expression of this 
receptor to be up-regulated in the adipose tissue of HFD-fed mice. In addition the 
expression of TLR2 was increased in both the visceral and subcutaneous fat depots 
of ob/ob mice versus lean control (S. C. Kim 2012). Ahmad et al. record the same 
observation when comparing the expression of the receptor in the subcutaneous 
adipose tissue of both obese and type 2 diabetic overweight subjects compared to 





Figure 49. Potential molecular mechanism mediating palmitate-induced activation of STAT3. 
Palmitate binds TLR2 triggering NF-κB in a MyD88-dependent manner. This promotes the secretion 
of interleukin-6 (IL-6), which docks to its receptor (IL-6 receptor [IL6R] α associated to a 
glycoprotein 130 homodimer). Once activated, the receptor drives the phosphorylation of JAK and in 
turn STAT3 Tyr705. STAT3 then translocates to the nucleus where it stimulates the transcription of 
pro-survival genes and promotes proliferation.  
 
 
Poulain-Godefroy and colleagues demonstrated that TLR2 induction with 
Pam3CSK4, a TLR2 agonist, promotes the release of IL-6 form both pre- and mature 
3T3-L1 adipocytes (Poulain-Godefroy 2010). Aligned with these findings, Ajuwon 
et al. reported that exposing 3T3-L1 cells to peptidoglycan stimulates the expression 
of both IL-6 and TLR2 (K. B. Ajuwon 2009). MyD88 is required for the secretion of 
IL-6 as MyD88-deficient mice fail to produce the gp130 cytokine when treated with 
TLR ligands (K. K. Takeda 2003). As illustrated in figure 12, TLR signalling can 
either be MyD88-dependent or MyD88-independent. Interestingly, TLR2 ligand-
mediated activation of NF-κB is abolished in MyD88-deficient macrophages, while 
the NF-κB cascade is still activated by a TLR4 ligand. This reveals that TLR2 
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signalling requires MyD88, unlike TLR4 signalling which appears to rely on both 
MyD88-dependent and –independent pathways (T. A. Kawai 1999).  
 
Exposure of MyD88-deficient macrophages to a TLR4 ligand (LPS) allowed 
further characterisation of the MyD88-independent cascade unveiling that although 
the expression of a range of ISGs was mediated by this cascade through the 
activation of IRF3, many pro-inflammatory cytokines such as IL-6 were not induced. 
On the contrary, exposure of these MyD88-deficient macrophages to a TLR2 ligand 
(macrophage-activating lipopeptide-2) failed to stimulate ISGs (T. T. Kawai 2001). 
Collectively, this data supports the model presented in figure 49, by which palmitate 
would induce IL-6 secretion through the TLR2/MyD88 cascade, resulting in the 
induction of STAT3 but not STAT1. Such model provides a mechanistic theory to 
the results discussed in Chapter 3. 
 
 
III. 4. 5. Palmitate-mediated induction of STAT3 Tyr705 
phosphorylation is a PI3K-independent 
Aside from inhibiting TLR4, the effect of blocking both p110α and p110δ on 
palmitate-mediated induction of p-STAT3 Tyr705 was also investigated. As the 
inhibitory effect of the SFA on the phosphorylation of Akt could be rescued through 
the inhibition of p110α, it seemed plausible that this would also prevent the 
palmitate-induced stimulation of STAT3. However, as shown in figure 34, A66 had 
no effect on this endpoint. Having postulated that the effect of palmitate would be 
modulated via TLR4, an inhibitor of p110δ (D030) was also tested (Figure 34). 
Indeed, Aksoy et al. reported this isoform of PI3K to control the subcellular 
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compartmentalisation of TLR4 (Aksoy 2012). Yet, inhibiting p110δ also failed to 
rescue palmitate-mediated stimulation STAT3 Tyr705.  
 
In their review, Akira and Takeda discuss the interaction between PI3K and 
the TLR pathway (Akira 2004). They draw the reader’s attention to the capacity of 
TLRs to bind the SH2 domain of the p85 regulatory subunit of PI3K. Upon binding, 
the catalytic subunit is recruited to the TLR-p85 complex allowing for the complete 
activation of PI3K. Furthermore, the authors note the presence of another PI3K 
binding site in the carboxyterminus of MyD88, which was also found to directly 
interact with Akt. Using a dominant negative mutant of p85 in human microvascular 
endothelial cells, Li et al. also provided evidence that PI3K is required for the 
transcriptional activity of NF-κB (X. T. Li 2003). In addition, they confirmed that 
inhibiting PI3K through this system hindered the production of IL-6 using an 
enzyme-linked immunosorbent assay. Together, these results seem to support that 
PI3K inhibition would alter palmitate-induced STAT3 activation if the latter were 
modulated through TLR2/MyD88/IL-6.  
 
However, the effect of PI3K inhibition on IL-6 reported by Li et al. is 
mediated by LPS, which interacts with TLR4 rather than TLR2 (X. T. Li 2003). 
Therefore, the fact that A66/D030 does not rescue the effect of palmitate does not 
contradict our model presented in figure 49 as the MyD88/PI3K interaction 
implicates TLR4. Consistent with such findings, Ortega-Molina et al. failed to 
observe a statistically significant decrease in IL-6 expression in the liver of HFD-fed 
mice treated with a pharmacological inhibitor of PI3K (CNIO-PI3Ki) versus mice on 
the same diet treated with vehicle (Ortega-Molina 2015). In addition, Ajuwon et al. 
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reported that exposing 3T3-L1 adipocytes to palmitate promotes NF-κB activity 
along with IL-6 production, but, importantly, the authors note that blocking PI3K 
using a non-specific, covalent inhibitor (wortmannin) magnified the response to 
palmitate alone (K. a. Ajuwon 2005).  
 
 The last inhibitor tested was myriocin, which targets SPT, an enzyme 
specialised in catalysing the first step of de novo ceramide synthesis. As with the 
other inhibitors tested, it had no effect on the palmitate-mediated stimulation of 
STAT3 Tyr705 phosphorylation (Figure 35). This result is consistent with the 
absence of effect of TAK 242, A66 and D030 on palmitate-induced activation of 
STAT3. Indeed, C16:0-ceramides are associated to the onset of obesity and glucose 
intolerance through their effect on PI3K and TLR4 (Holland 2011, Schilling 2013, 
Hla 2014). If neither PI3K nor TLR4 is involved in modulating the stimulatory effect 
of palmitate on STAT3, it is to be expected that C16:0- ceramides are not implicated 
in this molecular mechanism either.  
 
 
III. 4. 6. Comparing the effect of the different types of IFN on 
STAT1 and STAT3 
Time course experiments investigating the effect of three different types of 
IFN (IFN-α, IFN-γ and IFN-λ) on the phosphorylation of STAT1 Tyr701, STAT1 
Ser727, STAT3 Tyr705 and STAT3 Ser727 were carried out in 3T3-L1 and hMADS 
pre- and mature adipocytes (Figures 18 to 25 and 37 to 44). For clarity, the data 
obtained was superimposed in four sets of graphs (Figures 45 to 48). In 3T3-L1 pre-
adipocytes, IFN-α and IFN-γ to a lesser extent induced a rapid phosphorylation 
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(peaking at 1 h of treatment) of both STAT1 Tyr701 and STAT3 Tyr705. The 
phosphorylation of STAT1 Tyr701 is significantly stronger than that of STAT3 
Tyr705. The serine residues of both STAT1 and STAT3 were stimulated by IFN-γ in 
the short and long term (weak induction after 1 h of treatment, stronger induction 
after 24 h of treatment) and by IFN-α only in the short term (peaking at 1 h of 
treatment) (Figure 45).  
 
Comparing the response of pre-adipocytes to differentiated 3T3-L1 cells, we 
observe a considerable attenuation of IFN-α-mediated effect, which becomes 
comparable to that elicited by IFN-λ (Figure 46). Inversely, IFN-γ had a stronger 
effect on the phosphorylation of all residues in the mature murine adipocytes 
compared to pre-adipocytes. The trend previously recorded in pre-adipocytes can 
also be noted in mature cells: a short-term induction of the tyrosine residue is 
observed in both STAT1 and STAT3 with a stronger phosphorylation of STAT1 
Tyr701. Interestingly, IFN-γ-induced phosphorylation in the serine site followed an 
opposite pattern in STAT1 and STAT3. Indeed, after 1 h of treatment p-STAT3 
Ser727 is stimulated, its level then dips after 2 h of treatment and rises back up after 4 
h to gradually decrease again. The phosphorylation levels of STAT1 Ser727 respond 
to the IFN-γ treatment in the opposite manner.  
 
In hMADS pre-adipocytes, IFN-γ had a significant impact on the 
phosphorylation of the four residues considered but IFN-α and IFN-λ did not. As for 
murine cells, the effect of the cytokine was stronger on STAT1 than STAT3. For all 
residues, the induction peaked after 1 h of treatment (Figure 47). In this cell line, 
differentiation down-regulated the IFN-γ mediated effect except for STAT1 Ser727 
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(Figure 48). IFN-α significantly stimulated the phosphorylation of STAT1 Tyr701 as 
well as STAT1 Ser727 and STAT3 Tyr705 to a lesser extent. For both STAT1 
phosphorylation sites, IFN-α-induced stimulation peaked after 2 h of treatment, 
while for STAT3 Tyr705 the peak was recorded after 1 h of treatment similarly to 
IFN-γ-induced activation. For STAT3 Ser727, the three IFN tested only had a minor 
effect. 
 
The pattern of activation of the tyrosine residue mediated by IFN-γ is 
consistent with the findings of McGillicuddy et al. who reported a strong induction 
of STAT1 Tyr701 and a milder activation of STAT3 Tyr705 in both murine and human 
adipocytes (McGillicuddy 2009). IFN-α has been reported to induce the formation of 
a range of STATs homo- and heterodimers including STAT1 and STAT3 
homodimers, as well as STAT1-STAT3 heterodimers (L. Platanias 2005). However, 
to the best of our knowledge, no study has compared the effect of IFN-α on p-
STAT1 Tyr701 and p-STAT3 Tyr705 levels over time in adipocytes. Tanabe et al. 
were able to demonstrate that IFN-β, another type I IFN, induces the 
phosphorylation of STAT1 Tyr701 after exposing murine T lymphocytes to the 
cytokine for 30 min. They report that STAT3 Tyr705 was also phosphorylated but to a 
lesser degree (Tanabe 2005).  Such findings coincide with the observations reported 
in this chapter (Figures 45 to 48). 
 
Interestingly, in 3T3-L1 pre-adipocyte cells the tyrosine phosphorylation of 
STAT1 and STAT3 induced by IFN-α was more significant than that elicited by 
IFN-γ (Figure 45). This trend was however reversed in mature 3T3-L1 adipocytes 
(Figure 46). This likely reflects the inhibitory effect of IFN-α on adipogenesis 
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recently described by Lee and colleagues in the same cell type (K. U. Lee 2016). 
They reported that both STAT1 expression and tyrosine phosphorylation were 
enhanced by the cytokine after 1 h of treatment, while inhibiting STAT1 prevented 
IFN-α from down-regulating the modulators of adipogenesis PPARγ and C/EBPα. 
STAT1 inhibition also rescued IFN-α-mediated cell cycle arrest. This anti-
adipogenic property of IFN-α/STAT1 seems to corroborate the observation that 
STAT1 is more strongly activated in pre- rather than mature adipocytes.  
 
Surprisingly, in hMADS cells, the opposite response can be observed, with 
IFN-γ having a more potent effect than IFN-α in pre-adipocytes and in mature cells 
IFN-γ-mediated effect being milder than that mediated by IFN-α (Figures 47 and 
48). This result is supported by the study of McGillicuddy et al. demonstrating the 
anti-adipogenic effect of IFN-γ in human adipocytes (McGillicuddy 2009). Thus it 
seems that inhibition of the adipogenic process can be effected by either type I or 
type II IFN depending on the type of cell. Overall the pattern of serine 
phosphorylation was consistent with the current paradigm which supports that both 
type I and II IFN induce the phosphorylation of the serine residue of STAT1 and 
STAT3 (L. Platanias 2005). However, our data suggests a greater effect of type II 
IFN compared to type I IFN. Moreover, this effect is stronger in the long-term in 
murine cells but peaks in the short-term in human cells.  
 
As illustrated by figures 45 to 48, IFN-λ treatment failed to produce any 
significant effect on the phosphorylation levels of STAT1 and STAT3 across cell 
types despite a trend towards a minor induction of serine phosphorylation most 
noticeable in hMADS pre-adipocyte STAT3 Ser727 (Figure 47). These results do not 
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rule out the implication of type III IFN in STAT1/3 activation all together. Indeed, as 
reported by Dickensheets et al. IFN-λ2 (used in this experiment) was found to have a 
milder effect on the phosphorylation of STAT1 Tyr701 compared to IFN-λ1 and IFN-
λ3 (Dickensheets 2013). Moreover, the study investigated the IFN-λ-mediated 
induction of STAT1 in hepatocytes, lymphocytes and monocytes and recorded a 
striking variability of the cytokine-induced effect across cell types. Therefore, unlike 
IFN-λ2, IFN-λ1 or IFN-λ3 might have an effect on the phosphorylation of STAT in 
adipocytes. Further, an IFN-λ2-mediated effect might be observable at higher 
concentrations, as Dickensheets and colleagues recorded an effect at 50 and 500 
ng/mL (Dickensheets 2013). 
 
 
III. 4. 7. Limitations and future experiments 
One limitation of the findings exposed in the present chapter was a model of 
IFN-γ-induced insulin resistance could only be established in differentiated 3T3-L1 
cells, and even then the cytokine had only a mild inhibitory effect on p-Akt.  IFN-γ 
failed to impair insulin signalling in 3T3-L1 and hMADS pre-adipocytes as well as 
in hMADS mature adipocytes. A higher concentration of IFN-γ might have induced 
a significant inhibition of Akt phosphorylation in these cells. Besides, future 
experiments could attempt to develop such model of insulin resistance in SGBS cells 
rather than hMADS and thus exactly reproduce the experimental design of 
McGillicuddy et al. (McGillicuddy 2009).  
 
Another shortfall of this chapter was the inability to reproduce the palmitate-
mediated induction of pSTAT3 Tyr705 observed in mature 3T3-L1 adipocytes in 
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mature hMADS cells. A potential reason for this could be that the basal levels of p-
STAT3 Tyr705 is significantly higher in the latter cell line, thus subtle variations in 
phosphorylation might have gone undetected. Furthermore, we failed to successfully 
rescue the palmitate-mediated induction of pSTAT3 Tyr705 in mature murine cells. 
No positive control was included when testing the effect of A66, D030 or myriocin 
(figures 34 and 36) thus providing no guaranty that these worked efficiently. 
However, in the case of A66, experiments had been previously performed showing 
the inhibitor to successfully counteract the deleterious effect of palmitate on p-Akt 
levels. We were therefore confident that it efficiently inhibited p110α. Consequently, 
future experiments should seek to include appropriate positive controls for at least 
D030 and myriocin. These should also investigate whether inhibiting TLR2 would 
rescue palmitate-mediated induction of p-STAT3. If so this would validate the 
mechanistic model proposed in figure 49.  
 
Lastly, future experiments could further explore the effect IFN-λ on STAT 
phosphorylation in adipocytes by comparing the effect of IFN-λ1, IFN-λ2 and IFN-
λ3 side-by-side. These will need to include a valid positive control, the lack of which 
was another shortcoming of the data presented in the present chapter. Higher 
concentrations (comparable to the ones tested by Dickensheets and colleagues) 
might be required to observe a significant effect on the phosphorylation of the STAT 





CHAPTER 4.  EFFECTS OF SFA OVERLOAD ON LIPID 




IV. 1.   Overview of Chapter 4 
 
Having explored the impact of palmitate on the development of insulin 
resistance and investigated its effect on the downstream signalling of IFN, the 
present chapter focuses on the role of this lipid molecule in the modulation of other 
facets of adipocyte metabolism. Two processes disrupted in the obese insulin 
resistant state were studied: lipolysis and autophagy. While, the former describes the 
breakdown of stored lipids into FFAs, the latter is recognised as the cellular 
degradation of target cytosolic cargo through the activity of the autolysosome. 
Parallels can be drawn between such processes as both provide the cell with energy 
and molecular building blocks necessary for vital anabolic reactions to occur during 
nutrient deprivation. As both processes are sensitive to nutrient levels, it is 
unsurprising that crossovers exist in the molecular effectors in charge of their 
regulation: while insulin promotes the down-regulation of both lipolysis and 
autophagy, glucagon stimulates these two processes. Such similarities have led 
Singh and colleagues to coin the term “lipophagy” in reference to the type of 
autophagy targeting intracellular lipid stores (R. K. Singh 2009). Obesity-associated 
insulin resistance has been found to directly disrupt the lipophagic process by 
promoting low-grade systemic inflammation. The present chapter therefore 




IV. 1. 1. Aim of Chapter 4  
In order to gather insight on the effect of palmitate and IFN on lipophagy, we 
assessed whether treating 3T3-L1 and hMADS adipocytes with the SFA and the 
cytokine affected markers of lipolysis, including the phosphorylation of HSL and of 
PKA. The activation of the autophagic pathways was also evaluated through 
quantifying the expression of protein kinase R (PKR) and microtubule-associated 






IV. 2.   Introduction of Chapter 4 
IV. 2. 1. The regulation of lipolysis by blood glucose concentration 
Lipolysis, introduced in Chapter 1, describes the process by which TAG 
stores are hydrolysed to release FAs and glycerol into the circulation for endogenous 
use, thus allowing cells to cope with starvation. Having previously discussed its 
mechanisms and the critical role of key enzymes such as PKA and HSL, we will 
now focus on the implication of the glucagon/insulin tandem in its regulation. 
During fasting, glucagon elicits the pro-lipolytic activity of PKA through the 
stimulation of the cAMP pathway. Glucagon-mediated PKA activation also up-
regulates the gluconeogenic programme via CREB phosphorylation. Indeed, through 
passive diffusion, the activated PKA catalytic subunits enter the nucleus where they 
phosphorylate CREB, thus promoting the transcription of its target gluconeogenic 
genes characterised by CRE-containing promoters.  
 
As shown in figure 50, CREB-dependent transcription is promoted by 
association of CREB with CREB regulated transcription coactivators (CRTCs) 
(Altarejos 2011). Moreover, through the glucagon-mediated inhibition of salt-
inducible kinase 2 (SIK2), CRTC2 is dephosphorylated and migrates to the nucleus 
where it further simulates the gluconeogenic program (Altarejos 2011). 
Gluconeogenesis is also amplified as a result of low insulin concentration driving the 
dephosphorylation of FOXO1. Indeed, as for CREB and CRTC2, the 
phosphorylation status of FOXO1 determines its subcellular localisation: the loss of 
its phosphate group at Ser316 induces the translocation of the transcription factor to 




 In the post-prandial state, insulin drives the down-regulation of the lipolytic 
process through inhibiting the cAMP/PKA signalling. Firstly, it promotes cAMP 
degradation through the activation of cyclic nucleotide phosphodiesterase 3B, 
thereby hindering PKA activity (Ahmed 2010). Furthermore, the hormone was 
shown to inhibit AC while also promoting the internalisation of β-ARs (J. a. Jocken 
2008). Lastly, Strålfords and colleagues evidenced the insulin-induced 
dephosphorylation of HSL, attributed to the stimulation of a protein phosphatase 
(Stralfors 1989). It is therefore not unexpected that the obese insulin resistant state is 
associated with excessive basal lipolysis, as cells fail to respond to the anti-lipolytic 
effects of insulin (Duncan 2007). This leads to high levels of circulating FAs, which 
accumulate in the liver along with dietary FAs where they undergo esterification to 
TAGs. These can either accumulate in non-adipose tissues such as skeletal muscles, 
the pancreas and the liver (a process described as ectopic fat deposition), or be 
secreted into the blood as very low-density lipoproteins (Postic 2008). ER stress, cell 
death and mitochondrial dysfunction are additional consequences of unrestrained 
lipolysis. Together these metabolic disorders can seed life-threatening conditions 
such as T2D, liver steatosis and atherosclerosis (M. E. Schweiger 2014).  
 
Unlike basal lipolysis, catecholamine-mediated lipolysis is blunted with 
obesity. Several mechanisms are thought to underlie the onset of this metabolic 
disruption, including a decrease in expression and activity of both β-ARs and HSL 
along with a diminished access of lipases to their substrate. Whether blunted 
catecholamine-induced lipolysis is the cause or the consequence of the disorder is 
the object of an on-going debate (J. a. Jocken 2008). Interestingly, CRTC3 was 
found to play a critical role in the attenuation of catecholamine signalling (Y. A. 
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Song 2010). Indeed, it appears that the CREB coactivator promotes obesity through 
the inhibition of AC in adipose tissues, with Crtc3-/- knockout mice protected from 
diet-induced obesity and from hepatic steatosis (Freson 2007). Overall, the data 
presented in this section emphasises the crosstalk between glucose and lipid 
metabolism and highlights the critical role of PKA/cAMP signalling in the 
modulation of these processes. 
 
 
Figure 50. The role of CREB phosphorylation in the regulation of hepatic gluconeogenesis. Upon 
ligand engagement, the α-subunit of the stimulatory G-protein linked to the G protein-coupled 
receptor (GPCR) activates AC. This enzyme can then stimulate the synthesis of cAMP, which will 
promote the dissociation of the catalytic subunit of PKA. The latter will translocate to the nucleus 
where it enables the formation of the CREB-CBP-CRTC2 multi-protein complex through the 
phosphorylation of CREB. As a result of these molecular events along with the activation of FOXO1, 





IV. 2. 2. The mechanisms of autophagy 
The second aspect of lipophagy, which the present chapter will explore is 
autophagy. As mentioned in Chapter 1, it describes the catabolic process by which 
the cell degrades, through lysosomal activity, defective or threatening constituents 
such as intracellular pathogens and unfolded proteins (Cahova 2015). This process 
involves the formation of an autophagosome, which engulfs the components targeted 
for degradation. As illustrated by figure 51, two ubiquitin-like systems mark the 
synthesis of this double-membrane organelle. Firstly, the conjugation of the proteins 
encoded by autophagy related genes Atg5 and Atg12, triggered by the ATG7-
mediated activation of ATG12. Activated ATG12 then interacts with ATG10, which 
enables it to covalently bind ATG5 at Lys149 through its carboxyterminal glycine 
residue. Having recruited ATG16L, the resulting ATG5-ATG12-ATG16L complex 
associates with the phagophore to induce curvature in its structure through the 
asymmetric recruitment of LC3B. Once the autophagosome is formed, the complex 
dissociates from the membrane, thus making it a weak indicator of autophagy. In this 
system, parallels can be drawn between ATG7 and E1 ubiquitin-activating enzymes, 
on the one hand, and ATG10 and E2 ubiquitin-conjugating enzymes, on the other 
hand (Ohsumi 2001). 
 
 The second ubiquitin-like system required for autophagy is the ATG8 
system, the yeast homologue of the mammalian LC3B, mentioned above. Upon 
induction of autophagy, the cytosolic unprocessed form of the protein (proLC3B) is 
cleaved by ATG4, thereby producing LC3B-I characterised by its exposed 
carboxyterminal glycine. Acting like an E1 ubiquitin-activating enzyme, ATG7 
activates LC3B-I, which can consecutively be transferred to ATG3, thought to 
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assume the function of an E2-like enzyme. As illustrated by figure 51, conjugation of 
LC3B-I with the later enzyme precedes its interaction with 
phosphatidylethanolamine (PE), which produces LC3B-II. In an ATG5-ATG12 
dependent manner, the lipophilic PE group drives the integration of LC3B-II into the 
phagophore membrane as well as the autophagosome membrane (Barth 2010). 
There, the ATG8 homologue has been implicated in the selection of cargo for 
degradation along with membrane fusion in vitro.  
 
Following the expansion and fusion of the phagorphore membrane around 
the target cytosolic cargo, some LC3B-II is recycled and the maturation of the 
autophagosome unfolds (Glick 2010). This process involves the fusion for the outer 
membrane of the organelle with the endosome, which morphs into a lysosome, the 
resulting structure described as an “autolysosome”. The elements contained in the 
inner membrane of the autophagosome are then digested by the lysosomic 






Figure 51. The two ubiquitin-like systems necessary for the formation of the autophagosome. The 
first ubiquitin-like system implicated in the formation of the autpohagic organelle is the ATG12-
ATG5 complex. ATG7 (E1-like) activates ATG12, allowing for the activated enzyme to interact with 
ATG10 (E2-like). ATG12 is then conjugated to ATG5 and ATG16L. The resulting complex binds the 
isolation membrane and enables the recruitment of LC3B-II to the membrane as well. The latter is 
produced by the second ubiquitin-like system. Indeed, the cytosolic unprocessed form of LC3B-II, 
proLC3B, is initially cleaved by ATG4 to generate LC3B-I. Once activated by ATG7 (E1-like), this 
protein binds ATG3 (E2-like), which permits the conjugation of LC3B-I with 
phosphatidylethanolamine (PE). The protein complex is ruptured by ATG4, thereby producing LC3B-




Because LC3B-II does not dissociate from the membrane of the autophagic 
organelles, it has become a widely used marker of autophagy (Kirkin 2009). 
However, it is important to note that increased LC3B-II levels may indicate either an 
up-regulation of autophagosome synthesis or an impaired autophagosome turnover. 
Thus, in order to interpret fluctuations in this marker with less ambiguity, additional 
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controls should be included in the experimental design (Barth 2010). A commonly 
used control is the antibiotic bafilomycin A1, which inhibits of the vacuolar H+ 
ATPase regulating the lysosomal pH and thereby blocking the autophagic flux.  An 
up-regulation of LC3B-II levels occurring only in the absence of this antibiotic 
indicates a stimulation of a molecular event preceding autolysosme-mediated 
degradation, such as autophagosome synthesis. On the other hand, if a treatment 
induces the stimulation of LC3B-II levels both in the presence and absence of 
bafilomycin A1, it likely promotes the autophagic flux (Redmann 2017).  
 
Aside from LC3B-II, alternative molecules can also be used to assess the rate 
of this process such as p62/sequestosome 1. This nucleoporin forms a complex with 
both LC3B and poly-ubiquitinated protein aggregates thus allowing the latter to be 
targeted for autophagosomal degradation (Barth 2010). Komatsu and colleagues 
were able to demonstrate that the homeostatic levels of p62 were inversely correlated 
to the rate of autophagy as they report an increase in the intracellular accumulation 
of these protein aggregates in autophagy/ATG7-deficient mice (Komatsu 2007). 
 
 
IV. 2. 3. The importance of the endocrine system in the regulation 
of autophagy  
Over the last decade many studies have investigated the impact of insulin 
resistance on the regulation of autophagy. Findings are far from unequivocal and 
appear to be dependent on the tissue and cell type investigated as well as the model 
of insulin resistance used. We will focus on the work carried out on adipose tissue 
and adipocytes as it is relevant to the model used in the present work. Ex vivo, 
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evidence from genetic experiments and the use of pharmacological inhibitors 
indicates a critical role of autophagy in adipogenesis. For example, Baerga and 
colleagues reported that knockdown of Atg5 blocked the differentiation process in 
primary MEFs (Baerga 2009). The same year, similar results were obtained from 
knockdown experiments performed in 3T3-L1 pre-adipocytes targeting Atg5 and 
Atg7 (R. X. Singh 2009). In vivo, deletion of Atg7 in murine models induced the 
development of singular adipocytes characterised by multiple lipid droplets and an 
abnormally high mitochondria count. These mice, significantly leaner than WT, 
displayed enhanced insulin sensitivity and were protected from diet-induced obesity 
(R. X. Singh 2009). 
 
Insulin resistance appears to stimulate the rate of autophagy. Indeed, in obese 
patients both mRNA and protein levels of ATG5, LC3A and LC3B were increased 
compared to lean controls. In addition, elevated autophagosome numbers and a 
higher autophagic flux were associated with obesity (Kovsan 2011). In line with 
these findings, Nuñez and colleagues report that post-bariatric surgery weight loss in 
obese patients drove a reduction of the rate of autophagy in the subcutaneous adipose 
tissue. Such results are coherent with observations from a mouse model of diet-
induced obesity and diabetes: restricting the caloric intake of the mice by 40% for 
two weeks induced a reduction in the expression of autophagy markers, elevated at 
baseline (Nunez 2013). Various hypotheses have been formulated to rationalise the 
effect insulin resistance on autophagy-mediated regulation of lipid metabolism. Ost 
and colleagues proposed that the increase in autophagy merely reflects the 
attenuation of mTORC1 signalling caused by insulin resistance. Indeed, in addition 
to up-regulated autophagy markers in the adipose tissue of obese diabetic patients, 
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they observed a decrease in phosphorylation of protein S6 kinase, the main 
mTORC1 substrate (Ost 2010).  
 
Alternatively, insulin resistance may induce an increase in adipose tissue 
autophagy through ER stress. Such stress arises when the ER, where the bulk of 
protein synthesis occurs, fails to process misfolded proteins. These accumulate 
within the lumen of the organelle prompting a series of reactions known as the 
unfolded protein response (UPR), which either restores ER function or induces 
apoptosis (Cahova 2015). Autophagy is induced as part of the UPR in order to shield 
adipocytes from toxic protein aggregates. Lastly, Jansen and colleagues hypothesised 
that increased autophagic rates in the context of obesity allows to buffer 
inflammation in adipose tissue and avoid worsening of insulin resistance. Indeed, 
they revealed that inhibiting autophagy stimulated the expression of pro-
inflammatory cytokines in both adipose tissue explants and adipocytes, an effect 
enhanced in obese mice versus lean control (Jansen 2012). 
 
 
IV. 2. 4. The role of the IFN response in the regulation of 
autophagy 
Although other cytokines such as IL-4 and -10 were reported to have an 
inhibitory effect on autophagy, IFN-γ has emerged as an inducer of the self-
degradative process. Indeed, promoting autophagy is part of the immune strategy to 
facilitate clearance of intracellular bacterial pathogens. Despite the underlying 
mechanisms being only partially understood, it appears that IFN-γ-induced 
autophagy is mediated through both immunity-related GTPases (IRG) and members 
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of the 65 kDa guanylate binding protein family (Al-Zeer 2009). In the absence of 
infection, members of the IRG family are predominantly localised in the cytosol. 
However, some IRGs can be found at the ER, the Golgi or the endolysosomal 
membranes. Upon infection, IFN-induced proteins migrate to pathogen-containing 
vacuoles or phagosomes, where they are able to stimulate acidification and drive 
fusion with the lysosome permitting the elimination of the pathogen (Al-Zeer 2009). 
Interestingly, having investigated IFN-γ-induced autophagy in macrophages, 
Matsuzawa and colleagues concluded that this process required JAK1 and JAK2, 
PI3K and p38 MAPK but was independent of STAT1 (Matsuzawa 2012). Li and 
colleagues also identified IRF1 as a key modulator in this process in human 
hepatocellular carcinoma cells and demonstrate that, in this model, autophagy 
hinders growth and promotes cell death (P. D. Li 2012). 
 
Type I IFN was also found to elicit autophagy in a range of cancer cells in a 
JAK1-, STAT1- and STAT2-dependent manner (Schmeisser 2014). Similarly, 
STAT3 has been implicated in the regulation of autophagy. On the one hand, nuclear 
STAT3 does so through modulating the transcription of a panel of genes involved in 
both up- and down-regulation autophagy. The direction of STAT3 mediation appears 
to be context-dependent, as the transcription factor responds to a wide range of cues. 
On the other hand, cytoplasmic STAT3 is a constitutive inhibitor of autophagy as it 
sequesters PKR (You 2015). The pro-autophagic role of this kinase is further 





IV. 2. 5. PKR, a key modulator of autophagy 
The results of the transcription analysis, which originated the present project, 
drew the focus of our experimental work onto PKR, a critical modulator of the IFN-
mediated antiviral response, also known as eukaryotic translation initiation factor 2 α 
(EIF2α) kinase 2. Indeed, RNA sequencing data evidenced that expression of this 
kinase was down-regulated in the presence of the PI3K inhibitor A66. PKR is part of 
a family of protein kinases that modulate protein synthesis in response to 
environmental stresses through the phosphorylation EIF2α. More specifically, as this 
reaction drives the sequestration of the guanine nucleotide exchange factor EIF2β, 
guanosine diphosphate is no longer recycled leading to the inhibition of translation. 
The cellular antiviral response can then be launched at the gene expression level 
(Sadler 2008).  
 
Inactive PKR is constitutively expressed in all tissues at a basal level. 
However, upon viral infection, the kinase is induced by viral double-stranded RNA 
(dsRNA). Once activated, it dimerises to form a homodimer able to phosphorylate 
EIF2α. PKR induction by dsRNA is mediated through the two RNA-binding motifs 
found at the N-terminus of the kinase, which allows for the autophosphorylation of 
PKR through its intramolecular kinase domain (Sadler 2008). In addition to viral 
dsRNA, PKR can be activated by other pathogen-associated molecules. For instance, 
in bone-marrow-derived macrophages, Hsu and colleagues reported that the dsRNA-
responsive kinase is promptly activated by LPS, a ligand of TLR4 found at the 
surface of gram-negative bacteria. This LPS-mediated induction of PKR was 
dependent on TRIF and did not appear to alter the expression of a large number of 
NF-κB target genes. Interestingly, knocking out PKR disrupted LPS-induced STAT1 
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phosphorylation and protected the cell from apoptosis in response to LPS treatment 
(Hsu 2004). The pro-apoptotic role of PKR had first been suggested ten years earlier 
by Lee and colleagues who over-expressed the kinase in HeLa cells (S. a. Lee 1994). 
Additional studies in virus-infected cells confirmed this finding in both HeLa and 
U937 cells (Kibler 1997, Takizawa 1996, Yeung 1999).  
 
Further PKR activators have been identified such as protein activator of the 
IFN-induced protein kinase (PACT), a cellular protein which, unlike LPS, interacts 
directly with PKR. Along with its human homolog (retina and anterior neutral fold 
homeobox protein), PACT was shown to induce PKR in response to stressors 
including peroxide, sodium arsenite treatments and, relevantly to the present work, 
ceramides (Ruvolo 2001). This indirect ceramide-mediated stimulation of PKR hints 
to a role outside of it the immune response for the kinase. Indeed, studies are 
increasingly focussing on its involvement in nutrient sensing and inflammation in the 
context of obesity and insulin resistance. It was initially observed that the antiviral 
action of the kinase was linked with key inflammatory signalling pathway also 
involved in metabolic homeostasis such as IκB kinase and JNK (Lancaster 2016). 
Nakamura and colleagues then presented a series of interesting results pointing in 
this direction. Firstly, PKR activity was up-regulated in the liver and WAT of both 
ob/ob mice and mice fed with a HFD compared to lean control. Secondly, relevant to 
Chapter 5, Isg15 mRNA levels were found to be increased in the adipocytes of mice 
on the HFD compared to the lean control. They were also able to demonstrate that 
PKR activity was induced by lipid infusion in vivo and more specifically, that 
palmitic acid drove the same effect in MEFs. Interestingly, such effect of the SFA 




The data of Nakamura et al. indicates a direct interaction between PKR and 
IRS1, involved in modulating insulin signalling at the IR (T. F. Nakamura 2010). 
Furthermore, comparing the response of a Pkr-/- knockout mice to a HFD to a WT 
control, they evidenced the functional significance of PKR in the development of 
metabolic disorders as the deletion of PKR protected against insulin resistance, 
inflammation and obesity. Consistent data was published two years later by Cavalho-
Filho and colleagues who documented a similar role for PKR in human tissue 
(Carvalho-Filho 2012). Indeed, they noted that bariatric surgery resulted in a 
significant reduction of PKR activity in the liver, muscle and adipose tissues and that 
markers of ER stress, inflammation and insulin resistance were reduced following 
the procedure (Carvalho 2013). 
 
In light of these findings, the results of Cho and colleagues are rather 
unexpected as they put forward an anti-apoptotic role for PKR, evidencing with 
biophysical assays that palmitate directly binds PKR near the ATP binding site, thus 
preventing its autophosphorylation (Cho 2011). It is important to note that their 
research was carried out in human hepatocellular carcinoma cells as additional 
studies performed in tumour-cells supported anti-apoptotic PKR activity (S. F. Kim 
2000, Hiasa 2003). Also challenging the mainstream model of PKR function, the 
findings of Lancaster and colleagues suggest that PKR is not obligatory for HFD-
induced obesity and its associated metabolic and inflammatory dysregulations 
(Lancaster 2016). Indeed, they were unable to notice any significant differences in 
the response of their genetic Pkr-/- knockout model and that of WT mice to HFD. 
Both groups experienced the same changes in body composition over the 16 weeks 
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of the dietary intervention.  
 
Furthermore, Lancaster et al. reported that deleting PKR did not alter glucose 
tolerance and fasting plasma insulin concentrations, despite it lowering plasma 
insulin levels during oral glucose tolerance tests (Lancaster 2016). They reported 
that markers of HFD-induced hepatic steatosis (increased fasting plasma cholesterol 
levels, decreased fasting plasma FFA), found to be prevented by PKR loss by 
Nakamura and colleagues, was unaffected by the genetic knockout. Although the 
loss of PKR did moderately reduce adipose tissue inflammation in line with the 
results of the other studies, they were unable to attribute this observation to the 
protection against lipid-induced inflammation:  palmitate treatment ex vivo produced 
comparable increases in JNK and EIF2α in both WT and Pkr-/- knockout bone 
marrow-derived macrophages and similar concentrations of pro-inflammatory 
cytokines were measured in the media of both cell lines.  
 
Lancaster and colleagues argue that the discrepancies between their findings 
and the other two studies discussed can be explained by the genetic background of 
the mice used in the knockout model and the difference in cell types used. They also 
emphasised the lack of consistency in the phenotypes associated to PKR deletion 
from one study to another (Lancaster 2016). Interestingly, Flannery and colleagues 
produce results concurring with the finding of Lancaster and colleagues: using the 
same murine Pkr-/- knockout model, they reported that the genotype of the mice does 
not affect their HFD-induced weight gain (Flannery 2013). Therefore, further 
research is needed to validate the model by which PKR would integrate a cellular 
lipid sensing with the activation of inflammatory signalling pathways thus 
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connecting the nutrient-surplus and chronic hyperlipidaemia associated with obesity 
to the low-grade inflammation characteristic of this disease. 
 
 The metabolic role of PKR was recently extended to the modulation of 
autophagy. Indeed, a chemical screen aimed at establishing novel inducers of 
autophagy led Shen and colleagues to concentrate their research on STAT3. As 
mentioned in the previous section, they were able to demonstrate that through the 
interaction of its SH2 domain with the catalytic domain of PKR, cytoplasmic STAT3 
disrupts the enzymatic activity of PKR. They reported that both pharmacological and 
genetic inhibition of the transcription factor promoted the activity of PKR and 
consequently EIF2α phosphorylation (Shen 2012). Such inhibition of STAT3 
stimulated of autophagy in a PKR-dependent manner. This group then performed a 
chemical screen designed at identifying PKR-dependent autophagy inducers 
revealing palmitate as a key stimulator of this process (M. S. Niso-Santano 2013). 
Furthermore, their findings supported that the effect of the SFA relies on the 
disruption of the STAT3-PKR interaction and necessitates the activation of the pro-
inflammatory kinases MAPK8 and JNK1 as well as IRS1. Together, the studies 
discussed in this section shed light on the crosstalk between IFN and insulin pathway 




IV. 3.   Results of Chapter 4 
IV. 3. 1. Investigating the effect of FA- and IFN-γ-treatments on 
lipolysis in adipocytes  
 The first metabolic response to starvation investigated in adipocytes was the 
process of lipolysis. To this end, two endpoints were considered: on the one hand the 
phosphorylation levels of HSL and on the other hand, that of PKA substrate. As 
mentioned in the introduction of this chapter, these enzymes are mediators of 
lipolysis. Indeed, PKA is activated in response to increases in cAMP cellular 
concentration. The liberated catalytic subunit of PKA phosphorylates HSL, enabling 
the lipase to translocate to the lipid droplet from the cytoplasm. There, HSL 
catalyses the second step of the lipolytic process, i.e. breakdown of DAG to MAG. 
In addition, PKA prompts the conformational change of perilipin, a protein found at 
the surface of the droplet, thereby increasing the exposure of the lipids within the 
droplet to lipases. Therefore, an increase in phosphorylation levels of HSL and PKA 
would manifest a stimulation of the lipolytic process. Note that, in order to assess the 
effect of palmitate and IFN-γ on lipolysis, this cellular process was activated through 
an acute treatment with the epinephrine analogue, isoproterenol, a β-AR agonist. As 
for previous experiments, results were produced in both mature and pre-adipocytes 
from the 3T3-L1 and hMADS cell lines. 
 
 
IV. 3. 1. 1. Using 3T3-L1 cell line 
Figure 52 investigates the effect of IFN-γ and palmitate in murine pre-
adipocytes. Because previous experiments showed that the BSA used to solubilise 
palmitate-stimulated STAT phosphorylation, both BSA conjugated and 
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unconjugated palmitate was used. However, neither of the treatments tested 
compared to the corresponding controls induced a significant change in p-HSL S660 
or p-PKA substrate in 3T3-L1 pre-adipocytes. Interestingly, both conjugated 
palmitate and its BSA control drove a 70% drop in phosphorylation levels of HSL 
Ser660 compared to the isoproterenol-stimulated control, suggesting a BSA-mediated 
down-regulation of lipolysis. Consistent with this finding, such treatments also 
inhibited PKA substrate (perilipin) phosphorylation by 55% compared to the 
isoproterenol-stimulated control. LPS - included as positive control as it was 
demonstrated to stimulate lipolysis in adipose tissue of healthy subjects, as well as in 
human adipocytes - failed to induce p-HSL or p-PKA (Rittig 2016, Grisouard 2012).  
 
As pre-adipocytes have not yet undergone adipogenesis, the effect of 
isoproterenol acute stimulation on p-HSL and p-perilipin is rather weak compared to 
that in mature adipocytes (Figure 53). Indeed, there is no statistically significant 
difference between the phosphorylation levels of HSL and PKA substrate in 
untreated versus isoproterenol-stimulated pre-adipocytes. As for the undifferentiated 
cells, the lipolytic process in mature 3T3-L1 adipocytes was not affected by either 
IFN-γ, conjugated and unconjugated palmitate or LPS. However, unlike the pre-





                                                                              
Figure 52. IFN-γ, conjugated and unconjugated palmitate and LPS affect neither HSL nor PKA 
substrate phosphorylation in 3T3-L1 pre-adipocytes. For both figures A and B, 3T3-L1 pre-
adipocytes were treated in with IFN-γ (20 ng/mL) (lane 4), palmitate 3:1 BSA (500 μM) (lane 6), 
unconjugated palmitate (500 μM) (lane 8) and LPS (100 ng/mL) (lane 10) in 10% FBS/DMEM 
(HG) for 24 h. Equivalent volumes of MilliQ water (16 μL) (lane 3), BSA (400 μL) (lane 5), 
DMEM (LG) (400 μL) (lane 7) and PBS (40 μL) (lane 9) were used as control for these treatments. 
Following a 3 h serum deprivation (SF DMEM, HG, 0.2% BSA), cells were stimulated with 
isoproterenol (1 μM for 20 min). Cells were lysed with 60 μL 1% TX-100 lysis buffer per 6 cm Ø 
dish. 30 μg of protein were loaded per lane (10% SDS-acrylamide gel). Statistical difference 
between the water control and other treatments is indicated with $; statistical difference between the 
BSA FAF control and other treatments is indicated with *; statistical difference between the 
palmitate 3:1 BSA treatment and other treatments is indicated with # (p-value < 0.05). The red 




                                                         
Figure 53. IFN-γ, conjugated and unconjugated palmitate and LPS affect neither HSL nor PKA 
substrate phosphorylation in 3T3-L1 mature adipocytes. For both figures A and B, 3T3-L1 
mature adipocytes were treated in with IFN-γ (20 ng/mL) (lane 4), palmitate 3:1 BSA (500 μM) 
(lane 6), unconjugated palmitate (500 μM) (lane 8) and LPS (100 ng/mL) (lane 10) in 10% 
FBS/DMEM (HG) for 24 h. Equivalent volumes of MilliQ water (8 μL) (lane 3), BSA (200 μL) 
(lane 5), DMEM (LG) (200 μL) (lane 7) and PBS (20 μL) (lane 9) were used as control for these 
treatments. Following a 3 h serum deprivation (SF DMEM, HG, 0.2% BSA), cells were 
stimulated with isoproterenol (1 μM for 20 min). Cells were lysed with 80 μL 1% TX-100 lysis 
buffer per well. 44 μg of protein were loaded per lane (10% SDS-acrylamide gel). ** denotes a 
treatment statistically different from all other treatments (p-value < 0.05). The red arrow indicates 





IV. 3. 1. 2. Using hMADS cell line 
Figure 54 and 55 describe the experiments presented in the previous 
subsection in hMADS rather than 3T3-L1 cells. As for the murine cells, human pre-
adipocytes were markedly less sensitive to isoproterenol stimulation compared to the 
differentiated cells. This is likely reflecting an increase in AR expression upon 
differentiation. While the p-HSL signal, although poor, seemed not to be affected by 
the acute isoproterenol treatment, the phosphorylation of PKA substrate was 
marginally stimulated by the epinephrine analogue with a 45% increase compared to 
the untreated control (Figure 54). Besides, it appears that BSA inhibits both HSL 
and PKA substrate activation to a lesser extent than in 3T3-L1 pre-adipocytes. 
 
Figure 55 details the effect of the treatments on mature hMADS cells. As for 
differentiated 3T3-L1, isoproterenol induces a significant increase in lipolysis (even 
though the increase in PKA substrate phosphorylation observed in the isoproterenol-
stimulated control fell short of statistical significance). Unlike previous experiments, 
none of the treatments tested effected a change in phosphorylation levels except for 
LPS which appears to promote the activation of both proteins: a 52% increase in p-
HSL and a 45% increase in p-PKA substrate levels compared with the PBS-treated 
control. This result suggests LPS to be mildly enhancing lipolysis. 
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Figure 54. IFN-γ, conjugated and unconjugated palmitate and LPS affect neither HSL nor PKA 
substrate phosphorylation in hMADS pre-adipocytes. For both figures A and B, hMADS pre-
adipocytes were treated in with IFN-γ (20 ng/mL) (lane 4), palmitate 3:1 BSA (500 μM) (lane 6), 
unconjugated palmitate (500 μM) (lane 8) and LPS (100 ng/mL) (lane 10) in complete DMEM (LG) 
for 24 h. Equivalent volumes of MilliQ water (16 μL) (lane 3), BSA (400 μL) (lane 5), DMEM 
(LG) (400 μL) (lane 7) and PBS (40 μL) (lane 9) were used as control for these treatments. 
Following a 3 h serum deprivation (SF DMEM, LG, 0.2% BSA), cells were stimulated with 
isoproterenol (1 μM for 20 min). Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø 
dish. 24 μg of protein were loaded per lane (10% SDS-acrylamide gel). Statistical difference 
between the untreated control and other treatments is indicated with %; statistical difference 
between the BSA FAF control and other treatments is indicated with *; statistical difference 
between the palmitate 3:1 BSA treatment and other treatments is indicated with # (p-value < 0.05). 




                                                          
Figure 55. IFN-γ, conjugated and unconjugated palmitate and LPS affect neither HSL nor PKA 
substrate phosphorylation in hMADS mature adipocytes. For both figures A and B, hMADS 
mature adipocytes were treated in with IFN-γ (20 ng/mL) (lane 4), palmitate 3:1 BSA (500 μM) 
(lane 6), unconjugated palmitate (500 μM) (lane 8) and LPS (100 ng/mL) (lane 10) in complete 
DMEM (LG) for 24 h. Equivalent volumes of MilliQ water (8 μL) (lane 3), BSA (200 μL) (lane 
5), DMEM (LG) (200 μL) (lane 7) and PBS (20 μL) (lane 9) were used as control for these 
treatments. Following a 3 h serum deprivation (SF DMEM, LG, 0.2% BSA), cells were 
stimulated with isoproterenol (1 μM for 20 min). Cells were lysed with 80 μL 1% TX-100 lysis 
buffer per well. 68 μg of protein were loaded per lane (10% SDS-acrylamide gel). Statistical 
difference between the untreated control and other treatments is indicated with %; statistical 
difference between the LPS treatment and other treatments is indicated with &; ** denotes a 
treatment statistically different from all other treatments (p-value < 0.05). The red arrow indicates 





IV. 3. 2. Investigating the effect of palmitate on autophagy  
 Having investigated the effect of palmitate and IFN-γ on lipolysis, we 
focused our attention on the effect of the SFA on autophagy, the second cellular 
response to starvation that was explored in the introduction of this chapter. To this 
end, time course experiments were performed, treating both murine and human pre- 
and mature-adipocytes with unconjugated palmitate. The expression levels of LC3B-
II were used as an indicator of the activity of the autophagic pathway. Having 
selected the time point at which the SFA had the strongest effect on LC3B-II, further 
experiments were performed including bafilomycin A1 treatment as an additional 
control. Indeed, as explained in section 2. 2. of the introduction, this antibiotic is 
known to inhibit the autophagic flux and thus provides a mean of better interpreting 
variations in LC3B-II levels. 
 
 
IV. 3. 2. 1. Using 3T3-L1 cell line 
 Figure 56A presents the effect of palmitate on LC3B-II levels in 3T3-L1 pre-
adipocytes. The SFA induces a significant up-regulation of this marker of autophagy, 
with a peak stimulation at 24 h of 484% compared to the 24 h DMEM-treated 
control. LPS treatment did not affect LC3B-II expression after 1 h of treatment but 
further time points should be tested to rule out an effect of LPS on autophagy as 
palmitate had not effect at this time point either. An analogous time course 
experiment was performed in murine differentiated adipocytes. As shown in figure 
56B, the autophagic process of mature cells was not sensitive to palmitate. Indeed, at 
none of the time points tested did the SFA elicit an increase in the expression levels 
of LC3B-II compared to the controls. Interestingly, the basal expression levels of 
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this protein are considerable higher than those recorded in the pre-adipocytes. 
 
 In order to interpret palmitate-mediated induction autophagy in 3T3-L1 pre-
adipocytes, bafilomycin A1 was included as a control in the experiment presented in 
figure 57A. Although the maximal induction of LC3B-II expression was recorded 
after 24 h of palmitate treatment, the cells were treated for 4 h. Indeed, at the 24 h 
time point, the effect of bafilomycin A1 was too strong to allow for the detection of a 
palmitate-mediated effect when combining the antibiotic and SFA treatments (data 
not shown). Comparing the LC3B-II expression levels following palmitate treatment 
(lane 3) to those following the SFA treatment supplemented with the antibiotic, one 
can see that bafilomycin A1 drives the induction of the autophagy marker even 
further than palmitate alone. As explained in the introduction, stimulation of LC3B-
II levels in both the absence and presence of this antibiotic indicates that palmitate 
induces the autophagic flux. Having demonstrated that the SFA drives “true 
autophagy”, A66 was added to the palmitate treatment (in the presence or absence of 
bafilomycin A1) in order to evaluate the role of PI3K catalytic subunit p110α in this 
process. As the levels of LC3B-II are unaffected by the inhibitor, we can conclude 
that palmitate-mediated induction of autophagy in 3T3-L1 pre-adipocytes is p110α-
independent.  
 
Figure 57B investigates the effect of the same treatments on p62 expression 
levels of 3T3-L1 pre-adipocytes. This nucleoporin stands as an alternative marker to 
LC3B-II as it forms a complex with LC3B and poly-ubiquitinated protein aggregates 
targeted for autophagosomal degradation (Barth 2010). p62 expression levels are 
expected to be inversely correlated to the rate of autophagy and therefore of LC3B-II 
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expression levels, which is coherent with the data presented in figure 57B. This 
validates the pro-autophagic activity of palmitate discussed in the previous 
paragraph.  
 
In order, to further explore the signalling pathways involved in the regulation 
of palmitate-mediated induction of autophagy in 3T3-L1 pre-adipocytes, cells were 
treated with the SFA for 24 h in the presence or absence of A66, D030, TAK 242 
and myriocin. To maximise the potential effect of the inhibitors, these were added to 
the media 1 h before the start of the palmitate treatment. As seen in figure 58, none 
of the inhibitors tested has a statistically significant effect on palmitate-mediated 
induction of autophagy, although there is a trend indicating that inhibiting p110α 
would rescue this effect. Indeed, analysing the data using a one-way ANOVA (F 
(11, 21) = 10.80) yields a p-value of 0.58 when comparing the palmitate-treated 
sample to the palmitate- plus A66-treated sample. A two-way ANOVA examining 
the interaction between the effects of the SFA and the inhibitor also falls short of 
statistical significance, F (1, 7) = 3.55, p-value = 0.10. Overall, the data points 
towards the pro-autophagic role of palmitate being independent of the PI3K, TLR4 






       
 
Figure 56. A. Palmitate stimulates LC3B-II levels after 24 h of treatment in 3T3-L1 pre-adipocytes. B. LC3B-II levels were not altered following palmitate or LPS treatment in 3T3-
L1 mature adipocytes. For both figures A and B, cells were treated with unconjugated palmitate (500 μM) (lanes 3 to 7) and LPS (100 ng/mL) (lane 10) in 10% FBS/DMEM (HG). 
Equivalent volumes of DMEM (LG) (400 μL for figure A and 200 μL for figure B) (lanes 2 and 8) and PBS (40 μL for figure A and 20 μL for figure B) (lane 9) were used as control 
for the palmitate and LPS treatments, respectively. Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish for figure A and with 80 μL 1% TX-100 lysis buffer per 
well for figure B. 34 μg and 54 μg of protein were loaded per lane in figures A and B, respectively (15% SDS-acrylamide gel). Statistical difference between the 24 h DMEM control 
and other treatments is indicated with %; statistical difference between the 8 h palmitate treatment and other treatments is indicated with &; statistical difference between the 4 h 




       
 
Figure 57. A. Palmitate stimulates LC3B-II levels after 4 h of treatment in 3T3-L1 pre-adipocytes and adding bafilomycin A1 to the SFA treatment enhances this effect. B. Palmitate 
inhibits p62 levels after 4 h of treatment in 3T3-L1 pre-adipocytes. For both figures A and B, cells were treated with unconjugated palmitate (500 μM) (lanes 3, 6 and 9), bafilomycin 
A1 (10 nM) (lanes 5, 6 and 9) and A66 (2 μM) (lanes 7, 8 and 9) in 10% FBS/DMEM (HG) for 4 h. Equivalent volumes of DMEM (LG) (400 μL) (lane 2) and DMSO (8 μL) (lane 
4) were used as control for the palmitate and bafilomycin A1/A66 treatments, respectively. Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish. 30 μg of protein 
were loaded per lane (15% SDS-acrylamide gel). Statistical difference between the palmitate treatment and other treatments is indicated with #; statistical difference between the 
bafilomycin A1 treatment and other treatments is indicated with %; statistical difference between the “palmitate + bafilomycin A1” treatment and other treatments is indicated with 
$; statistical difference between the A66 treatment and other treatments is indicated with *; statistical difference between the “palmitate + A66” treatment and other treatments is 
indicated with & (p-value < 0.05). Note that to avoid overcrowding figures A and B, only differences relevant our analysis are shown, the results in full of the one-way ANOVA 





Figure 58. None of the inhibitors tested rescue palmitate-mediated stimulation of LC3B-II levels after 
24 h of treatment in 3T3-L1 pre-adipocytes. Cells were treated with unconjugated palmitate (500 μM) 
(lanes 3, 6, 8, 10 and 12), A66 (2 μM) (lanes 5 and 6), D030 (2 μM) (lanes 7 and 8), TAK 242 (2 μM) 
(lanes 9 and 10) and myriocin (2 μM) (lanes 11 and 12) in 10% FBS/DMEM (HG) for 24 h. 
Equivalent volumes of DMEM (LG) (400 μL) (lane 4) and DMSO (8 μL) (lane 4) were used as 
control for the palmitate and inhibitor treatments, respectively. Inhibitors and DMSO were added to 
the media 1 h prior to palmitate treatment. Cells were lysed with 100 μL 1% TX-100 lysis buffer per 
6 cm Ø dish. 31 μg of protein were loaded per lane (15% SDS-acrylamide gel). Statistical difference 
between the palmitate treatment and other treatments is indicated with #; all other statistical 
differences between treatments is indicated with * (p-value < 0.05). Note that to avoid overcrowding 
the figure, only differences relevant our analysis are shown, the results in full of the one-way 
ANOVA analyses can be found in appendix VII. 10. Data from three independent experiments. 
 
 
IV. 3. 2. 2. Using hMADS cell line 
 As for previous experiments, the experiments exploring autophagy in mouse 
adipocytes were reproduced in human cells. As shown in figure 59, human pre- and 
mature-adipocytes responded to the palmitate time course treated a similar fashion as 
mouse adipocytes: while LC3B-II expression in pre-adipocyte was significantly 
induced by the SFA with a peak at the 24 h time point (+395% compared to the 24 h 
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DMEM-treated control) (Figure 59A), the expression of this marker of autophagy 
was not altered by palmitate in mature hMADS adipocytes (Figure 59B). As for the 
mouse adipocytes, the hour-long LPS treatment did not elicit any effect on LC3B-II 
expression in hMADS adipocytes. However, the effect of palmitate on LC3B-II 
levels in hMADS pre-adipocytes could not be reproduced despite using the same 
aliquot of palmitate was used to produce the data in figure 59.  Therefore, no further 
experiments investigating autophagy in hMADS were performed. 
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Figure 59. A. Palmitate stimulates LC3B-II levels after 24 h of treatment in hMADS pre-adipocytes. B. LC3B-II levels were not altered following palmitate or LPS treatment in 
hMADS mature adipocytes. For both figures A and B, cells were treated with unconjugated palmitate (500 μM) (lanes 3 to 7) and LPS (100 ng/mL) (lane 10) in 10% FBS/DMEM 
(HG). Equivalent volumes of DMEM (LG) (400 μL for figure A and 200 μL for figure B) (lanes 2 and 8) and PBS (40 μL for figure A and 20 μL for figure B) (lane 9) were used as 
control for the palmitate and LPS treatments, respectively. Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish for figure A and with 80 μL 1% TX-100 lysis 
buffer per well for figure B. 12 μg and 30 μg of protein were loaded per lane in figures A and B, respectively (15% SDS-acrylamide gel). Statistical difference between the 8 h 




IV. 3. 3. The effect of palmitate on PKR expression and activity 
 The following section investigates the effect of palmitate on both PKR 
expression and its activity in adipocytes. To this end, a time course experiment was 
performed exploring how palmitate treatment affects the expression levels of the 
kinase in all four cell models previously utilised (3T3-L1 and hMADS pre- and 
mature adipocytes). Additionally, we assessed the consequences of inhibiting PKR 
pharmacologically on the expression levels of LC3B-II following palmitate 
treatment in 3T3-L1 pre-adipocytes. 
 
 
IV. 3. 3. 1. Using 3T3-L1 cell line 
 While figure 60A presents the result of the time course experiment carried 
out in mouse pre-adipocytes enquiring into the effect of palmitate on PKR 
expression levels, figure 60B does so in mouse mature adipocytes. In both types of 
cells, the SFA treatment (as well as the hour-long LPS treatment) had no significant 
effect on the expression of this kinase. Because palmitate was shown to induce the 
autophagic process in 3T3-L1 pre-adipocytes, the role of PKR activity was 
investigated in this context by using a PKR specific inhibitor named C16. While 
some cells were treated for 24 h with the SFA in the absence of C16, which resulted 
in an increase in LC3B-II expression consistent with previous results (+200% 
compared to the DMEM-treated control), other cells were treated with a combination 
of the SFA and the inhibitor (Figure 61). The inhibitor failed to rescue the palmitate-
mediated induction of LC3B-II expression suggesting that the SFA regulates 




IV. 3. 3. 2. Using hMADS cell line 
 The experiments presented in figure 60 were replicated in hMADS pre- and 
mature adipocytes (Figure 62). Similarly to the response of the mouse cells, the 




       
 
Figure 60. A. PKR levels were not altered following palmitate or LPS treatment in 3T3-L1 pre-adipocytes. B. PKR levels were not altered following palmitate or LPS treatment in 
3T3-L1 mature adipocytes. For both figures A and B, cells were treated with unconjugated palmitate (500 μM) (lanes 3 to 7) and LPS (100 ng/mL) (lane 10) in 10% FBS/DMEM 
(HG). Equivalent volumes of DMEM (LG) (400 μL for figure A and 200 μL for figure B) (lane 2 and 8) and PBS (40 μL for figure A and 20 μL for figure B) (lane 9) were used as 
control for the palmitate and LPS treatments, respectively. Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish for figure A and with 80 μL 1% TX-100 lysis 





Figure 61. Inhibiting PKR does not rescue palmitate-mediated induction of autophagy in 3T3-L1 pre-
adipocytes. Cells were treated with unconjugated palmitate (500 μM) (lanes 3 and 6) and C16 (2 μM) 
(lanes 5 and 6) in 10% FBS/DMEM (HG). Equivalent volumes of DMEM (LG) (400 μL) (lane 2) and 
DMSO (8 μL) (lane 4) were used as control for the palmitate and C16 treatments, respectively. Cells 
were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish. 13 μg of protein were loaded per 
lane (15% SDS-acrylamide gel). Statistical difference between the palmitate treatment and other 
treatments is indicated with &; statistical difference between the palmitate treatment and other 
treatments is indicated with $ (p-value < 0.05). Data from four independent experiments. 
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Figure 62. A. PKR levels were not altered following palmitate or LPS treatment in hMADS pre-adipocytes. B. PKR levels were not altered following palmitate or LPS treatment in 
hMADS mature adipocytes. For both figures A and B, cells were treated with unconjugated palmitate (500 μM) (lanes 3 to 7) and LPS (100 ng/mL) (lane 10) in 10% FBS/DMEM 
(HG). Equivalent volumes of DMEM (LG) (400 μL for figure A and 200 μL for figure B) (lane 2 and 8) and PBS (40 μL for figure A and 20 μL for figure B) (lane 9) were used as 
control for the palmitate and LPS treatments, respectively. Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish for figure A and with 80 μL 1% TX-100 lysis 
buffer per well for figure B. 11 μg and 47 μg of protein were loaded per lane in figures A and B, respectively (10% SDS-acrylamide gel). Statistical difference between the LPS 
treatment and other treatments is indicated with & (p-value < 0.05). Data from three independent experiments. 
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IV. 4.   Discussion of Chapter 4 
IV. 4. 1. Evidence supporting the anti-lipolytic effect of palmitate 
 In this chapter, the regulation of the so-called lipophagy was investigated, 
focusing firstly on lipolysis and then on autophagy. We report that neither palmitate 
nor IFN-γ affected the markers selected to assess lipolytic activity (p-HSL Ser660 and 
p-PKA) in 3T3-L1 and hMADS pre- and mature adipocytes (Figures 52 to 55). 
Because the experimental conditions and treatments used had proven to elicit insulin 
resistance in most of the cell types tested in Chapter 3, such models would have been 
expected to induce catecholamine resistance as well. Indeed, impaired 
catecholamine-induced lipolysis has been reported in the obese insulin resistant state 
(J. a. Jocken 2008). A number of studies have documented this metabolic disruption 
in the whole body of obese subjects (Horowitz 2000, Connacher 1991). At the level 
of subcutaneous adipose tissue, Jocken and colleagues evidenced in vivo blunted 
glycerol release in response to intravenous infusion of a non-selective β-adrenergic 
agonist isoprenaline in obese compared to lean subjects (J. G. Jocken 2008). This 
demonstrates without ambiguity impeded catecholamine-induced lipolysis in this 
type of tissue. 
 
 In vitro, Burns and colleagues were able to verify the effect of FFAs, 
including palmitate, on lipolysis rates in human adipose tissue cells as early as 1978 
(Burns 1978). Using adipocytes isolated from human subcutaneous tissue samples, 
they measured the concentration of FAs released in the medium after incubating the 
cells with the SFA in the presence of isoproterenol (10-7 M). Following a 4 h-long 
incubation, they reported a 35% inhibition of FA release mediated by palmitate (500 
μM). Thirty years later, Müller and colleagues published results supporting the data 
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of Burns and colleagues in adipocytes from rat origin (G. W. Muller 2008). Testing 
the same concentrations of isoproterenol (1 μM) and of palmitate (500 μM) used in 
the experiments presented in the results section of the present chapter, they treated 
the cells for 2 h with the SFA prior to the addition of the β-AR agonist. After a 
further 2 h-long incubation, they measured the release of glycerol and FA and 
assessed the effect of the SFA treatment on the expression levels of HSL and PKA. 
Consistently, Müller and colleagues were able to report an inhibitory effect of 
palmitate on these markers of lipolysis. 
 
 
IV. 4. 2. Understanding the discrepancies between published data 
and the present results 
 To understand the reason why the data presented in this chapter does not 
support the anti-lipolytic role of palmitate evidenced in the literature reviewed 
above, one may compare the experimental designs used. Indeed, although identical 
concentrations of palmitate and isoproterenol were employed, our experiments 
included an acute treatment with the β-AR agonist. Instead, in the study of Burns and 
colleagues, isoproterenol was added to the media for the entire duration of the 
palmitate treatment. Muller et al. on the other hand stimulated the cells with 
isoproterenol for a total of 2 h. The rational for performing an acute isoproterenol 
treatment in the experiments reviewed in this chapter was to avoid the 
desensitisation of the β-AR reported to occur over time when 3T3-L1 adipocytes are 
treated with either isoproterenol or insulin (Hupfeld 2003). Furthermore, the duration 
of the treatment performed in our experiments was significantly greater than in the 
literature (27 h in total versus 4 h).  
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Aside from experimental design, it is possible that the choice of endpoint was 
not optimal to demonstrate the anti-lipolytic effect of palmitate under the conditions 
tested: the effect of the SFA may be mediated through another phosphorylation site 
of HSL than Ser660. Indeed, this residue is one of five involved in HSL regulation in 
murine adipocytes, also including Ser563, Ser565, Ser600 and Ser659. While Ser563, 
Ser650 and Ser660 have been shown to be phosphorylated by PKA, the 
phosphorylation of Ser600 is mediated through Erk and finally that of Ser565 depends 
on AMPK and calcium/calmodulin-dependent kinase II (Watt 2006). However, 
Gaidhu and colleagues did report the decrease of p-HSL Ser660 in the WAT of mice 
fed a HFD for 8 weeks versus a control group on a standard chow diet (Gaidhu 
2010). From quantifying glycerol release induced by epinephrine exposure, they 
were able to demonstrate that this difference in p-HSL Ser660 was associated with a 
blunted epinephrine-stimulated lipolysis in the HFD group.  
 
Investigating the effect of palmitate on ATGL expression and 
phosphorylation levels could have been informative. This enzyme is pivotal in TAG 
hydrolysis as it catalyses 95% of reactions together with HSL in mice WAT (M. S. 
Schweiger 2006). However, Zimmermann and colleague evidenced that the 
phosphorylation of ATGL is independent of PKA (Zimmermann 2004). This may be 
of relevance to our results as neither p-HSL Ser660 nor p-PKA substrate was affected 
by the SFA treatment. Lastly, two additional factors could shed light on the 
discrepancy between our findings and the literature. Firstly, the type of cells used. 
Indeed, to the best of our knowledge the anti-lipolytic effect of palmitate has not 
been confirmed in 3T3-L1 adipocytes, instead, research has been carried out in 
primary adipocytes.  
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Secondly, the data published by Muller and colleagues as well as Burns and 
colleagues does not include a control for the palmitate treatment solubilised in a 
BSA solution. Therefore, the SFA-mediated effect reported in these studies could 
merely correspond to a BSA-mediated inhibition of lipolysis. This is plausible as in 
the experiments presented in figures 52 to 55, BSA significantly hinders the 
phosphorylation of HSL and PKA substrate. Alternatively, the effect associated with 
BSA observed in the present chapter might merely reflect an artifact arising from 
protein loading or electrophoresis. Indeed, irregularities can be observed around the 
molecular weight of BSA (66 kDa) in lanes of BSA and BSA conjugated palmitate 
suggesting that large quantities of BSA migrated through the gel. This phenomenon 
is particularly prevalent in the experiment performed in murine and human pre-
adipocytes (Figures 52 and 55). As expression levels of HSL and perilipin are low in 




IV. 4. 3. Palmitate stimulates autophagy in 3T3-L1 pre-adipocytes  
In the second part of this chapter, the pro-autophagic effect of palmitate was 
demonstrated. Indeed, the SFA was found to stimulate LC3B-II both in the presence 
and the absence of bafilomycin A1 in 3T3-L1 pre-adipocytes but none of the other 
cell types tested (mature 3T3-L1 adipocytes, pre- and mature hMADS) (Figure 57A). 
Although initial results indicated the same effect in hMADS pre-adipocytes, these 
findings could not be reproduced (Figures 59A). This is consistent with in vivo 
experiments associating obesity and HFD with increased rates of autophagy in both 
murine and human models (Kovsan 2011, Nunez 2013). In vitro, Yin and colleagues 
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were able to demonstrate the pro-autophagic effect of palmitate (500 μM) in mature 
3T3-L1 adipocytes (Yin 2015). Indeed, following 12 h of SFA treatment they report 
the stimulation of both LC3-II levels and autophagosome formation using 
immunoblot analysis and fluorescence microscopy, respectively. This does not align 
with our findings in mature murine adipocytes, although this specific time point was 
not tested in our time course experiments (Figure 56B). It appears no study has 
focused on the autophagic response of 3T3-L1 pre-adipocytes to palmitate treatment.  
 
This difference in the response of pre- and mature 3T3-L1 adipocytes to 
palmitate treatment is likely to reflect cellular variations in lipid metabolism. Indeed, 
autophagy has been shown in various cell types to protect against palmitate-mediated 
induction of apoptosis. For instance, Cai et al. demonstrated that while palmitate 
induced both apoptosis and autophagy in hepatocytes, inhibiting autophagy 
stimulated the rate of cell apoptosis and, inversely, inducing autophagy down-
regulated palmitate-induced apoptosis (Cai 2014). Similar findings were produced in 
podocytes, a type of cell found in the kidneys, and in bone marrow mesenchymal 
stem cells (X. C. Jiang 2017, Y. W. Liu 2018). As mature adipocytes have a 
significantly higher capacity for esterification and storage of FA as TAG compared 
to pre-adipocytes, the deleterious effect of palmitate is likely to be neutralised in 
mature adipocytes. Thus, the autophagic response is not necessary to protect mature 
adipocytes unlike pre-adipocytes, explaining our results of figure 56. 
 
As PI3K is found upstream of the autophagic inhibitor mTORC1, it was 
expected to be pivotal in the modulation of the degradative process (Figure 2). To 
explore the potential role of this kinase in palmitate-mediated induction of 
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autophagy, 3T3-L1 pre-adipocytes were treated with pharmacological inhibitors 
targeting two catalytic subunits of PI3K (p110α and p110δ) (Figure 58). Although 
these treatments failed to statistically rescue the SFA-induced up-regulation of 
LC3B-II levels, a trend in this direction was observed following the inhibition of 
p110α. This is in line with the published evidence linking insulin resistance with 
increase autophagy in adipose tissue discussed above. Indeed, as shown in Chapter 3, 
A66 rescues palmitate-induced insulin resistance in 3T3-L1 and the data presented in 
this chapter suggests that this inhibitor might also block the pro-autophagic effect of 
the SFA. Emphasising the importance of PI3K in the regulation of palmitate-induced 
autophagy, a recent paper by Niso-Santano and colleagues reports the dependence of 
palmitate-stimulated autophagy on AMPK, an energy-sensing kinase shown to be 
induced by PI3K in mouse adipocytes (M. M.-S.-Y. Niso-Santano 2015). 
Nevertheless, Foukas et al. failed to observe any significant effect of p110α 
inactivation in the autophagic activity of MEFs derived from p110αD933A/WT embryos 
(L. B. Foukas 2013). 
 
The role of TLR4 in palmitate-induced autophagy was also investigated 
using TAK 242. As illustrated by figure 58, this inhibitor did not rescue the effect of 
the SFA. However, the findings of Xu and colleagues still point at a critical role of 
this receptor in the regulation of autophagy (Y. J. Xu 2007). Indeed, they evidenced 
that LPS was able to induce autophagy in a TLR4-dependent manner in both human 
and murine macrophages. This study emphasises the interconnectivity of the 
autophagic and immune programmes and proposes the former as a cellular strategy 
to clear bacterial infections. Similarly to TAK 242, myriocin failed to rescue the 
effect of palmitate on autophagy, clearing SPT from a regulatory role in this process 
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(Figure 58). Nonetheless, published studies still implicate ceramides in the induction 
of the autophagic programme as reviewed by Jiang and Ogretmen (W. a. Jiang 
2014).   
 
 
IV. 4. 4. The unclear role of PKR in autophagy 
 The last section of the present chapter focused on the role of PKR in the 
autophagic process. Quantitative immunoblot analysis revealed that over the time 
points tested, palmitate treatment failed to induce the expression level of this protein 
in 3T3-L1 and hMADS pre- and mature adipocytes. As highlighted in the 
introduction of the present chapter, Nakamura and colleagues were able to 
demonstrate that PKR activity was up-regulated in the liver and WAT of both ob/ob 
mice and mice fed with a HFD compared to lean control (T. F. Nakamura 2010). In 
addition, their findings suggest that palmitic acid infusion stimulated PKR activity 
both in vivo and in MEFs cultured for 2 h in the presence of the SFA (500 μM). 
Furthermore, they provide compelling evidence for physical interaction between 
PKR and IRS1, a downstream effector of insulin signalling. Emphasising the 
importance of PKR in cellular metabolism, the Pkr-/- knockout mice produced by 
Nakamura et al. was protected from HFD-induced metabolic disorders including 
insulin resistance, inflammation and obesity. Cavalho and colleagues, who compared 
the phosphorylation of PKR as well as the overall PKR content in visceral adipose 
tissues of obese and lean subjects, present concordant data (Carvalho 2013) (see 
introduction IV. 2. 5.). 
 
In light of such findings, one could have expected figures 60 to 62 to unveil a 
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palmitate-induced stimulation of PKR. However, our results indicate that the SFA 
does not affect the expression of kinase. This discrepancy could be due to a 
difference in endpoint considered: while Nakamura et al. focused on the 
phosphorylation levels of PKR, the experiments presented in the present chapter 
assess the protein content. Yet, Carvalho and colleagues did measure an up-
regulation of PKR contents in the adipose tissue of obese subjects versus lean 
controls. Another factor to consider is the difference in cell types used to perform the 
experiments. Nakamura et al. report their findings in MEFs as well as WAT lysate, 
the same model chosen by Carvalho et al. When discussing the difference between 
our results and those of these two studies, it is important to stress that other studies 
failed to demonstrate the pro-apoptotic role of PKR defended by Nakamura and 
colleagues. For instance, Lancaster and colleagues report that PKR is not obligatory 
for HFD-induced obesity and its associated metabolic and inflammatory 
dysregulations (Lancaster 2016). Potential reasons for the heterogeneity of the 
literature examining the role of PKR have been discussed in further detail in the 
introduction of the present chapter (see introduction IV. 2. 5.).  
 
To further investigate the role of PKR in the context of the autophagy, the 
activity of the kinase was blocked using C16, a pharmacological inhibitor. As 
mentioned in the introduction of this chapter, the findings of Niso-Santano and 
colleagues form a compelling argument in favour of a regulatory role of PKR in 
palmitate-induced autophagy. Indeed, they demonstrated that in a cancerous human 
cell line, the pro-autophagic effect of palmitate depended on this kinase (M. M.-S.-
Y. Niso-Santano 2015). Having produced a Pkr-/- knockdown cell line, they reported 
that palmitate-mediated induction of green fluorescent protein (GFP)-LC3 dots in 
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cultured cells was hindered compared to the control cell line. Furthermore, an earlier 
study published by the same group, revealed that the pro-autophagic effect of 
palmitate was mediated by the disruption of the STAT3-PKR complex (M. S. Niso-
Santano 2013). Therefore, one could have expected that inhibition of PKR to rescue 
the palmitate-induced up-regulation of autophagy, however C16 had no effect on the 
pro-autophagic effect of palmitate. 
 
 
IV. 4. 5. Limitations and future experiments 
A limitation of the data presented in Chapter 4 is that it fails to align with the 
consensus supporting the anti-lipolytic action of palmitate. As discussed in the 
present section, this inconsistency may reflect differences in the experimental design 
used in the present work versus published studies. Therefore, future experiments 
may involve adding isoproterenol for the entire duration of the palmitate treatment, 
as well as shortening the latter to 4 h. However, prolonged exposure to isoproterenol 
might lead to desensitisation of the receptor. Moreover, we may wish to consider 
alternative endpoints such as the expression and phosphorylation levels of HSL 
Ser563, Ser565, Ser600 and ATGL. Using primary adipocytes may yield more 
conclusive results. Finally, it is important to note that immunoblotting only allows 
for the quantitation of phosphorylation state of the enzymes of interest (e.g. PKA, 
HSL, ATGL), which does not necessarily represent lipolytic activity as lipolysis is 
regulated by a large number of lipolytic enzymes and regulatory proteins. Therefore 
an activity-based assay measuring the release of lipolytic products such as FFA or 




 Another shortfall of this chapter was that palmitate-induced autophagy could 
only be demonstrated in pre-adipocytes, not in mature adipocytes. This may 
constitute a limitation to our findings as they become less relevant to the topic of 
lipid metabolism. Indeed, in this type of cells, autophagy might be induced in 
response to molecular damage triggered by palmitate, rather than representing 
lipophagy. In addition, the inhibitors tested failed to significantly rescue the 
palmitate-induced stimulation of LC3B-II expression in 3T3-L1 adipocytes. 
Although a trend in this direction was recorded when treating the cells with A66, this 
effect fell short of achieving statistical significance. Moreover, no positive control 
was included to demonstrate that these inhibitors successfully blocked their targets. 
Therefore, future experiments could test higher concentration of inhibitors, while 
also including positive controls. A TLR2 inhibitor could also be tested in view of the 
model proposed in the discussion of Chapter 3 (Figure 49). Lastly, the role of PKR 
in the context of autophagy could be further explore by considering the effect of 
palmitate on the phosphorylation levels of PKR rather than its impact on protein 
expression. Again using primary adipocytes may produce more conclusive data.  
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V. 1.   Overview of Chapter 5 
 
Isg15 is one of the main effectors of IFN-α. It is of particular interest because 
the transcriptome analysis, which originated the present work, evidenced that the 
expression of this gene was affected by the A66 treatment in mouse adipocytes. 
Furthermore, due to the nature of the peptide encoded by Isg15, this ISG was 
identified as a potential key modulator of the pathways studied in Chapters 3 and 4. 
Indeed, ISG15 has the ability to conjugate to a large number of proteins via a 
reaction similar to ubiquitination, known as ISGylation (D. a. Zhang 2011). Thus, it 
is likely to affect the activity of various cellular processes including those mediated 
by palmitate. In addition, a cytokine role has emerged for unconjugated ISG15, 
which could be another way by which this peptide could alter SFA-dependent 
cellular processes. In order to investigate the role of ISG15, experiments were 
performed in both WT adipocytes and 3T3-L1 cells transduced with either an empty 
vector (used as a control) or an Isg15-targeting shRNA construct. This RNAi 
technique, detailed in the material and methods chapter, allowed for the sustained 
silencing of the gene of interest in the resulting cell line. We were therefore enabled 
to study the consequences of knocking down Isg15 on cellular responses to palmitate 





V. 1. 1. Aim of Chapter 5  
The first step in understanding the role of ISG15 in relation to SFA-induced 
pathways was to assess whether palmitate had an effect on ISG15 expression levels 
in mouse and human adipocytes. Secondly, since palmitate was demonstrated to 
stimulate Tyr phosphorylation of STAT3 in mature 3T3-L1 (Chapter 3), we 
investigated whether recombinant ISG15 elicited the activation of this transcription 
factor. The consequences of knocking down Isg15 were evaluated, considering the 
cellular response to palmitate-induced insulin resistance, palmitate-mediated 
induction of STAT3 and LC3B-II. Lastly, mass spectrometry was employed to 
evaluate the impact of palmitate on ISGylation. Together, these experiments 






V. 2.   Introduction of Chapter 5 
V. 2. 1. The molecular mechanisms of ISGylation 
The process of ISGylation, by which ISG15 is attached to target proteins, 
relies on the coordinated activity of three enzymes also involved in ubiquitin 
conjugation (D. a. Zhang 2011). As described in figure 63, it is initiated by the E1-
mediated activation of ISG15, which is then transferred to the active site of E2, the 
conjugating enzyme. The E3 enzyme then enables the ligation of activated ISG15 to 
the lysine residue of the substrate. Ubiquitin-activating enzyme E1-like (UBE1L) 
and ubiquitin-conjugating enzyme H8 are the two proteins ensuring the roles of E1 
and E2 in human cells, respectively (D. a. Zhang 2011). Three human proteins have 
been identified as the E3 ligase including estrogen-responsive finger protein, 
homologous to E6-associated protein carboxyterminus and regulator of chromosome 
condensation 1 containing protein 5 and human homolog of drosophila Ariadne. 
USP18 ensures the deconjugation of ISG15 from its target proteins (D. a. Zhang 
2011). Interestingly, USP18, which expression is highly induced by type I IFN, 
competes with JAK1 to bind IFNAR2 in a STAT2-dependent manner. This results in 
USP18 hindering the JAK/STAT pathway in a manner that is independent from 
deISGylation (Arimoto 2017). The protease is therefore a key effector of the 







Figure 63. Steps of the ISGylation process. Free IFN-stimulated gene 15 (ISG15) is activated by E1 
ubiquitin-activating enzyme E1-like (UBE1L) which catalyses adenylation and creates a thioester 
bond with ISG15. The activated protein then interacts with and covalently binds ubiquitin-
conjugating enzyme H8 (UBCH8), the bona fide E2 enzyme for ISG15. Ligation to the lysine residue 
of the target substrate is capacitated by ligase E3. Ubiquitin-specific protease 18 (USP18) 
unconjugates ISG15 and its substrate thereby restoring the pool of free ISG15. EFP: estrogen-
responsive finger protein; HERC5: HECT (homologous to E6AP carboxyterminus) and regulator of 




Although similar to ubiquitination, ISGylation has not been implicated in 
proteasomal degradation of its substrates. Rather, this process is thought to interfere 
with the ubiquitin system through competition for E2 and E3 or else the 
sequestration of ubiquitin in ISG15-ubiquitin mixed chains (Villarroya-Beltri 2017). 
The biological relevance of ISGylation has mainly been studied in the context of the 
cellular antiviral response. Evidence from in vitro studies and mice knockouts 
indicate a protective role of ISG15 against certain pathogens including influenza A 
and B virus and the Herpes simplex virus (Lenschow 2007). Interestingly, the 
antiviral effect of the protein is not systematically modulated via ISGylation. Indeed, 
Werneke and colleagues evidenced that susceptibility to chikunguya virus, enhanced 
in ISG15 knockout mice, is independent of UBE1L mediated conjugation. This 
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suggests that unconjugated ISG15 is likely to mediate the cellular response to this 
specific infection (Werneke 2011).  
 
 
V. 2. 2. ISG15, a modulator of immunity 
The biological function of unconjugated ISG15 is likely to be potentiated via 
its cytokine activity (Figure 64). Indeed, the protein was found to be secreted from a 
range of cells, including granulocytes, fibroblasts and epithelial cells, and was 
detected in the serum of healthy human treated with IFN-β (D'Cunha 1996, 
Bogunovic 2012). Sixteen years later, a study by Bogunovic and colleagues 
established ISG15 as an extracellular cytokine promoting the production of IFN-γ 
mainly from human natural killer cells, as well as from T cells, in response to 
mycobacterial disease (Bogunovic 2012). Although additional studies have focused 
on the topic of ISG15-regulated IFN-γ immunity, the cellular mechanisms involved 
remain unclear (Fan 2013). However, progress was made recently with the 
identification of leukocyte function-associated antigen-1 (LFA-1) as the receptor for 
extracellular ISG15 in natural killer cells. More specifically, Swaim and colleagues 
were able to evidence the interaction of the small peptide with CD11a, which 
combined with CD18, forms the LFA-1 integrin receptor (Swaim 2017). In addition, 
they evidenced that pharmacological inhibition of the receptor prevents ISG15-





Figure 64. ISG15 and its role as a cytokine. Upon mycobacterial infection, cells implicated in the 
immune response system including macrophages and granulocytes secrete type I IFN, which is 
detected by lymphocytes B and T. These white blood cells in turn produce ISG15, which induce the 
secretion of IFN-γ by natural killer cells. 
 
 
Importantly, the work of Bogunovic and colleagues revealed species-specific 
differences in the biological functions mediated by ISG15 (Bogunovic 2012). 
Indeed, patients bearing a genetic ISG15 deficiency did not display the expected 
enhanced susceptibility to viral infection recorded in ISG15-deficient mice. 
However, they were more susceptible to mycobacterial infections as their 
lymphocytes secreted less IFN-γ due to the lack of free ISG15. Furthermore, 
fibroblasts derived from ISG15-deficient patients not only failed to display enhanced 
susceptibility to viral infections but also demonstrated enhanced viral protection 
(Speer 2016). Meuwissen and colleagues explained this human-specific gain-of-
function by a dip in levels of USP18, the protease involved in the down-regulation of 
IFN signalling (Meuwissen 2016). Indeed, in human but not mice, ISG15 is 
necessary to maintain USP18 cellular concentration. Lower USP18 activity therefore 
magnifies the antiviral IFN response in human ISG15-deficient cells. Therefore, in 
stark contrast with ISG15-deficient patients who exhibit increased type I IFN 
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immunity at both immunological and clinical levels, no sign of enhanced IFN 
response was described in the murine model (Villarroya-Beltri 2017). 
 
 
V. 2. 3. The role of ISG15 in autophagy 
With the IFN cascade playing such a critical role in autophagy, it is therefore 
unsurprising that ISG15 has also surfaced as a key player in this cellular process. 
Indeed, ISG15 was found to interact with both p62 and histone deacetylase 6 
involved in the transport of misfolded proteins and the fusion of the autophagosome 
with the lysosome (Nakashima 2015). Furthermore, using ISG15-GFP fusion 
protein, Villarroya and colleagues provided evidence that ISGylation prompts 
protein aggregation and degradation by the lysosome (Villarroya-Beltri 2017). These 
findings indicate that protein ISGylation may enable selective autophagy. Recently, 
a study by Xu et al. substantiated the regulatory role of ISG15 in autophagy (D. Z. 
Xu 2015). The authors reported an anti-autophagic role of ISG15 inducer, type I IFN 
in human neuroglioma H4 cells and in HepG2 hepatoma cells. Such findings contrast 
with the results of Schmeisser and colleagues mentioned in Chapter 4, which 
supported a pro-autophagic role for type I IFN in a range of cancer cells in a JAK1-, 
STAT1- and STAT2-dependent manner (Schmeisser 2014).  
 
Moreover, Xu et al. demonstrated that knocking down ISG15 or UBE1L 
restored autophagy in type I IFN-treated cells. They also showed that by competing 
with the ubiquitination process, ISGylation of the mammalian orthologue of yeast 
ATG6, beclin 1, down-regulates PIK3C3, a kinase necessary for autophagy. 
Inversely, they demonstrated a pro-autophagic effect of the enzyme involved in the 
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deISGylation process, USP18 (D. Z. Xu 2015). Such findings appear to be in 
contradiction with the data of Nakamura and colleagues. Indeed, they reported Isg15 
mRNA levels as well as pro-autophagic Pkr mRNA levels to be increased in the 
adipocytes of mice on a HFD compared to the standard chow-fed control 






V. 3.   Results of Chapter 5 
V. 3. 1. Investigating the effect of FA and IFN-γ on ISG15 
expression in adipocytes 
As explained in the introduction, ISG15 is likely to affect the activity of 
many proteins including those modulated by SFAs through its role as a cytokine 
and/or in protein ISGylation. To investigate these possibilities, the first experiment 
performed assessed whether palmitate induces expression of ISG15 and how it 
compared to the effect of IFN-γ. Two read-outs were considered: free ISG15 and 
total ISG15 (including the conjugated proteins). 
 
 
V. 3. 1. 1. Using 3T3-L1 cell line 
A time course experiment comparing the effect of IFN-γ and palmitate on 
ISG15 expression was initially performed in 3T3-L1 pre-adipocytes (Figure 65). 
Although IFN-γ stimulated ISG15 expression with a 121% increase in protein levels 
following a 24 h treatment compared to the untreated control, palmitate did not have 
an effect. Neither IFN-γ nor palmitate stimulated total ISG15 levels over the 
timeframe investigated. As illustrated by figure 66, the time course was reproduced 
in 3T3-L1 mature adipocytes. Compared to the undifferentiated cells, lower 
expression levels of ISG15 were detected in the mature adipocytes. In this cell type, 
IFN-γ nor palmitate prompted an increase in the levels of free ISG15 or total ISG15.  
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Figure 65. A. IFN-γ but not palmitate stimulates ISG15 levels in 3T3-L1 pre-
adipocytes. B. Neither IFN-γ nor palmitate enhances total ISG15 levels in 3T3-L1 
pre-adipocytes. For both figures A and B, 3T3-L1 pre-adipocytes were treated with 
IFN-γ (20 ng/mL) (lanes 3 to 7), unconjugated palmitate (500 μM) (lanes 9 to 13) 
and LPS (100 ng/mL) (lane 15) in 10% FBS/DMEM (HG). Equivalent volumes of 
MilliQ water (40 μL) (lane 2) and DMEM (LG) (1 mL) (lanes 8 and 14) were used 
as control for the IFN and palmitate treatments, respectively. Cells were lysed with 
100 μL 1% TX-100 lysis buffer per 10 cm Ø dish. 65 μg of protein were loaded 
per lane (12% Tris-Tricine-SDS gel). Statistical difference between the 24 h IFN-γ 
treatment and other treatments is indicated with $; statistical difference between 
the 8 h IFN-γ treatment and other treatments is indicated with £ (p-value < 0.05). 




                          
Figure 66. A. Neither palmitate nor IFN-γ stimulates ISG15 levels in 3T3-L1 
mature adipocytes. B. Neither IFN-γ nor palmitate enhances total ISG15 levels in 
3T3-L1 mature adipocytes. For both figures A and B, 3T3-L1 mature adipocytes 
were treated with IFN-γ (20 ng/mL) (lanes 3 to 7), unconjugated palmitate (500 
μM) (lanes 9 to 13) and LPS (100 ng/mL) (lane 15) in 10% FBS/DMEM (HG). 
Equivalent volumes of MilliQ water (8 μL) (lane 2) and DMEM (LG) (200 μL) 
(lanes 8 and 14) were used as control for the IFN and palmitate treatments, 
respectively. Cells were lysed with 80 μL 1% TX-100 lysis buffer per well. 103 μg 





V. 3. 1. 2. Using hMADS cell line 
The time course experiment presented in the previous subsection was also 
conducted in human pre- and mature adipocytes. Figure 67 details the results of the 
former experiment. As for mouse cells, free-ISG15 expression peaked after treating 
the cells for 24 h with IFN-γ. A 123% increase in signal is recorded compared to 
untreated control. The cytokine did not alter the expression of total ISG15. Palmitate 
treatment affected neither endpoint. As shown in figure 68, ISG15 expression is 
considerably weaker in mature adipocytes as for murine cells. Therefore, the 
apparent inhibition of total ISG15 driven by both treatments is likely to be explained 
by the poor quality of the signal. Indeed, such effect could not be reproduced (data 
not shown). 
 
Table 13. Summary of the effect of IFN-γ and palmitate treatment on ISG15 and total ISG15 levels in 
mouse and human cell lines compared to the untreated control. Effects recorded in this table achieved 
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Figure 67. A. IFN-γ but not palmitate stimulates ISG15 levels in hMADS pre-
adipocytes. B. Neither IFN-γ nor palmitate enhances total ISG15 levels in hMADS 
pre-adipocytes. For both figures A and B, hMADS pre-adipocytes were treated 
with IFN-γ (20 ng/mL) (lanes 3 to 7), unconjugated palmitate (500 μM) (lanes 9 to 
13) and LPS (100 ng/mL) (lane 15) in complete DMEM (LG). Equivalent volumes 
of MilliQ water (40 μL) (lane 2) and DMEM (LG) (1 mL) (lane 8 and 14) were 
used as control for the IFN and palmitate treatments, respectively. Cells were 
lysed with 100 μL 1% TX-100 lysis buffer per 10 cm Ø dish. 33 μg of protein 
were loaded per lane (12% Tris-Tricine-SDS gel). ** denotes a treatment 





                          
Figure 68. A. IFN-γ but not palmitate stimulates ISG15 levels in hMADS mature 
adipocytes. B. IFN-γ and palmitate reduce total ISG15 levels in hMADS mature 
adipocytes. For both figures A and B, hMADS mature adipocytes were treated 
with IFN-γ (20 ng/mL) (lanes 3 to 7), unconjugated palmitate (500 μM) (lanes 9 to 
13) and LPS (100 ng/mL) (lane 15) in complete DMEM (LG). Equivalent 
volumes of MilliQ water (8 μL) (lane 2) and DMEM (LG) (200 μL) (lane 8 and 
14) were used as control for the IFN and palmitate treatments, respectively. Cells 
were lysed with 80 μL 1% TX-100 lysis buffer per well. 116 μg of protein were 
loaded per lane (12% Tris-Tricine-SDS gel). Statistical difference between the 
untreated control and other treatments is indicated with £; statistical difference 
between the 24 h IFN-γ treatment and other treatments is indicated with $ (p-value 




V. 3. 2. ISG15 induces STAT3 in mature 3T3-L1 adipocytes 
Having investigated the effect of SFA on ISG15 expression, we sought to 
assess whether free ISG15 operating as a cytokine could mediate the effects of 
palmitate in adipocytes. To this end, we tested if recombinant ISG15 could induce 
the signalling pathways previously identified to be stimulated by palmitate. More 
specifically, we verified whether recombinant ISG15 could promote the 
phosphorylation of STAT3 Tyr705 in 3T3-L1 mature adipocytes. Figure 69 presents 
the results of such time course experiment. ISG15 induced a time–dependent 
increase in STAT3 phosphorylation starting at approximately 2 h and up to the 
longest time point tested (48 h). After 48 h of treatment, the recombinant protein 
induces a statistically significant 117% increase in p-STAT3 Tyr705 compared to 
untreated control. The stimulation of the transcription factor gradually dampens as 
the length of the treatment reduces. After 1 hour of treatment, the effect of ISG15 is 
negligible. Another time course experiment should be performed over a shorter 
timeframe to dismiss a potential biphasic response similar to that induced by leptin 






Figure 69. ISG15 stimulates STAT3 tyrosine phosphorylation in 3T3-L1 mature adipocytes following 
prolonged treatment. 3T3-L1 mature adipocytes were treated with recombinant human ISG15 (100 
ng/mL) (lanes 3, 4, 5, 6, 7 and 8) in 10% FBS/DMEM (HG). Equivalent volumes of MilliQ water (4 
μL) (lanes 2 and 9) were used as control for the ISG15 treatments, respectively. Cells were lysed with 
80 μL 1% TX-100 lysis buffer per well. 147 μg of protein were loaded per lane (10% SDS-acrylamide 
gel). Statistical difference between the 48 h ISG15 treatment and other treatments is indicated with % 
(p-value < 0.05). Data from three independent experiments. 
 
 
V. 3. 3. Use of RNAi experiments to study the potential role of 
ISG15 in palmitate-induced insulin resistance 
This section presents the outcomes of RNAi experiments, aimed at 
establishing the role of the IFN pathway in palmitate-mediated insulin resistance by 
targeting a specific gene of the IFN cascade (Isg15) for knockdown. We developed 
as stable 3T3-L1 Isg15 knockdown cell line (Isg15-KD) using an RNAi technique 
relying on the delivery of shRNA into the cells through viral infection. Such 
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approach has the benefit of producing long-term silencing of the gene and thus 
allows for experiments to be performed in both pre- and mature-adipocytes.  
 
 
V. 3. 3. 1. Effects of silencing Isg15 on insulin sensitivity in 
3T3-L1 pre-adipocytes 
Figure 70 demonstrates the efficacy of the Isg15-KD. Indeed, it compares the 
expression levels of free ISG15 and total ISG15 of the adipocytes transduced with 
the empty pGIPZ and those transduced with the GIPZ containing the Isg15-targeting 
shRNA following stimulation with either IFN-α or IFN-γ. Although total ISG15 
levels do not seem to differ from one cell line to the other, the expression of 
unconjugated ISG15 is four times higher in the cells transduced with the empty 
vector compared to the Isg15-KD pre-adipocytes. As expected, type I IFN drives a 
much more significant induction of ISG15 than type II. Figure 71 compares the IFN-
α-mediated induction of ISG15 in WT pre-adipocytes and in the two transduced cell 
lines. Consistent with the results presented in figure 70, levels of total ISG15 are not 
significantly affected by the treatment across cell lines. However, the expression of 
free ISG15 is up-regulated in both the WT pre-adipocytes and the cells transduced 
with the empty vector. The magnitude of this stimulation is comparable in both cell 
types. As noted in figure 70, the cytokine treatment fails to induce the expression of 






                                
Figure 70. A. IFN-α stimulates ISG15 levels in 3T3-L1 pre-adipocytes transduced 
with the empty vector but not the Isg15-KD cell line. IFN-γ has not effect on either 
cells lines. B. Neither IFN-α nor IFN-γ stimulates total ISG15 levels in 3T3-L1 
pre-adipocytes transduced with the empty vector and the Isg15-KD cell line. 3T3-
L1 pre-adipocytes transduced with either the pGIPZ empty vector or with the 
pGIPZ-Isg15 shRNA construct were treated for 24 h in SF DMEM (HG, 0.2% 
BSA) with IFN-α (20 ng/mL) (lanes 5 and 6) and IFN-γ (20 ng/mL) (lanes 7 and 
8). Equivalent volumes of MilliQ water (40 μL) (lanes 3 and 4) were used as 
control. Cells were lysed with 100 μL 1% TX-100 lysis buffer per 10 cm Ø dish. 
65 μg of protein were loaded per lane (12% Tris-Tricine-SDS gel). ** denotes a 
treatment statistically different from all other treatments (p-value < 0.05). Data 




                         
Figure 71. A. IFN-α stimulates ISG15 levels in 3T3-L1 WT pre-adipocytes and 3T3-L1 
pre-adipocytes transduced with the empty vector to similar levels but not the Isg15-KD 
cell line. B. IFN-α has no significant effect on total ISG15 levels in WT and transduced 
3T3-L1 pre-adipocytes. WT 3T3-L1 pre-adipocytes and 3T3-L1 pre-adipocytes 
transduced with either the pGIPZ empty vector or with the pGIPZ-Isg15 shRNA 
construct were treated for 24 h in SF DMEM (HG, 0.2% BSA) with IFN-α (20 ng/mL) 
(lanes 3, 6 and 9). Equivalent volumes of MilliQ water (16 μL) (lanes 2, 5 and 8) were 
used as control. Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish. 
27 μg of protein were loaded per lane (12% Tris-Tricine-SDS gel). Statistical 
difference between the IFN-α treatment (WT cells) and other treatments is 
indicated with £; statistical difference between the IFN-α treatment (empty 
vector cells) and other treatments is indicated with % (p-value < 0.05). Data from 




Having successfully produced a stable Isg15-KD cell line, we assessed 
whether conjugated or unconjugated palmitate affected ISG15 expression. As 
revealed by figures 72 and 73, neither types of SFA altered the expression levels of 
free ISG15 (or total ISG15) in either the cells transduced with the empty vector or 
those transduced with the pGIPZ-Isg15 shRNA construct. This is consistent with the 
absence of palmitate-mediated effect on ISG15 expression levels recorded in WT 
3T3-L1 pre-adipocytes detailed in figure 65. Investigating the phosphorylation of 
Akt Thr308, it appears that silencing Isg15 enhances cellular susceptibility to 
palmitate-induced insulin resistance (Figure 74). Indeed, following acute insulin 
stimulation, the Isg15-KD cell line treated with BSA-conjugated palmitate showed a 
statistically significant 63% and 58% decrease in p-Akt levels compared to the 
insulin-stimulated control and BSA-treated control, respectively. On the other hand, 
the control cell line was unresponsive to the deleterious effect of the SFA, 
suggesting it is more sensitive to insulin. Similarly to the WT strain of 3T3-L1 pre-
adipocytes, IFN-α failed to induce insulin resistance in either type of transduced cell 
lines. As shown in panel C of figure 75, the difference in response to conjugated 
palmitate is quite substantial between the two transduced cell lines with p-Akt levels 




             
 
Figure 72. Empty vector. IFN-α but not palmitate stimulates ISG15 expression in 3T3-L1 pre-adipocytes transduced with the empty vector. Isg15-KD. Both IFN-α and palmitate 
fail to stimulate ISG15 expression in Isg15-KD 3T3-L1 pre-adipocytes. 3T3-L1 pre-adipocytes transduced with either the pGIPZ empty vector or with the pGIPZ-Isg15 shRNA 
construct were treated with IFN-α (20 ng/mL) (lane 4), unconjugated palmitate (500 μM) (lane 6) and palmitate 3:1 BSA (500 μM) (lane 8) for 24 h in 10% FBS/DMEM (HG).  
Following a 3 h serum deprivation (SF DMEM, HG, 0.2% BSA), cells were stimulated with insulin (100 nM for 15 min) except for the first untreated control (lane 1). Equivalent 
volumes of MilliQ water (40 μL) (lane 3), DMEM (LG) (1 mL) (lane 5) and BSA FAF (1 mL) (lane 7) were used as control for the IFN-α, unconjugated and unconjugated palmitate 
treatments, respectively. Cells were lysed with 100 μL 1% TX-100 lysis buffer per 10 cm Ø dish. 87 μg of protein were loaded per lane in Empty vector (left) and 92 μg in Isg15-KD 
(right) (12% Tris-Tricine-SDS gel). ** denotes a treatment statistically different from all other treatments (p-value < 0.05). Data from four independent experiments. 
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Figure 73. Empty vector. Both IFN-α and palmitate fail to stimulate total ISG15 expression in 3T3-L1 pre-adipocytes transduced with the empty vector. Isg15-KD. Both IFN-α and 
palmitate fail to stimulate total ISG15 expression in Isg15-KD 3T3-L1 pre-adipocytes. 3T3-L1 pre-adipocytes transduced with either the pGIPZ empty vector or with the pGIPZ-
Isg15 shRNA construct were treated with IFN-α (20 ng/mL) (lane 4), unconjugated palmitate (500 μM) (lane 6) and palmitate 3:1 BSA (500 μM) (lane 8) for 24 h in 10% 
FBS/DMEM (HG).  Following a 3 h serum deprivation (SF DMEM, HG, 0.2% BSA), cells were stimulated with insulin (100 nM for 15 min) except for the first untreated control 
(lane 1). Equivalent volumes of MilliQ water (40 μL) (lane 3), DMEM (LG) (1 mL) (lane 5) and BSA FAF (1 mL) (lane 7) were used as control for the IFN-α, unconjugated and 
unconjugated palmitate treatments, respectively. Cells were lysed with 100 μL 1% TX-100 lysis buffer per 10 cm Ø dish. 87 μg of protein were loaded per lane in Empty vector (left) 




       
 
Figure 74. Knockdown of ISG15 increases susceptibility to palmitate-induced insulin resistance in 3T3-L1 pre-adipocytes. 3T3-L1 pre-adipocytes transduced with either the pGIPZ 
empty vector or with the pGIPZ-Isg15 shRNA construct were treated with IFN-α (20 ng/mL) (lane 4), unconjugated palmitate (500 μM) (lane 6) and palmitate 3:1 BSA (500 μM) 
(lane 8) for 24 h in 10% FBS/DMEM (HG).  Following a 3 h serum deprivation (SF DMEM, HG, 0.2% BSA), cells were stimulated with insulin (100 nM for 15 min) except for the 
first untreated control (lane 1). Equivalent volumes of MilliQ water (40 μL) (lane 3), DMEM (LG) (1 mL) (lane 5) and BSA FAF (1 mL) (lane 7) were used as control for the IFN-α, 
unconjugated and unconjugated palmitate treatments, respectively. Cells were lysed with 100 μL 1% TX-100 lysis buffer per 10 cm Ø dish. 87 μg of protein were loaded per lane in 
Empty vector (left) and 82 μg in Isg15-KD (right) (10% SDS-acrylamide gel). Statistical difference between the IFN-α treatment and other treatments is indicated with $; statistical 
difference between the palmitate 3:1 BSA treatment and other treatments is indicated with £; ** denotes a treatment statistically different from all other treatments (p-value < 0.05). 
Data from four independent experiments. 
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Figure 75. Comparison of the effect of IFN-α, unconjugated and BSA-conjugated palmitate on A. ISG15 expression (top left), B. total ISG15 expression (top right) and C. insulin-
stimulated Akt Thr308 phosphorylation (bottom) in 3T3-L1 pre-adipocytes transduced with the pGIPZ empty vector (blue) and the pGIPZ-Isg15 shRNA construct (red). Cells were 
treated with IFN-α (20 ng/mL), unconjugated palmitate and palmitate 3:1 BSA (500 μM) for 24 h in 10% FBS/DMEM (HG).  Following a 3 h serum deprivation (SF DMEM, HG, 
0.2% BSA), cells were stimulated with insulin (100 nM for 15 min) except for the first untreated control. Equivalent volumes of MilliQ water (40 μL), DMEM (LG) (1 mL) and BSA 




















































































Figure 76 explores the effect of inhibiting p110α on palmitate-induced 
insulin resistance in the two transduced cell lines, using the phosphorylation levels of 
Akt as read-out. In line with the findings reported in figure 74, the pre-adipocytes 
transfected with the empty vector appear protected from palmitate-induced insulin 
resistance unlike the Isg15-KD cell line. Indeed, the p-Akt levels were not 
significantly affected by the SFA treatment compared to the p-Akt levels recorded in 
both the BSA-treated and the insulin-stimulated controls in pre-adipocytes 
transduced with the empty vector. In the Isg15-KD cells however, palmitate drove a 
48% and 46% decrease in p-Akt versus the insulin-stimulated and the BSA-treated 
controls, respectively. The p-Akt levels recorded for the two controls are statistically 
different from the untreated control unlike those measured for cells treated with 
palmitate. As this is not the case in pre-adipocytes transduced with the empty vector 
(the p-Akt levels recorded for the two controls as well as for the SFA-treated cells 
are not statistically different from the untreated cells), we can conclude that the 
palmitate effect on Akt phosphorylation is greater in Isg15-KD pre-adipocytes.  
 
Adding A66 to the palmitate treatment rescues the effect of the SFA in both 
cell lines although the difference in p-Akt levels between cells treated with palmitate 
alone and a combination of palmitate and A66 is only statistically significant in 
Isg15-KD pre-adipocytes. As shown in figure 77, the latter cell line seems less 




       
 
Figure 76. A66 rescues the effect of palmitate on the phosphorylation of Akt in both 3T3-L1 pre-adipocytes transduced with the empty vector and Isg15-KD 3T3-L1 pre-adipocytes. 
3T3-L1 pre-adipocytes transduced with either the pGIPZ empty vector or with the pGIPZ-Isg15 shRNA construct were treated with palmitate 3:1 BSA (500 μM) (lanes 4 and 5) and 
A66 (1 μM) (lanes 5 and 6) for 24 h in 10% FBS/DMEM (HG).  Following a 3 h serum deprivation (SF DMEM, HG, 0.2% BSA), cells were stimulated with insulin (100 nM for 15 
min) except for the first untreated control (lane 1). Equivalent volumes of BSA FAF (400 μL) (lane 3) and DMSO (40 μL)  (lane 7) were used as control for the unconjugated 
palmitate treatment and A66 treatment, respectively. In both figures, cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish. 29 μg of protein were loaded per lane 
(10% SDS-acrylamide gel). Statistical difference between the untreated control and other treatments is indicated with &; statistical difference between the palmitate 3:1 BSA 
treatment and other treatments is indicated with £; statistical difference between the DMSO control and other treatments is indicated with %; ** denotes a treatment statistically 





Figure 77. Comparison of the effect of unconjugated palmitate and A66 on Akt Thr308 
phosphorylation in 3T3-L1 pre-adipocytes transduced with the pGIPZ empty vector (blue) and the 
pGIPZ-Isg15 shRNA construct (red). Cells were treated with palmitate 3:1 BSA (500 μM) and A66 (1 
μM) for 24 h in 10% FBS/DMEM (HG).  Following a 3 h serum deprivation (SF DMEM, HG, 0.2% 
BSA), cells were stimulated with insulin (100 nM for 15 min) except for the first untreated control. 
Equivalent volumes of BSA FAF (400 μL) and DMSO (40 μL) were used as control for the 
unconjugated palmitate treatment and A66 treatment, respectively. 
 
 
V. 3. 3. 2. Effects of silencing Isg15 on palmitate-induced 
autophagy in 3T3-L1 pre-adipocytes 
 Having investigated the consequences of silencing ISG15 on palmitate-
mediated insulin resistance, we explored the effect of this manipulation on palmitate-
induced stimulation of autophagy. In Chapter 4, the SFA was shown to elicit a 
significant increase in the expression levels of LC3B-II in 3T3-L1 pre-adipocytes. 
Therefore, the role of ISG15 in the modulation of the pro-autophagic effect of 
palmitate was evaluated in the same cell type. As illustrated by figure 78A, both the 
cells transduced with the empty vector and those transduced with the shRNA-Isg15 
construct responded to the palmitate treatment with a large increase in expression of 
the autophagy marker, LC3B-II. Interestingly, knocking down Isg15 appeared to dull 
the palmitate-mediated induction: the SFA drove a 638% increase in LC3B-II levels 


































increase was measured in the Isg15-KD cell line comparing the same conditions. The 
one-way ANOVA analysis confirms the statistical difference between the responses 
of the two cell lines to the palmitate treatment (F(9,20) = 57.69, p-value = 0.00; 
Tukey HSD post hoc test between “empty vector - palmitate treatment” and “Isg15-
KD - palmitate treatment”: p-value = 0.00). 
 
 Figure 78B explores the potential molecular mechanisms implicated in the 
modulation of palmitate-induced autophagy by ISG15. Indeed, in addition to the 
experimental conditions of figure 78A, C16 (PKR-selective inhibitor) was included 
in the presence or absence of palmitate. The effect of the SFA alone is consistent 
with figure 78A, with a more significant increase in LC3B-II expression in the 
control cells versus the knockdown cells following the palmitate treatment. 
Interestingly, blocking PKR partially rescues the pro-autophagic effect of the SFA in 
both cell types. This is rather unexpected as C16 had no effect on palmitate-induced 
autophagy in WT 3T3-L1 pre-adipocytes (Figure 61). When comparing the fold 
decrease in LC3B-II expression between the palmitate treatment and the palmitate 
treatment supplemented with C16, the ratios are the same for both cell lines (0.7), 
implying that this effect is irrespective of whether Isg15 is silenced. 
 
 Figure 79A aims at confirming the nature of the effect of palmitate on 
autophagy by including bafilomycin A1 to the treatments. Treating the cells for 24 h 
with the antibiotic induced too large of a stimulation of LC3B-II expression to detect 
any cumulative effect of palmitate and bafilomycin A1 (data not shown). Therefore, 
the duration of the treatment was reduced from 24 h to 4 h. At this time point, the 
palmitate treatment does up-regulate LC3B-II levels, however no difference can be 
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observed in the responses of the cell lines. Nevertheless, the cells transduced with 
the empty vector are more sensitive to the effect of the antibiotic alone. In both cell 
lines, combining the bafilomycin A1 and palmitate treatments elicits an even greater 
stimulation of LC3B-II expression than does either treatment on its own. As 
explained in the previous chapter, an up-regulation of LC3B-II levels in both the 
absence and presence of bafilomycin A1 indicates a stimulation of the autophagic 
flux, inhibited by the antibiotic.  
 
Considering another marker of autophagy, p62, we were able to verify the 
pro-autophagic effect of palmitate (Figure 79B). When comparing the expression of 
p62 of the DMEM-treated control cells with that of palmitate-treated control cells, 
the 65% decrease observed in the latter group is statistically significant. However, 
comparing these treatments in the knockdown cell line, the difference measure is 
smaller (52% decrease following palmitate treatment) and not statistically 
significant. This is in line with the data presented in figure 78A, which indicated that 
cells transduced with the empty vector were more sensitive to the pro-autophagic 
effect of palmitate.  
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Figure 78. A. Unconjugated palmitate stimulates the expression of LC3B-II in 3T3-L1 pre-adipocytes transduced with the empty vector and to a lesser extent in Isg15-KD 3T3-L1 
cells. 3T3-L1 pre-adipocytes transduced with either the pGIPZ empty vector or with the pGIPZ-Isg15 shRNA construct were treated with unconjugated palmitate (500 μM) (lanes 3 
and 8) and LPS (100 ng/mL) (lanes 5 and 10) for 24 h in 10% FBS/DMEM (HG). Equivalent volumes of DMEM (LG) (400 μL) (lanes 2 and 7) and PBS (40 μL) (lanes 4 and 9) 
were used as control for the unconjugated palmitate and LPS treatments, respectively. B. Inhibiting PKR in both cell type hinders the pro-autophagic effect of palmitate. 3T3-L1 pre-
adipocytes transduced with either the pGIPZ empty vector or with the pGIPZ-Isg15 shRNA construct were treated with unconjugated palmitate (500 μM) (lanes 3, 6, 9 and 12) and 
C16 (2 μM) (lanes 5, 6, 11 and 12) for 4 h in 10% FBS/DMEM (HG). Equivalent volumes of DMEM (LG) (400 μL) (lanes 2 and 8) and DMSO (8  μL) (lanes 4 and 10) were used as 
control for the unconjugated palmitate and C16 treatments, respectively. For both figures A and B, cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish. 28 μg of 
protein were loaded per lane (15% SDS-acrylamide gel). Statistical difference between the “palmitate + C16” treatment (empty vector cells) and other treatments is indicated with %; 
statistical difference between the palmitate treatment (Isg15-KD cells) and other treatments is indicated with &; statistical difference between the palmitate + C16” treatment (Isg15-
KD cells) and other treatments is indicated with £; ** denotes a treatment statistically different from all other treatments (p-value < 0.05). Data from three independent experiments. 
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Figure 79. A. Palmitate stimulates LC3B-II levels after 4 h of treatment in both 3T3-L1 pre-adipocytes transduced with the empty vector and the Isg15-shRNA. Adding bafilomycin 
A1 to the SFA treatment enhances this effect to a greater extent in the cells transduced with the empty vector. B. Palmitate inhibits p62 levels after 4 h of treatment in both 3T3-L1 
pre-adipocytes transduced with the empty vector and the Isg15-shRNA. For both figures A and B, 3T3-L1 pre-adipocytes transduced with either the pGIPZ empty vector or with the 
pGIPZ-Isg15 shRNA construct were treated with unconjugated palmitate (500 μM) (lanes 3, 6, 9 and 12) and bafilomycin A1 (10 nM) (lanes 5,  6, 11 and 12) for 4 h in 10% 
FBS/DMEM (HG). Equivalent volumes of DMEM (LG) (400 μL) (lanes 2 and 8) and DMSO (8 μL) (lanes 4 and 10) were used as control for the unconjugated palmitate and 
bafilomycin A1 treatments, respectively. Cells were lysed with 100 μL 1% TX-100 lysis buffer per 6 cm Ø dish. 25 μg and 33 μg of protein were loaded per lane in figures A and B, 
respectively (15% SDS-acrylamide gel). Statistical difference between the palmitate treatment (empty vector cells) and other treatments is indicated with %; statistical difference 
between the bafilomycin A1 treatment (empty vector cells) and other treatments is indicated with $; statistical difference between the palmitate treatment (Isg15-KD cells) and other 
treatments is indicated with &; statistical difference between the palmitate + bafilomycin A1” treatment (Isg15-KD cells) and other treatments is indicated with £; ** denotes a 
treatment statistically different from all other treatments (p-value < 0.05). Data from three independent experiments. 
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V. 3. 3. 3. Effects of silencing Isg15 on insulin sensitivity in 
3T3-L1 mature adipocytes 
The set of experiments presented in the previous section in transduced 3T3-
L1 pre-adipocytes was reproduced in mature cells. As observed in WT 3T3-L1, 
ISG15 is less expressed in differentiated cells in the transduced cell lines. 
Nevertheless, a substantial decrease in ISG15 expression following IFN-α treatment 
can be noticed when comparing mature 3T3-L1 transduced with the empty vector 
versus the Isg15-KD cells (Figure 80). Indeed, while the type I cytokine drives a 
statistically significant increase in unconjugated ISG15 in the former cell line 
(+261% compared to the water treated control), no significant effect was recorded in 
the later cell line. As illustrated by panel A of figure 83, a 175% difference in IFN-α-
induced stimulation of ISG15 expression was noted between the two types of cells. 
A more subtle stimulation of total ISG15 levels was also monitored in cells bearing 
the empty vector with a statistically significant increase of 44% compared to the 
water treated control. Such stimulation was absent in the Isg15-KD (Figure 81). 
Together these results indicate that the target gene was successfully silenced in 
differentiated cells. Note, as for pre-adipocytes, palmitate treatment did not promote 
free or conjugated ISG15 expression. 
 
Considering the effect of knocking down Isg15 on insulin sensitivity, the 
overall trend in mature adipocytes follows that noted in pre-adipocytes despite the 
differences between the two cell lines being milder in mature adipocytes. When 
comparing the phosphorylation of Akt Thr308 in the mature adipocytes transduced 
with the empty vector and the Isg15-KD cells, none of the variations in p-Akt levels 
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under the various treatments including with palmitate are statistically significant 




       
 
Figure 80. Empty vector. IFN-α but not palmitate stimulates ISG15 expression in 3T3-L1 mature adipocytes transduced with the empty vector. Isg15-KD. Both IFN-α and 
palmitate fail to stimulate ISG15 expression in Isg15-KD 3T3-L1 mature adipocytes. 3T3-L1 mature adipocytes transduced with either the pGIPZ empty vector or with the pGIPZ-
Isg15 shRNA construct were treated with IFN-α (20 ng/mL) (lane 4), unconjugated palmitate (500 μM) (lane 6) and palmitate 3:1 BSA (500 μM) (lane 8) for 24 h in 10% 
FBS/DMEM (HG).  Following a 3 h serum deprivation (SF DMEM, HG, 0.2% BSA), cells were stimulated with insulin (100 nM for 15 min) except for the first untreated control 
(lane 1). Equivalent volumes of MilliQ water (8 μL) (lane 3), DMEM (LG) (200 μL) (lane 5) and BSA FAF (200 μL) (lane 7) were used as control for the IFN-α, unconjugated and 
unconjugated palmitate treatments, respectively. Cells were lysed with 80 μL 1% TX-100 lysis buffer per well. 222 μg of protein were loaded per lane in Empty vector (left) and 185 
μg in Isg15-KD (right) (12% Tris-Tricine-SDS gel). ** denotes a treatment statistically different from all other treatments (p-value < 0.05). Data from three independent experiments. 
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Figure 81. Empty vector. IFN-α but not palmitate stimulates total ISG15 expression in 3T3-L1 mature adipocytes transduced with the empty vector. Isg15-KD. Both IFN-α and 
palmitate fail to stimulate total ISG15 expression in Isg15-KD 3T3-L1 mature adipocytes. 3T3-L1 mature adipocytes transduced with either the pGIPZ empty vector or with the 
pGIPZ-Isg15 shRNA construct were treated with IFN-α (20 ng/mL) (lane 4), unconjugated palmitate (500 μM) (lane 6) and palmitate 3:1 BSA (500 μM) (lane 8) for 24 h in 10% 
FBS/DMEM (HG).  Following a 3 h serum deprivation (SF DMEM, HG, 0.2% BSA), cells were stimulated with insulin (100 nM for 15 min) except for the first untreated control 
(lane 1). Equivalent volumes of MilliQ water (8 μL) (lane 3), DMEM (LG) (200 μL) (lane 5) and BSA FAF (200 μL) (lane 7) were used as control for the IFN-α, unconjugated and 
unconjugated palmitate treatments, respectively. Cells were lysed with 80 μL 1% TX-100 lysis buffer per well. 222 μg of protein were loaded per lane in Empty vector (left) and 185 




           
 
Figure 82. Empty vector. Both IFN-α and palmitate fail to induce insulin resistance in 3T3-L1 mature adipocytes transduced with the empty vector. Isg15-KD. Both IFN-α and 
palmitate fail induce insulin resistance in Isg15-KD 3T3-L1 mature adipocytes. 3T3-L1 mature adipocytes transduced with either the pGIPZ empty vector or with the pGIPZ-Isg15 
shRNA construct were treated with IFN-α (20 ng/mL) (lane 4), unconjugated palmitate (500 μM) (lane 6) and palmitate 3:1 BSA (500 μM) (lane 8) for 24 h in 10% FBS/DMEM 
(HG).  Following a 3 h serum deprivation (SF DMEM, HG, 0.2% BSA), cells were stimulated with insulin (100 nM for 15 min) except for the first untreated control (lane 1). 
Equivalent volumes of MilliQ water (8 μL) (lane 3), DMEM (LG) (200 μL) (lane 5) and BSA FAF (200 μL) (lane 7) were used as control for the IFN-α, unconjugated and 
unconjugated palmitate treatments, respectively. Cells were lysed with 80 μL 1% TX-100 lysis buffer per well. 224 μg of protein were loaded per lane in Empty vector (left) and 111 
μg in Isg15-KD (right) (10% SDS-acrylamide gel). ** denotes a treatment statistically different from all other treatments (p-value < 0.05). Data from three independent experiments. 
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A.      B.   
 
C.         
 
Figure 83. Comparison of the effect of IFN-α, unconjugated and BSA-conjugated palmitate on A. ISG15 expression (top left), B. total ISG15 expression (top right) and C. Akt Thr308 
phosphorylation (bottom) in 3T3-L1 mature adipocytes transduced with the pGIPZ empty vector (blue) or with the pGIPZ-Isg15 shRNA construct (red). Cells were treated with IFN-
α (20 ng/mL), unconjugated palmitate and palmitate 3:1 BSA (500 μM) for 24 h in 10% FBS/DMEM (HG).  Following a 3 h serum deprivation (SF DMEM, HG, 0.2% BSA), cells 
were stimulated with insulin (100 nM for 15 min) except for the first untreated control. Equivalent volumes of MilliQ water (8 μL), DMEM (LG) (200 μL) and BSA FAF (200 μL) 















































































Further experiments were performed to investigate the effect of A66 on the 
phosphorylation of Akt in the presence or absence of palmitate (Figure 84). The 
effect of the SFA recorded coincides with the results presented in figure 82, with a 
trend suggesting that the control cell line is more resistant to the effect of palmitate 
than the Isg15-KD cells are more susceptible to palmitate-induced insulin resistance 
compared to empty vector. Interestingly, the Isg15-KD cells are considerably less 
sensitive to the stimulatory effect of A66, which echoes the observations made in 
pre-adipocytes. The difference in response is clearly observable in figure 85. This 
suggests that the effect of A66 is mediated through ISG15 expression and points at 
an interaction between PI3K and ISG15. Overall our data indicates that ISG15 is a 




       
 
Figure 84. A66 stimulates insulin-induced phosphorylation of Akt in 3T3-L1 mature adipocytes transduced with the empty vector but not in Isg15-KD 3T3-L1 mature adipocytes. 
3T3-L1 mature adipocytes transduced with either the pGIPZ empty vector or with the pGIPZ-Isg15 shRNA construct were treated with palmitate 3:1 BSA (500 μM) (lanes 4 and 5) 
and A66 (1 μM) (lanes 5 and 6) for 24 h in 10% FBS/DMEM (HG).  Following a 3 h serum deprivation (SF DMEM, HG, 0.2% BSA), cel ls were stimulated with insulin (100 nM for 
15 min) except for the first untreated control (lane 1). Equivalent volumes of BSA FAF (200 μL) (lane 3) and DMSO (20 μL) (lane 7) were used as control for the unconjugated 
palmitate treatment and A66 treatment, respectively. In both figures, cells were lysed with 80 μL 1% TX-100 lysis buffer per well. 25 μg of protein were loaded per lane (10% SDS-
acrylamide gel). Statistical difference between the untreated control and other treatments is indicated with &; statistical difference between the “palmitate + A66” treatment and other 
treatments is indicated with $; statistical difference between the DMSO control and other treatments is indicated with %; ** denotes a treatment statistically different from all other 





Figure 85. A66 enhances the insulin-stimulated phosphorylation of Akt in 3T3-L1 mature adipocytes 
transduced with the pGIPZ empty vector (blue) but not in Isg15-KD 3T3-L1 mature adipocytes (red). 
Cells were treated with palmitate 3:1 BSA (500 μM) and A66 (1 μM) for 24 h in 10% FBS/DMEM 
(HG).  Following a 3 h serum deprivation (SF DMEM, HG, 0.2% BSA), cells were stimulated with 
insulin (100 nM for 15 min) except for the first untreated control. Equivalent volumes of BSA FAF 




V. 3. 3. 4. Effects of silencing Isg15 on lipid-induced 
stimulation of STAT3 Tyr705 in 3T3-L1 mature adipocytes 
Having investigated the effect of silencing Isg15 on the insulin sensitivity of 
mature 3T3-L1 adipocytes, the effect of this knockdown on the phosphorylation of 
STAT3 Tyr705 was explored. As discussed in Chapter 3, palmitate was demonstrated 
to induce the phosphorylation of this residue in differentiated 3T3-L1 cells following 
8 h of treatment. LPS was also found to elicit the activation of this transcription 
factor. Figure 86 presents the response of the two transduced cell lines to palmitate 
and LPS treatments. In the control cells (lanes 1 to 5), both lipids stimulated the 
phosphorylation of STAT3, unlike in the Isg15-KD cells.  
 
On the one hand, palmitate drove a 98% and 59% increase in p-STAT3 



































the other hand, LPS prompted a 426% and 384% increase in the phosphorylation 
levels of STAT3 compared to untreated and PBS-treated controls, respectively. 
Unlike LPS, the effect of palmitate fell short of reaching statistical significance (one-
way ANOVA F(9,28) = 26.24, p-value = 0.00; Tukey HSD post hoc test between 
“untreated control” and “palmitate treatment”: p-value = 0.17; Tukey HSD post hoc 
test between “DMEM-treated control” and “palmitate treatment”: p-value = 0.78). 
However, a paired 2-tailed student t-test associated difference in p-STAT3 levels 
measured in the untreated control and the palmitate-treated cells with a p-value of 
0.00. Focussing on the response of the Isg15-KD cells, none of the treatments had an 
effect on the phosphorylation of STAT3 Tyr residue. 
 
 Comparing the effect of LPS in the two cell lines, silencing Isg15 induced a 
drastic decrease in LPS-mediated stimulation of STAT3. The 398% difference 
between the two cell lines reaches statistical significance using a one-way ANOVA 
(Tukey HSD post hoc test between “LPS treatment” in control cells and “LPS 
treatment” in Isg15-KD cells: p-value = 0.00). The more modest 110% difference in 
the response of the two cell lines to palmitate treatment fell short of statistical 
significance when analysing the data using a one-way AONVA (Tukey HSD post 
hoc test between “palmitate treatment” in control cells and “palmitate treatment” in 
Isg15-KD cells: p-value = 0.16). Subjecting the data to an unpaired 2-tailed student 
t-test, the difference between the effect of the SFA in the two cell lines reaches a 




Therefore, it seems that overall both palmitate and LPS stimulate the 
phosphorylation of STAT3 Tyr705 in the control cell line, but not in the Isg15-KD 




Figure 86. LPS and to a lesser extent unconjugated palmitate stimulate the phosphorylation of STAT3 
Tyr705 in 3T3-L1 mature adipocytes transduced with the empty vector but not in Isg15-KD 3T3-L1 
cells. 3T3-L1 mature adipocytes transduced with either the pGIPZ empty vector or with the pGIPZ-
Isg15 shRNA construct were treated with unconjugated palmitate (500 μM) (lanes 3, 6, 9 and 12) and 
LPS (100 ng/mL) (lanes 5 and 10) for 8 h in 10% FBS/DMEM (HG). Equivalent volumes of DMEM 
(LG) (200 μL) (lanes 2 and 7) and PBS (20 μL) (lanes 4 and 9) were used as control for the 
unconjugated palmitate and LPS treatments, respectively. Cells were lysed with 80 μL 1% TX-100 
lysis buffer per well. 171 μg of protein were loaded per lane (10% SDS-acrylamide gel). ** denotes a 









V. 3. 4. Insights from mass spectrometric analysis on the role of 
protein ISGylation 
The last step of the present investigation was to perform a mass spectrometric 
analysis on anti-ISG15 immunoprecipitates derived from mature 3T3-L1 adipocytes 
treated with palmitate or IFN-α. This would allow the isolation of proteins 
conjugated to ISG15, a.k.a. ISGylated proteins. The aim of such experiment was to 
discover which ISGylated proteins would be induced or inhibited by the two 
treatments and whether some overlaps existed. Figure 87 shows the western blot of 
IP samples derived from 3T3-L1 mature adipocytes treated with IFN-α or palmitate 
and incubated with or without an ISG15 specific antibody. The pattern observed 
validates that ISG15 and ISGylated proteins were successfully pulled-down with the 
applied IP protocol. A clear band at 17 kDa corresponding to ISG15 can be noticed 
in the lanes where IFN-α-treated cells were run. THP-1 cells treated with LPS were 






Figure 87. ISG15 IP test following denaturation in 3T3-L1 mature adipocytes. 3T3-L1 mature 
adipocytes were treated with IFN-α (20 ng/mL) (lanes 3 and 5) and palmitate 3:1 BSA (500 μM) (lane 
6) for 12 h in 10% FBS/DMEM (HG). THP-1 cells were treated with LPS (100 ng/mL) (lane 7) for 
the same duration and in the same conditions. As additional controls, a sample containing only 
protein A beads in lysate buffer (lane 1) and a sample of untreated cells incubated with no antibody 
were ran (lane 2). Cells were lysed with 100 μL 2% SDS, 150 mM NaCl, Tris-HCl, pH 8.0 lysis 
buffer. After boiling the samples for 5 min, these were diluted 1:10 with 1% TX-100 lysis buffer. The 




As recorded in table 14, in total, the MS2 intensity (which can be used as a 
measure of the relative detection of a protein) of 264 proteins was down-regulated by 
IFN-α. That of 76 was stimulated by the same treatment. Levels of 322 and 108 
proteins were inhibited and induced by the palmitate treatment, respectively. Levels 
of 42 proteins were up-regulated following the palmitate and IFN-α treatments 
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compared to the unstimulated control incubated in the ISG15 antibody. Levels of 
174 proteins were down-regulated by both treatments; levels of 21 proteins were 
induced by IFN-α but inhibited by the SFA and, inversely, levels of 38 other proteins 
were induced by palmitate but inhibited by IFN-α. These hits were submitted to the 
DAVID database to derive biological themes (particularly gene ontology terms) and 
functionally-related gene groups of the lists of differentially expressed genes. The 
clusters identified are summarised in table 14.  
 
Overall, there is a striking similarity between the gene clusters found to be 
down-regulated by palmiate and IFN-α, with the prevalence of genes involved in 
mitochondrial functions, ribosomal proteins, chaperonins, tubulin and heat shock 
proteins (HSP). For instance, the gene cluster down-regulated by palmitate with the 
third highest enrichment score (21.5) was also the one down-regulated by IFN-α 
with the highest enrichment score (22.2). This cluster included ribosomal proteins 
such as ribosomal proteins L13, S2 and S3A1. Another cluster down-regulated by 
both treatments included genes involved in mitochondrial functions such as 
cytochrome c oxidase subunit II and ubiquinol-cytochrome c reductase, Rieske iron-
sulfur polypeptide 1, both implicated in the mitochondrial electron transport chain. 
Genes encoding the ATP synthase, proton transporting, mitochondrial F1 complex 
were also found in this cluster. Interestingly, one gene cluster down-regulated by 
both palmitate and IFN-α includes genes encoding the chaperonin containing T-
complex protein 1 (CCT), which is key in the biogenesis of tubulin, a globular 





Lastly, the expression of glycerol-3-phosphate dehydrogenase 1 (GPD1), 
which ensures the reduction of dihydroxyacetone phosphate into glycerol-3-
phosphate (G3P) was also down-regulated by both treatments. This reaction is 
critical for lipid biosynthesis as it enables glycerol production and in turn 
triglyceride synthesis (Yeh 2008). The expression of two other dehydrogenases are 
also inhibited by the palmitate and IFN-α treatments: malate dehydrogenase 1 
(MDH1) and lactate dehydrogenase A (LDHA). The former, located in the 
cytoplasm similarly to GPD1, reversibly catalyses the oxidation of L-malate to 
oxaloacetate as part of the citric acid cycle (Minarik 2002). The latter guaranties the 
inter-conversion of L-lactate to pyruvic acid within the cytosol (Valvona 2016). The 
lactate and the G3P produced by LDHA and GPD1, respectively, feed into the citric 
acid cycle modulated by MDH1, thus connecting the three enzymes together. 
 
Surprisingly, the list of genes induced by the IFN-α could not be classified 
into any gene cluster by the DAVID software (Table 14). Therefore no overlap could 
be identified in the biological functions of genes up-regulated by palmitate and IFN-
α or between those of genes induced by IFN-α and inhibited by palmitate. As the 
mass spectrometric analysis identified Isg15 as belonging to the latter category, 









Table 14. Overview of the gene clusters identified by the database for annotation, visualisation and integrated discovery (DAVID) software to be either up- or down-regulated by 
IFN-α and palmitate. Mature 3T3-L1 cells were treated for 12 h with either palmitate (500 μM) or IFN-α (20 ng/mL) in 10% FBS/DMEM (HG). Cells were then lysed and the lysate 
was incubated with an ISG15-specific antibody. The samples were analysed using mass spectrometry. Information on the number of edges of the predicted network and the average 
node degree were derived from the Search Tool for the Retrieval of Interacting Genes/Protein (STRING) analysis performed on each gene list. Gene clusters are organised from 
highest to lowest enrichment score. The full DAVID analysis can be found in the appendix V.II. 11. HSP: heat shock protein; NADH: nicotinamide adenine dinucleotide. 
 
 Up-regulated by IFN-α 
Down-regulated by 
IFN-α 
















Number of genes 76 264 108 322 42 174 21 38 
Number of edges* 254 2121 394 2681 89 1066 23 25 
Average node 
degree* 
6.8 16.2 7.4 16.9 4.3 12.4 2.2 1.3 
Number of gene 
clusters in 
DAVID 
0 14 4 14 0 9 0 1 
General function 


































































The STRING database was employed to derive known and predicted protein 
interactions, both physical and functional. This database compiles experimental data, 
computational prediction methods as well as public text collections. Figures 87 and 
88 represent the networks of predicted associations between proteins encoded by 
genes down-regulated and up-regulated by palmitate treatment of mature 3T3-L1 
adipocytes, respectively. As these proteins were isolated by IP using an ISG15-
specific antibody, one can assume that such proteins were either ISGylated or 
interact with ISGylated proteins. Only the hits with the largest and lowest fold 
increase are represented in order to avoid over-crowding the figures. The number of 
edges and the average node degree recorded in table 14 provide an insight on how 
tightly knit these networks are when all hits are included. Overall, the palmitate-
induced genes are fewer and showed lesser association than the palmitate-inhibited 
genes with 108 versus 322 nodes, 394 versus 2681 edges and 7.4 versus 16.9 average 
node degree (table 14).  
 
As shown in figure 88, similar gene clusters can be identified with STRING 
and DAVID software, in the case of the genes down-regulated by palmitate. Circled 
in green are the coenzyme A dehydrogenases also recorded in table 14; circled in 
purple are proteins implicated in keratin production; circled in blue are ribosomal 
proteins; circled in orange are dehydrogenases critical for the critic acid cycle and in 
yellow are proteins important for molecular chaperones. The remaining clusters 
identified by the DAVID analysis are likely to be represented in the STRING 
network generated using the total hits obtained from mass spectrometric analysis, 
however such network was too dense for visualisation. ISG15, circled in red, is 
directly connected to HSP90αB1. Through its ATPase activity and its interaction 
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with various co-chaperones, this molecular chaperone ensures the maturation and the 
maintenance of the structural integrity of a range of protein targets involved in cell 
cycle control and signal transduction. It is able to modulate transcription via different 
strategies, including the regulation of epigenetic modifiers such are histone 
deacetylases and DNA methyl transferase, or else the removal of histones from the 
promoter of certain genes to permit their expression (Khurana 2015). Interestingly, 
Cheng et al. reported that the phosphorylation of STAT1 is indispensable for the 
activation of Hsp90β gene during heat shock response (Cheng 2010).  
 
The STRING analysis also predicts the interaction of ISG15 with 
peptidylprolyl isomerase A (PPIA), also known as cyclophilin-A (Figure 88). Also 
implicated in protein folding, this enzyme accelerates the process by catalysing the 
cis-trans isomerisation of proline imidic peptide bonds in oligopeptides. It functions 
as a growth factor secreted upon oxidative stress to mitigate tissue damage. In 
endothelial cells, PPIA was shown to stimulate both the Akt and NF-κB pathways 
(Wei 2013). The following year, Ramachandran et al. evidenced increased 
concentration of PPIA in the plasma of T2D and coronary artery disease patients 
compared to healthy individuals (Ramachandran 2014).  The network generated by 
the STRING software also indicates an association between ISG15 and the 40S 
subunit ribosomal proteins S2, S3, S4x and S19. Of these four ribosomal proteins, 
ribosomal protein S3 has the specificity of being involved in DNA repair.  
 
Lastly, ISG15 appears to interact with phospholipase A2 (PLAA), an enzyme 
found in abundance in snake venom but also occurs in all organisms studied. It is 
specialised in the hydrolysis of the sn-2 position of glycerophospholipids thus 
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producing arachidonic acid as well as lysophospholipids (Harris 2013). This reaction 
has been implicated in various biological processes including inflammation as well 
as protein ubiquitination. Indeed, Hall et al. demonstrated that PLAA is necessary 
for ubiquitin-mediated sorting of membrane proteins targeted for lysosomal 
degradation in MEFs (Hall 2017). A recent study by Papadopoulos et al. also 
implicated PLAA in autophagy, more specifically, the clearance of ruptured 







Figure 88. Network view of predicted associations between proteins encoded by genes that were 
down-regulated following palmitate treatment (500 μM, 12 h) of mature 3T3-L1 in 10% FBS/DMEM 
(HG). Each coloured line represents a specific type of evidence supporting the predicted functional 
association. A light blue line indicates a know interaction from curated databases; a pink line 
indicates a known interaction experimentally determined; a dark green line indicates a predicted 
interaction based on gene neighbourhood; a dark blue line indicates a predicted interaction based on 
the cooccurence of two genes across the genome; a light green line indicates that putative homologs 
are coexpressed in other species; a black line indicated that putative homologs are co-mentioned in 
PubMed abstracts; a purple line indicates protein homology (bit score > 60). Note that to avoid over-
crowding the figure, this analysis only includes 66 of the 322 genes that were down-regulated by 
palmitate treatment. For this subset, the maximum fold increase compared to the untreated control 
was set to 0.1. ISG15, circled in red, was also included despite a fold increase of 0.2. Circled in green 
are the coenzyme A dehydrogenases; circled in purple are proteins implicated in keratin production; 
circled in blue are the ribosomal proteins; circled in orange the dehydrogenases critical for the critic 







 Figure 89 represents the network of predicted associations linking the 
proteins encoded by genes that were the most highly induced by palmitate (the full 
network is not represented because the high number of nodes made it illegible). The 
STRING software was able to identify gene clusters similar to those proposed by the 
DAVID software. The most noticeable one, circled in black, corresponds to 
ribonucloproteins, the cluster associated with the highest enrichment score in the 
DAVID analysis (Table 14). Circled in blue is the cluster of ribosomal proteins also 
recorded in table 14; circled in pink are the histone proteins; lastly, in grey is a 
cluster formed of two nicotinamide adenine dinucleotide dehydrogenases and a 
cytochrome c oxidase, the fourth cluster identified by the DAVID software to be 
induced by palmitate. Similarly to figure 88, only a portion of the mass spectrometric 
data was used to produce figure 89 to avoid over crowding it. Nevertheless, all 






Figure 89. Network view of predicted associations between proteins encoded by genes that were up-
regulated following palmitate treatment (500 μM, 12 h) of mature 3T3-L1 in 10% FBS/DMEM (HG). 
See figure 88 for the code of the coloured lines. Note that to avoid over-crowding the figure, this 
analysis only includes 53 of the 108 genes that were up-regulated by palmitate treatment. For this 
subset, the minimum fold increase compared to the untreated control was set to 2. Circled in blue are 
the ribosomal proteins; circled in pink are the histone proteins; circled in black is a cluster of 
ribonucleoproteins; circled in grey is a cluster of NADH dehydrogenases. 
 
 
 Figure 90 presents the network of predicted associations between proteins 
encoded by genes that were simultaneously up-regulated by the IFN-α treatment and 
down-regulated by the palmitate treatment. This subgroup of protein is of particular 
interest as it includes ISG15, circled in red. Compared to the previous figures, this 
network is sparser with a total of only 21 nodes, 23 edges and an average node 
degree of 2.2 (table 14), which explains why no gene cluster was identified by the 
DAVID software. However, visualising the network produced by the STRING 
software, a cluster is clearly apparent and groups ISG15 with four other proteins 
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implicated in the ubiquitin proteasome system: ubiquitin C (UBC), ubiquitin-like 
modifier activating enzyme 1 (UBA1), proteasome 26S subunit protein (PSMC6) 
and USP14. 
 
UBC is at the core of this system as it covalently binds target proteins and 
can link to other ubiquitin molecules to form polyubiquitin chains (Ryu 2007). 
UBA1, on the other hand, is implicated in catalysing ubiquitin conjugation of the 
proteins targeted for degradation (Groen 2015). PSMC6, component of the 26S 
proteasome, is critical in the ATP-dependent degradation of ubiquitinated protein 
(Rock 1994). The last player of the ubiquitin proteasome system found to directly 
interact with ISG15 was USP14, a proteasome-associated deubiquitinase involved in 
the release of ubiquitin from ubiquitinated proteins (B. L. Lee 2016). Collectively, 







Figure 90. Network view of predicted associations between proteins encodes by genes that were both 
up-regulated following IFN-α treatment (20 ng/mL, 12 h) of mature 3T3-L1 adipocytes and down-
regulated following palmitate treatment (500 μM, 12 h) of the same cell type in 10% FBS/DMEM 
(HG). See figure 88 for the code of the coloured lines. Circled in blue is a cluster of proteins involved 






V. 4.   Discussion of Chapter 5 
V. 4. 1. ISG15 promotes insulin sensitivity 
 In this chapter, the importance of ISG15 in the pathways investigated so far 
was explored. Palmitate was found to have no effect on the expression of this protein 
(Figures 65 to 68). However, such finding does not rule out a SFA-mediated effect 
on ISGylation or the cytokine activity of ISG15. To gather a more thorough 
understanding of how this ISG may modulate the metabolic effects of palmitate, an 
Isg15-KD cell line was generated, using an RNAi technique to silence the gene of 
interest. Such technique relied on the intracellular delivery of shRNA via viral 
vector, which has the benefit of producing a sustained knockdown and thus 
differentiable KD cell line. We were able to reduce the expression of ISG15 induced 
by IFN-α by 83% and 55% in pre- and mature adipocytes, respectively (Figures 75A 
and 83A). Interestingly, levels of ISG15 conjugated protein were only mildly 
affected by the knockdown (Figures 75B and 83B).  
 
Investigating whether silencing Isg15 would affect the insulin sensitivity of 
the cells following palmitate treatment, the phosphorylation of Akt in Isg15-KD cells 
was compared to that of the control cell line (Figures 75C and 83C). Overall, it 
seems that the adipocytes transfected with the empty vector failed to show signs of 
SFA-induced insulin resistance unlike the Isg15-KD cell line. The differences in the 
responses of the two cell lines were enhanced in pre-adipocytes versus mature 
adipocytes. This data thus indicates that silencing Isg15 elicits a deleterious effect on 
cellular insulin sensitivity. Interestingly, similarly to the cellular response of WT 
3T3-L1, exposing the adipocytes transfected with the empty vector to the p110α 
inhibitor rescues the inhibitory effect of the SFA on insulin sensitivity, especially in 
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mature adipocytes (Figures 77 and 85). The Isg15-KD cells, however, seem 
insensitive to the effect of A66. 
 
This role of Isg15 in the modulation of the metabolic effect of insulin is 
completely novel. It is therefore a limited endeavour to discuss it in the context of 
published literature. Nevertheless, a few studies have investigated the crosstalk 
between ISG15 and the PI3K/Akt pathway. For instance, Kaur and colleagues were 
the first to highlight the interaction between ISG15 and class I PI3K (S. S.-K. Kaur 
2008). Indeed, using MEFs designed with a deletion of the regulatory subunits of 
PI3K (p85α and p85β), they established that IFN-α-induction of ISG15 expression 
required PI3K. Furthermore, they demonstrated that Isg15 mRNA translation was 
impaired in the PI3K knockout cells in an Akt-dependent manner. Investigating the 
role of ISG15 in Akt-induced phagocytosis triggered by vaccinia virus infection, 
Yángüez et al. report that Isg15-/- macrophages displayed reduced p-Akt basal levels 
compared to Isg15+/+ cells (Yanguez 2013). They concluded that the regulation of 
macrophagic antiviral response by ISG15 relies on the PI3K/Akt signalling cascade.  
 
Such results are therefore consistent with the data presented in this chapter as 
silencing Isg15 was shown to hinder Akt phosphorylation under the conditions 
tested. Moreover, we demonstrate that Isg15-KD cells did not benefit from the 
positive metabolic effect of inhibiting p110α, thus emphasising the interaction 
between ISG15 and PI3K and the importance of ISG15 in facilitating the 
downstream signalling of insulin. Also in line with our data, Tian and colleagues 
demonstrate in a recent study the dependence of mammalian reovirus replication on 
the PI3K/Akt pathway (Tian 2015). More specifically, they evidenced that the 
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reovirus-induced activation of PI3K/Akt stimulated the transcription of ISGs, 
including ISG15, and that both pharmacological and genetic inhibition of the kinase 
cascade down-regulated the expression of ISG15. Using the same PI3K inhibitor 
(LY294002) on human mammary epithelial MCF-10A cells, Tsai et al. also noted a 
reduction of ISG15 expression (Tsai 2011). 
 
 
V. 4. 2. The pro-autophagic role of ISG15  
The present chapter also evidenced that knocking down Isg15 hinders the 
pro-autophagic effect of palmitate in 3T3-L1 pre-adipocytes (Figure 78A). Thus our 
data would indicate ISG15 to act as an inducer of autophagy in accordance with the 
findings of Nakamura and colleagues (T. F. Nakamura 2010). Indeed, as discussed in 
the introduction of this chapter, they revealed that both Isg15 and pro-autophagic Pkr 
mRNA were stimulated on the adipocytes of mice on a HFD versus lean control. 
This aligns with the data reviewed by Schmeisser and colleagues advocating type I 
IFN, the main inducer of ISG15, as a promoter of autophagy in cancerous cells 
(Schmeisser 2014). Their model highlights the capacity of type I IFN to activate the 
PI3K/Akt axis, leading them to discuss the dichotomy by which the cytokine 
stimulates autophagy as well as the anti-autophagic PI3K/Akt pathway.  
 
Such paradox is echoed in the data presented in the present chapter, as 
silencing Isg15 is simultaneously associated with reduced p-Akt levels and an 
impaired autophagic response. To explain this potential contradiction, Schmeisser et 
al. postulate the existence of a negative feedback loop by which certain ISGs might 
inhibit the downstream signalling of PI3K/Akt allowing for the induction of 
277 
 
autophagy. In support of this theory, they examine the evidence suggesting that type 
I IFN hinders mTORC1 activity (induced by PI3K) thus triggering autophagy in 
tumour cells and lymphoblasts (Schmeisser 2014). Although, due to its pro-
autophagic properties, Isg15 would not be one of such ISGs, this stands for a 
compelling model. 
 
An additional model tying the role of ISG15 in the modulation of autophagy 
and insulin signalling involves mTORC2. This multi-protein complex is activated by 
Akt and is critical for the optimal downstream signalling of the kinase (Tang 2016). 
Tang and colleagues recently demonstrated the mTORC2-mediated regulation of de 
novo lipogenesis and insulin sensitivity. Investigating the effects of HFD in 
mTORC2-deficient mice, they establish this complex as a critical element of the 
nutrient-sensing machinery regulating the metabolic effect of insulin and the onset of 
insulin resistance. mTORC2 is also involved in the regulation of autophagy. Indeed, 
it was found to down-regulate the pro-autophagic transcription factor FOXO3 
through the stimulation of Akt at least in skeletal muscle cells (Jung 2010). 
Interestingly, Kaur and colleagues were able to establish a crosstalk between 
mTORC2 and ISG15 in MEFs (S. S.-K. Kaur 2012). By deleting elements of the 
complex, they revealed type I IFN-mediated activation of Akt to be dependent on 
mTORC2. Furthermore, they demonstrate that a fully functional complex is required 







V. 4. 3. The crosstalk between ISG15 and STAT3 
As illustrated by figure 79B, inhibiting PKR hindered palmitate-induced 
stimulation of autophagy in both transduced cell types, although this could not be 
observed in WT 3T3-L1 pre-adipocytes (Figure 61). This reflects the findings of 
Shen et al., who report that PKR depletion down-regulated autophagy in MEFs 
(Shen 2012). Furthermore, in line with the study of Nakamura et al., the authors 
report that palmitate stimulates autophagy in a PKR-dependent manner. Relevantly 
to the present work, Nakamura and colleagues notice an elevation of Isg15 mRNA 
expression in the adipocytes of HFD-fed mice versus a lean control (T. F. Nakamura 
2010). Such observation supports the data presented in figure 78B as the palmitate-
mediated induction of LC3B-II levels is reduced in the Isg15-KD cells compared to 
the control. Hence, the pro-autophagic effect of palmitate appears to be modulated 
by both PKR and ISG15. 
 
 Interestingly, Shen and colleagues provide evidence for a physical and 
functional STAT3-PKR interaction. Indeed, using published crystallographic 
structures along with computerised docking experiments, the authors identify the 
SH2 domain of the transcription factor as the binding site for the carboxyterminus of 
PKR (Shen 2012). In addition, they demonstrated that STAT3 coimmunoprecipitates 
with this moiety of the kinase but not with its N-terminus. Further point mutation 
experiments confirmed this model. Shen and colleagues also report a cytoplasmic 
STAT3-mediated anti-autophagic effect both in human osteosarcoma cells and 
MEFs in vitro and in vivo. This validates their initial findings demonstrating that 
STAT3 inhibitors stimulated the autophagic process. The data presented in that study 
indicated that the binding of cytoplasmic STAT3 to the catalytic site of PKR inhibits 
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the pro-autophagic activity of the kinase. Palmitate appears to have the same ability 
as STAT3 inhibitors to disrupt STAT3-PKR interaction, thus restoring PKR-
mediated modulation of autophagy. 
 
The link between STAT3, palmitate and ISG15 is investigated in figure 86. It 
shows that both palmitate- and LPS-mediated inductions of STAT3 Tyr705 
phosphorylation are abrogated by silencing ISG15 in mature 3T3-L1 adipocytes. 
Moreover, treating the cells with recombinant ISG15 induced the phosphorylation of 
STAT3 Tyr705 (Figure 69). Putting such findings into perspective with the study of 
Shen et al., it is likely that ISG15 promotes the phosphorylation of STAT3 through 
the stimulation of palmitate-PKR binding previously demonstrated by Cho et al. 
(Cho 2011). Indeed, this interaction between the SFA and the kinase prevents the 
binding of cytoplasmic STAT3 to PKR, therefore enabling the pro-autophagic effect 
of palmitate and PKR while also permitting free cytoplasmic STAT3 to be 
phosphorylated.  
 
 Such transcription-independent regulatory effect of cytoplasmic STAT3 on 
autophagy complements the model proposed in figure 49 by which palmitate would 
regulate the expression of pSTAT3 Tyr705 through the TLR2-mediated secretion of 
gp130 cytokines such as IL-6. Indeed, Shen et al. note that PKR fails to bind 
STAT1, which would explain why palmitate was shown to induce the 
phosphorylation of STAT3 but not STAT1 in Chapter 3. Further, various elements of 
the model described in figure 49 are known to stimulate autophagy. For instance, IL-
6 was reported to promote autophagy in human CD11b+ peripheral blood 
mononuclear cells (Roca 2009). Thus, palmitate and STAT3 may regulate autophagy 
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through the synergy of a transcription-dependent and a transcription-independent 
process. It is likely that enhanced autophagy has beneficial metabolic consequences, 
such as enhanced insulin sensitivity, and that this is facilitated by ISG15. 
 
 
V. 4. 4. The impact of palmitate on ISGylation 
 The last part of the present investigation involved the mass spectrometric 
analysis of ISG15-immunoprecipitates derived for differentiated 3T3-L1 adipocytes 
treated overnight with either palmitate or IFN-α. The lysates were incubated with an 
antibody specific to ISG15, thus allowing for the isolation of ISGylated proteins and 
their binding partners. Mass spectrometric analysis allowed for identification of 
ISGylated proteins differentially expressed following the treatments. Using both 
DAVID and STRING software, we were able to cluster the genes identified by mass 
spectrometry and to compare those induced or inhibited by the treatments (Figures 
87, 88 and 89 and table 14).  
 
The results produced by the two softwares were consistent and revealed that 
palmitate down-regulates the expression of various ‘ISGylated’ (referring to both 
directly ISGylated and interacting with ISGylated proteins) mitochondrial proteins 
(Figure 88). This is of interest as mitochondrial dysfunction is a core element of 
insulin resistance. Indeed, the eukaryotic organelle is pivotal for generating the 
energy required for glucose and lipid metabolism. Kim et al. have reviewed the 
biological mechanisms associating mitochondrial failure to the onset of metabolic 
disorders and discussed the current evidence demonstrating that improving 
mitochondrial function can alleviate such symptoms (J. W. Kim 2008). In addition to 
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mitochondrial proteins, the SFA also inhibited the expression of ISGylated proteins 
involved in ribosomal structure and activity, tubulins, molecular chaperones, 
histones, proteins implicated in the citric acid cycle, keratins and HSP (Figure 88). 
The diversity of gene clusters identified highlights the importance of ISGylation and 
the wide range of biological processes regulated by it.  
 
Interestingly, the molecular chaperone down-regulated by palmitate, i.e. 
CCT, was also inhibited by IFN-α. Its structure is characterised by eight homologous 
subunits, which mediate the folding of 10 to 15% of newly synthesised eukaryotic 
proteins as well as the refolding of other proteins, misfolded due to cellular stress 
(Cui 2015). CCT has been shown to mediate the folding of a variety of proteins 
implicated in cell growth and proliferation, including tubulins, another gene cluster 
simultaneously inhibited by palmitate and IFN-α (Cui 2015). Relevantly to the 
present work, Kasembeli et al. also evidenced the role of these chaperonins in the 
folding of STAT3 (Kasembeli 2014). Therefore, CCT might be the missing link 
explaining how ISG15 modulates the phosphorylation of STAT3 Tyr705 recorded in 
figure 86. We can postulate that palmitate induces the deISGylation of these 
chaperonins stimulating their activity, including the folding of STAT3, allowing for 
the palmitate-mediated up-regulation of p-STAT3 Tyr705 levels and autophagic rates.  
 
Mass spectrometric analysis of human skeletal muscle revealed that the 
abundance of T-complex protein 1 (TCP1) - a member of the CCT complex 
identified in the DAVID analysis - was increased two-fold in obese and type 2 
diabetic participant versus lean control (Hwang 2010). Besides, Guest et al. 
evidenced that pharmacological Akt inhibition resulted in the down-regulation of 
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TCP1 in a SUM breast cancer cell line (Guest 2015). Futher supporting the role of 
CCT in the regulation of insulin sensitivity through the PI3K/Akt pathway, CCT2, 
one of the eight subunits of CCT, has been identified as a substrate for ribosomal 
protein S6 kinase (S6K) 1, found downstream of mTORC1 (Jastrzebski 2011). This 
phospho-proteomic screen validated the ealier findings of Abe et al. who 
demonstrated that CCT2 was phosphorylated by S6K upon insulin stimulation of 
HEK 293T cells (Abe 2009). Furthermore, they confirmed that inhibiting PI3K using 
LY294002 rescued this effect. The modulation of CCP through ISGylation might 
explain the role of ISG15 in the regulation of insulin sensitivity.  
 
Despite the findings of figure 66, which indicate the absence of a palmitate-
mediated effect on ISG15 expression and on protein ISGylation, the mass 
spectrometric analysis shows that ISG15 expression was reduced following the 
palmitate treatment. This appears contradictory in the context of autophagy as both 
ISG15 and palmitate promote the same pro-autophagic effect. Therefore, if cells 
were exposed to the SFA, one might expect an increase in ISG15 expression. 
However, it is important to remember that the decrease evidenced by the mass 
spectrometric data only indicates a dip in the amount of free ISG15. Therefore, a 
stimulation of ISG15 expression might go undetected if the rate of protein 
ISGylation is also enhanced at the same time.  
 
STRING analysis of ISGylated proteins down-regulated by palmitate 
identified seven direct associations between ISG15 and other proteins (Figure 88). 
One of them, HSP90αB1, is a molecular chaperone implicated in the maturation and 
the maintenance of the structural integrity of proteins involved in cell cycle control 
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and signal transduction (Khurana 2015). Interestingly, in the last few years, HSP90 
has surfaced as a key modulator of insulin signalling and glucose homeostasis. 
Indeed, Lee et al. revealed that pharmacological inhibition of HSP90 could improve 
glucose homeostasis in db/db mice, while rescuing insulin sensitivity in diet-induced 
obese mice (J. G. Lee 2013). The role of isoform HSP90αB1 was further 
investigated this year by Jing et al., who evidenced that its expression was up-
regulated in skeletal muscle of diet-induced obese mice compared to lean control 
(Jing 2018). In addition, isoform specific knockdown of HSP90αB1 using siRNA in 
primary human skeletal muscle myotubes improved substrate metabolism, insulin 
sensitivity as well as mitochondrial respiration capacity. Therefore, the direct 
interaction between HSP90αB1 and ISG15 could explain the effect of the latter on 
insulin sensitivity reported in this chapter. 
 
STRING analysis also predicts the interaction of ISG15 and PPIA (Figure 
88). As mentioned in the results section of this chapter, this enzyme catalyses the 
cis-trans isomerisation of proline imidic peptide bonds in oligopeptide and was 
shown to significantly induce Akt phosphorylation in endothelial cells (Wei 2013). 
In diabetes, increased plasma concentration of PPIA was reported for T2D patients 
compared to healthy individuals (Ramachandran 2014). Indeed, the high glucose 
levels and reactive oxygen species characteristic of this condition stimulate 
monocytes to secrete PPIA, which acts as a pro-inflammatory cytokine (Tian-tian 
2013). Considering the competition between ISGylation and ubiquitination, the 
decreased in ISGylated PPIA might reflect an increase in ubiquitinated PPIA. This 
would lead to the neutralisation of PPIA activity through proteasome degradation: 
PPIA-mediated stimulation of Akt would be hindered, thus contributing to palmitate-
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induced insulin resistance.  
 
A similar rationale could be applied to explain the down-regulation of 
ISGylated PLAA, another protein found to directly interact with ISG15, also shown 
to stimulate Akt phosphorylation. Indeed, this phospholipase was found to induce 
Akt phosphorylation in a p110α-dependent manner in macrophages (D. K. Park 
2003). Recently, Kuefner et al. were able to demonstrate the critical role of a subset 
of PLAA, PLAA group IIA, in the modulation of insulin sensitivity and metabolism 
(Kuefner 2017). Having engineered a mouse expressing the human gene encoding 
this protein (mice do not express itdue to a frameshift mutation), the mice were fed 
either a HFD or a chow diet for 10 weeks, the former appear to have maintained their 
original weight and adiposity. In addition, the mutant mice were found to show 
increased insulin sensitivity and glucose tolerance (Kuefner 2017). Besides from its 
role in the Akt pathway, PLAA is directly linked with ubiquitination has surfaced for 
PLAA as it was evidenced to act within a multi-protein complex including the 
deubiquitinating enzyme YOD1, ubiquitin regulatory X domain-containing protein 1 
and the AAA-ATPase p97 (Papadopoulos 2016). Interestingly, PLAA was also 
identified as a promoter of autophagy, which points at the same contradiction as that 
unveiled for ISG15: the phospholipase stimulates autophagy, while simultaneously 
benefiting insulin sensitivity through up-regulating the anti-autophagic PI3K/Akt 
pathway (Papadopoulos 2016).  
 
 This crosstalk between the ubiquitination and ISGylation systems is 
emphasised by the data presented in figure 90. Indeed, visualising the network of 
predicted associations between proteins encoded by genes that were up-regulated by 
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the IFN-α treatment and down-regulated by the palmitate treatment, one can identify 
ISG15 integrated within a cluster of four other proteins implicated in the ubiquitin 
proteasome system. It is interesting to note that the two treatments elicit opposite 
effects on the expression of ISGylated-ubiquitin related proteins. This might underlie 
the mechanistic differences in the onset of IFN- and palmitate-induced insulin 
resistance explored in Chapter 1.  
 
 
V. 4. 5. Limitations and future experiments  
A limitation of the findings presented in Chapter 5 could be that the response 
of the cell line bearing the empty vector to the palmitate treatment is rather different 
from that of the WT cell line. Indeed, the SFA does not inhibit Akt phosphorylation 
in the control cell line (Figures 75C and 83C). This is unlikely to be due to 
variability in reagent preparation and experimental conditions as treatments of the 
control cell line and the Isg15-KD cell line were performed simultaneously. Issues 
such as differentiation variability or batch effects are also improbable as these would 
have also affected the results collected for the WT cell line as the same number of 
repeats were performed. Thus, this phenomenon might be associated with the 
process of having transduced the cells with the pGIPZ vector. However, because we 
were able to demonstrate that both the WT adipocytes and the cell line transfected 
with the empty vector expressed similar amount of ISG15, this does not undermine 





Another limitation to the results discussed above is that mature adipocytes 
expressed considerably less ISG15 than pre-adipocytes. This is likely to explain why 
the differences between the two transduced cell lines is more noticeable in pre-
adipocytes. Nevertheless, variations in the cellular responses to A66 are more 
detectable in mature cells (Figure 85) and the phosphorylation of STAT3 following 
palmitate exposure is still very different between the two differentiated cell lines 
(Figure 86). Reproducing the experiments presented in this chapter in Isg15-KD 
human cells would be very valuable to assert potential clinical significance. 
Therefore, knocking-down this ISG in hMADS could be the next experimental step 
to be taken.  
 
It is common practice to use three different shRNA hairpins to validate 
results obtained with one. Indeed, effects observed can stem from partial 
complementarity of the strand to an unintended target gene, known as off-target 
effects. However, only one shRNA hairpin for Isg15 was available from Dharmacon 
making this strategy inapplicable. However, future experiments might include a 
rescue experiment as another mean to exclude the possibility of off-target effects. 
This involves the co-transduction of the cells with an optimised version of the WT-
Isg15 that is shRNA-resistant. An alternative and straight forward technique could 
also be considered in the future to confirm our findings such as clustered regularly 
interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 
(Cas9) gene inactivation of Isg15. This system would allow to edit-out our target 





 Regarding the mass spectrometry experiment, an obvious limitation would be 
the fact that no repeat was performed due to time limitations. In addition, only a 
small fraction of the detected protein was confirmed as ISGylated by detection of the 
characteristic Gly-Gly-Arg motif. Therefore for most hits, we are unsure whether the 
protein is truly ISGylated or if they interact with ISGylated proteins. Consequently, 
future experiments should focus on validating targets by IP of specific proteins and 
then confirm ISGylation through either mass spectrometry or by immunoblotting 
with anISG15-specific antibody. As not all hits would be able to be validated this 
way, proteins of interest would have to be selected beforehand. In addition, 
alternative biological readouts could be investigated such as mitochondrial function, 
which could be done through Seahorse analysis. Indeed, the mass spectrometric data 
revealed that both palmitate and IFN-α treatments potentially affected the ISGylation 








 The present investigation aimed at identifying the molecular mechanisms 
underlying the onset of insulin resistance mediated by dietary FA and the impact of 
insulin pathway activity on this process. To this end, two cell-based models were 
employed: on one hand, the widely used murine 3T3-L1 adipocytes, and on the other 
hand, human hMADS adipocytes to ascertain the therapeutic potential of the 
findings. More specifically, the present work had the purpose of validating the 
findings of a transcriptome analysis performed on 3T3-L1 adipocytes treated with 
palmitate in the presence or absence of a p110α selective inhibitor. Sequencing 
analysis permitted the identification of an array of genes of expression was altered in 
response to the treatments, including genes known to be induced by type I IFN. 
These were up-regulated by palmitate in a p110α-dependent manner. This was of 
particular interest as IFN had been established in the literature to induce insulin 
resistance through the sustained activation of the downstream effectors of IFN, 
transcription factors STAT1 and STAT3. 
 
The groundwork of the investigation was to propose models of palmitate- and 
IFN-mediated insulin resistance and examine the consequences of p110α inhibition 
in such models. This would enable further insight to be gathered on the findings of 
Foukas et al. regarding the beneficial phenotypic effect of such inhibition in the 
p110αD933A/WT mice (L. C. Foukas 2006). In 3T3-L1 pre- and mature adipocytes and 
mature hMADS cells, palmitate was demonstrated to inhibit insulin-stimulated p-Akt 
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levels, an effect rescued by the p110α inhibitor, A66. Thereby, we could validate this 
cellular model of palmitate-induced insulin resistance as well as the positive 
metabolic impact of p110α inhibition. The model of IFN-γ-induced insulin resistance 
could only be established in mature 3T3-L1 adipocytes. In this case, adding A66 to 
the treatment also rescued the inhibition of Akt phosphorylation. Despite a similar 
trend observed in hMADS adipocytes, the effect was not statistically significant, 
likely due to cell line chosen. Indeed, IFN-γ-mediated insulin resistance had been 
described in SGBS cells (McGillicuddy 2009) before, but it has not been reported in 
hMADS. 
 
In addition to these preliminary experiments, palmitate-induced 
phosphorylation of STAT1 and STAT3 was probed to confirm the interaction 
between the palmitate and the IFN pathway suggested by the transcriptome analysis 
data. Overall, it appears that the SFA prompts the phosphorylation of STAT3 Tyr705 
after 8 h of treatment in mature 3T3-L1 (Figure 20A). The STAT1 Ser727, STAT1 
Tyr701 and STAT3 Ser727 were unaffected by palmitate treatment. Furthermore, the 
SFA elicited no reproducible effect in the other cell types tested (3T3-L1 pre-
adipocytes, hMADS pre- and mature adipocytes). Collectively, these results indicate 
that palmitate-mediated phosphorylation of STAT3 Tyr705 occurs through a 
mechanism independent of IFN secretion, as STAT1 would have otherwise been 
induced by the SFA, as IFN is known to potently stimulate phosphorylation of this 
residue. To the best of our knowledge, no study so far has investigated the effect of 
palmitate on the phosphorylation of STAT3 or STAT1 in adipocytes. 
 
The differential regulation of STAT1 and STAT3 activity had previously 
290 
 
been reported, implicating leptin, specific nutrients, IFN and gp130 cytokines as 
modulators (Vaisse 1996, de Castro Barbosa 2009, McGillicuddy 2009, Sato 1997, 
Pensa 2013). Evidence indicates that IFN triggers the sustained activation of STAT1, 
while also inducing the activation of STAT3 in a weaker and more transient manner. 
The opposite pattern of activation is promoted by gp130 cytokines (Pensa 2013). 
This observation led us to hypothesize that palmitate-mediated phosphorylation of 
STAT3 Tyr705 is modulated through the secretion of gp130 cytokines rather than of 
IFN. This inference is strengthened by the fact that no evidence in the literature 
indicates that palmitate stimulates the secretion of IFN or that adipocytes secrete 
IFN. Various studies, on the other hand, highlight the ability of SFA to induce gp130 
cytokines in various cell types, including 3T3-L1 (Weigert 2004, Oberbach 2010, 
Staiger 2004, K. a. Ajuwon 2005) 
 
From reviewing the studies published on this topic, it is probable that the 
reason why the tyrosine residue, but not the serine residue, of STAT3 was 
phosphorylated in response to palmitate treatment is the critical role of Tyr705 in 
enabling the transcriptional activity of STAT3 dimers (P. B.-N. Heinrich 2003). 
Moreover, it has been shown that the insulin signalling pathway stimulates serine 
phosphorylation while inhibiting IL-6 modulated tyrosine phosphorylation 
(Andersson 2007). In addition, phosphorylation of STAT3 Ser727 was also 
demonstrated to down-regulate p-STAT3 Tyr705 levels (Cheng 2010). Therefore, as 
palmitate impairs the insulin sensitivity of the cell, STAT3 Ser727 phosphorylation is 
no longer induced and inhibition of STAT3 Tyr705 phosphorylation mediated by both 
Ser727 phosphorylation and insulin is alleviated. Gp130 cytokines can then freely 




Various inhibitors (A66, D030, TAK 242 and myriocin) were tested to 
explore the molecular mechanisms underlying palmitate-mediated stimulation of p-
STAT3 Tyr705 in 3T3-L1 mature adipocytes. Interestingly, none of these rescued the 
effect of SFA. TAK 242 was indeed expected to have an effect as a body of studies 
indicates that its target TLR4 mediates palmitate signalling and has the ability to 
bind the SFA (Shi 2006, Holland 2011, Schilling 2013, Turpin 2014, Pal 2012, 
Nicholas 2017). The receptor, abundantly expressed in differentiated 3T3-L1 and 
adipose tissue, was also found to be pivotal in the IFN response (Faure 2001, T. T. 
Kawai 2001, Noppert 2007, M. K. Song 2006). Furthermore, TLR4 was shown to 
stimulate STAT3 expression in bladder epithelial cells (Ying 2013). Yet, a study in 
mature 3T3-L1 demonstrated that palmitate did not significantly affect the 
expression of TLR4 target genes (M. K. Song 2006). We therefore postulate that 
another receptor is likely to be mediating the effect of palmitate on STAT3. TLR2 
would be a probable candidate as it is highly expressed in 3T3-L1, activated by SFA 
and implicated in the pathogenesis of obesity (Poulain-Godefroy 2010, J. Senn 2006, 
S. C. Kim 2012). Besides, in line with the aforementioned model implicating gp130 
cytokines in the palmitate-mediated phosphorylation of STAT3 Tyr705, evidence 
suggests that TLR2 mediates the release of a gp130 cytokine, IL-6, in both pre- and 
mature 3T3-L1 adipocytes (Poulain-Godefroy 2010).  
 
Palmitate-mediated regulation of STAT3 activity was also revealed to be 
p110α- and p110δ-independent despite strong evidence in the literature for a 
crosstalk between the PI3K and TLR pathways (Akira 2004, X. T. Li 2003). 
However, this interaction seems to be mainly mediated by TLR4, not TLR2, which 
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might explain why inhibiting PI3K did not affect palmitate-induced activation of 
STAT3. In light on such results, it was unsurprising to find that myriocin, which 
blocks de novo ceramide synthesis, failed to rescue SFA-mediated effect as C16:0-
ceramides are associated to the onset of obesity and glucose intolerance through their 
effect on PI3K and TLR4 (Holland 2011, Schilling 2013, Hla 2014). The final 
section of Chapter 3 investigated IFN-α- and IFN-λ2-mediated activation of STAT1 
and STAT3 in order to confidently extend the statement that palmitate induces 
STAT3 activation without stimulating IFN-γ secretion to all types of IFNs. This 
could be done for IFN-α, which similar to IFN-γ induced both STAT1 and STAT3 
phosphorylation. However, IFN-λ2 failed to stimulate these transcription factors. 
Additional experiments testing higher concentrations of IFN-λ2 and including a 
valid positive control would be required before drawing conclusions from this 
experiment. The phosphorylation of STAT1 and STAT3 following IFN-λ1 and IFN-
λ3 treatment should also be explored. 
 
Having explored the effect of SFA on the development of insulin resistance 
and investigated its effect on the downstream signalling of IFN, we went on to 
investigate the role of palmitate in the modulation of lipolysis and autophagy, two 
metabolic processes disrupted in the insulin resistant state. Two markers of lipolysis 
were considered: the phosphorylation of HSL and of perilipin, both substrates of 
PKA. Contrary to published data, we observed that palmitate did not affect either of 
these markers (Burns 1978, G. W. Muller 2008, Hupfeld 2003). Variations in 
experimental design may justify this discrepancy. Considering an alternative 
endpoint such as ATGL expression and phosphorylation levels, or else performing 
an activity-based assay measuring the release of lipolytic products such as FFA or 
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glycerol, could provide more conclusive results.  
 
To assess the role of palmitate in autophagy, LC3B-II expression was 
monitored. In 3T3-L1 pre-adipocytes, the SFA triggered a significant increase in this 
marker, both in the presence and the absence of bafilomycin A1 indicating an 
induction of the autophagic flux. This is consistent with both in vivo and in vitro 
experiments associating obesity and HFD with impaired rates of autophagy and 
demonstrating the pro-autophagic effect of palmitate (Kovsan 2011, Nunez 2013, 
Ying 2013). Inhibiting PI3K and TLR4 failed to rescue the SFA-induced up-
regulation of LC3B-II levels, although a trend in this direction was observed when 
treating the cells with the p110α inhibitor A66. Since, A66 also rescues palmitate-
induced insulin resistance, such trend corroborates published evidence linking 
insulin resistance with increased autophagy in adipose tissue reviewed in the 
introduction of Chapter 4.  
 
 The last section of Chapter 4 focused on the role of PKR in the autophagic 
process, as according to prior reports, this kinase was expected to be a key player in 
this process in the context of insulin resistance and obesity (T. F. Nakamura 2010, 
Carvalho 2013, M. M.-S.-Y. Niso-Santano 2015). Palmitate did not alter the 
expression level of PKR in 3T3-L1 and hMADS pre- and mature adipocytes. The 
possible impact of PKR activity on autophagy was further explored using C16, a 
pharmacological inhibitor targeting the kinase, yet it had no effect on the pro-
autophagic effect of the SFA. Such findings, although in opposition with the 
aforementioned literature, are consistent with the study of Lancaster and colleagues 
who report that PKR is not obligatory for HFD-induced obesity and its associated 
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metabolic and inflammatory dysregulations (Lancaster 2016). The heterogeneity of 
the data could be due to a difference in endpoint considered and the type of cells 
used. Therefore, future experiments might probe the phosphorylation levels of PKR 
rather than its expression in primary adipocytes rather than 3T3-L1 and hMADS. 
Considering the findings of Chapter 4, it is important to note that palmitate-induced 
autophagy could only be demonstrated in pre-adipocytes, not in mature adipocytes, 
reducing the relevance of our findings to regulation of lipid metabolism. Indeed, in 
pre-adipocytes, autophagy might be induced in response to molecular damage 
triggered by palmitate, rather than representing lipophagy.  
 
The last chapter of this investigation explored the role of ISG15 in the 
cellular response to SFA. Due to its role as a cytokine and its ability to conjugate to a 
large number of proteins through ISGylation, this protein was likely to affect various 
cellular processes including those impacted by palmitate. Our first set of experiments 
revealed that palmitate had no effect on ISG15 expression levels in mouse and 
human adipocytes. Subsequently, the consequences of knocking down Isg15 on 
palmitate-induced insulin resistance, palmitate-mediated induction of STAT3 and 
LC3B-II, were evaluated using an RNAi technique relying on the intracellular 
delivery of shRNA via viral vector. Overall, ISG15 seemed to promote insulin 
sensitivity as the insulin-stimulated Akt phosphorylation levels of the Isg15-KD cell 
were more affected by the palmitate treatment than the control cell line. In addition, 
the Isg15-KD cells failed to respond to the beneficial effect of A66 on insulin 
sensitivity. This role of ISG15 in the modulation of the metabolic effect of insulin is 
completely novel but echoes studies linking ISG15 to the PI3K/Akt pathway in 




Another finding derived from the RNAi experiments was that silencing Isg15 
hindered the pro-autophagic effect of palmitate in 3T3-L1 pre-adipocytes, indicating 
that ISG15 has a positive role in autophagy. This raises the issue of a paradox by 
which ISG15 has a pro-autophagic effect despite stimulating the anti-autophagic 
PI3K/Akt pathway. Interestingly, inhibiting PKR hindered palmitate-induced 
stimulation of autophagy in both transduced cell types (Isg15-KD and empty vector 
control cell), although this could not be observed in WT 3T3-L1 pre-adipocytes. 
This suggests that at least in the transduced cells, the pro-autophagic effect of 
palmitate is modulated by both PKR and ISG15. This can explain why palmitate-
mediated phosphorylation of STAT3 is abrogated by silencing Isg15 in mature 3T3-
L1 adipocytes, and why treating the cells with recombinant ISG15 induced the 
phosphorylation of STAT3 Tyr705. Indeed, if ISG15 promotes the pro-autophagic 
effect of palmitate and PKR, it stimulates the formation of palmitate-PKR 
complexes. Such complexes prevent the binding of cytoplasmic STAT3 to PKR, 
thus permitting free cytoplasmic STAT3 to be phosphorylated.  
 
Lastly, mass spectrometry was employed to evaluate the impact of palmitate 
on ISGylation. Analysing the data using the DAVID and the STRING software 
revealed a striking overlap between the ‘ISGylated’ proteins which expression was 
down-regulated by the palmitate and the IFN-α treatments. These included 
‘ISGylation’ of various mitochondrial proteins, which is interesting as mitochondrial 
dysfunction is a core element of insulin resistance. The two treatments also inhibited 
the detection of ‘ISGylated’ CCT, involved in the folding of STAT3 (Kasembeli 
2014). This protein might therefore be involved in ISG15-mediated regulation of 
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STAT3 phosphorylation. The STRING analysis also predicts the interaction of 
ISG15 with PPIA and PLAA, two proteins known to stimulate the Akt pathway (Wei 
2013, D. K. Park 2003). In addition, PLAA was implicated in the ubiquitin system 
and autophagy (Papadopoulos 2016). It would therefore be interesting to validate 
these targets by investigating their role in the context of SFA-induced insulin 
resistance and autophagy and clarify the regulatory role of ISG15 in their 
downstream signalling. The results of the mass spectrometric analysis also 
emphasised the crosstalk between the ubiquitination and ISGylation systems, thus 
highlighting the importance of ISG15 in the regulation of protein homeostasis in the 
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VII. 1.   Genes identified by the transcriptome analysis 
 
Table 15. List of genes identified by the transcriptome analysis. The name of the genes is followed by 
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VII. 2.   Media preparation 
 
Table 16. Media used in the culture of 3T3-L1 cells. All DMEM, sera and antibiotics used were from 
Life Technologies, Gibco.  
 
 10% Calf serum/DMEM 10% FBS/DMEM SF DMEM 
Media 
500 mL 1X DMEM + 
GlutaMAXTM (4.5 g/L D-
Glucose) 
500 mL 1X DMEM + 
GlutaMAXTM (4.5 g/L 
D-Glucose) 
500 mL 1X DMEM + 
GlutaMAXTM (4.5 g/L 
D-Glucose) 
Serum 
50 mL Newborn Calf 
Serum Heat Inactivated 
FBS 50 mL  - 
















Table 17. Media used in the culture of hMADS cells. All DMEM and additional supplements were 
purchased from Lonza, BioWhittaker while sera and antibiotics were from Life Technologies, Gibco. 
 
 hMADS complete media hMADS SF media Ham’s F12 
Media 
500 mL 1X DMEM (1 g/L 
glucose) 
500 mL 1X DMEM (1 
g/L glucose) 
Ham’s F12 with L-
Glutamine 
Serum 50 mL FBS - - 
Antibiotics 5 mL 100X P/S 5 mL 100X P/S 5 mL 100X P/S 
Additional supplements 
5 mL Hepes buffer (1 M)  5 mL Hepes buffer (1 M)  - 
5 mL L-Glutamine  
(200 mM) 






VII. 3.   Recipes for cell differentiation 
VII. 3. 1. 3T3-L1 differentiation 
1. IBMX solution: dissolve IBMX (Sigma-Aldrich) in a solution made of 0.1 N 
potassium hydroxide to a final concentration of 0.0111 g/mL. Filter sterilise through 
a 0.22 μm syringe filter. 
 
2. Insulin stock solution: 1 mM in 0.02 M HCl. Filter sterilise through a 0.22 μm 
syringe filter and store at 4ºC. 
 
3. Dexamethasone stock solution (Sigma-Aldrich): make up 10 mM in 100% ethanol. 
Filter sterilise through a 0.22 μm syringe filter and store at 4ºC. 
 
4. Rosiglitazone (Cayman Chemical): make up 10 mM in dimethyl sulfoxide 
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(DMSO). Keep in aliquots at -20ºC. 
 
5. MDI Induction Media: 
To required volume of 10% FBS/DMEM supplemented with P/S add: 
 1:100 IBMX (final concentration: 0.5 mM); 
 1:1,000 insulin (final concentration: 1 μM); 
 1:10,000 dexamethasone (final concentration: 1 μM); 
 1:10,000 rosiglitazone (final concentration: 1 μM). 
 
6. Insulin media: to required volume of 10% FBS/DMEM supplemented with P/S 
add insulin diluting 1:5,000 (200 nM). 
 
VII. 3. 2.  hMADS differentiation 
1. Transferrin (Sigma-Aldrich): dilute 100 mg in 10 mL PBS and sterile filter the 
solution (10 mg/mL). Dilute 1:10 in PBS to get 1 mg/mL aliquots. 
 
2. Triiodothyronine (T3) (Sigma-Aldrich): dissolve 1.346 mg in 1 mL DMSO to get 
2 mM. Dilute 1:1,000 in DMSO to get 2 μM. 
 
3. Differentiation media: to the required volume of a solution made up of equal 
volumes of SF DMEM supplemented with P/S and Ham’s F12 supplemented with 
P/Sadd: 
 1:100 IBMX (final concentration: 0.5 mM); 
 1:1,000 human insulin (Sigma-Aldrich) (final concentration: 1.74 μM); 
 1:10,000 dexamethasone (final concentration: 1 μM); 
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 1:10,000 rosiglitazone (final concentration: 1 μM); 
 1:10,000 T3 (final concentration: 0.2 nM); 
 1:100 Transferrin (final concentration: 10 μg/mL). 
 
 
VII. 4.   Stock solutions for treatments 
VII. 4. 1. 5 mM stock palmitate – 10% BSA: 
1. 75 mM palmitate solution: weigh 19.2 mg palmitic acid (Sigma-Aldrich) in a 1.5 
mL eppendorf tube. Dissolve in 1 mL 0.1N NaOH by heating at 70oC in heating 
block and vortexing. 
 
2. Coupling to BSA (palmitate to BSA molar ratio ~3:1): prepare 14.5 mL 10% FFA 
free-BSA (Sigma-Aldrich) (1.5 mM) in antibiotics-free SF DMEM (low glucose 
[LG]) (Life Technologies, Gibco). Place 9.5 mL of the BSA solution in a water bath 
at 40ºC (the remaining 5 mL are used as control). Add 670 μL of the palmitate 
solution dropwise into the BSA solution while stirring at 40oC and stir the solution 
for 30 min. Filter sterilize through 0.45 μm filter and make 1 mL aliquots which are 
stored at -20oC. 
 
 
VII. 4. 2. 5 mM unconjugated stock palmitate 
The same protocol at the palmitate 3:1 BSA was used to make unconjugated 





VII. 5.   1% TX-100 lysis buffer  
 
1. To make 400 mL 2X lysis buffer, the final molarity is in brackets: 
Tris base (Sigma-Aldrich) (50 mM)      4.8 g 
Sodium chloride (Fisher Scientific) (100 mM)    4.7 g 
Sodium fluoride (Sigma-Aldrich) (50 mM)     1.7 g 
EDTA (Sigma-Aldrich) (5 mM)      1.2 g 
Ethylene glycol tetraacetic acid (Sigma-Aldrich) (2 mM)  0.61 g 
Sodium β-glycerophosphate pentahydrate (Alfa Aesar) (40 mM) 9.8 g 
Sodium pyrophosphate (Alfa Aesar) (10 mM)   2.1 g 
1% TX-100 (Alfa Aesar)      8 mL (drop-wise) 
 Adjust pH to 7.4 with concentrated HCl; 
 Add deionised water up to 400 mL. 
 
2. On ice add inhibitors to 5 mL of 2X lysis buffer diluted in 4.8 mL of deionised 
water. The concentration of the stock solutions is in brackets: 
Phenylmethylsulfonyl fluoride (100 mM in ethanol) (Thermo Scientific) 100 μL 
Sodium orthovanadate (Sigma-Aldrich) (100 mM)    100 μL 
Aprotinin (Sigma-Aldrich) (10 mg/mL in MilliQ water)   10 μL 
Leupeptin (Sigma-Aldrich) (10 mg/mL MilliQ water)   10 μL 







VII. 6.   Electrophoresis sample buffer 4X 
 
 250 mM Tris-HCl, pH 6.8  
 8 % SDS (Fisher Scientific) 
 40 % glycerol (Fisher Scientific) 
 0.04 % bromophenol blue sodium salt (Sigma-Aldrich) 
Mix 25 mL 1M DTT with 75 mL buffer just before use. 
 
For 75 mL (prepare as for 100 mL – this takes into account the dilution from the 
addition of the DTT solution), heat and stir (50C):  
1M Tris-HCl pH 6.8       25 mL 
SDS         8 g 
Glycerol         40 mL 
Bromophenol blue       40 mg 
 
 
VII. 7.   SDS-PAGE gel preparation (two mini gels – 10% SDS-
acrylamide) 
 
1. Separating gel:  
1.5 M Tris-HCl pH 8.8 (375.6 mM)     4.5 mL 
Deionised water       7.1 mL 
30% acrylamide solution (Sigma-Aldrich) (1.4 M)   6.0 mL  
10% SDS (3.5 mM)       180 μL 
10% ammonium persulfate (Sigma-Aldrich) (4.4 mM)  180 μL 
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Tetramethylethylenediamine (TEMED) (Sigma-Aldrich) (~ 99%) 10 μL 
 Mix and pour between plates. 
 Layer deionised water on top. 
 Allow to set for 30 min. 
Note: for a 15% SDS-acrylamide the volumes of water and acrylamide are switched 
to 4.1 and 9.0 mL, respectively. 
 
2. Stacking gel: 
1 M Tris-HCl pH 6.8 (125.5 mM)    1.25 mL 
Deionised water      6.8 mL 
30% acrylamide solution (720.4 mM)   1.7 mL 
10% SDS (3.5 mM)      100 μL 
10% ammonium persulfate (4.4 mM)   100 μL 
TEMED       10 μL 
 Mix and pour between plates on top of the separating gel after removing the 
layer of deionised water. 
 Place a 1.5 mm comb into each gel. 
 Allow to set for 30 min. 
 When set submerge with 1X running buffer. 
 
3. Running buffer 10X: 
Glycine (VWR International) (1.9 M)    144 g 
Tris base (247.6 mM)       30 g 
SDS (34.7 mM)        10 g 





4. Transfer buffer 10X: 
Glycine (1.9 M)        144 g 
Tris base (247.6 mM)       30 g 
 Mix and make up a total volume of 1L with deionised water. Store at room 
temperature. 
 
Transfer buffer 1X: 
10X transfer buffer stock solution      100 mL 
Methanol         200 mL 
Deionised water        700 mL 
 Store at 4ºC. 
 
5. TBS-T buffer 10X: 
Tris base (199.9 mM)       24.22 g 
NaCl (VWR International) (1.5 M)    87.66 g 
 Add 900 mL deionised water and dissolve; 
 Adjust pH to 7.4 with HCl 37%; 
 Add 10 mL Tween-20 while stirring; 







 VII. 8.   Tris-Tricine gel 
 
1. Separating gel: 
Deionised water      5.4 mL 
30% acrylamide solution (1.7 M)    9 mL 
Gel buffer       8 mL 
10% ammonium persulfate (3.9 mM)   200 μL 
TEMED       20 μL 
 Mix and pour between plates. 
 Layer deionised water on top. 
 Allow to set for 30 min. 
 
2. Stacking gel: 
Deionised water      5.56 mL 
30% acrylamide solution (539.5 mM)   1.3 mL 
Gel buffer       3.2 mL 
10% ammonium persulfate (4.3 mM)   100 μL 
TEMED       10 μL 
 
 When set submerge with anode buffer under the tank and cathode buffer between 
the gel. 
 
3. Anode buffer 10X (pH 8.9): 
Tris base (2 M)        242 g 
 Adjust pH to 8.9 with 37% HCl and make up a total volume of 1L with deionised 
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water. Store at room temperature. 
 
4. Cathode buffer 10X: 
Tricine (VWR International) (1 M)    179 g 
Tris base (1 M)        121g 
SDS (34.7 mM)        10 g 
 Mix and make up a total volume of 1L with deionised water. Store at room 
temperature. 
 
5. Gel buffer (pH 8.45): 
Tris base (3 M)        72.66 g 
SDS (2.1 mM)        0.6 g  
 Adjust pH to 8.45 with 37% HCl and make up a total volume of 200 mL with 
deionised water. Store at room temperature. 
 
 
 VII. 9.   Primary antibody solution 
 
 Dissolve 1.5 g of BSA in 50 mL TBS-T. 
 Add 50 μL 1:1,000 NaN2 (20%) to the BSA solution. 







 VII. 10.   2X HBS buffer 
 
Hepes       50 mM 
NaCl        280 mM 
Na2HPO4 (Sigma-Aldrich)    1.5 mM 
 Adjust pH to 7.0 using 37% HCl and filter sterilise. Store at -20ᵒC. 
 
 
 VII. 11.   One-way ANOVA analyses 
 
For figure 41B: 
One-way ANOVA: 
 
Sum of Squares df Mean Square F Sig. 
Between Groups 3.793 12 .316 8.674 .000 
Within Groups .692 19 .036     
Total 4.485 31       
 




Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 
2.00 -.20451 .17426 .990 -.8593 .4503 
3.00 -.69594 .19089 .062 -1.4133 .0214 
4.00 -.24224 .19089 .981 -.9596 .4751 
5.00 .63186 .19089 .117 -.0855 1.3492 
6.00 -.13416 .19089 1.000 -.8515 .5832 
7.00 -.01005 .17426 1.000 -.6649 .6448 
8.00 .10621 .17426 1.000 -.5486 .7610 
9.00 .38077 .17426 .611 -.2741 1.0356 
10.00 .44897 .17426 .384 -.2059 1.1038 
11.00 -.06575 .17426 1.000 -.7206 .5891 
12.00 -.49977 .19089 .362 -1.2171 .2176 
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13.00 .29596 .19089 .925 -.4214 1.0133 
2.00 
1.00 .20451 .17426 .990 -.4503 .8593 
3.00 -.49143 .17426 .269 -1.1463 .1634 
4.00 -.03773 .17426 1.000 -.6926 .6171 
5.00 .83637* .17426 .006 .1815 1.4912 
6.00 .07035 .17426 1.000 -.5845 .7252 
7.00 .19445 .15586 .983 -.3912 .7802 
8.00 .31072 .15586 .725 -.2750 .8964 
9.00 .58528 .15586 .050 -.0004 1.1710 
10.00 .65347* .15586 .021 .0678 1.2392 
11.00 .13876 .15586 .999 -.4469 .7245 
12.00 -.29526 .17426 .874 -.9501 .3596 
13.00 .50047 .17426 .248 -.1544 1.1553 
3.00 
1.00 .69594 .19089 .062 -.0214 1.4133 
2.00 .49143 .17426 .269 -.1634 1.1463 
4.00 .45370 .19089 .496 -.2636 1.1710 
5.00 1.32780* .19089 .000 .6105 2.0451 
6.00 .56178 .19089 .221 -.1556 1.2791 
7.00 .68589* .17426 .035 .0311 1.3407 
8.00 .80215* .17426 .009 .1473 1.4570 
9.00 1.07671* .17426 .000 .4219 1.7315 
10.00 1.14491* .17426 .000 .4901 1.7997 
11.00 .63019 .17426 .066 -.0246 1.2850 
12.00 .19617 .19089 .997 -.5212 .9135 
13.00 .99190* .19089 .003 .2746 1.7092 
4.00 
1.00 .24224 .19089 .981 -.4751 .9596 
2.00 .03773 .17426 1.000 -.6171 .6926 
3.00 -.45370 .19089 .496 -1.1710 .2636 
5.00 .87410* .19089 .009 .1568 1.5914 
6.00 .10808 .19089 1.000 -.6093 .8254 
7.00 .23219 .17426 .973 -.4227 .8870 
8.00 .34845 .17426 .722 -.3064 1.0033 
9.00 .62301 .17426 .071 -.0318 1.2778 
10.00 .69121* .17426 .033 .0364 1.3460 
11.00 .17649 .17426 .997 -.4783 .8313 
12.00 -.25753 .19089 .970 -.9749 .4598 
13.00 .53820 .19089 .269 -.1791 1.2555 
5.00 
1.00 -.63186 .19089 .117 -1.3492 .0855 
2.00 -.83637* .17426 .006 -1.4912 -.1815 
3.00 -1.32780* .19089 .000 -2.0451 -.6105 
4.00 -.87410* .19089 .009 -1.5914 -.1568 
6.00 -.76601* .19089 .030 -1.4834 -.0487 
7.00 -.64191 .17426 .058 -1.2967 .0129 
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8.00 -.52565 .17426 .196 -1.1805 .1292 
9.00 -.25109 .17426 .953 -.9059 .4038 
10.00 -.18289 .17426 .996 -.8377 .4719 
11.00 -.69761* .17426 .031 -1.3524 -.0428 
12.00 -1.13162* .19089 .001 -1.8490 -.4143 
13.00 -.33590 .19089 .847 -1.0532 .3814 
6.00 
1.00 .13416 .19089 1.000 -.5832 .8515 
2.00 -.07035 .17426 1.000 -.7252 .5845 
3.00 -.56178 .19089 .221 -1.2791 .1556 
4.00 -.10808 .19089 1.000 -.8254 .6093 
5.00 .76601* .19089 .030 .0487 1.4834 
7.00 .12410 .17426 1.000 -.5307 .7789 
8.00 .24037 .17426 .965 -.4145 .8952 
9.00 .51493 .17426 .217 -.1399 1.1698 
10.00 .58312 .17426 .110 -.0717 1.2380 
11.00 .06841 .17426 1.000 -.5864 .7232 
12.00 -.36561 .19089 .769 -1.0829 .3517 
13.00 .43012 .19089 .570 -.2872 1.1475 
7.00 
1.00 .01005 .17426 1.000 -.6448 .6649 
2.00 -.19445 .15586 .983 -.7802 .3912 
3.00 -.68589* .17426 .035 -1.3407 -.0311 
4.00 -.23219 .17426 .973 -.8870 .4227 
5.00 .64191 .17426 .058 -.0129 1.2967 
6.00 -.12410 .17426 1.000 -.7789 .5307 
8.00 .11626 .15586 1.000 -.4694 .7020 
9.00 .39083 .15586 .421 -.1949 .9765 
10.00 .45902 .15586 .220 -.1267 1.0447 
11.00 -.05570 .15586 1.000 -.6414 .5300 
12.00 -.48971 .17426 .273 -1.1445 .1651 
13.00 .30601 .17426 .848 -.3488 .9608 
8.00 
1.00 -.10621 .17426 1.000 -.7610 .5486 
2.00 -.31072 .15586 .725 -.8964 .2750 
3.00 -.80215* .17426 .009 -1.4570 -.1473 
4.00 -.34845 .17426 .722 -1.0033 .3064 
5.00 .52565 .17426 .196 -.1292 1.1805 
6.00 -.24037 .17426 .965 -.8952 .4145 
7.00 -.11626 .15586 1.000 -.7020 .4694 
9.00 .27456 .15586 .846 -.3111 .8603 
10.00 .34276 .15586 .603 -.2429 .9285 
11.00 -.17196 .15586 .994 -.7577 .4137 
12.00 -.60598 .17426 .086 -1.2608 .0489 
13.00 .18975 .17426 .994 -.4651 .8446 
9.00 
1.00 -.38077 .17426 .611 -1.0356 .2741 
2.00 -.58528 .15586 .050 -1.1710 .0004 
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3.00 -1.07671* .17426 .000 -1.7315 -.4219 
4.00 -.62301 .17426 .071 -1.2778 .0318 
5.00 .25109 .17426 .953 -.4038 .9059 
6.00 -.51493 .17426 .217 -1.1698 .1399 
7.00 -.39083 .15586 .421 -.9765 .1949 
8.00 -.27456 .15586 .846 -.8603 .3111 
10.00 .06819 .15586 1.000 -.5175 .6539 
11.00 -.44652 .15586 .251 -1.0322 .1392 
12.00 -.88054* .17426 .003 -1.5354 -.2257 
13.00 -.08481 .17426 1.000 -.7396 .5700 
10.00 
1.00 -.44897 .17426 .384 -1.1038 .2059 
2.00 -.65347* .15586 .021 -1.2392 -.0678 
3.00 -1.14491* .17426 .000 -1.7997 -.4901 
4.00 -.69121* .17426 .033 -1.3460 -.0364 
5.00 .18289 .17426 .996 -.4719 .8377 
6.00 -.58312 .17426 .110 -1.2380 .0717 
7.00 -.45902 .15586 .220 -1.0447 .1267 
8.00 -.34276 .15586 .603 -.9285 .2429 
9.00 -.06819 .15586 1.000 -.6539 .5175 
11.00 -.51472 .15586 .119 -1.1004 .0710 
12.00 -.94873* .17426 .002 -1.6036 -.2939 
13.00 -.15301 .17426 .999 -.8078 .5018 
11.00 
1.00 .06575 .17426 1.000 -.5891 .7206 
2.00 -.13876 .15586 .999 -.7245 .4469 
3.00 -.63019 .17426 .066 -1.2850 .0246 
4.00 -.17649 .17426 .997 -.8313 .4783 
5.00 .69761* .17426 .031 .0428 1.3524 
6.00 -.06841 .17426 1.000 -.7232 .5864 
7.00 .05570 .15586 1.000 -.5300 .6414 
8.00 .17196 .15586 .994 -.4137 .7577 
9.00 .44652 .15586 .251 -.1392 1.0322 
10.00 .51472 .15586 .119 -.0710 1.1004 
12.00 -.43401 .17426 .430 -1.0889 .2208 
13.00 .36171 .17426 .677 -.2931 1.0165 
12.00 
1.00 .49977 .19089 .362 -.2176 1.2171 
2.00 .29526 .17426 .874 -.3596 .9501 
3.00 -.19617 .19089 .997 -.9135 .5212 
4.00 .25753 .19089 .970 -.4598 .9749 
5.00 1.13162* .19089 .001 .4143 1.8490 
6.00 .36561 .19089 .769 -.3517 1.0829 
7.00 .48971 .17426 .273 -.1651 1.1445 
8.00 .60598 .17426 .086 -.0489 1.2608 
9.00 .88054* .17426 .003 .2257 1.5354 
10.00 .94873* .17426 .002 .2939 1.6036 
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11.00 .43401 .17426 .430 -.2208 1.0889 
13.00 .79573* .19089 .022 .0784 1.5131 
13.00 
1.00 -.29596 .19089 .925 -1.0133 .4214 
2.00 -.50047 .17426 .248 -1.1553 .1544 
3.00 -.99190* .19089 .003 -1.7092 -.2746 
4.00 -.53820 .19089 .269 -1.2555 .1791 
5.00 .33590 .19089 .847 -.3814 1.0532 
6.00 -.43012 .19089 .570 -1.1475 .2872 
7.00 -.30601 .17426 .848 -.9608 .3488 
8.00 -.18975 .17426 .994 -.8446 .4651 
9.00 .08481 .17426 1.000 -.5700 .7396 
10.00 .15301 .17426 .999 -.5018 .8078 
11.00 -.36171 .17426 .677 -1.0165 .2931 
12.00 -.79573* .19089 .022 -1.5131 -.0784 
 
 
For figure 44A: 
One-way ANOVA: 
 
Sum of Squares df Mean Square F Sig. 
Between Groups 5274.881 12 439.573 51.129 0.000 
Within Groups 214.932 25 8.597   
 
Total 5489.813 37     
 
 




Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 
2.00 -.56907 2.39406 1.000 -9.3010 8.1628 
3.00 -29.05084* 2.39406 .000 -37.7828 -20.3189 
4.00 -3.18435 2.39406 .976 -11.9163 5.5476 
5.00 -3.91556 2.39406 .902 -12.6475 4.8164 
6.00 -15.60824* 2.39406 .000 -24.3402 -6.8763 
7.00 -33.95632* 2.39406 .000 -42.6882 -25.2244 
8.00 -20.89835* 2.67664 .000 -30.6609 -11.1358 
9.00 -.26340 2.39406 1.000 -8.9953 8.4685 
10.00 -.00657 2.39406 1.000 -8.7385 8.7254 
11.00 .01358 2.39406 1.000 -8.7183 8.7455 
12.00 -.14760 2.39406 1.000 -8.8795 8.5843 
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13.00 -.00320 2.39406 1.000 -8.7351 8.7287 
2.00 
1.00 .56907 2.39406 1.000 -8.1628 9.3010 
3.00 -28.48176* 2.39406 .000 -37.2137 -19.7498 
4.00 -2.61528 2.39406 .995 -11.3472 6.1166 
5.00 -3.34649 2.39406 .965 -12.0784 5.3854 
6.00 -15.03917* 2.39406 .000 -23.7711 -6.3072 
7.00 -33.38725* 2.39406 .000 -42.1192 -24.6553 
8.00 -20.32928* 2.67664 .000 -30.0919 -10.5667 
9.00 .30567 2.39406 1.000 -8.4263 9.0376 
10.00 .56250 2.39406 1.000 -8.1694 9.2944 
11.00 .58266 2.39406 1.000 -8.1493 9.3146 
12.00 .42147 2.39406 1.000 -8.3105 9.1534 
13.00 .56587 2.39406 1.000 -8.1660 9.2978 
3.00 
1.00 29.05084* 2.39406 .000 20.3189 37.7828 
2.00 28.48176* 2.39406 .000 19.7498 37.2137 
4.00 25.86649* 2.39406 .000 17.1346 34.5984 
5.00 25.13527* 2.39406 .000 16.4034 33.8672 
6.00 13.44260* 2.39406 .000 4.7107 22.1745 
7.00 -4.90548 2.39406 .694 -13.6374 3.8264 
8.00 8.15249 2.67664 .170 -1.6101 17.9151 
9.00 28.78743* 2.39406 .000 20.0555 37.5194 
10.00 29.04427* 2.39406 .000 20.3123 37.7762 
11.00 29.06442* 2.39406 .000 20.3325 37.7963 
12.00 28.90323* 2.39406 .000 20.1713 37.6352 
13.00 29.04764* 2.39406 .000 20.3157 37.7796 
4.00 
1.00 3.18435 2.39406 .976 -5.5476 11.9163 
2.00 2.61528 2.39406 .995 -6.1166 11.3472 
3.00 -25.86649* 2.39406 .000 -34.5984 -17.1346 
5.00 -.73122 2.39406 1.000 -9.4631 8.0007 
6.00 -12.42389* 2.39406 .001 -21.1558 -3.6920 
7.00 -30.77197* 2.39406 .000 -39.5039 -22.0401 
8.00 -17.71400* 2.67664 .000 -27.4766 -7.9514 
9.00 2.92094 2.39406 .987 -5.8110 11.6529 
10.00 3.17778 2.39406 .976 -5.5541 11.9097 
11.00 3.19793 2.39406 .975 -5.5340 11.9299 
12.00 3.03674 2.39406 .983 -5.6952 11.7687 
13.00 3.18115 2.39406 .976 -5.5508 11.9131 
5.00 
1.00 3.91556 2.39406 .902 -4.8164 12.6475 
2.00 3.34649 2.39406 .965 -5.3854 12.0784 
3.00 -25.13527* 2.39406 .000 -33.8672 -16.4034 
4.00 .73122 2.39406 1.000 -8.0007 9.4631 
6.00 -11.69267* 2.39406 .003 -20.4246 -2.9608 
7.00 -30.04076* 2.39406 .000 -38.7727 -21.3088 
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8.00 -16.98279* 2.67664 .000 -26.7454 -7.2202 
9.00 3.65216 2.39406 .936 -5.0798 12.3841 
10.00 3.90900 2.39406 .903 -4.8229 12.6409 
11.00 3.92915 2.39406 .900 -4.8028 12.6611 
12.00 3.76796 2.39406 .922 -4.9640 12.4999 
13.00 3.91237 2.39406 .902 -4.8196 12.6443 
6.00 
1.00 15.60824* 2.39406 .000 6.8763 24.3402 
2.00 15.03917* 2.39406 .000 6.3072 23.7711 
3.00 -13.44260* 2.39406 .000 -22.1745 -4.7107 
4.00 12.42389* 2.39406 .001 3.6920 21.1558 
5.00 11.69267* 2.39406 .003 2.9608 20.4246 
7.00 -18.34808* 2.39406 .000 -27.0800 -9.6162 
8.00 -5.29011 2.67664 .738 -15.0527 4.4725 
9.00 15.34483* 2.39406 .000 6.6129 24.0768 
10.00 15.60167* 2.39406 .000 6.8697 24.3336 
11.00 15.62182* 2.39406 .000 6.8899 24.3537 
12.00 15.46063* 2.39406 .000 6.7287 24.1926 
13.00 15.60504* 2.39406 .000 6.8731 24.3370 
7.00 
1.00 33.95632* 2.39406 .000 25.2244 42.6882 
2.00 33.38725* 2.39406 .000 24.6553 42.1192 
3.00 4.90548 2.39406 .694 -3.8264 13.6374 
4.00 30.77197* 2.39406 .000 22.0401 39.5039 
5.00 30.04076* 2.39406 .000 21.3088 38.7727 
6.00 18.34808* 2.39406 .000 9.6162 27.0800 
8.00 13.05797* 2.67664 .003 3.2954 22.8206 
9.00 33.69292* 2.39406 .000 24.9610 42.4248 
10.00 33.94975* 2.39406 .000 25.2178 42.6817 
11.00 33.96990* 2.39406 .000 25.2380 42.7018 
12.00 33.80872* 2.39406 .000 25.0768 42.5406 
13.00 33.95312* 2.39406 .000 25.2212 42.6850 
8.00 
1.00 20.89835* 2.67664 .000 11.1358 30.6609 
2.00 20.32928* 2.67664 .000 10.5667 30.0919 
3.00 -8.15249 2.67664 .170 -17.9151 1.6101 
4.00 17.71400* 2.67664 .000 7.9514 27.4766 
5.00 16.98279* 2.67664 .000 7.2202 26.7454 
6.00 5.29011 2.67664 .738 -4.4725 15.0527 
7.00 -13.05797* 2.67664 .003 -22.8206 -3.2954 
9.00 20.63495* 2.67664 .000 10.8724 30.3975 
10.00 20.89178* 2.67664 .000 11.1292 30.6544 
11.00 20.91193* 2.67664 .000 11.1494 30.6745 
12.00 20.75075* 2.67664 .000 10.9882 30.5133 
13.00 20.89515* 2.67664 .000 11.1326 30.6577 
9.00 
1.00 .26340 2.39406 1.000 -8.4685 8.9953 
2.00 -.30567 2.39406 1.000 -9.0376 8.4263 
341 
 
3.00 -28.78743* 2.39406 .000 -37.5194 -20.0555 
4.00 -2.92094 2.39406 .987 -11.6529 5.8110 
5.00 -3.65216 2.39406 .936 -12.3841 5.0798 
6.00 -15.34483* 2.39406 .000 -24.0768 -6.6129 
7.00 -33.69292* 2.39406 .000 -42.4248 -24.9610 
8.00 -20.63495* 2.67664 .000 -30.3975 -10.8724 
10.00 .25683 2.39406 1.000 -8.4751 8.9888 
11.00 .27699 2.39406 1.000 -8.4549 9.0089 
12.00 .11580 2.39406 1.000 -8.6161 8.8477 
13.00 .26021 2.39406 1.000 -8.4717 8.9921 
10.00 
1.00 .00657 2.39406 1.000 -8.7254 8.7385 
2.00 -.56250 2.39406 1.000 -9.2944 8.1694 
3.00 -29.04427* 2.39406 .000 -37.7762 -20.3123 
4.00 -3.17778 2.39406 .976 -11.9097 5.5541 
5.00 -3.90900 2.39406 .903 -12.6409 4.8229 
6.00 -15.60167* 2.39406 .000 -24.3336 -6.8697 
7.00 -33.94975* 2.39406 .000 -42.6817 -25.2178 
8.00 -20.89178* 2.67664 .000 -30.6544 -11.1292 
9.00 -.25683 2.39406 1.000 -8.9888 8.4751 
11.00 .02015 2.39406 1.000 -8.7118 8.7521 
12.00 -.14103 2.39406 1.000 -8.8730 8.5909 
13.00 .00337 2.39406 1.000 -8.7285 8.7353 
11.00 
1.00 -.01358 2.39406 1.000 -8.7455 8.7183 
2.00 -.58266 2.39406 1.000 -9.3146 8.1493 
3.00 -29.06442* 2.39406 .000 -37.7963 -20.3325 
4.00 -3.19793 2.39406 .975 -11.9299 5.5340 
5.00 -3.92915 2.39406 .900 -12.6611 4.8028 
6.00 -15.62182* 2.39406 .000 -24.3537 -6.8899 
7.00 -33.96990* 2.39406 .000 -42.7018 -25.2380 
8.00 -20.91193* 2.67664 .000 -30.6745 -11.1494 
9.00 -.27699 2.39406 1.000 -9.0089 8.4549 
10.00 -.02015 2.39406 1.000 -8.7521 8.7118 
12.00 -.16119 2.39406 1.000 -8.8931 8.5707 
13.00 -.01678 2.39406 1.000 -8.7487 8.7151 
12.00 
1.00 .14760 2.39406 1.000 -8.5843 8.8795 
2.00 -.42147 2.39406 1.000 -9.1534 8.3105 
3.00 -28.90323* 2.39406 .000 -37.6352 -20.1713 
4.00 -3.03674 2.39406 .983 -11.7687 5.6952 
5.00 -3.76796 2.39406 .922 -12.4999 4.9640 
6.00 -15.46063* 2.39406 .000 -24.1926 -6.7287 
7.00 -33.80872* 2.39406 .000 -42.5406 -25.0768 
8.00 -20.75075* 2.67664 .000 -30.5133 -10.9882 
9.00 -.11580 2.39406 1.000 -8.8477 8.6161 
10.00 .14103 2.39406 1.000 -8.5909 8.8730 
342 
 
11.00 .16119 2.39406 1.000 -8.5707 8.8931 
13.00 .14441 2.39406 1.000 -8.5875 8.8763 
13.00 
1.00 .00320 2.39406 1.000 -8.7287 8.7351 
2.00 -.56587 2.39406 1.000 -9.2978 8.1660 
3.00 -29.04764* 2.39406 .000 -37.7796 -20.3157 
4.00 -3.18115 2.39406 .976 -11.9131 5.5508 
5.00 -3.91237 2.39406 .902 -12.6443 4.8196 
6.00 -15.60504* 2.39406 .000 -24.3370 -6.8731 
7.00 -33.95312* 2.39406 .000 -42.6850 -25.2212 
8.00 -20.89515* 2.67664 .000 -30.6577 -11.1326 
9.00 -.26021 2.39406 1.000 -8.9921 8.4717 
10.00 -.00337 2.39406 1.000 -8.7353 8.7285 
11.00 .01678 2.39406 1.000 -8.7151 8.7487 
12.00 -.14441 2.39406 1.000 -8.8763 8.5875 
 
 
For figure 44B: 
One-way ANOVA: 
 
Sum of Squares df Mean Square F Sig. 
Between Groups 42.460 12 3.538 14.663 0.000 
Within Groups 6.274 26 .241   
 
Total 48.734 38     
 
 




Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 
2.00 -.17884 .40109 1.000 -1.6364 1.2787 
3.00 -.25472 .40109 1.000 -1.7123 1.2029 
4.00 -3.16896* .40109 .000 -4.6266 -1.7114 
5.00 -.31549 .40109 1.000 -1.7731 1.1421 
6.00 -.52497 .40109 .979 -1.9826 .9326 
7.00 -2.38119* .40109 .000 -3.8388 -.9236 
8.00 -1.97388* .40109 .002 -3.4315 -.5163 
9.00 -.28693 .40109 1.000 -1.7445 1.1707 
10.00 -.20049 .40109 1.000 -1.6581 1.2571 
11.00 .21710 .40109 1.000 -1.2405 1.6747 
12.00 .17535 .40109 1.000 -1.2822 1.6329 
343 
 
13.00 -.03305 .40109 1.000 -1.4906 1.4245 
2.00 
1.00 .17884 .40109 1.000 -1.2787 1.6364 
3.00 -.07589 .40109 1.000 -1.5335 1.3817 
4.00 -2.99013* .40109 .000 -4.4477 -1.5325 
5.00 -.13665 .40109 1.000 -1.5942 1.3209 
6.00 -.34613 .40109 .999 -1.8037 1.1115 
7.00 -2.20235* .40109 .001 -3.6599 -.7448 
8.00 -1.79504* .40109 .007 -3.2526 -.3375 
9.00 -.10809 .40109 1.000 -1.5657 1.3495 
10.00 -.02166 .40109 1.000 -1.4792 1.4359 
11.00 .39594 .40109 .998 -1.0617 1.8535 
12.00 .35418 .40109 .999 -1.1034 1.8118 
13.00 .14579 .40109 1.000 -1.3118 1.6034 
3.00 
1.00 .25472 .40109 1.000 -1.2029 1.7123 
2.00 .07589 .40109 1.000 -1.3817 1.5335 
4.00 -2.91424* .40109 .000 -4.3718 -1.4567 
5.00 -.06077 .40109 1.000 -1.5184 1.3968 
6.00 -.27024 .40109 1.000 -1.7278 1.1873 
7.00 -2.12646* .40109 .001 -3.5840 -.6689 
8.00 -1.71915* .40109 .011 -3.1767 -.2616 
9.00 -.03220 .40109 1.000 -1.4898 1.4254 
10.00 .05423 .40109 1.000 -1.4034 1.5118 
11.00 .47182 .40109 .991 -.9858 1.9294 
12.00 .43007 .40109 .996 -1.0275 1.8877 
13.00 .22168 .40109 1.000 -1.2359 1.6793 
4.00 
1.00 3.16896* .40109 .000 1.7114 4.6266 
2.00 2.99013* .40109 .000 1.5325 4.4477 
3.00 2.91424* .40109 .000 1.4567 4.3718 
5.00 2.85347* .40109 .000 1.3959 4.3111 
6.00 2.64399* .40109 .000 1.1864 4.1016 
7.00 .78778 .40109 .745 -.6698 2.2454 
8.00 1.19509 .40109 .190 -.2625 2.6527 
9.00 2.88203* .40109 .000 1.4244 4.3396 
10.00 2.96847* .40109 .000 1.5109 4.4261 
11.00 3.38606* .40109 .000 1.9285 4.8436 
12.00 3.34431* .40109 .000 1.8867 4.8019 
13.00 3.13592* .40109 .000 1.6783 4.5935 
5.00 
1.00 .31549 .40109 1.000 -1.1421 1.7731 
2.00 .13665 .40109 1.000 -1.3209 1.5942 
3.00 .06077 .40109 1.000 -1.3968 1.5184 
4.00 -2.85347* .40109 .000 -4.3111 -1.3959 
6.00 -.20948 .40109 1.000 -1.6671 1.2481 
7.00 -2.06570* .40109 .001 -3.5233 -.6081 
344 
 
8.00 -1.65839* .40109 .016 -3.1160 -.2008 
9.00 .02856 .40109 1.000 -1.4290 1.4861 
10.00 .11500 .40109 1.000 -1.3426 1.5726 
11.00 .53259 .40109 .976 -.9250 1.9902 
12.00 .49084 .40109 .987 -.9668 1.9484 
13.00 .28244 .40109 1.000 -1.1751 1.7400 
6.00 
1.00 .52497 .40109 .979 -.9326 1.9826 
2.00 .34613 .40109 .999 -1.1115 1.8037 
3.00 .27024 .40109 1.000 -1.1873 1.7278 
4.00 -2.64399* .40109 .000 -4.1016 -1.1864 
5.00 .20948 .40109 1.000 -1.2481 1.6671 
7.00 -1.85622* .40109 .005 -3.3138 -.3986 
8.00 -1.44891 .40109 .052 -2.9065 .0087 
9.00 .23804 .40109 1.000 -1.2195 1.6956 
10.00 .32447 .40109 1.000 -1.1331 1.7821 
11.00 .74207 .40109 .808 -.7155 2.1997 
12.00 .70031 .40109 .858 -.7573 2.1579 
13.00 .49192 .40109 .987 -.9657 1.9495 
7.00 
1.00 2.38119* .40109 .000 .9236 3.8388 
2.00 2.20235* .40109 .001 .7448 3.6599 
3.00 2.12646* .40109 .001 .6689 3.5840 
4.00 -.78778 .40109 .745 -2.2454 .6698 
5.00 2.06570* .40109 .001 .6081 3.5233 
6.00 1.85622* .40109 .005 .3986 3.3138 
8.00 .40731 .40109 .997 -1.0503 1.8649 
9.00 2.09426* .40109 .001 .6367 3.5518 
10.00 2.18069* .40109 .001 .7231 3.6383 
11.00 2.59828* .40109 .000 1.1407 4.0559 
12.00 2.55653* .40109 .000 1.0989 4.0141 
13.00 2.34814* .40109 .000 .8906 3.8057 
8.00 
1.00 1.97388* .40109 .002 .5163 3.4315 
2.00 1.79504* .40109 .007 .3375 3.2526 
3.00 1.71915* .40109 .011 .2616 3.1767 
4.00 -1.19509 .40109 .190 -2.6527 .2625 
5.00 1.65839* .40109 .016 .2008 3.1160 
6.00 1.44891 .40109 .052 -.0087 2.9065 
7.00 -.40731 .40109 .997 -1.8649 1.0503 
9.00 1.68695* .40109 .013 .2294 3.1445 
10.00 1.77338* .40109 .008 .3158 3.2310 
11.00 2.19097* .40109 .001 .7334 3.6486 
12.00 2.14922* .40109 .001 .6916 3.6068 
13.00 1.94083* .40109 .003 .4832 3.3984 
9.00 
1.00 .28693 .40109 1.000 -1.1707 1.7445 
2.00 .10809 .40109 1.000 -1.3495 1.5657 
345 
 
3.00 .03220 .40109 1.000 -1.4254 1.4898 
4.00 -2.88203* .40109 .000 -4.3396 -1.4244 
5.00 -.02856 .40109 1.000 -1.4861 1.4290 
6.00 -.23804 .40109 1.000 -1.6956 1.2195 
7.00 -2.09426* .40109 .001 -3.5518 -.6367 
8.00 -1.68695* .40109 .013 -3.1445 -.2294 
10.00 .08643 .40109 1.000 -1.3712 1.5440 
11.00 .50403 .40109 .984 -.9536 1.9616 
12.00 .46227 .40109 .992 -.9953 1.9199 
13.00 .25388 .40109 1.000 -1.2037 1.7115 
10.00 
1.00 .20049 .40109 1.000 -1.2571 1.6581 
2.00 .02166 .40109 1.000 -1.4359 1.4792 
3.00 -.05423 .40109 1.000 -1.5118 1.4034 
4.00 -2.96847* .40109 .000 -4.4261 -1.5109 
5.00 -.11500 .40109 1.000 -1.5726 1.3426 
6.00 -.32447 .40109 1.000 -1.7821 1.1331 
7.00 -2.18069* .40109 .001 -3.6383 -.7231 
8.00 -1.77338* .40109 .008 -3.2310 -.3158 
9.00 -.08643 .40109 1.000 -1.5440 1.3712 
11.00 .41759 .40109 .997 -1.0400 1.8752 
12.00 .37584 .40109 .999 -1.0817 1.8334 
13.00 .16745 .40109 1.000 -1.2901 1.6250 
11.00 
1.00 -.21710 .40109 1.000 -1.6747 1.2405 
2.00 -.39594 .40109 .998 -1.8535 1.0617 
3.00 -.47182 .40109 .991 -1.9294 .9858 
4.00 -3.38606* .40109 .000 -4.8436 -1.9285 
5.00 -.53259 .40109 .976 -1.9902 .9250 
6.00 -.74207 .40109 .808 -2.1997 .7155 
7.00 -2.59828* .40109 .000 -4.0559 -1.1407 
8.00 -2.19097* .40109 .001 -3.6486 -.7334 
9.00 -.50403 .40109 .984 -1.9616 .9536 
10.00 -.41759 .40109 .997 -1.8752 1.0400 
12.00 -.04175 .40109 1.000 -1.4993 1.4158 
13.00 -.25014 .40109 1.000 -1.7077 1.2074 
12.00 
1.00 -.17535 .40109 1.000 -1.6329 1.2822 
2.00 -.35418 .40109 .999 -1.8118 1.1034 
3.00 -.43007 .40109 .996 -1.8877 1.0275 
4.00 -3.34431* .40109 .000 -4.8019 -1.8867 
5.00 -.49084 .40109 .987 -1.9484 .9668 
6.00 -.70031 .40109 .858 -2.1579 .7573 
7.00 -2.55653* .40109 .000 -4.0141 -1.0989 
8.00 -2.14922* .40109 .001 -3.6068 -.6916 
9.00 -.46227 .40109 .992 -1.9199 .9953 
10.00 -.37584 .40109 .999 -1.8334 1.0817 
346 
 
11.00 .04175 .40109 1.000 -1.4158 1.4993 
13.00 -.20839 .40109 1.000 -1.6660 1.2492 
13.00 
1.00 .03305 .40109 1.000 -1.4245 1.4906 
2.00 -.14579 .40109 1.000 -1.6034 1.3118 
3.00 -.22168 .40109 1.000 -1.6793 1.2359 
4.00 -3.13592* .40109 .000 -4.5935 -1.6783 
5.00 -.28244 .40109 1.000 -1.7400 1.1751 
6.00 -.49192 .40109 .987 -1.9495 .9657 
7.00 -2.34814* .40109 .000 -3.8057 -.8906 
8.00 -1.94083* .40109 .003 -3.3984 -.4832 
9.00 -.25388 .40109 1.000 -1.7115 1.2037 
10.00 -.16745 .40109 1.000 -1.6250 1.2901 
11.00 .25014 .40109 1.000 -1.2074 1.7077 
12.00 .20839 .40109 1.000 -1.2492 1.6660 
 
 
For figure 57A: 
One-way ANOVA: 
 
Sum of Squares df Mean Square F Sig. 
Between Groups 260.518 8 32.565 79.181 .000 
Within Groups 7.403 18 .411     
Total 267.921 26       
 




Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 
2.00 .04985 .52362 1.000 -1.7849 1.8845 
3.00 -4.34094* .52362 .000 -6.1756 -2.5062 
4.00 .01578 .52362 1.000 -1.8189 1.8505 
5.00 -5.54768* .52362 .000 -7.3824 -3.7130 
6.00 -7.80320* .52362 .000 -9.6379 -5.9685 
7.00 -.31785 .52362 .999 -2.1526 1.5168 
8.00 -3.92443* .52362 .000 -5.7591 -2.0897 
9.00 -7.54794* .52362 .000 -9.3826 -5.7132 
2.00 
1.00 -.04985 .52362 1.000 -1.8845 1.7849 
3.00 -4.39079* .52362 .000 -6.2255 -2.5561 
4.00 -.03407 .52362 1.000 -1.8688 1.8006 
347 
 
5.00 -5.59753* .52362 .000 -7.4322 -3.7628 
6.00 -7.85305* .52362 .000 -9.6878 -6.0183 
7.00 -.36770 .52362 .998 -2.2024 1.4670 
8.00 -3.97428* .52362 .000 -5.8090 -2.1396 
9.00 -7.59779* .52362 .000 -9.4325 -5.7631 
3.00 
1.00 4.34094* .52362 .000 2.5062 6.1756 
2.00 4.39079* .52362 .000 2.5561 6.2255 
4.00 4.35672* .52362 .000 2.5220 6.1914 
5.00 -1.20674 .52362 .388 -3.0414 .6280 
6.00 -3.46226* .52362 .000 -5.2970 -1.6276 
7.00 4.02309* .52362 .000 2.1884 5.8578 
8.00 .41651 .52362 .996 -1.4182 2.2512 
9.00 -3.20700* .52362 .000 -5.0417 -1.3723 
4.00 
1.00 -.01578 .52362 1.000 -1.8505 1.8189 
2.00 .03407 .52362 1.000 -1.8006 1.8688 
3.00 -4.35672* .52362 .000 -6.1914 -2.5220 
5.00 -5.56346* .52362 .000 -7.3982 -3.7288 
6.00 -7.81898* .52362 .000 -9.6537 -5.9843 
7.00 -.33363 .52362 .999 -2.1683 1.5011 
8.00 -3.94021* .52362 .000 -5.7749 -2.1055 
9.00 -7.56372* .52362 .000 -9.3984 -5.7290 
5.00 
1.00 5.54768* .52362 .000 3.7130 7.3824 
2.00 5.59753* .52362 .000 3.7628 7.4322 
3.00 1.20674 .52362 .388 -.6280 3.0414 
4.00 5.56346* .52362 .000 3.7288 7.3982 
6.00 -2.25552* .52362 .010 -4.0902 -.4208 
7.00 5.22983* .52362 .000 3.3951 7.0645 
8.00 1.62325 .52362 .107 -.2114 3.4580 
9.00 -2.00026* .52362 .027 -3.8350 -.1656 
6.00 
1.00 7.80320* .52362 .000 5.9685 9.6379 
2.00 7.85305* .52362 .000 6.0183 9.6878 
3.00 3.46226* .52362 .000 1.6276 5.2970 
4.00 7.81898* .52362 .000 5.9843 9.6537 
5.00 2.25552* .52362 .010 .4208 4.0902 
7.00 7.48535* .52362 .000 5.6506 9.3201 
8.00 3.87877* .52362 .000 2.0441 5.7135 
9.00 .25526 .52362 1.000 -1.5794 2.0900 
7.00 
1.00 .31785 .52362 .999 -1.5168 2.1526 
2.00 .36770 .52362 .998 -1.4670 2.2024 
3.00 -4.02309* .52362 .000 -5.8578 -2.1884 
4.00 .33363 .52362 .999 -1.5011 2.1683 
5.00 -5.22983* .52362 .000 -7.0645 -3.3951 
6.00 -7.48535* .52362 .000 -9.3201 -5.6506 
8.00 -3.60658* .52362 .000 -5.4413 -1.7719 




1.00 3.92443* .52362 .000 2.0897 5.7591 
2.00 3.97428* .52362 .000 2.1396 5.8090 
3.00 -.41651 .52362 .996 -2.2512 1.4182 
4.00 3.94021* .52362 .000 2.1055 5.7749 
5.00 -1.62325 .52362 .107 -3.4580 .2114 
6.00 -3.87877* .52362 .000 -5.7135 -2.0441 
7.00 3.60658* .52362 .000 1.7719 5.4413 
9.00 -3.62351* .52362 .000 -5.4582 -1.7888 
9.00 
1.00 7.54794* .52362 .000 5.7132 9.3826 
2.00 7.59779* .52362 .000 5.7631 9.4325 
3.00 3.20700* .52362 .000 1.3723 5.0417 
4.00 7.56372* .52362 .000 5.7290 9.3984 
5.00 2.00026* .52362 .027 .1656 3.8350 
6.00 -.25526 .52362 1.000 -2.0900 1.5794 
7.00 7.23009* .52362 .000 5.3954 9.0648 
8.00 3.62351* .52362 .000 1.7888 5.4582 
 
 
For figure 57B: 
One-way ANOVA: 
 
Sum of Squares df Mean Square F Sig. 
Between Groups 3.092 8 .386 12.898 .000 
Within Groups .539 18 .030 
  
Total 3.631 26 
   
 




Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 
2.00 -.02187 .14133 1.000 -.5171 .4733 
3.00 .50345* .14133 .045 .0082 .9987 
4.00 -.37725 .14133 .226 -.8725 .1180 
5.00 -.51649* .14133 .037 -1.0117 -.0213 
6.00 .20339 .14133 .868 -.2918 .6986 
7.00 -.23770 .14133 .750 -.7329 .2575 
8.00 .43723 .14133 .109 -.0580 .9324 
9.00 .29603 .14133 .505 -.1992 .7912 
2.00 
1.00 .02187 .14133 1.000 -.4733 .5171 
3.00 .52532* .14133 .033 .0301 1.0205 
349 
 
4.00 -.35538 .14133 .288 -.8506 .1398 
5.00 -.49461 .14133 .050 -.9898 .0006 
6.00 .22526 .14133 .796 -.2700 .7205 
7.00 -.21583 .14133 .829 -.7110 .2794 
8.00 .45910 .14133 .082 -.0361 .9543 
9.00 .31790 .14133 .418 -.1773 .8131 
3.00 
1.00 -.50345* .14133 .045 -.9987 -.0082 
2.00 -.52532* .14133 .033 -1.0205 -.0301 
4.00 -.88069* .14133 .000 -1.3759 -.3855 
5.00 -1.01993* .14133 .000 -1.5151 -.5247 
6.00 -.30006 .14133 .489 -.7953 .1952 
7.00 -.74115* .14133 .001 -1.2364 -.2459 
8.00 -.06622 .14133 1.000 -.5614 .4290 
9.00 -.20742 .14133 .856 -.7026 .2878 
4.00 
1.00 .37725 .14133 .226 -.1180 .8725 
2.00 .35538 .14133 .288 -.1398 .8506 
3.00 .88069* .14133 .000 .3855 1.3759 
5.00 -.13924 .14133 .983 -.6345 .3560 
6.00 .58063* .14133 .015 .0854 1.0758 
7.00 .13955 .14133 .982 -.3557 .6348 
8.00 .81447* .14133 .000 .3193 1.3097 
9.00 .67327* .14133 .004 .1781 1.1685 
5.00 
1.00 .51649* .14133 .037 .0213 1.0117 
2.00 .49461 .14133 .050 -.0006 .9898 
3.00 1.01993* .14133 .000 .5247 1.5151 
4.00 .13924 .14133 .983 -.3560 .6345 
6.00 .71987* .14133 .002 .2247 1.2151 
7.00 .27879 .14133 .578 -.2164 .7740 
8.00 .95371* .14133 .000 .4585 1.4489 
9.00 .81251* .14133 .001 .3173 1.3077 
6.00 
1.00 -.20339 .14133 .868 -.6986 .2918 
2.00 -.22526 .14133 .796 -.7205 .2700 
3.00 .30006 .14133 .489 -.1952 .7953 
4.00 -.58063* .14133 .015 -1.0758 -.0854 
5.00 -.71987* .14133 .002 -1.2151 -.2247 
7.00 -.44108 .14133 .103 -.9363 .0541 
8.00 .23384 .14133 .764 -.2614 .7291 
9.00 .09264 .14133 .999 -.4026 .5879 
7.00 
1.00 .23770 .14133 .750 -.2575 .7329 
2.00 .21583 .14133 .829 -.2794 .7110 
3.00 .74115* .14133 .001 .2459 1.2364 
4.00 -.13955 .14133 .982 -.6348 .3557 
5.00 -.27879 .14133 .578 -.7740 .2164 
6.00 .44108 .14133 .103 -.0541 .9363 
8.00 .67493* .14133 .004 .1797 1.1701 
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9.00 .53373* .14133 .029 .0385 1.0289 
8.00 
1.00 -.43723 .14133 .109 -.9324 .0580 
2.00 -.45910 .14133 .082 -.9543 .0361 
3.00 .06622 .14133 1.000 -.4290 .5614 
4.00 -.81447* .14133 .000 -1.3097 -.3193 
5.00 -.95371* .14133 .000 -1.4489 -.4585 
6.00 -.23384 .14133 .764 -.7291 .2614 
7.00 -.67493* .14133 .004 -1.1701 -.1797 
9.00 -.14120 .14133 .981 -.6364 .3540 
9.00 
1.00 -.29603 .14133 .505 -.7912 .1992 
2.00 -.31790 .14133 .418 -.8131 .1773 
3.00 .20742 .14133 .856 -.2878 .7026 
4.00 -.67327* .14133 .004 -1.1685 -.1781 
5.00 -.81251* .14133 .001 -1.3077 -.3173 
6.00 -.09264 .14133 .999 -.5879 .4026 
7.00 -.53373* .14133 .029 -1.0289 -.0385 
8.00 .14120 .14133 .981 -.3540 .6364 
 
 
For figure 58: 
One-way ANOVA: 
 
Sum of Squares df Mean Square F Sig. 
Between Groups 24.740 11 2.249 10.795 .000 
Within Groups 4.375 21 .208     
Total 29.115 32       
 




Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
1.00 
2.00 .10994 .37269 1.000 -1.2526 1.4725 
3.00 -2.12355* .37269 .001 -3.4861 -.7610 
4.00 -.03592 .37269 1.000 -1.3985 1.3266 
5.00 -.20743 .37269 1.000 -1.5700 1.1551 
6.00 -1.21472 .41669 .205 -2.7381 .3087 
7.00 .22884 .37269 1.000 -1.1337 1.5914 
8.00 -2.07124* .41669 .003 -3.5946 -.5479 
9.00 .11698 .37269 1.000 -1.2456 1.4795 
10.00 -1.40005* .37269 .041 -2.7626 -.0375 
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11.00 .02819 .37269 1.000 -1.3344 1.3907 
12.00 -1.59404* .41669 .035 -3.1174 -.0707 
2.00 
1.00 -.10994 .37269 1.000 -1.4725 1.2526 
3.00 -2.23348* .37269 .000 -3.5960 -.8709 
4.00 -.14586 .37269 1.000 -1.5084 1.2167 
5.00 -.31737 .37269 .999 -1.6799 1.0452 
6.00 -1.32466 .41669 .128 -2.8480 .1987 
7.00 .11890 .37269 1.000 -1.2437 1.4815 
8.00 -2.18118* .41669 .002 -3.7046 -.6578 
9.00 .00704 .37269 1.000 -1.3555 1.3696 
10.00 -1.50999* .37269 .022 -2.8725 -.1474 
11.00 -.08175 .37269 1.000 -1.4443 1.2808 
12.00 -1.70398* .41669 .020 -3.2274 -.1806 
3.00 
1.00 2.12355* .37269 .001 .7610 3.4861 
2.00 2.23348* .37269 .000 .8709 3.5960 
4.00 2.08762* .37269 .001 .7251 3.4502 
5.00 1.91612* .37269 .002 .5536 3.2787 
6.00 .90882 .41669 .578 -.6146 2.4322 
7.00 2.35239* .37269 .000 .9898 3.7149 
8.00 .05230 .41669 1.000 -1.4711 1.5757 
9.00 2.24052* .37269 .000 .8780 3.6031 
10.00 .72350 .37269 .724 -.6391 2.0860 
11.00 2.15174* .37269 .000 .7892 3.5143 
12.00 .52951 .41669 .974 -.9939 2.0529 
4.00 
1.00 .03592 .37269 1.000 -1.3266 1.3985 
2.00 .14586 .37269 1.000 -1.2167 1.5084 
3.00 -2.08762* .37269 .001 -3.4502 -.7251 
5.00 -.17150 .37269 1.000 -1.5341 1.1911 
6.00 -1.17880 .41669 .236 -2.7022 .3446 
7.00 .26476 .37269 1.000 -1.0978 1.6273 
8.00 -2.03532* .41669 .003 -3.5587 -.5119 
9.00 .15290 .37269 1.000 -1.2096 1.5155 
10.00 -1.36412* .37269 .050 -2.7267 -.0016 
11.00 .06412 .37269 1.000 -1.2984 1.4267 
12.00 -1.55811* .41669 .042 -3.0815 -.0347 
5.00 
1.00 .20743 .37269 1.000 -1.1551 1.5700 
2.00 .31737 .37269 .999 -1.0452 1.6799 
3.00 -1.91612* .37269 .002 -3.2787 -.5536 
4.00 .17150 .37269 1.000 -1.1911 1.5341 
6.00 -1.00730 .41669 .436 -2.5307 .5161 
7.00 .43627 .37269 .986 -.9263 1.7988 
8.00 -1.86381* .41669 .009 -3.3872 -.3404 
9.00 .32441 .37269 .999 -1.0381 1.6870 
10.00 -1.19262 .37269 .123 -2.5552 .1699 
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11.00 .23562 .37269 1.000 -1.1269 1.5982 
12.00 -1.38661 .41669 .096 -2.9100 .1368 
6.00 
1.00 1.21472 .41669 .205 -.3087 2.7381 
2.00 1.32466 .41669 .128 -.1987 2.8480 
3.00 -.90882 .41669 .578 -2.4322 .6146 
4.00 1.17880 .41669 .236 -.3446 2.7022 
5.00 1.00730 .41669 .436 -.5161 2.5307 
7.00 1.44356 .41669 .074 -.0798 2.9669 
8.00 -.85652 .45646 .760 -2.5253 .8123 
9.00 1.33170 .41669 .124 -.1917 2.8551 
10.00 -.18533 .41669 1.000 -1.7087 1.3381 
11.00 1.24291 .41669 .182 -.2805 2.7663 
12.00 -.37931 .45646 .999 -2.0481 1.2895 
7.00 
1.00 -.22884 .37269 1.000 -1.5914 1.1337 
2.00 -.11890 .37269 1.000 -1.4815 1.2437 
3.00 -2.35239* .37269 .000 -3.7149 -.9898 
4.00 -.26476 .37269 1.000 -1.6273 1.0978 
5.00 -.43627 .37269 .986 -1.7988 .9263 
6.00 -1.44356 .41669 .074 -2.9669 .0798 
8.00 -2.30008* .41669 .001 -3.8235 -.7767 
9.00 -.11186 .37269 1.000 -1.4744 1.2507 
10.00 -1.62889* .37269 .011 -2.9914 -.2663 
11.00 -.20065 .37269 1.000 -1.5632 1.1619 
12.00 -1.82288* .41669 .011 -3.3463 -.2995 
8.00 
1.00 2.07124* .41669 .003 .5479 3.5946 
2.00 2.18118* .41669 .002 .6578 3.7046 
3.00 -.05230 .41669 1.000 -1.5757 1.4711 
4.00 2.03532* .41669 .003 .5119 3.5587 
5.00 1.86381* .41669 .009 .3404 3.3872 
6.00 .85652 .45646 .760 -.8123 2.5253 
7.00 2.30008* .41669 .001 .7767 3.8235 
9.00 2.18822* .41669 .002 .6648 3.7116 
10.00 .67119 .41669 .887 -.8522 2.1946 
11.00 2.09943* .41669 .002 .5760 3.6228 
13.00 .47720 .45646 .994 -1.1916 2.1460 
9.00 
1.00 -.11698 .37269 1.000 -1.4795 1.2456 
2.00 -.00704 .37269 1.000 -1.3696 1.3555 
3.00 -2.24052* .37269 .000 -3.6031 -.8780 
4.00 -.15290 .37269 1.000 -1.5155 1.2096 
5.00 -.32441 .37269 .999 -1.6870 1.0381 
6.00 -1.33170 .41669 .124 -2.8551 .1917 
7.00 .11186 .37269 1.000 -1.2507 1.4744 
8.00 -2.18822* .41669 .002 -3.7116 -.6648 
10.00 -1.51703* .37269 .021 -2.8796 -.1545 
11.00 -.08879 .37269 1.000 -1.4513 1.2738 
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12.00 -1.71102* .41669 .019 -3.2344 -.1876 
10.00 
1.00 1.40005* .37269 .041 .0375 2.7626 
2.00 1.50999* .37269 .022 .1474 2.8725 
3.00 -.72350 .37269 .724 -2.0860 .6391 
4.00 1.36412* .37269 .050 .0016 2.7267 
5.00 1.19262 .37269 .123 -.1699 2.5552 
6.00 .18533 .41669 1.000 -1.3381 1.7087 
7.00 1.62889* .37269 .011 .2663 2.9914 
8.00 -.67119 .41669 .887 -2.1946 .8522 
9.00 1.51703* .37269 .021 .1545 2.8796 
12.00 1.42824* .37269 .035 .0657 2.7908 
13.00 -.19399 .41669 1.000 -1.7174 1.3294 
11.00 
1.00 -.02819 .37269 1.000 -1.3907 1.3344 
2.00 .08175 .37269 1.000 -1.2808 1.4443 
3.00 -2.15174* .37269 .000 -3.5143 -.7892 
4.00 -.06412 .37269 1.000 -1.4267 1.2984 
5.00 -.23562 .37269 1.000 -1.5982 1.1269 
7.00 -1.24291 .41669 .182 -2.7663 .2805 
8.00 .20065 .37269 1.000 -1.1619 1.5632 
9.00 -2.09943* .41669 .002 -3.6228 -.5760 
10.00 .08879 .37269 1.000 -1.2738 1.4513 
12.00 -1.42824* .37269 .035 -2.7908 -.0657 
13.00 -1.62223* .41669 .030 -3.1456 -.0988 
12.00 
1.00 1.59404* .41669 .035 .0707 3.1174 
2.00 1.70398* .41669 .020 .1806 3.2274 
4.00 -.52951 .41669 .974 -2.0529 .9939 
5.00 1.55811* .41669 .042 .0347 3.0815 
6.00 1.38661 .41669 .096 -.1368 2.9100 
7.00 .37931 .45646 .999 -1.2895 2.0481 
8.00 1.82288* .41669 .011 .2995 3.3463 
9.00 -.47720 .45646 .994 -2.1460 1.1916 
10.00 1.71102* .41669 .019 .1876 3.2344 
11.00 .19399 .41669 1.000 -1.3294 1.7174 
13.00 1.62223* .41669 .030 .0988 3.1456 
 
 
 VII. 11.   Gene clusters identified with DAVID analysis 
 
Clusters of genes down-regulated by IFN-α: 
Gene Group 1    Enrichment Score: 22.194215092754717 
UNIPROT ID      Gene Name 
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270106  ribosomal protein L13 (Rpl13) 
75617   ribosomal protein S25 (Rps25) 
20055   ribosomal protein S16 (Rps16) 
66489   ribosomal protein L35 (Rpl35) 
16898   ribosomal protein S2 (Rps2) 
67891   ribosomal protein L4 (Rpl4) 
66481   ribosomal protein S21 (Rps21) 
66480   ribosomal protein L15 (Rpl15) 
20091   ribosomal protein S3A1 (Rps3a1) 
319195  ribosomal protein L17 (Rpl17) 
19944   ribosomal protein L29 (Rpl29) 
20085   ribosomal protein S19 (Rps19) 
19896   ribosomal protein L10A (Rpl10a) 
20084   ribosomal protein S18 (Rps18) 
19989   ribosomal protein L7 (Rpl7) 
19988   ribosomal protein L6 (Rpl6) 
27367   ribosomal protein L3 (Rpl3) 
20116   ribosomal protein S8 (Rps8) 
 Gene Group 2    Enrichment Score: 19.707222786005513 
17709   cytochrome c oxidase subunit II (COX2) 
18674   solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3 (Slc25a3) 
28080   ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit (Atp5o) 
66694   ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 (Uqcrfs1) 
66945   succinate dehydrogenase complex, subunit A, flavoprotein (Fp) (Sdha) 
67680   succinate dehydrogenase complex, subunit B, iron sulfur (Ip) (Sdhb) 
11950   ATP synthase, H+ transporting, mitochondrial F0 complex, subunit B1 (Atp5f1) 
11949   ATP synthase, H+ transporting, mitochondrial F1 complex, γ polypeptide 1 (Atp5c1) 
66043   ATP synthase, H+ transporting, mitochondrial F1 complex, δ subunit (Atp5d) 
11947   ATP synthase, H+ transporting mitochondrial F1 complex, β subunit (Atp5b) 
67003   ubiquinol cytochrome c reductase core protein 2 (Uqcrc2) 
 Gene Group 3    Enrichment Score: 15.981115871725025 
17709   cytochrome c oxidase subunit II (COX2) 
18674   solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3 (Slc25a3) 
71803   solute carrier family 25 (mitochondrial carrier), member 18 (Slc25a18) 
67863   solute carrier family 25 (mitochondrial carrier oxoglutarate carrier), member 11 (Slc25a11) 
11950   ATP synthase, H+ transporting, mitochondrial F0 complex, subunit B1 (Atp5f1) 
66525   translocase of inner mitochondrial membrane 50 (Timm50) 
66477   upregulated during skeletal muscle growth 5 (Usmg5) 
27376   solute carrier family 25 (mitochondrial carrier, dicarboxylate transporter), member 10 (Slc25a10) 
68316   apolipoprotein O (Apoo) 
67003   ubiquinol cytochrome c reductase core protein 2 (Uqcrc2) 
76614   inner membrane protein, mitochondrial (Immt) 




Gene Group 4    Enrichment Score: 15.234748256234331 
73710   tubulin, β 2B class IIB (Tubb2b) 
22152   tubulin, β 3 class III (Tubb3) 
545486  tubulin, β 1 class VI (Tubb1) 
67951   tubulin, β 6 class V (Tubb6) 
22146   tubulin, α 1C (Tuba1c) 
22145   tubulin, α 4A (Tuba4a) 
53857   tubulin, α 8 (Tuba8) 
22154   tubulin, β 5 class I (Tubb5) 
 Gene Group 5    Enrichment Score: 14.434590025344846 
12462   chaperonin containing Tcp1, subunit 3 (γ) (Cct3) 
12469   chaperonin containing Tcp1, subunit 8 (theta) (Cct8) 
21454   t-complex protein 1 (Tcp1) 
12466   chaperonin containing Tcp1, subunit 6a (zeta) (Cct6a) 
12464   chaperonin containing Tcp1, subunit 4 (δ) (Cct4) 
 Gene Group 6    Enrichment Score: 13.89506787916256 
22608   Y box protein 1 (Ybx1) 
15384   heterogeneous nuclear ribonucleoprotein A/B (Hnrnpab) 
319765  insulin-like growth factor 2 mRNA binding protein 2 (Igf2bp2) 
15382   heterogeneous nuclear ribonucleoprotein A1 (Hnrnpa1) 
51810   heterogeneous nuclear ribonucleoprotein U (Hnrnpu) 
19655   RNA binding motif protein, X chromosome (Rbmx) 
59093   poly(rC) binding protein 3 (Pcbp3) 
50926   heterogeneous nuclear ribonucleoprotein D-like (Hnrnpdl) 
20382   serine/arginine-rich splicing factor 2 (Srsf2) 
56258   heterogeneous nuclear ribonucleoprotein H2 (Hnrnph2) 
 Gene Group 7    Enrichment Score: 13.6047232828136 
232440  H2A histone family, member J (H2afj) 
50708   histone cluster 1, H1c (Hist1h1c) 
15078   H3 histone, family 3A (H3f3a) 
15441   heterochromatin protein 1, binding protein 3 (Hp1bp3) 
100041230       histone cluster 1, H4m (Hist1h4m) 
319189  histone cluster 2, H2bb (Hist2h2bb) 
319177  histone cluster 1, H2ba (Hist1h2ba) 
 Gene Group 8    Enrichment Score: 12.77028867995201 
16828   lactate dehydrogenase A (Ldha) 
17449   malate dehydrogenase 1, NAD (soluble) (Mdh1) 
16832   lactate dehydrogenase B (Ldhb) 
14555   glycerol-3-phosphate dehydrogenase 1 (soluble) (Gpd1) 
333433  glycerol-3-phosphate dehydrogenase 1-like (Gpd1l) 
 Gene Group 9    Enrichment Score: 12.431775536731928 
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50797   coatomer protein complex, subunit β 2 (β prime) (Copb2) 
319670  echinoderm microtubule associated protein like 5 (Eml5) 
18786   phospholipase A2, activating protein (Plaa) 
13427   dynein cytoplasmic 1 intermediate chain 2 (Dync1i2) 
17101   lysosomal trafficking regulator (Lyst) 
22388   WD repeat domain 1 (Wdr1) 
 Gene Group 10   Enrichment Score: 11.401680937202153 
16675   keratin 27 (Krt27) 
74127   keratin 80 (Krt80) 
16691   keratin 8 (Krt8) 
16907   lamin B2 (Lmnb2) 
 Gene Group 11   Enrichment Score: 10.255814479261028 
93747   enoyl Coenzyme A hydratase, short chain, 1, mitochondrial (Echs1) 
97212   hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A 
hydratase (trifunctional protein), α subunit (Hadha) 
66885   acyl-Coenzyme A dehydrogenase, short/branched chain (Acadsb) 
52538   acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) (Acaa2) 
 Gene Group 12   Enrichment Score: 10.044014527244453 
15482   heat shock protein 1-like (Hspa1l) 
15525   heat shock protein 4 (Hspa4) 
15512   heat shock protein 2 (Hspa2) 
15511   heat shock protein 1B (Hspa1b) 
 Gene Group 13   Enrichment Score: 7.382807945264915 
11844   ADP-ribosylation factor 5 (Arf5) 
11843   ADP-ribosylation factor 4 (Arf4) 
19349   RAB7, member RAS oncogene family (Rab7) 
68365   RAB14, member RAS oncogene family (Rab14) 
 Gene Group 14   Enrichment Score: 3.664447304141587 
68316   apolipoprotein O (Apoo) 
72736   thioredoxin-related transmembrane protein 1 (Tmx1) 
54563   nucleoporin 210 (Nup210) 
103963  ribophorin I (Rpn1) 
 
Clusters of genes down-regulated by palmitate:  
Gene Group 1    Enrichment Score: 27.340953338322766 
UNIPROT ID      Gene Name 
110308  keratin 5 (Krt5) 
13346   desmin (Des) 
16682   keratin 4 (Krt4) 
53622   keratin 85 (Krt85) 
357 
 
68239   keratin 42 (Krt42) 
16680   keratin 84 (Krt84) 
16678   keratin 1 (Krt1) 
94179   keratin 23 (Krt23) 
16675   keratin 27 (Krt27) 
16907   lamin B2 (Lmnb2) 
16905   lamin A (Lmna) 
16669   keratin 19 (Krt19) 
16668   keratin 18 (Krt18) 
16667   keratin 17 (Krt17) 
16666   keratin 16 (Krt16) 
16664   keratin 14 (Krt14) 
16663   keratin 13 (Krt13) 
16661   keratin 10 (Krt10) 
66809   keratin 20 (Krt20) 
105866  keratin 72 (Krt72) 
268481  keratin 222 (Krt222) 
109052  keratin 75 (Krt75) 
223917  keratin 79 (Krt79) 
16691   keratin 8 (Krt8) 
19132   peripherin (Prph) 
16687   keratin 6A (Krt6a) 
406222  keratin 74 (Krt74) 
 Gene Group 2    Enrichment Score: 22.546153995797393 
68263   pyruvate dehydrogenase (lipoamide) β (Pdhb) 
11429   aconitase 2, mitochondrial (Aco2) 
13382   dihydrolipoamide dehydrogenase (Dld) 
17448   malate dehydrogenase 2, NAD (mitochondrial) (Mdh2) 
18597   pyruvate dehydrogenase E1 α 1 (Pdha1) 
27402   pyruvate dehydrogenase complex, component X (Pdhx) 
78920   dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex) (Dlst) 
67834   isocitrate dehydrogenase 3 (NAD+) α (Idh3a) 
12974   citrate synthase (Cs) 
 Gene Group 3    Enrichment Score: 21.491599483468587 
68193   ribosomal protein L24 (Rpl24) 
68052   ribosomal protein S13 (Rps13) 
270106  ribosomal protein L13 (Rpl13) 
19935   mitochondrial ribosomal protein L23 (Mrpl23) 
16898   ribosomal protein S2 (Rps2) 
67427   ribosomal protein S20 (Rps20) 
20091   ribosomal protein S3A1 (Rps3a1) 
66481   ribosomal protein S21 (Rps21) 
20085   ribosomal protein S19 (Rps19) 
26961   ribosomal protein L8 (Rpl8) 
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20084   ribosomal protein S18 (Rps18) 
19989   ribosomal protein L7 (Rpl7) 
26451   ribosomal protein L27A (Rpl27a) 
319195  ribosomal protein L17 (Rpl17) 
19896   ribosomal protein L10A (Rpl10a) 
20102   ribosomal protein S4, X-linked (Rps4x) 
 Gene Group 4    Enrichment Score: 18.046271492856555 
17709   cytochrome c oxidase subunit II (COX2) 
18674   solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3 (Slc25a3) 
28080   ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit (Atp5o) 
66694   ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 (Uqcrfs1) 
67680   succinate dehydrogenase complex, subunit B, iron sulfur (Ip) (Sdhb) 
11950   ATP synthase, H+ transporting, mitochondrial F0 complex, subunit B1 (Atp5f1) 
11949   ATP synthase, H+ transporting, mitochondrial F1 complex, γ polypeptide 1 (Atp5c1) 
11947   ATP synthase, H+ transporting mitochondrial F1 complex, β subunit (Atp5b) 
66043   ATP synthase, H+ transporting, mitochondrial F1 complex, δ subunit (Atp5d) 
12866   cytochrome c oxidase subunit VIIa 2 (Cox7a2) 
66525   translocase of inner mitochondrial membrane 50 (Timm50) 
57279   solute carrier family 25 (mitochondrial carnitine/acylcarnitine translocase), member 20 
(Slc25a20) 
22273   ubiquinol-cytochrome c reductase core protein 1 (Uqcrc1) 
66477   upregulated during skeletal muscle growth 5 (Usmg5) 
27376   solute carrier family 25 (mitochondrial carrier, dicarboxylate transporter), member 10 (Slc25a10) 
76614   inner membrane protein, mitochondrial (Immt) 
 Gene Group 5    Enrichment Score: 16.895639297974952 
381314  isoleucine-tRNA synthetase 2, mitochondrial (Iars2) 
70120   tyrosyl-tRNA synthetase 2 (mitochondrial) (Yars2) 
353172  glycyl-tRNA synthetase (Gars) 
226414  aspartyl-tRNA synthetase (Dars) 
 Gene Group 6    Enrichment Score: 15.19979199086473 
16828   lactate dehydrogenase A (Ldha) 
17449   malate dehydrogenase 1, NAD (soluble) (Mdh1) 
16833   lactate dehydrogenase C (Ldhc) 
17448   malate dehydrogenase 2, NAD (mitochondrial) (Mdh2) 
14555   glycerol-3-phosphate dehydrogenase 1 (soluble) (Gpd1) 
333433  glycerol-3-phosphate dehydrogenase 1-like (Gpd1l) 
 Gene Group 7    Enrichment Score: 13.544274556436427 
12462   chaperonin containing Tcp1, subunit 3 (γ) (Cct3) 
12469   chaperonin containing Tcp1, subunit 8 (theta) (Cct8) 
21454   t-complex protein 1 (Tcp1) 
12466   chaperonin containing Tcp1, subunit 6a (zeta) (Cct6a) 
 Gene Group 8    Enrichment Score: 12.954545575472325 
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545486  tubulin, β 1 class VI (Tubb1) 
22146   tubulin, α 1C (Tuba1c) 
22145   tubulin, α 4A (Tuba4a) 
22144   tubulin, α 3A (Tuba3a) 
22154   tubulin, β5 class I (Tubb5) 
 Gene Group 9    Enrichment Score: 11.987323744852933 
18949   pinin (Pnn) 
15382   heterogeneous nuclear ribonucleoprotein A1 (Hnrnpa1) 
110809  serine/arginine-rich splicing factor 1 (Srsf1) 
51810   heterogeneous nuclear ribonucleoprotein U (Hnrnpu) 
18458   poly(A) binding protein, cytoplasmic 1 (Pabpc1) 
23881   GTPase activating protein (SH3 domain) binding protein 2 (G3bp2) 
56403   synaptotagmin binding, cytoplasmic RNA interacting protein (Syncrip) 
50926   heterogeneous nuclear ribonucleoprotein D-like (Hnrnpdl) 
140488  insulin-like growth factor 2 mRNA binding protein 3 (Igf2bp3) 
 Gene Group 10   Enrichment Score: 11.291158146169026 
232440  H2A histone family, member J (H2afj) 
50708   histone cluster 1, H1c (Hist1h1c) 
14958   H1 histone family, member 0 (H1f0) 
319189  histone cluster 2, H2bb (Hist2h2bb) 
 Gene Group 11   Enrichment Score: 10.89155859219692 
15482   heat shock protein 1-like (Hspa1l) 
15525   heat shock protein 4 (Hspa4) 
15512   heat shock protein 2 (Hspa2) 
15511   heat shock protein 1B (Hspa1b) 
 Gene Group 12   Enrichment Score: 10.583684643167981 
11370   acyl-Coenzyme A dehydrogenase, very long chain (Acadvl) 
110842  electron transferring flavoprotein, α polypeptide (Etfa) 
93747   enoyl Coenzyme A hydratase, short chain, 1, mitochondrial (Echs1) 
11363   acyl-Coenzyme A dehydrogenase, long-chain (Acadl) 
 Gene Group 13   Enrichment Score: 9.232047295064406 
14827   protein disulfide isomerase associated 3 (Pdia3) 
18453   prolyl 4-hydroxylase, β polypeptide (P4hb) 
12304   protein disulfide isomerase associated 4 (Pdia4) 
72736   thioredoxin-related transmembrane protein 1 (Tmx1) 
 Gene Group 14   Enrichment Score: 3.8351172602377406 
98238   leucine rich repeat containing 59 (Lrrc59) 
72736   thioredoxin-related transmembrane protein 1 (Tmx1) 
54563   nucleoporin 210 (Nup210) 
103963  ribophorin I (Rpn1) 
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109154  malectin (Mlec) 
 
Clusters of genes up-regulated by palmitate: 
Gene Group 1    Enrichment Score: 12.916387525035683 
UNIPROT_ID      Gene Name 
56258   heterogeneous nuclear ribonucleoprotein H2 (Hnrnph2) 
76936   heterogeneous nuclear ribonucleoprotein M (Hnrnpm) 
225027  serine/arginine-rich splicing factor 7 (Srsf7) 
233908  fused in sarcoma (Fus) 
53379   heterogeneous nuclear ribonucleoprotein A2/B1 (Hnrnpa2b1) 
20384   serine/arginine-rich splicing factor 5 (Srsf5) 
20382   serine/arginine-rich splicing factor 2 (Srsf2) 
56194   pre-mRNA processing factor 40A (Prpf40a) 
71514   splicing factor proline/glutamine rich (polypyrimidine tract binding protein associated) (Sfpq) 
319765  insulin-like growth factor 2 mRNA binding protein 2 (Igf2bp2) 
17975   nucleolin (Ncl) 
110611  high density lipoprotein (HDL) binding protein (Hdlbp) 
15388   heterogeneous nuclear ribonucleoprotein L (Hnrnpl) 
15384   heterogeneous nuclear ribonucleoprotein A/B (Hnrnpab) 
59093   poly(rC) binding protein 3 (Pcbp3) 
23983   poly(rC) binding protein 1 (Pcbp1) 
19655   RNA binding motif protein, X chromosome (Rbmx) 
11991   heterogeneous nuclear ribonucleoprotein D (Hnrnpd) 
56215   apoptotic chromatin condensation inducer 1 (Acin1) 
18521   poly(rC) binding protein 2 (Pcbp2) 
22185   U2 small nuclear ribonucleoprotein auxiliary factor (U2AF) 2 (U2af2) 
22608   Y box protein 1 (Ybx1) 
 Gene Group 2    Enrichment Score: 10.63922038334072 
67891   ribosomal protein L4 (Rpl4) 
66489   ribosomal protein L35 (Rpl35) 
75617   ribosomal protein S25 (Rps25) 
20044   ribosomal protein S14 (Rps14) 
19899   ribosomal protein L18 (Rpl18) 
19921   ribosomal protein L19 (Rpl19) 
 Gene Group 3    Enrichment Score: 7.899364663937192 
50709   histone cluster 1, H1e (Hist1h1e) 
15078   H3 histone, family 3A (H3f3a) 
100041230       histone cluster 1, H4m (Hist1h4m) 
319177  histone cluster 1, H2ba (Hist1h2ba) 
51788   H2A histone family, member Z (H2afz) 




Gene Group 4    Enrichment Score: 3.7185121222254582 
104130  NADH dehydrogenase (ubiquinone) 1 β subcomplex, 11 (Ndufb11) 
227197  NADH dehydrogenase (ubiquinone) Fe-S protein 1 (Ndufs1) 
67003   ubiquinol cytochrome c reductase core protein 2 (Uqcrc2) 
12859   cytochrome c oxidase subunit Vb (Cox5b) 
 
Clusters of genes down-regulated by IFN-α and up-regulated by palmitate: 
Gene Group 1    Enrichment Score: 4.443951870351887 
UNIPROT_ID      Gene Name 
20382   serine/arginine-rich splicing factor 2 (Srsf2) 
19655   RNA binding motif protein, X chromosome (Rbmx) 
319765  insulin-like growth factor 2 mRNA binding protein 2 (Igf2bp2) 
15384   heterogeneous nuclear ribonucleoprotein A/B (Hnrnpab) 
56258   heterogeneous nuclear ribonucleoprotein H2 (Hnrnph2) 
59093   poly(rC) binding protein 3 (Pcbp3) 
 
Clusters of genes down-regulated by IFN-α and by palmitate: 
Gene Group 1    Enrichment Score: 14.186454203920169 
UNIPROT_ID      Gene Name 
270106  ribosomal protein L13 (Rpl13) 
16898   ribosomal protein S2 (Rps2) 
20091   ribosomal protein S3A1 (Rps3a1) 
66481   ribosomal protein S21 (Rps21) 
20085   ribosomal protein S19 (Rps19) 
20084   ribosomal protein S18 (Rps18) 
19989   ribosomal protein L7 (Rpl7) 
19896   ribosomal protein L10A (Rpl10a) 
319195  ribosomal protein L17 (Rpl17) 
 Gene Group 2    Enrichment Score: 13.760325061844586 
17709   cytochrome c oxidase subunit II (COX2) 
18674   solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3 (Slc25a3) 
66694   ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 (Uqcrfs1) 
67680   succinate dehydrogenase complex, subunit B, iron sulfur (Ip) (Sdhb) 
11950   ATP synthase, H+ transporting, mitochondrial F0 complex, subunit B1 (Atp5f1) 
66525   translocase of inner mitochondrial membrane 50 (Timm50) 
66477   upregulated during skeletal muscle growth 5 (Usmg5) 
27376   solute carrier family 25 (mitochondrial carrier, dicarboxylate transporter), member 10 (Slc25a10) 
76614   inner membrane protein, mitochondrial (Immt) 
 Gene Group 3    Enrichment Score: 10.608146960576038 
12462   chaperonin containing Tcp1, subunit 3 (γ) (Cct3) 
12469   chaperonin containing Tcp1, subunit 8 (theta) (Cct8) 
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21454   t-complex protein 1 (Tcp1) 
12466   chaperonin containing Tcp1, subunit 6a (zeta) (Cct6a) 
 Gene Group 4    Enrichment Score: 10.054782828918649 
66043   ATP synthase, H+ transporting, mitochondrial F1 complex, δ subunit (Atp5d) 
28080   ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit (Atp5o) 
18674   solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3 (Slc25a3) 
11950   ATP synthase, H+ transporting, mitochondrial F0 complex, subunit B1 (Atp5f1) 
11949   ATP synthase, H+ transporting, mitochondrial F1 complex, γ polypeptide 1 (Atp5c1) 
11947   ATP synthase, H+ transporting mitochondrial F1 complex, β subunit (Atp5b) 
 Gene Group 5    Enrichment Score: 9.365775548954282 
68263   pyruvate dehydrogenase (lipoamide) β (Pdhb) 
18597   pyruvate dehydrogenase E1 α 1 (Pdha1) 
12974   citrate synthase (Cs) 
27402   pyruvate dehydrogenase complex, component X (Pdhx) 
 Gene Group 6    Enrichment Score: 8.598916979719728 
545486  tubulin, β 1 class VI (Tubb1) 
22146   tubulin, α 1C (Tuba1c) 
22145   tubulin, α 4A (Tuba4a) 
22154   tubulin, β 5 class I (Tubb5) 
 Gene Group 7    Enrichment Score: 8.22309435226446 
15482   heat shock protein 1-like (Hspa1l) 
15525   heat shock protein 4 (Hspa4) 
15512   heat shock protein 2 (Hspa2) 
15511   heat shock protein 1B (Hspa1b) 
 Gene Group 8    Enrichment Score: 7.259714237111446 
16828   lactate dehydrogenase A (Ldha) 
17449   malate dehydrogenase 1, NAD (soluble) (Mdh1) 
14555   glycerol-3-phosphate dehydrogenase 1 (soluble) (Gpd1) 
333433  glycerol-3-phosphate dehydrogenase 1-like (Gpd1l) 
 Gene Group 9    Enrichment Score: 6.089571025094121 
98238   leucine rich repeat containing 59 (Lrrc59) 
72736   thioredoxin-related transmembrane protein 1 (Tmx1) 
54563   nucleoporin 210 (Nup210) 
103963  ribophorin I (Rpn1) 
  
 
